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Abstract 
 Fine control of the physical and chemical properties of customized 
materials is a field that is rapidly advancing. This is especially critical in pursuits 
to develop and optimize novel nanoparticle drug delivery. Specifically, I aim to 
apply chemistry concepts to test the hypothesis “Silicate ester prodrugs of 
paclitaxel, customized to have the proper hydrophobicity and hydrolytic lability, 
can be formulated with well-defined, biocompatible, amphiphilic block copolymers 
into nanoparticles that are effective drugs.” Chapter 1 briefly describes the 
context and motivation of the scientific pursuits described in this thesis. In 
Chapter 2, a family of model silicate esters is synthesized, the hydrolysis rate of 
each compound is benchmarked, and trends are established based upon the 
steric bulk and leaving group ability of the silicate substituents. These trends are 
then applied to the synthesis of labile silicate ester prodrugs in Chapter 3. The 
bulk of this chapter focuses on the synthesis, hydrolysis, and cytotoxicity of 
prodrugs based on paclitaxel, a widely used chemotherapeutic agent. In Chapter 
4, a new methodology for the synthesis of narrowly dispersed, “random” 
poly(lactic-co-glycolic acid) polymers by a constant infusion of the glycolide 
monomer is detailed. Using poly(ethylene glycol) as a macroinitiator, amphiphilic 
block copolymers were synthesized. Co-formulating a paclitaxel silicate and an 
amphiphilic block copolymer via flash nanoprecipitation led to highly prodrug-
loaded, kinetically trapped nanoparticles. Studies to determine the structure, 
morphology, behavior, and efficacy of these nanoparticles are described in 
Chapter 5. Efforts to develop a general strategy for the selective end-
functionalization of the polyether block of these amphiphilic block copolymers are 
discussed in Chapter 6. Examples of this strategy include functionalization of the 
polyether with an azide or a maleimide. Finally, Chapter 7 provides an outlook for 
future development of the strategies described in this thesis and summarizes the 
results and conclusions of the experimental results that led to the development of 
the therapeutic, paclitaxel silicate-loaded, polymeric nanoparticles. 
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Chapter 1  
General Overview and Motivation 
 
1. General Overview. 
 1. A Philosophical Viewpoint. Development of novel and successful drug 
delivery strategies is arguably one of the most daunting, complex, and important 
problems faced today. The challenges to developing such techniques are 
numerous, including (but not limited to): i) control of the physicochemical and 
biological properties of a small molecule drug, ii) optimization of a biocompatible 
excipient to facilitate drug delivery, and iii) assurance of both the efficacy and 
safety of a new formulation. These numerous and widely diverse challenges 
necessitate a broad-based and highly interdisciplinary approach to achieve 
progress in the field. In this light, chemists must consider “How can we (as the 
chemistry community) best apply our knowledge and skills to difficult, inter-
disciplinary yet practical problems?” I would argue that our collective expertise in 
synthesizing precisely customized materials, both discrete small molecules and 
macromolecules, is one potential key to well-defined and highly generalizable 
solutions in drug delivery. 
2. Flash Nanoprecipitation. One fundamental drawback hindering the 
development and clinical application of many new drugs is limited aqueous 
solubility.  An emerging technology, termed flash nanoprecipitation (FNP) is one 
strategy that, in the most general sense, formulates hydrophobic compounds in 
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an aqueous medium.1 In this process, water and a miscible organic solvent, in 
which an amphiphilic block copolymer (BCP) and an organic active are co-
dissolved, are rapidly mixed in a confined volume. In the resulting, predominantly 
aqueous suspension, the organic compound and hydrophobic block of the BCP 
are co-encapsulated within the newly formed nanoparticle, which is effectively 
solubilized by the hydrophilic block.  
Prud’homme and coworkers further refined the FNP process to optimize it 
for drug delivery by engineering new impingement jet mixers: the confined 
impingement jet (CIJ) mixer2,3 and the multi-inlet vortex (MIV) mixer.4 In their 
model work, FNP studies utilized β-carotene as a highly hydrophobic drug model 
and poly(ethylene glycol)-b-poly(styrene) (PEG-b-PS) as the amphiphilic block 
copolymer. These studies demonstrated the potential of FNP methodology; 
namely, this technique results in nanoparticles that exhibit i) high encapsulation 
efficiencies, ii) high drug loading, and iii) nanoparticle sizes of approximately 100 
nm. Specifically, Dr. Zhengxi Zhu, a student of Prof. Christopher Macosko 
(Department of Chemical Engineering and Materials Science, University of 
Minnesota), demonstrated that β-carotene could be loaded in the core of a block 
copolymer at loading levels > 80 weight percent (wt%)5 – a loading level that is 
significantly higher than most commonly employed drug encapsulation 
methodologies (typically 5-10 wt%).  
???????????????????????????????????????? ????????????????????
1 Horn, D.; Rieger, J. Organic Nanoparticles in the Aqueous Phase – Theory, Experiment, and 
Use. Angew. Chem. Int. Ed. 2001, 40, 4330–4361. 
2 Johnson, B. K.; Prud’homme, R. K. Chemical Processing and Micromixing in Confined 
Impinging Jets.  AIChE 2003, 49, 2264–2282.   
3 Johnson, B. K.; Prud’homme, R. K.  Flash NanoPrecipitation of Organic Actives and Block 
Copolymers using a Confined Impinging Jets Mixer. Aust. J. Chem. 2003, 56, 1021–1024. 
4 Liu, Y.; Cheng, C.; Liu, Y.; Prud’homme, R. K.; Fox, R. O.  Mixing in a Multi-Inlet Vortex Mixer 
(MIVM) for Flash Nano-Precipitation.  Chem. Eng. Sci. 2008, 63, 2829–2842. 
5 Zhu, Z. Polymer Stabilized Nanosuspensions Formed via Flash Nanoprecipitation: Nanoparticle 
Formation, Formulation, and Stability. Ph.D. Dissertation, University of Minnesota, Minneapolis, 
MN, 2010, 1–213. 
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Members of the Macosko group, with collaborative input from the Hoye 
group, made advancements in the CIJ mixer design. These efforts led to the 
development of the modified confined impingement jet (CIJ-D)6 mixing FNP 
methodology (Figure 1-1). This simple, hand-operated apparatus allowed for 
rapid analysis of the particle-forming behavior of new materials and introduced a 
post-impingement mixing stage. Particles made from this CIJ-D method were 
shown to produce nanoparticles of similar size and stability as that of the MIV 
mixer.6 Thus, the CIJ-D has been used extensively in the production of 
nanoparticles in this thesis. 
Figure 1-1. A modified confined impingement jet mixer for a flash 
nanoprecipitation: during the rapid impingement mixing, hydrophobic solutes are 
efficiently trapped in the nanoparticle core and rapidly diluted in bulk water, 
thereby minimizing aggregation. These well-dispersed particles formed have 
been shown to remain stable for several days.6 
 
 
 
???????????????????????????????????????? ????????????????????
6 Han, J.; Zhu, Z.; Qian, H.; Wohl, A. R.; Beaman, C. J.; Hoye, T. R.; Macosko, C. W. A Simple 
Confined Impingement Jets Mixer for Flash NanoPrecipitation. J. Pharm. Sci. 2012, 101, 4018–
4023. 
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 3. Previous Efforts to Encapsulate Paclitaxel via FNP. Previous attempts 
to expand the β-carotene studies and instead encapsulate a hydrophobic drug, 
paclitaxel (PTX, 1.01, the active ingredient in Taxol®), in biocompatible BCPs 
have been largely unsuccessful.5,7 These results are attributable to the tendency 
of PTX to crystallize outside of the nanoparticle core upon aging via Ostwald 
ripening (i.e., the dissolution of PTX molecules from the nanoparticle core and 
subsequent crystallization on a bulk PTX crystal). Early work led to improvement 
of the nanoparticle stability by conjugating PTX to, among others hydrophobic 
compounds, the nonpolar fatty acid derivative docosanyl diglycolate (1.02) to 
yield the yet more hydrophobic paclitaxel drug derivative 1.03 (Scheme 1-1).7,8 
Altering the physical characteristics of the parent drug molecule successfully 
created more stable nanoparticles via FNP. However, efficacy of these drug 
derivatives were found to be significantly (ca. 10-fold) less cytotoxic than the 
parent drug, presumably due to the unfavorable chemical properties – an 
exceedingly slow rate of hydrolysis to the active PTX parent – of the new ester 
drug derivative.8 The results described above strongly suggest that further 
optimization of these FNP-based drug delivery systems requires attention to both 
physical and chemical properties. 
 
 
 
 
???????????????????????????????????????? ????????????????????
7 Saad, W. S. Drug Nanoparticle Formation via Flash Nanoprecipitation: Conjugation to 
Encapsulate and Control the Release of Paclitaxel. Ph.D. Dissertation, Princeton University, 
Princeton, NJ, 2007. 1–198. 
8 Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. O.; Harasym, 
N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prud’homme, R. K.; Mayer, L. D. 
Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the 
Hydrophobicity of Prodrug Conjugates. J. Med. Chem. 2008, 51, 3288–3296. 
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Scheme 1-1. The representative conjugation of 1.01 with 1.02 to synthesize a 
hydrophobic paclitaxel derivative 1.03.8 
 
  
 
2. General Project Goals. 
 1. The Over-Arching Hypothesis. 
 
“Silicate ester prodrugs of paclitaxel, customized to have the proper 
hydrophobicity and hydrolytic lability, can be formulated with well-
defined, biocompatible, amphiphilic block copolymers into 
nanoparticles that are effective drugs.” 
 2. Simultaneous Control of Physical and Chemical Properties of Small 
Molecules. As alluded earlier, the majority of this thesis is devoted to the 
development and application of general solutions to far-reaching challenges. 
Thus, the first aim is to develop novel ideas to independently control the physical 
and chemical properties for application to drug delivery concepts (e.g., FNP). A 
new, general silicate ester prodrug strategy has been designed to allow for 
control of both the hydrophobic character of a prodrug and the rate of hydrolysis 
to the active parent drug (c.f., Scheme 3-1 and related text in Chapter 3). In 
pursuing this route, general trends have been established through the analysis of 
multiple model systems, and this information was most extensively applied to the 
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synthesis of paclitaxel silicate ester prodrugs. In the course of these studies, the 
general applicability intentionally incorporated into this methodology was 
exploited to include other potential drugs, including the synthesis of silicate 
esters of curcumin (1.04, Figure 1-2). 
Figure 1-2. The chemical structure of curcumin 1.04. 
 
 
 
 3. Synthesis of Well-Defined Block Copolymers. Early work on the 
formulation of loaded nanoparticles suggested that commonly employed, 
biocompatible BCPs such as poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-
PLA) or poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-b-PCL)  failed to 
produce stable nanoparticles, whereas poly(ethylene glycol)-b-poly(lactic-co-
glycolic acid) (PEG-b-PLGA) polymers showed promise.5 However, typical 
methods for the synthesis of PLGA [i.e., random transesterification of lactide and 
glycolide with a Sn(II) catalyst] typically give poorly defined, broadly dispersed 
polymers.9 Therefore, a new route to synthesize poly(ethylene glycol)-b-
poly(lactic-co-glycolic acid) (PEG-b-PLGA) block copolymers of narrow molecular 
weights was developed in collaboration with Dr. Haitao Qian, a post-doctoral 
associate in the Hoye group. Additionally, carefully choosing the end groups of 
these polymers allows selective functionalization of either the hydrophobic or 
hydrophilic terminus of these block copolymers to induce in vivo targeting or 
imaging. The described unique materials may then be used in a number of 
applications, including drug delivery projects. 
???????????????????????????????????????? ????????????????????
9 Dechy-Cabaret, O.; Martin-Vaca, B.; Bourissou, D. Controlled Ring-Opening Polymerization of 
Lactide and Glycolide. Chem. Rev. 2004, 104, 6147–6176. 
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Chapter 2 
Model Silicate Ester Prodrugs: Synthesis 
and Determination of Hydrolysis Rate 
Trends 
 
1. Introduction. 
 Orthosilicates [Si(OR)4] are a class of organic compounds that have been 
known for more than 160 years.10  However, their application to generally control 
physical and chemical properties is a novel application of an age-old chemical 
entity. Several attractive features of this new class of prodrugs have the potential 
to be exploited: i) the ease of synthesis, ii) diversity of amenable compounds, iii) 
the ability to incorporate alkyl chains of varying lengths to control hydrophobic 
character, iv) the tunable hydrolysis rate via the steric bulk of the alkoxy 
substituents, and v) the open “chemical space” in the patent literature.  
1. Silicate Nomenclature. Prior to delving into the physical and chemical 
properties of orthosilicates/alkoxysilanes/silicate esters, it is helpful to 
unambiguously define the naming system to be used in this thesis for such 
compounds. Confusion arises from the historical practice of naming such silicon-
centric entities as derivatives of different parent compounds. The end result is 
???????????????????????????????????????? ????????????????????
10 Ebelmen, M. Ann. Chim. Phys.  1845.  15, 319. 
Chapter 2 Model Silicate Ester Prodrugs? 
?
??
?
that multiple common names are often encountered in the literature for identical 
compounds. 
A series of instructive examples crystallizes many of these issues. Most 
generally, names for compounds containing silicon are named from the simplest 
silane, SiH4. As heavy atom substituents are added, the name of the silane is 
adjusted appropriately. For instance, (Et)3SiH, (EtO)3SiH, and Si(OEt)4 are 
named triethylsilane, triethoxysilane, and tetraethoxysilane, respectively. Among 
these examples, Si(OEt)4 uniquely contains four Si-O bonds, and thus it is 
commonly named as a derivative of orthosilicic acid [Si(OH)4] rather than as a 
silane derivative. Therefore, Si(OEt)4 is often referred to as tetraethyl orthosilicate 
(TEOS).11 
The naming of Si(OEt)4 and analogous compounds (i.e., those containing 
four Si-O bonds) is further complicated by repeated references to them as a 
silicon or silicate esters.12 Omission of the “ester” and discussion of these 
compounds merely as “silicates” may induce confusion arising from the 
prevalence of silicate anions (SiO44-) in inorganic chemistry and geology. 
However, references to “silicates” throughout this thesis will always denote 
compounds of the general form Si(OR1)(OR2)(OR3)(OR4) rather than the anion 
SiO44-. 
2. Previous Work Utilizing Silicate Esters and Silyl Ethers in Biomaterials 
and Prodrugs. Prior to work performed in the labs of Prof. Thomas Hoye and 
???????????????????????????????????????? ????????????????????
11 Arkles, B. Silicon Esters. In Kirk-Othmer Encyclopedia of Chemical Technology, Fourth Edition, 
Volume 22; Kroschwitz, J. I.; Howe-Grant, M., ed. John Wiley & Sons, Inc: New York, 1997, 69–
81. 
12 Wright, J. R. Bolt, R. O.; Goldschmidt, A.; Abbott, A. D. Silicate Esters and Related 
Compounds. I. Synthesis of Certain Tetraalkoxysilanes, Polyalkoxysilanes, Bis-(trialkoxysilyl)-
alkanes, and Related Intermediates. J. Am. Chem. Soc. 1957, 80, 1733–1737. 
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Prof. Christopher Macosko,13,14 tetraalkoxysilanes attractively lack ample, direct 
precedent as prodrugs. This feature was viewed as the general innovative 
strategy described in Chapters 2 and 3 of this thesis. During the preparation of 
this manuscript, however, multiple reports of related research (i.e., studies using 
silicon-based derivatives of drugs) appeared in the literature. For instance, 
Cheng and co-workers published efforts toward trialkoxyalkylsilane drug 
derivatives to incorporate the drugs into well-defined silica-based nanoparticles.15 
Cheng’s general strategy employed derivatization of a drug molecule via a 
thioether ester linker to form either the trimethoxysilyl camptothecin (Figure 2-1, 
2.01) or trimethoxysilyl paclitaxel (Figure 2-1, 2.02).  Importantly, rather than 
using the trimethyl silicate ester as a promoiety, the trialkoxyalkylsilane merely 
“anchored” the drug derivative into nanoparticles comprised of bulk silica. While 
favorable biocompatibility and biodistribution studies of these compounds were 
reported, no biological efficacy data of 2.01 or 2.02 has yet been published. In 
the case of 2.02, efficacy of this drug may be diminished by the undesirably high 
in vivo stability of the thioether ester linker. Without additional data, this 
conclusion remains speculative; however, it is consistent with previously reported 
cytotoxicity data of other paclitaxel drug derivatives functionalized at the C2’ 
position.16 
 
 
???????????????????????????????????????? ????????????????????
13 Hoye, T. R.; Ji, S.; Miura, Y.; Zhu, Z.; Macosko, C. W. PCL-b-PEG Nanoparticles for Drug 
Delivery: Package and Contents. Presented at IPRIME annual meeting. Minneapolis, MN, May 
31, 2007. 
14 Wohl, A. R.; Hoye, T. R.; Zhu, Z.; Macosko, C. W. Orthosilicate Prodrug Models: Synthesis, 
Hydrolysis, and Encapsulation in Block Copolymer Nanoparticles. National Meeting of the AIChE, 
Nov. 2010.   
15 Tang, L.; Fan, T. M.; Borst, L. B.; Cheng, J. Synthesis and Biological Response of Size-
Specific, Monodisperse Drug-Silica Nanoconjugates. ACS Nano, 2012, 6, 3954–3966. 
16 Kingston, D. G. I.  The Shape of Things to Come: Structural and Synthetic Studies of Taxol and 
Related Compounds.  Phytochemistry 2007, 68, 1844–1854. 
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Figure 2-1. The structure of the thioether ester silicate drug derivatives (2.01 and 
2.02) as reported by Cheng.15 
 
 
Alternatively, silyl ethers have been used as hydrolytically degradable 
biomaterials by DeSimone and co-workers.17 Their relevant work produced a 
variety of biomaterials (e.g., drug delivery vehicles, stents, and sutures) based on 
dialkyldialkoxysilanes that were susceptible to degradation under acid catalysis. 
Additionally, the rate of degradation was modulated via the steric bulk of the 
dialkyl substituents (specifically, ethyl, i-propyl, and t-butyl substituents were 
examined) composing the silyl ether. Finally, in vitro assays established the 
nontoxic biological properties of the (presumably hydrolyzed) byproducts. This 
excellent work provides strong encouragement for the general silicate prodrug 
strategy and motivation to spur the development of tetraalkoxysilanes as 
prodrugs. 
During the preparation of this thesis, DeSimone and co-workers expanded 
upon their earlier report by publishing the use of dialkoxydialkysilanes as 
prodrugs of camptothecin (2.03a-c), dasatinib (2.04a-c), gemcitabine (2.05a-c).18 
???????????????????????????????????????? ????????????????????
17 Parrott, M. C.; Luft, J. C.; Byrne, J. D.; Fain, J. H.; Napier, M. E.; DeSimone, J. M. Tunable 
Bifunctional SIlyl Ether Cross-Linkers for the Design of Acid-Sensitive Biomaterials. J. Am. Chem. 
Soc. 2010, 132, 17928–17932.  
18 Parrott, M. C.; Finniss, M.; Luft, J. C.; Pandya, A.; Gullapalli, A.; Napier, M. E.; DeSimone, J. M. 
Incorporation and Controlled Release of Silyl Ether Prodrugs from PRINT Nanoparticles. J. Am. 
Chem. Soc. 2012, 134, 7978–7982. 
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This manuscript expanded upon their previous expertise in biomaterials by 
incorporating two biologically inert alkyl groups of varying steric bulk [ethyl (2.03-
2.05a), i-propyl (2.03-2.05b), t-butyl (2.03-2.05c)] and hydroxyl ethyl acrylate as 
the third non-drug substituent. Using the acrylate moiety, they cross-linked the 
prodrugs with a PEG-diacrylate [2.06, molecular weight (MW) = ca. 1000]. These 
large macromolecules were then formulated into nanoparticles. They further 
demonstrated that the hydrolysis and release of the free drug was time-
dependent and related to the steric bulk of the two alkyl moieties,18 analogous to 
their previous biomaterials work.17 
Figure 2-2. The structure of all reported dialkoxydialkyl silicate drug derivatives 
2.03a-c, 2.04a-c and 2.05a-c reported by DeSimone.18  
 
 
3. Established Orthosilicate Chemistry. Generally, silicate esters (and 
other organosilicon species19,20) have been widely studied for applications other 
than that of drug delivery.11 A number of variables (e.g., solvent-dependence, 
???????????????????????????????????????? ????????????????????
19 Bassindale, A. R.; Taylor, P. G. Reaction Mechanisms of Nucleophilic Attack at Silicon. In The 
Chemistry of Organic Silicon Comounds. Patai, S.; Rappoport, Z., eds. John Wiley & Sons, Inc: 
New York, 1989, 839–892 and references therein. 
20 Holmes, R. R. The Stereochemistry of Nucleophilic Substitution at Tetracoordinated Silicon. 
Chem. Rev. 1990, 90, 17–31 and references therein. 
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catalyst and reagent concentration, etc.) and their effects on both the acid- and 
base-catalyzed hydrolysis rate of tetramethyl (TMOS) and tetraethyl (TEOS) 
orthosilicates21  have been extensively studied. TMOS and TEOS were 
specifically chosen for these extensive, albeit typically dated, studies due to 
industrial applications in sol-gel forming processes. The techniques used to 
monitor the hydrolysis of these silicates include Karl-Fisher titrations,22 gas 
chromatography,23 Raman spectroscopy,24 and nuclear magnetic resonance 
(NMR) spectroscopy.25,26 The most relevant (to this thesis) conclusions resulting 
from the acid-catalyzed hydrolysis studies are that the hydrolysis occurs via i) an 
SN2 mechanism, ii) a solvent-dependent rate, and iii) pseudo-first order kinetics if 
a large excess of water is present.27 
Surprisingly, there is relatively little literature data in which the hydrolysis 
rate of a series of orthosilicates has been systematically and carefully studied 
under identical reaction conditions. Rather, qualitative inferences have often 
been drawn from the behavior of these labile compounds. For instance, gelation 
times (a proxy for hydrolysis) of tetramethyl, tetraethyl, and tetra-n-butyl 
orthosilicates were found to be approximately two days, 10 days, and 25 days, 
???????????????????????????????????????? ????????????????????
21 Aelion, R.; Loebel, A.; Eirich, F. Hydrolysis of Ethyl Silicate. J. Am. Chem. Soc. 1950. 69, 61–
75. 
22 Brinker, C. J. Hydrolysis and Condensation of Silicates: Effects on Structure. J.Non-Cryst. 
Solids 1988, 100, 31–50. 
23 Ro, J. C.; Chung, I. J. Sol-Gel Kinetics of Tetraethylorthosilicate (TEOS) in Acid Catalyst. J. 
Non-Cryst. Solids 1989, 110, 26–32.   
24 Zerda, T. W.; Hoang, G. Effects of Solvents on the Hydrolysis Reaction of Tetramethyl 
Orthosilicate. Chem. Mater. 1990, 2, 372–376. 
25 Turner, C. W.; Franklin, K. J. Studies of the Hydrolysis and Condensation of 
Tetraethylorthosilicate by Multinuclear (1H 17O 29Si) NMR Spectroscopy. J. Non-Cryst. Solids 
1986, 91, 402–415. 
26 Assink, R. A.; Kay, B. D.; Study of Sol-Gel Chemical Reaction Kinetics by NMR. Annu. Rev. 
Mater. Sci. 1991, 21, 491–513. 
27 Zerda, T. W.; Hoang, G. Effects of Solvents on the Hydrolysis Reaction of Tetramethyl 
Orthosilicate. Chem. Mater. 1990, 2, 372–376. 
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respectively, when the compounds were stored without “special precautions.”11 
While not ultimately satisfying or precisely informative, early observations such 
as these gave an indication of the subtle steric alterations that influence the rate 
of hydrolysis of silicate esters. 
The most pertinent set of experiments that attempted to quantify the 
absolute hydrolysis rates of several silicate esters involved four different 
compounds; all symmetrical tetraalkoxysilanes (see Table 2-1). These 
experiments demonstrated an approximately six-fold slower hydrolysis rate with 
increasing aliphatic chain length (from ethyl to n-hexyl) and an approximately 17-
fold slower hydrolysis rate with a branched side chain.22 Unfortunately, these 
studies are compromised by the selected analytical method. The Karl Fisher 
titration was used determine the change in water concentration during the 
reaction, but, since the Karl Fisher reagents are now known to consume both 
water and silanols, the measured rate constants are considered unreliable.28 
These studies provide a degree of precedence regarding the steric dependence 
of the rate of hydrolysis, but, more precise quantitative measurements of these 
trends is required to harness orthosilicate esters for novel applications.  
 
 
 
 
 
 
 
???????????????????????????????????????? ????????????????????
28 Brinker, C. J.; Scherer, G. W. Hydrolysis and Condensation II: Silicates. In Sol-Gel Science: 
The Physics and Chemistry of Sol-Gel Processing. Academic Press, Inc: San Diego, CA, 1990, 
97–233. 
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Table 2-1. Acid-catalyzed hydrolysis rates, as analyzed by Karl Fisher titrations,22 
of four symmetrical silicate esters. 
 Si(OR)4  k (102) a  
 R =   (mol-1 s-1 [H+]-1) 
    
 Ethyl  5.1   
 n-Butyl  1.9  
 n-Hexyl  0.83   
 2,3-Dimethylbutyl  0.30  
  a Conducted at 20 °C. 
 
 
2.  Methodology Development. 
1. Considerations and Early Attempts. As is the case in many 
experimental designs, establishing experimental methodology that is capable of 
differentiating the possible outcomes with confidence is critical. Thus, the first 
step necessary toward determining the potential of silicate ester prodrugs is to 
demonstrate that a reliable and accurate measurement of the hydrolysis rate 
could be achieved. It is important to emphasize at this point that the aim in these 
studies is to establish relative hydrolysis rate trends via observed hydrolysis rates 
(kobs) rather than the absolute hydrolysis rate constants (k). This goal is guided 
by both the ease of experimentation (e.g., precise control of temperature within 
the Varian 500 MHz NMR spectrometer at the University of Minnesota is not 
trivial) and consideration of the final application (i.e., hydrolysis within a 
preformed nanoparticle) of the silicate ester hydrolysis. Namely, it is difficult to 
identify, much less control, the actual microenvironment [e.g., water content, 
Chapter 2 Model Silicate Ester Prodrugs? 
?
???
?
solvent diffusion rates, effective pH, and physical state (crystalline vs. 
amorphous) of the silicate ester] within a nanoparticle core. Thus, the model 
hydrolysis rate trends are needed to guide optimization of the prodrug design 
based primarily upon empirical observations of the prodrug hydrolysis and/or 
drug release rates.  
Dr. Yutaka Miura, a post-doctoral associate in the Hoye labs, conducted 
the initial attempts to monitor orthosilicate hydrolysis reactions. He first attempted 
to employ gas chromatography-mass spectrometry (GC-MS), but this technique 
yielded irreproducible results.29 Employing 29Si NMR experiments was found to 
be impractical due to problems arising from low sensitivity, and the lengthy 29Si 
NMR experiments that were required to collect the data with sufficient signal-to-
noise ratios proved unduly time-consuming and expensive.29  
2. In situ 1H NMR Spectroscopic Measurements. The more sensitive 1H 
NMR spectroscopy was considered as a viable alternative. Previous work 
utilizing 1H NMR spectroscopy to measure kinetic rates has been successful. 
This tactic is particularly highlighted by the careful and detailed efforts of Raines 
and co-workers to establish the pD (since the experiments were performed in a 
deuterated environment, pD is analogous to the more commonly encountered pH 
values) dependency of hydrazone hydrolysis rates.30 Proton NMR spectroscopy 
has also been applied to study hydrolysis intermediates of orthosilicates. 
However, these experiments employed substoichiometric levels of water, 
complicating analysis of the hydrolysis rate since pseudo-first order kinetics could 
not be assumed and the hydrolysis was not exhaustive.26 Thus, further studies 
were initiated to develop a technique reliant upon 1H NMR spectroscopy to 
???????????????????????????????????????? ????????????????????
29 Miura, Y. University of Minnesota, Minneapolis, MN. Personal communication, 2008. 
30 Kalia, J.; Raines, R. T. Hydrolytic Stability of Hydrazones and Oximes. Angew. Chem. Int. Ed. 
2008, 47, 7523–7526. 
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quickly, conveniently, and accurately establish the relative hydrolysis rate trends 
for a series of silicate esters of varying steric and electronic character. 
Initially a variety of reactive environments were screened to benchmark 
standard conditions that would allow: i) solubility of a majority of the silicate ester 
models and prodrugs, ii) fast yet measurable hydrolysis rates, and iii) a sufficient 
excess of water to allow pseudo first-order kinetics to be accurately assumed. A 
series of experiments were conducted by catalyzing the hydrolysis of TEOS with 
acetic acid [1 volume percent (vol%)] in a mixture of deuterated water and 
deuterated acetone. In these early experiments, the ratio of the deuterated 
water/acetone co-solvents was systematically varied. The vol% of water ranged 
from 90-10% (with deuterated acetone used as the organic solvent in the amount 
necessary to “balance” the water level). The co-solvent composition 
corresponded to variations in the observed rate of greater than four orders of 
magnitude (see Table 2-2). This change in rate represents half-lives ranging from 
less than two minutes (90 vol% water) to much greater than two weeks (10 vol% 
water). This correlation of a progressive decrease in the hydrolysis rate that 
corresponds to increasing acetone content is in agreement with the increased 
rates previously observed in more polar media. 22,27  
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Table 2-2. Acetic acid-catalyzed observed hydrolysis rates of TEOS in co-solvent 
mixtures containing varying volumes of water.  
 Entry D2O d6-acetone acetic acid t1/2a  
 # (vol)% (vol)% (vol)% (observed, min) 
 
 1 b 10 89 1 > 25000   
 2 50 49 1 55  
 3 70 29 1 7.4   
 4 90 9 1 0.86  
  a Error bars are not provided because less than three measurements were 
taken. The values provided here are thus intended as approximations only. 
  b Measurement taken by Dr. Yutaka Miura.29 
 
3. Establishment of “Standard” Hydrolysis Conditions and Reproducibility 
of the 1H NMR Measurements. Settling upon a set of “standard hydrolysis 
conditions” took into account multiple factors. First, many of the envisioned 
silicate ester models and prodrugs are, by design, highly hydrophobic. Therefore, 
the water content was minimized (to 10 vol%) to allow dissolution of a majority of 
the silicate models and prodrugs. By default, a large volume of d6-acetone was 
then required. A stronger acid catalyst [trifluoroacetic acid (TFA)] was included to 
illicit observed hydrolysis rates on a reasonable time scale.  
Thus, after varying the solvent composition, acid strength, and amount of 
acid catalyst, we settled upon a solvent mixture composed of 90 vol% d6-
acetone, 9 vol% D2O, and 1 vol% TFA. Data obtained from this system is used to 
report the measured kobs and t1/2 values analyzed under the assumption of 
pseudo-first order kinetics. For convenience, the measured krel values in this 
section are referenced to the thoroughly studied and readily available TEOS 
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(2.07). The hydrolysis of 2.07 was analyzed to define the reproducibility of this 
new 1H NMR methodology and “standard” hydrolysis conditions. The results and 
inferred reproducibility of a series of five sequential hydrolysis experiments 
(Scheme 2-1) of 2.07 to orthosilicic acid (2.08) and four equivalents of ethanol 
are shown in Table 2-3.  
Scheme 2-1. The defined “standard hydrolysis conditions” were used to measure 
the observed hydrolysis rate of 2.07, yielding orthosilicic acid 2.08 and ethanol. 
 
 
Table 2-3. The reproducibility of the in situ 1H NMR hydrolysis rate measurement 
of 2.07 was found to be reliable.  
 Entry a t1/2 (min) kobs (10-3 s-1)  
       
 1 3.3 3.5   
 2 3.0 3.8  
 3 3.0 3.9   
 4 3.2  3.6  
 5 3.1 3.7   
  a The trials were run sequentially and analyzed immediately thereafter. 
Experimentation and analysis were completed in less than two total hours 
for the five trials. 
 
In this study, the variation in the observed hydrolysis rate was confirmed 
to be approximately ± 5% from the mean value. Further appealing, this technique 
allows for the rapid accumulation of data – all five trials reported in Table 2-3 
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were completed in less than two hours. Based upon these results, this 
methodology was deemed to be fast, convenient, and reproducible; therefore, it 
was used in the future hydrolysis experiments unless otherwise noted.  
  
3.  Hydrolysis Rates of Symmetrical Tetraalkoxy Silicates. 
1. Controlling the Hydrophobicity. With the basic 1H NMR methodology 
established, the opportunity to determine the degree of dependency between the 
hydrophobic character and the hydrolysis rate of the silicate esters was available.  
This distinction is one key to the eventual application of silicate esters to a 
prodrug strategy. The ability to significantly alter physical properties (e.g., 
hydrophobic character) and chemical properties (e.g., rate of hydrolysis) is a 
potential, significant advantage of the concept. 
Toward this goal, a series of easily obtained, linear, aliphatic, and 
symmetrical orthosilicate models was examined. The most common of these 
models [i.e., 2.07 and TMOS (2.09)] are readily available from a variety of 
commercial sources. Other compounds (those with non-obvious commercial 
applications) such as tetra-n-butyl, tetra-n-hexyl, tetra-n-octyl, and tetraphytyl 
orthosilicates (2.11,31 2.12,31,32 2.13,32 and 2.14,33 respectively) were 
conveniently prepared via procedures related to those reported in the literature. 
In a routine experiment, a symmetrical tetraalkoxysilane was prepared by treating 
silicon tetrachloride (SiCl4, 2.10) with an excess of the desired alcohol (and often 
co-dissolved with an amine base) in a hydrocarbon or ethereal solvent (c.f., 
???????????????????????????????????????? ????????????????????
31 Ridge, D.; Todd, M. Studies in the Formation Mechanisms of Alkyl Orthosilicates. J. Chem. 
Soc. 1949, 2637–2640. 
32 Gerrard, W.; Woodhead, A. H. Interaction of Alcohols with Silicon Tetrachloride. J. Chem. Soc. 
1951, 519–522. 
33 Key resonances observed in crude 1H NMR (500 MHz, CDCl3): δ = 5.37 [br t, J = 6 Hz, 4H, 
Si(OCH2CH)4] and 4.31 [overlapping d’s, 8H, Si(OCH2CH)4, observed as a mixture cis and trans 
isomers]. 
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Scheme 2-2). As expected, these reactions proceed cleanly to yield the desired, 
symmetrical orthosilicates of varying hydrophobicities that can be purified via 
distillation or silica chromatography.  
Scheme 2-2. The general synthetic routes utilized to access linear 
tetraalkoxysilane models. 
 
 
Applying our previously optimized hydrolysis conditions (see Section 
2.2.3), the kobs for models 2.07, 2.09, and 2.11-2.13 was observed to decrease 
only slightly with longer (and subtly more sterically encumbered) hydrocarbon 
chains (Table 2-4, below in section 2.3.2). TMOS (2.09) was found to hydrolyze 
too rapidly (t1/2 < 1.5 min) under the described conditions to be measured 
accurately.29 However, analysis of the kobs values for the remaining models 2.07 
and 2.11-2.13 shows incrementally smaller changes as two additional methylene 
units were systematically added to the linear hydrocarbon backbone (see Table 
2-4). In other words, the data suggests an approaching “plateau effect” of the 
observed hydrolysis rate as the length of the aliphatic chains progressively 
increases, consistent with minimal variation of the steric environment at the 
central silicon atom. The acquisition of data is eventually limited by the solubility 
of the silicate esters. For instance, attempts to observe the hydrolysis of 2.14 
failed due to the compound’s insolubility (even in solvent mixtures containing as 
little as 1 vol% water). 
Both chemical intuition and qualitative observations confirm the vast 
difference in hydrophobicity of the models. For example, 2.07 is a water-soluble 
Chapter 2 Model Silicate Ester Prodrugs? 
?
???
?
compound while 2.13 is minimally soluble in co-solvent mixtures of acetone:water 
(10:1 , v/v). On the other hand, quantification34 of such values [the log partition 
coefficient (log P) value] is often not rigorously established. Instead, such values 
are commonly approximated via computation of the calculated log partition 
coefficient (clog P) by one of a myriad of different software tools. One option that 
has been used in pharmaceutics35,36 is the ALOGPS 2.1 program.37 Using this 
free online software,38 clog P values of 2.07 and 2.13 were calculated to be 2.67 
and 9.85, respectively – thereby suggesting a difference of greater than seven 
orders of magnitude in their respective solubilities. It is important to note that 
these numbers are not meant to be taken as precise measurements; rather, they 
are reported here simply to confirm that the hydrophobicity of these compounds 
differ by several orders of magnitude whereas their relative rates of hydrolysis 
differ by less than a factor of 10. Overall, the described models support the ability 
to make significant changes in the hydrophobicity of the silicate prodrugs while 
minimally altering their hydrolysis rate. 
2. Slowing the Hydrolysis Rate: Branched Tetraalkoxy Silicates. With 
preliminary evidence of our ability to control hydrophobicity in hand attention 
turned to the ability to control the hydrolysis rate. The most obvious solution to 
???????????????????????????????????????? ????????????????????
34 Experiment quantification of these differences is historically performed by measuring the 
equilibrium solubility of a compound in a mixture of water and n-octanol and applying the 
measured concentrations to equation the following equation: log P = [soluteoctanol]/[solutewater]. A 
larger log P (or clog P) value is indicative of a more hydrophobic compound. For a 
comprehensive review of the history and theory, see: Leo, A.; Hansch, C.; Elkins, D. Partition 
Coefficients and Their Uses. Chem. Rev. 1971, 71, 525–616 and references cited therein. 
35 Tetko, I. V.; Poda, G. I. Application of ALOGPS 2.1 to Predict log D Distribution Coefficient for 
Pfizer Proprietary Compounds. J. Med. Chem. 2004, 47, 5601–5604 
36 Tetko, I. V.; Bruneau, P. Application of ALOGPS to Predict 1-Octanol/Water Distribution 
Coefficients, logP, and logD, of AstraZeneca In-House Database. J. Pharm. Sci. 2004, 93, 3103–
10. 
37 Tetko, I. V., Tanchuk, V. Y. Application of Associative Neural Networks for Prediction of 
Lipophilicity in ALOGPS 2.1 Program. J. Chem. Inf. Comput. Sci. 2002, 42, 1136–1145. 
38 http://www.vcclab.org/lab/alogps/ accessed June 19, 2012. 
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slow the rate of hydrolysis of the silicate models was to simply increase the steric 
bulk of the substituents at the central silicon atom.39,40 Predictably, hydrolysis of 
the commercially purchased tetra-i-propyl orthosilicate (TIPOS, 2.15) resulted in 
a significantly slower rate than was observed with the linear silicates (ca. 20-fold 
slower as compared to 2.07) – a value consistent with (but not identical to) those 
previously reported for alpha-branched tetraalkoxysilanes.22 
Further attempts to analyze the hydrolysis of yet more sterically hindered, 
symmetrical compounds such as a tetramenthoxy orthosilicate (2.17)41 or a tetra-
t-butyl orthosilicate (2.18) failed. Model 2.17 was successfully synthesized from 
menthol (2.16) and SiCl4 (Scheme 2-3) and purified, but 2.17 was found to be 
insoluble in a D2O:d6-acetone (1:10, v/v) solution, thus preventing analysis of its 
kobs. 2.18 is not readily available from commercial sources, and its synthesis is 
known to result in incomplete substitution of the tert-butanol unless silicon 
fluorides are used, preventing convenient access to the model compound.42,43  
 
 
 
 
 
???????????????????????????????????????? ????????????????????
39 Clausen, R. P.; Bols, M. The First Tri- and Tetraalkoxysilanes with Four Different Substituents. 
J. Org. Chem. 1997, 62, 4457–4464. 
40 Pedlow, G. W., Jr.; Miner, C. S., Jr. Organic Orthosilicates Stable Against Hydrolysis. U.S. 
Patent 2,566,365, June 15, 1946. 
41 Beckmann, J.; Dakternieks, D.; Tiekink, E. R. T. Chiral Trialkoxysilanols Derived from Terpene 
Alchols. Molecular Structures of Tris([(1S)-endo-]-( – )-bornoxy)silanols and tetrakis(( – )-
menthoxy)silane. J. Organomet. Chem. 2002, 648, 188–192. 
42 Miner, C. S., Jr.; Bryan, L. A.; Holysz, R. P.; Pedlow, G. W., Jr. Ind. Eng. Chem. Tert-
Alkoxyaminosilanes. 1947, 39, 1368. 
43 Hyde, J. F.; Curry, J. W. The Preparation of Tetra-i-butoxysilane and Tri-t-butoxyfluorosilane. J. 
Am. Chem. Soc. 1955, 77, 3140–3141. 
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Scheme 2-3. The synthetic efforts toward highly sterically hindered 
tetraalkoxysilane models 2.17 and 2.18. 
 
 
 All hydrolysis results for the symmetrical tetraalkoxy silicate ester models 
are summarized in Table 2-4.  
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Table 2-4. The observed kinetic data for symmetrical, tetraalkoxysilanes with krel 
referenced to TEOS as krel = 1.   
 Model R t1/2 (min) kobs (10-3 s-1) krel a  
     
 2.09 Methyl - > 10 >2  
 2.07 Ethyl 3.1 ± 0.1 3.7 ± 0.2 1.0 ± 0.05 
 2.11 n-Butyl 12 ± 1 0.94 ± 0.07 0.25 ± 0.02  
 2.12 n-Hexyl 17 ± 1  0.69 ± 0.02 0.19 ± 0.01 
 2.13 n-Octyl 21 ± 1 0.55 ± 0.02 0.15 ± 0.01  
 2.14 b Phytyl n.d. c n.d. n.d.   
 2.15 i-Propyl 81 ± 2 0.15 ± 0.01 0.039 ± 0.002  
 2.17 b Menthyl n.d. n.d. n.d.  
 2.18 d t-Butyl n.d. n.d. n.d.  
 a krel = 1.0 for 2.07, hydrolyzed in the 1:10 D2O:d6-acetone solution with 1 
vol% TFA. 
 b The compound was insoluble in the 1:10 D2O:d6-acetone solution.  
 c n.d. = not determined  
 d The synthesis was not readily attainable.  
 
3. Rate Determining Step of the Hydrolytic Cleavage. Throughout these 
beginning studies, the observed hydrolysis rate was determined by comparative 
integration of 1H NMR spectra during the in situ hydrolysis of the silicate models. 
This data was also utilized to provide insight to identify the rate determining step 
of the hydrolysis. Figure 2-3 provides representative 1H NMR spectra taken 
during the hydrolysis of 2.15 to isopropanol 2.16 (Scheme 2-4) Resonances 
assigned to the diminishing orthosilicate methine (downfield, ?) and incoming i-
propanol (2.20) methine (upfield, ?) are obvious in Figure 2-3. it is equally 
important to note, however, the absence of any spectroscopically observed 
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intermediates (i.e., 2.19). While intermediates of the form of 2.19 are undoubtedly 
formed in situ, the spectroscopic evidence verifies that they are rapidly 
consumed at a rate significantly faster than that of the starting material.  
This key observation identifies the initial hydrolysis event as the slow, rate-
limiting step. Thus, the four sequential hydrolysis steps may be considered as a 
“chink in the armor” scenario. In other words, the initial hydrolysis event 
drastically reduces the steric hindrance at the silicon atom, allowing the 
subsequent hydrolytic cleavages to proceed at an immeasurably fast rate under 
the described conditions. Importantly, this leads to a rational hypothesis for the 
development of more rapidly hydrolyzed prodrugs beyond simple sterics. 
Specifically, inclusion of a single, rapidly hydrolyzed substituent to a prodrug may 
potentially yield a clean yet more rapidly hydrolysable moiety while still allowing 
for control of the hydrophobic character (c.f., section 2.4.4 and 3.3.8).  
Scheme 2-4. Hydrolysis of 2.15 and the structure of its presumably formed but 
unobserved (via spectroscopic analysis) intermediate(s) 2.19. 
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Figure 2-3. Selected, representative 1H NMR spectra taken during the hydrolysis 
of 2.15 (?) to 2.20 (?). The displayed spectra are at (a) 0.2 half-lives (black, 
top), (b) 1.0 half-lives (blue, middle), and (c) 2.0 half-lives (red, bottom). For 
clarity, the black and blue spectra are offset from the scale by ca. 0.2 and 0.1 
parts per million (ppm), respectively.     
 
 
4. Symmetrical Tetraaryl Orthosilicates. In addition to the described 
tetraalkoxysilane models, tetraarylsilanes were also briefly explored with Dr. 
Yutaka Miura. His successful synthesis of the tetracresoxy silicate ester 2.2344 
and tetra-2,4,6-trimethylphenoxy silicate ester 2.2445 (from their 2.21 and 2.22, 
respectively, see Scheme 2-5)29 led to hydrolysis studies of these compounds. 
???????????????????????????????????????? ????????????????????
44 Original synthesis performed by Dr. Yutaka Miura. 1H NMR (500 MHz, CDCl3): 7.01 (d, J = 7.0 
Hz, 8H, Ar-H), 6.89 (d, J = 7.0 Hz, 8H, Ar-H), and 2.27 (s, 12H, p-CH3). 13C NMR (125 MHz, 
CDCl3): δ = 150.6, 132.3, 130.2, 119.4, and 20.8. 
45 Original synthesis performed by Dr. Yutaka Miura. 1H NMR (500 MHz, CDCl3): δ = 6.76 (s, 8H, 
Ar-H), 2.18 (s, 12H, p-CH3), and 2.16 (s, 24H, o-CH3). 13C NMR (125 MHz, CDCl3): δ = 148.4, 
131.9, 129.4, 128.4, 20.7, and 17.2. 
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Again, the increased steric bulk of 2.24 relative to 2.23 slowed the observed 
hydrolysis rate. Surprisingly, Dr. Miura reported a minimal difference in the 
measured kobs when comparing the mild acetic acid catalyst with TFA.29 This is in 
contrast to model compound 2.24 and, even more starkly, control experiments 
performed with 2.07 (c.f., section 2.2.3) that noted significantly different kobs 
values based on acid strength. These experiments advance a strategy for the 
synthesis of more rapidly hydrolyzing orthosilicates. Namely, the inclusion of 
substituents that are better leaving groups (in this case, a phenoxy-like 
compound) may induce a more rapid initial hydrolytic cleavage as the rate-
determining first step in the overall hydrolysis. 
Scheme 2-5. The synthesis and hydrolysis of tetraaryl orthosilicate models 2.23 
and 2.24. 
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Table 2-5. The observed hydrolysis rate data for tetraaryl orthosilicate models.a  
 Model Acid t1/2 (min) b kobs (10-3 s-1) b 
     
 2.07 TFA 3.1 ± 0.1 3.7 ± 0.2  
 2.07 AcOD >24000 --  
   2.23 c TFA 6.0 1.9  
   2.23 c AcOD 10  1.2  
 2.24 TFA 64 0.18  
 2.24 AcOD 1300 0.0010  
 a Entries in italics and gray are reproduced from Table 2-2 for convenience. 
 b kobs and t1/2 values were not run in triplicate and thus error bars are not 
included. 
 c Hydrolysis experiments performed by Dr. Yutaka Miura.29  
 
 
4.  Observed Hydrolysis Rates of Unsymmetrical, Tetraalkoxy Silicate 
Esters. 
1. Mixed Menthoxy Trialkoxy Silicate Esters. After completing our initial 
studies, more advanced, mixed model systems were considered to model a 
silicate ester containing a drug moiety. Considerably fewer examples of such 
unsymmetrical compounds [e.g., Si(OR1)3(OR2)] exist vis-à-vis the number of 
reports of symmetrical orthosilicates [e.g., Si(OR1)4]. Yet fewer of these 
unsymmetrical silicate ester compounds describe product purification via a 
methodology other than distillation39 – a requirement for the successful 
implementation of silicate prodrugs. Therefore, further expansion of the model 
systems was needed to explore both potential purification strategies and study 
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the degree to which the relative hydrolysis rates could be controlled by the 
sacrificial alkoxy substituents. Thus, incorporation of menthol (2.16) as an alkoxy, 
drug-like substituent along with three alkoxy substituents was employed to 
generate a suite of models (2.25-2.28) with varying aliphatic character and steric 
bulk. These compounds are easily synthesized by silylation with a 
trialkoxychlorosilane and purified by standard silica chromatography via medium 
pressure liquid chromatography (MPLC). The pure compounds were then 
subjected to the aforementioned hydrolysis conditions (see Scheme 2-6). 
Scheme 2-6. The synthesis of a suite of menthol-containing silicate esters 2.25-
2.28 and hydrolysis of these menthoxytrialkoxy silicate ester models. 
 
 
We observed that the previously established trends defined in the 
symmetrical models 2.07, 2.11-2.13 were generally reproduced.  Nonetheless, 
the absolute rate of hydrolysis was slower, likely owing to the increased steric 
bulk originating from the inclusion of the menthoxy substituent. Again, these 
model systems are designed to deduce the trends of the hydrolysis rates, and so 
such differentiation in the absolute rate is not critical.  
The trends in these new menthol-containing models are more instructive 
and detailed in Table 2-6. Specifically, the menthoxytriethoxy silicate ester 2.25 
was found to hydrolyze more than five times slower than the tetraethoxysilane 
2.07. Conversely, the menthoxytri-i-propoxy silicate 2.25 hydrolyzed only three 
times more slowly than the TIPOS 2.12. This likely reflects the similarity in the 
steric nature of the i-propoxy and menthoxy substituents. (i.e., the sterics of an i-
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propoxy substituent is more similar to menthol than is an ethoxy substituent). 
Nonetheless, these menthol-based models demonstrate a consistently 
decreasing hydrolysis rate similar to those observed in the symmetrical 
orthosilicate models. The similarity of the trends is more pronounced when 
models 2.25-2.28 are referenced (krel’) to 2.25 rather than 2.07 (Table 2-6). In the 
case when the menthoxy silicate esters are compared to a more relevant “parent” 
compound, the trends yet more closely resemble those reported earlier in Table 
2-4. 
Table 2-6. The observed hydrolysis rates and half-lives for 
menthoxytrialkoxysilane models 2.25-2.28.a  
Prodrug R t1/2 (min) kobs (10-3 s-1) krel b krel’ c 
     
 2.07 Ethyl 3.1 ± 0.1 3.7 ± 0.2 1.0 ± 0.05 N/A 
 2.22 Ethyl 17 ± 1 0.67 ± 0.04 0.18 ± 0.01 1.0 ± 0.06 
 2.23 n-Butyl 49 ± 2  0.24 ± 0.01 0.065 ± 0.003 0.36 ± 0.02 
 2.24 n-Octyl 79 ± 5 0.15 ± 0.01 0.040 ± 0.003 0.22 ± 0.01 
 2.25 i-Propyl 210 ± 10 0.056 ± 0.01 0.015 ± 0.001 0.084 ± 0.004 
 a Entries in italics and gray are reproduced from Table 2-4 for convenience. 
 b krel values are referenced to compound 2.07, krel = 1.0. 
 c krel’ values are referenced to compound 2.25 , krel’ = 1.0. 
 
2. A Mixed Triethyl Cresol Orthosilicate. In addition to the mixed alkoxy 
silicate models 2.25-2.28, a mixed cresol triethyl silicate ester 2.30 was 
synthesized from cresol 2.29 (see Scheme 2-7). Interest in this compound was 
motivated by the unusually fast reported rate of hydrolysis during catalysis by a 
weak acid of 2.23.29 Comparing the hydrolysis of 2.30 when catalyzed by acetic 
acid vis-à-vis TFA again showed a pronounced difference in the observed rates. 
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Interestingly, the absolute magnitude of these rates were found to be of an 
intermediate value between the rates observed in TEOS 2.07 and the 
tetracresoxy silicate ester 2.23 (Table 2-7). This result is suggestive of a silicate 
ester that exhibits an intermediate number of more labile substituents. 
Scheme 2-7. The synthesis of a cresol-containing silicate ester (2.30) and its 
subsequent hydrolysis. 
 
 
Table 2-7. Comparison of the observed hydrolysis rate data for 2.30 with TEOS 
2.07 and tetraaryloxysilane 2.23.a  
Prodrug Acid t1/2 (min) b kobs (10-3 s-1) b 
     
 2.07 TFA 3.1 ± 0.1 3.7 ± 0.2  
 2.07 AcOD >24000 --  
 2.23 c TFA 6.0 1.9  
 2.23 c AcOD 10  1.2  
 2.26 TFA 9.1 1.3  
 2.26 AcOD 7100 0.0016  
 a Entries in italics and gray are reproduced from Table 2-4 and 2-6 for 
convenience. 
 b krel and t1/2 values were not run in triplicate and thus error bars are not 
included. 
 c Hydrolysis experiments performed by Dr. Yutaka Miura.29  
 
Chapter 2 Model Silicate Ester Prodrugs? 
?
???
?
3. Steroid-Containing Silicate Esters. While estradiol (2.31) and 
hydrocortisone (2.33) are not targeted as final prodrug candidates, these two 
steroidal compounds served as yet more complex and instructive model systems 
in the development of the silicate ester prodrugs. The trivial silylation of 2.31 with 
triethoxychlorosilane (Scheme 2-8) yields the bis-triethoxy silicate ester prodrug 
of estradiol (2.32). Similar treatment of 2.33 exclusively gives the mono-triethoxy 
silicate prodrug of hydrocortisone (2.34). Notably, even in the presence of up to 
four equivalents of both the trialkoxychlorosilane and amine base, silylation was 
not observed at the C11 or C17 hydroxyl. Presumably the increased steric bulk of 
the hydroxyl groups at these positions severely retards the rate of substitution.  
Scheme 2-8. The application of the silicate ester prodrug strategy to synthesize 
estradiol and hydrocortisone silicate ester prodrugs. 
 
 
Steroid models 2.32 and 2.34-2.36 present an opportunity to address an 
outstanding question: will the three sacrificial alkoxy substituents dictate the rate 
of hydrolysis in different steric and electronic environments? Three different 
environments are tested in these steroids: an electron-rich aryl hydroxyl (C3 in 
2.32), a sterically hindered, neo-pentyl hydroxyl (C17 in 2.32), and a sterically 
accessible hydroxyl (C21 in 2.34-2.36).  
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Gratifyingly, the local environment of the silicate ester was found to play 
only a minor (yet observable) role in the hydrolysis rate [catalyzed by TFA in a 
co-solvent mixture of 10:1 d6-acetone:D2O (v/v) — the “standard hydrolysis” 
conditions]. Despite the vastly different steric and electronic environments of the 
prodrug silicates, the observed relative hydrolysis rate varied by less than one 
order of magnitude from the TEOS model 2.07 (Table 2-8). Specifically, the C17 
silicate ester of 2.32 varied by a factor of only four from the TEOS model, despite 
extreme differences in the steric nature of the fourth substituent – a neo-pentyl 
hydroxyl in 2.32 vs. an ethoxy in TEOS. Yet more encouraging, the observed 
hydrolysis rates of 2.32 and the triethoxy cresoxy silicate ester model 2.30 were 
found to be the same within error. Thus, the dominant influence on the observed 
hydrolysis rate was the three sacrificial ethoxy groups rather than the single drug-
like substrate, and the estradiol silicate prodrug model 2.32 hydrolyzed at rates 
consistent with previous model systems.  
A small series of hydrocortisone silicates of varying aliphatic character 
were also analyzed. Comparing the hydrolysis rate of the triethoxy 
hydrocortisone silicate ester (2.34) to model compound 2.07 (both silicate esters 
contained four linear, alkoxy substituents), the observed hydrolysis rates were 
found to be the same within error (Table 2-8). This further validation of the model 
system strategy was found to be particularly encouraging – the extensive amount 
of experimental effort that comprises sections 2.2 and 2.3 was not wasted!  
Linear hydrocortisone analogs of the tri-n-butoxy (2.35) and tri-n-octyloxy 
(2.36) silicate esters were also synthesized and hydrolyzed. As observed in the 
symmetrical silicate ester models, the change in the observed hydrolysis rate 
was less than one order of magnitude among hydrocortisone prodrugs 2.34-2.36 
despite drastically different hydrophobicities. Although the trends do not match 
precisely to the symmetrical silicate models, this is in fact encouraging – even 
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less variation was observed in the kobs of between the extremes of the 
hydrophobic character in the hydrocortisone prodrugs (2.34 and 2.36).  
Table 2-8. The observed hydrolysis rate data for the estradiol orthosilicate 2.32 
and the hydrocortisone orthosilicates 2.34-2.36. a   
 Prodrug t1/2 (min) kobs (10-3 s-1) krel  
    
 2.07 3.1 ± 0.1 3.7 ± 0.2 1.0 ± 0.05 
 2.32 (C3) 9.5 ± 0.5 1.3 ± 0.1 0.35 ± 0.02  
 2.32 (C17) 14 ± 1  0.92 ± 0.04 0.25 ± 0.02 
 2.34 3.4 ± 0.1 3.4 ± 0.1 0.92 ± 0.03  
 2.35 b 5.0 2.3 0.62  
 2.36 b 7.8 0.15 0.40  
 a Entries in italics and gray are reproduced from Table 2-4 for convenience. 
 b krel and t1/2 values were not run in triplicate and thus error bars are not 
included. 
 
4. Controlling the Hydrolysis Rate: Acyloxy Silicate Esters. At this point, 
two of the basic tenets of the novel silicate ester prodrug strategy were on solid 
experimental ground. Our ability to control the hydrophobic character of the 
silicate esters largely independent of the hydrolysis rate and the ability to control 
the rate of hydrolysis through the three sacrificial alkoxy groups had been 
established. Efforts therefore turned toward the identification of prodrugs with an 
increasingly fast hydrolysis rate. Previous studies were conducted by Dr. Yutaka 
Miura. He developed a series of silanes of progressively minimized steric bulk by 
synthesizing mixed species 2.37-2.41 (Figure 2-4). He confirmed the expected 
outcome: namely, the inclusion of progressively less bulky alky and/or hydro 
substituent(s) sped the rate of hydrolysis.13  
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Figure 2-4. The hydrolysis rate trend of menthoxy-based silanes 2.37-2.41 of 
varying steric bulk as established by Dr. Yutaka Miura. 13,29  
 
 
However, the biocompatibility of the byproducts of hydrolysis [e.g., 
Si(OH)4-n(R)n, where R=alkyl] was doubtful. This, in turn, led to concerns 
regarding prodrug approval by the FDA in the final drug delivery application. 
These concerns centered largely on the established toxicity of silanes (especially 
when inhaled)46 and the unknown biological consequences arising from the ease 
of oxidation of such silanes and silanols in the presence of water.47  
Hesitant to incorporate a potentially insurmountable barrier into the drug 
delivery strategy, a strategy to speed the hydrolysis of silicate prodrugs would 
necessitate looking beyond simple steric effects. Building on our previous work 
(see section 2.3.3) that established the rate-limiting step of the silicate ester 
hydrolysis as the first Si-O bond cleavage, we hypothesized that incorporation of 
a single, labile substituent would lead to a more rapid, complete hydrolysis. It is 
established in the case of mixed organosilicon substrates that better leaving 
groups would lead to more rapid hydrolysis that is, in our case, desirable.48 
However, incorporation of better leaving groups is a “double-edged sword.” 
???????????????????????????????????????? ????????????????????
46 Takebayashi, T. Acute Inhilation Toxicity of High Concentrations of Silane in Male ICR Mice. 
Arch. Toxicol. 1993, 67, 55–60. 
47 Anglin, E. J.; Cheng, L.; Freeman, W. R.; Sailor, M. J. Porous Silicon in Drug Delivery Devices 
and Materials. Adv. Drug Deliver. Rev. 2008, 60, 1266–1277. 
48 Corriu, R. J. P.; Henner, B. J. L. Mechanism of Nucleophilic Substitution at Silicon: Kinetic 
Evidence on the Slow Formation of a Penta-Coordinate Silicon Intermediate. J. Organomet. 
Chem. 1975, 102, 407–416. 
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These faster-hydrolyzing prodrugs may be exceptionally sensitive to purification 
via MPLC silica chromatography and significantly more difficult to isolate.  
Reports of tetraacetoxy49 and mixed acyloxy silicates50 (and particularly 
their reported labilities) provided inspiration to assess yet more labile silicate 
models. These compounds were typically synthesized via an exchange reaction 
of a tetraalkyl orthosilicate with an anhydride11,51 followed by distillation to access 
the pure material. Unfortunately, isolation of high molecular weight prodrugs via 
distillation is likely unattainable. Therefore, the first step toward applying these 
concepts to our silicate ester strategy was to determine the practicality of other 
means of purification.  
Previous syntheses of acetoxytriethoxysilane (2.42) via a substituent 
exchange between 2.07 and acetic anhydride under harsh conditions (e.g., 
prolonged heating up to 180 °C) have led to low yields (e.g., 9%).52 Thus, we 
altered the reaction conditions by treating triethoxychlorosilane with an excess of 
acetic acid and pyridine (despite literature that suggests such reactions fail to 
proceed cleanly to full conversion).11 Nonetheless, analysis of the crude 1H NMR 
and GC/MS data provided ample evidence of at least partial conversion.53 This 
allowed attempts to purify 2.42 by eluting the crude mixture through silica gel. 
However, passing 2.42 through as little as a one inch plug of silica in a Pasteur 
pipet resulted in extensive (near quantitative) decomposition. Likewise, utilization 
???????????????????????????????????????? ????????????????????
49 Friedel, C.; Ladenburg, A. Liebigs Annalen der Chemie, 1868, 145, 174–178. 
50 Schuyten, H. A.; Weaver, J. W.; Reid, J. D. Preparation of Substituted Acetoxy Silanes. J. Am. 
Chem. Soc. 1947, 69, 2110–2112. 
51 Kopylov, V. M.; Kireev, V. V.; Ivanov, V. V.; Astaf’ev, G. Y.; Kozlov, Y. V. Reaction of 
Acetoxysilanes with Hydroxy Compounds. Rus. J. Gen. Chem. 2001, 71, 1924–1928. 
52 Roth, M. J.; Brook, M. A.; Penny, H. B. Hydrosilane Cleavage Reactions Accelerated by 
Tartaric Acid and Dimethyl Sulphoxide. J. Organomet. Chem. 1996, 521, 65–74. 
53 Crude 1H NMR data for 2.38 (500 MHz, CDCl3): δ = 3.94 [q, J = 7.1 Hz, 6H, Si(OCH2CH3)3], 
2.13 [s, 3H, SiOC(O)CH3], and 1.25 [t, J = 7.1 Hz, 6H, Si(OCH2CH3)3]. GC/MS: (Method: 50°C, 
hold for two min; ramp at 20°C/min for 10 min, hold at 250°C for three min) tR = 5.48 min; m/z 222 
(5, M+), 177 (100, M+ - OEt), and 135 (20). 
Chapter 2 Model Silicate Ester Prodrugs? 
?
???
?
of salicylic acid 2.43 to synthesize the cyclic organosilane 2.44 succeeded54 (as 
previously reported55), but decomposition was again observed upon subjecting 
the crude material to silica chromatography. In contrast to these results, the 
synthesis of the exceedingly hindered tri-t-butoxyacetoxysilane 2.46 [from the 
commercially available tri-t-butoxysilanol (2.45), see Scheme 2-9] was 
synthesized via treatment with acetic anhydride and 4-dimethylaminopyridine 
(DMAP). These conditions led to greater than 90% conversion to 2.46. Yet more 
importantly, 2.46 was isolable by MPLC purification. 
Scheme 2-9. Attempts toward the synthesis of labile acyloxy silicate esters. 
 
  
From these preliminary results, it was clear that added steric bulk would 
be crucial in the development of a new series of chromatographable silicate 
esters that incorporate a labile acyloxy. Menthol (2.16) was utilized as a bulky, 
secondary alcohol toward this end.39 A series of trimenthoxysilanes was initially 
synthesized by a one-pot method in which the trimenthoxychlorosilane 2.47 was 
not isolated.41 Yields were seemingly improved by a two pot procedure in which a 
???????????????????????????????????????? ????????????????????
54 Crude 1H NMR data (500 MHz, CDCl3) showed a complex mixture of > 4 different products. 
Crude GC/MS for 2.40: (Method: 50°C, hold for two min; ramp at 20°C/min for 11 min, hold at 
270°C for three min) tR = 7.90 min; m/z 194 (60, M+), 179 (50, M+ - Me), 135 (100), and 91 (10). 
55 Cragg, R. H.; Lane, R. D. Contributios to Group IV Organometallic Chemistry IV. Preparation 
and Properties of Some Organosilicon Derivatives of Salicylic and Related Acids. J. Organomet. 
Chem. 1981, 212, 301–310. 
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crude sample of 2.47 was subjected to further substitution with the desired 
carboxylic acid to synthesize either 2.49 or 2.50 (Scheme 2-10). Typical yields for 
these compounds were ca. 50-60% after purification by MPLC and were likely 
suppressed due to the instability of the acyloxysilane during exposure to silica 
gel. Finally, the mixed ethoxytrimenthoxysilane 2.48 was also synthesized, and 
its observed hydrolysis rate served as an accurate comparison of 
tetraalkoxysilane vs. trialkoxyacyloxysilane. 
Scheme 2-10. The synthesis of trimenthoxyethoxysilane 2.48 and 
trimenthoxyacyloxysilanes 2.49 and 2.50. 
 
 
For this family of trimenthoxy models 2.48-2.50, the “standard” hydrolysis 
conditions were ineffective; these highly hydrophobic compounds were insoluble 
in a solution containing 9 vol% water. Thus, a co-solvent system consisting of a 
1:1:98 TFA:D2O:d6-acetone (v/v/v) solution was used to ensure complete 
dissolution of these trimenthoxysilane models. Since the SN2 mechanism of 
these acid-catalyzed hydrolyses is medium-dependent,24 the krel values reported 
in Table 2-9 have now been referenced to the hydrolysis of 2.07 in this modified 
co-solvent system. Notably, the absolute rate of hydrolysis was found to be 
slowed by ca. one order of magnitude in this modified co-solvent ratio.  
Consistent with the previous sections (see section 2.3), increasing the 
steric bulk significantly slowed the observed hydrolysis rates of these menthol-
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containing silicate esters. As anticipated, the added steric bulk of 2.48 caused a 
significant decrease in the observed hydrolysis rate (relative to that of 2.07). 
Specifically, ethoxytrimenthoxysilane 2.48 was observed to hydrolyze 400-fold 
more slowly than 2.07. Tetramenthoxysilane 2.17 (soluble in this modified co-
solvent system) was also found to hydrolyze much more slowly – at least three 
orders of magnitude more slowly than 2.07. (The hydrolysis experiment was 
discontinued after 400 h, by which point less than one half-life was completed.)  
Incorporation of an acyloxy substituent to these trimenthoxysilanes 
resulted in much more readily hydrolyzed analogs than 2.17 and 2.48. Specific 
observed rate enhancements include a five-fold faster hydrolysis rate of the 
pivaloxy-containing 2.50 as compared to 2.48. This is notable because 2.50 is 
the more sterically-hindered silicate ester, yet the incorporation of the acyloxy 
moiety induces a more rapid hydrolysis. The acetoxy-containing silane 2.49, 
meanwhile, magnifies this observation. 2.49 exhibited a hydrolysis rate that was 
> 1500 times faster than the sterically-similar model 2.48. Furthermore, 2.49 
hydrolyzed approximately four times faster than the significantly less 
encumbered tetraethoxysilane 2.07. This observation, in particular, effectively 
highlights the optimism and potential surrounding acyloxysilanes as rapidly 
hydrolyzing promoieties.  
Yet more sterically hindered trialkoxyacyloxysilanes were designed and 
synthesized to explore the extreme limits of steric hindrance vis-à-vis labile 
substituents in mixed alkyl/acyl silicate esters. Specifically, di-t-
butoxydichlorosilane 2.51 was synthesized in the presence of excess t-butanol 
and pyridine. 2.51 could be easily distilled for future use. or utilized crude in a 
one pot procedure to synthesize species such as the di-t-
butoxymenthoxychlorosilane 2.52. Incredibly, 2.52 was (inadvertently) found to 
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be reasonably stable to purification via MPLC chromatography.56. Even when 
stored neat at room temperature in a vesicle that was not air-tight, 2.52 
underwent minimal hydrolysis over the course of several weeks, further 
highlighting the excessive steric bulk of this compound. Nonetheless, 2.52 was 
found to remain reactive; dissolving 2.52 in bulk methanol in preparation of 
characterization via high resolution mass spectrometry (HRMS) resulted in rapid 
and quantitative conversion to the menthoxymethoxy-di-t-butoxysilane.  
With a ready supply of pristine 2.52 in hand, a series of derivatization 
studies were conducted. As in the trimenthoxy series, a mixed tetraalkoxysilane, 
ethoxymenthoxy-di-t-butoxysilane, (2.53) was synthesized to serve as a 
comparable model to the acyloxy-containing silanes (Scheme 2-11).56 The 
synthesis of menthoxy-di-t-butoxyacetoxysilane 2.54 and menthoxy-di-t-
butoxypropionoxysilane 2.55 proceeded as expected (Scheme 2-11). However, 
attempts to synthesize analogous α-branched acyloxy silanes (e.g., 2.56 and 
2.57) failed despite prolonged reaction times and/or treatment with significant 
reagent excesses.57 
???????????????????????????????????????? ????????????????????
56 This work was done jointly with National Science Foundation (NSF)/Lando fellowship 
undergraduate student Paul Alperin. 
57 No evidence consistent with the synthesis of either 2.56 or 2.57 was observed via TLC, 
GC/MS, or crude 1H NMR spectroscopy. 
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Scheme 2-11. The synthesis of menthoxy-di-t-butoxyethoxy 2.53 and menthoxy-
di-t-butoxyacyloxy silicate esters 2.54 and 2.55.?
  
 
Again, the 1:1:98 TFA:D2O:d6-acetone (v/v/v) solution was necessarily 
employed for the kinetic hydrolysis experiments, thereby ensuring complete 
dissolution and accurate comparison with models 2.48-2.50. Similar to 2.48, the 
observed hydrolysis rate of 2.53 was exceedingly slow and, in this case, 
discontinued after > 400 h, prior to complete hydrolysis. Interestingly, the 
extreme steric bulk from the t-butoxy and menthoxy groups exemplified even 
minor differences in the hydrolysis rates of similar acyloxy silanes. While the 
acetoxy-containing silane 2.54 hydrolyzed on a reasonable time scale (albeit 
considerably slower than 2.49), inclusion of a single methylene unit in the 
carboxylic acid tail of 2.55 significantly increased the half-life of the hydrolysis, 
again leading to the discontinuation of the study after greater than 400 h. Full 
results for all of these models are presented in Table 2-9. 
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Table 2-9. The observed kinetic data for all acyloxy-containing silicate esters 
2.49-2.50 and 2.54-2.55 and comparison to their sterically hindered 
tetraalkoxysilane analogues 2.48 and 2.53, respectively. a   
 Silane R t1/2 (min) kobs (10-3 s-1) krel’ a  
     
 2.07 Ethyl 33 ± 1 0.35 ± 0.01 1 ± 0.03 
 2.17 Menthyl > 24000 n.d. b < 0.001 
 2.48 Ethyl 13000 ± 1000 0.00092 ± 0.00004 0.0025 ± 0.0002  
 2.49 C(O)CH3 8.7 ± 0.6  1.3 ± 0.1 3.8 ± 0.3 
 2.50 C(O)(CH3)3 2400 ± 300 0.0048 ± 0.0001 0.014 ± 0.002  
 2.53 Ethyl > 24000 n.d. < 0.001  
 2.54 C(O)CH3 5100 ± 200 0.0022 ± 0.0001 0.0065 ± 0.0003  
 2.55 C(O)CH2CH3 > 24000 n.d. < 0.001  
 a krel’ are referenced to TEOS 2.07 in a 1:98 D2O:d6-acetone solution. 
 b n.d. = not determined. 
 
In addition to providing important, new information regarding the relative 
rates of hydrolysis of these highly hindered, acyloxy-containing models (2.54 and 
2.55), these experiments also provided the first spectral evidence of a sufficiently 
long-lived hydrolysis intermediate. This unique intermediate (see Scheme 2-12) 
is hypothesized to be the menthoxy-di-t-butoxysilanol 2.58 based on the results 
of analogous work done on a related, paclitaxel-based system (see section 3.3.8) 
and a publication that describes the synthesis of a trimenthoxysilanol41 and 
another that claims to identify of a silanol (although the lack of spectroscopic data 
presented makes it difficult to validate this claim).58 However, no incontrovertible 
???????????????????????????????????????? ????????????????????
58 Theis, B.; Weib, J.; Lippert, W. P.; Bertermann, R.; Burschka, C.; Tacke, R. Zwitterionic and 
Anionic Multinuclear Pentacoordinate Silicon(IV) Complexes with Bridging (R,R)-Tartrato(4) 
Ligands and SiO5 Skeletons: Synthesis and Reactivity in Aqueous Solution. Chem. Eur. J. 2012, 
18, 2202–2206. 
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data was collected that indisputably corroborates this claim the structure of 2.58. 
Regardless, the significant rate enhancement observed as a result of the 
inclusion of acyloxy substituents provides strong evidence to support our ability 
to accelerate silicate prodrug hydrolysis if it is deemed necessary in the prodrug 
work. 
Scheme 2-12. The hydrolysis of labile di-t-butoxymenthoxysilanes. 
 
 
 
5.  Aminotrialkoxysilanes. 
1. Introduction. Interest in developing mixed, cyclic aminoalkoxysilane 
prodrugs was prompted by compounds such as doxorubicin (Figure 2-5, 2.59). 
Doxorubicin, a small molecule with chemotherapeutic properties, is currently 
administered after formulation in a pegylated liposome59 – making it an attractive 
target for further prodrug loading optimization via synthesis of a silicate prodrug 
and subsequent FNP techniques. To undertake this task, pursuit of a novel class 
of cyclic aminoalkoxy silicate esters was necessary. General encouragement for 
such endeavors was found in the large number of 1,3,2-dioxasilolanes (81 
examples found during a Reaxys® search) and 1,3,2-dioxasilinanes (96 
examples found during a Reaxys® search). Interest in models for compounds 
???????????????????????????????????????? ????????????????????
59 Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of Pegylated Liposomal 
Doxorubicin. Clin. Pharmacokinet. 2003, 42, 419–436. 
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such as 2.60 was further piqued by the lack of analogous nitrogen-containing 
examples, with only one characterized, tetravalent silicon compound reported.60  
Figure 2-5. The structure of doxorubicin and a proposed aminotrialkoxysilanes 
prodrug. 
 
 
2. Attempts to Synthesize Mixed Cyclic Aminoalkoxy Silicate Esters. 
Again, design of a model system to determine the feasibility of prodrugs such as 
structure 2.60 was deemed especially crucial due to the limited literature 
precedent, as was the case for the phosphonic acid silicate esters. An obvious 
first reaction was the cyclization of racemic 1-aminopropan-2-ol (2.61). 
Anticipating lability in the uncommon Si-N bond,61 di-t-butoxydichlorosilane was 
chosen as the first silylating agent in these initial experiments. Unfortunately, all 
attempts to synthesize the 1,3,2-azaoxsilolane (e.g., 2.64 in Scheme 2-13) failed 
despite repeated attempts to optimize reagent stoichiometry, molarity, and 
reaction time.  In the presence of substoichiometric amounts of the 
dichlorosilane, the reaction proceeded to give a complex mixture of products, 
???????????????????????????????????????? ????????????????????
60 Diedrich, F.; Ebker, C.; Klingbiel, U.; Reiche, C.; Labahn, T.; Magull, J.; Noltemeyer, M. N,N-
Bis(silyl)ethylenediamine und 1,3-Diaza-2-silacyclopentane – Synthese, Reaktionen, Strukturen. 
Z. Naturforsch., B: Chem. Sci. 2002, 57, 99–106. 
61 Wutz, P. G. M.; Greene, T. W. Protection for the Amino Group. In Greene’s Protective Groups 
in Organic Synthesis, Fourth Edition. John Wiley & Sons, Inc: Hoboken, NJ, 2007. 
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including the tentatively assigned 2.63 (Scheme 2-13).62 While crude GC/MS 
data from early time points were suggestive of the formation of intermediate 2.62, 
none of the compounds observed via GC/MS analysis could be correlated with 
the five-membered, cyclized (and desired) product 2.64.  
Likewise, attempts to synthesize a 1,3,2-diazasilinanes (e.g., 2.67 in 
Scheme 2-14) from propane 1,3-diamine 2.65 resulted predominantly in the 
mono-substitution of the dichlorosilane to give 2.6663 (Scheme 2-13). In this 
case, evidence for the transient cyclized product 2.6764 was obtained, albeit in 
low quantities [< 10% of the area under the curve (AUC) in the GC/MS trace]. In 
an effort to illicit more complete conversion, the reaction times was prolonged, 
but 2.67 was not observed to any extent. Instead, a larger molecular weight peak 
(hypothesized to be an oligomeric compound) was observed, growing in intensity 
with the reaction progress.65  
 
 
 
 
 
???????????????????????????????????????? ????????????????????
62 Crude GC/MS data for 2.63 (Method: 30°C, hold for 1.5 min; ramp at 27°C/min for 13 min, hold 
at 300°C for 1.5 min) tR = 11.75 min; m/z 249 (20 M+ - OtBu), 192 {40, Si(O)[O(CH3)CHCH2NH2]2}, 
175 (300), 136 {100, Si(OH)2[O(CH3)CHCH2NH2]2}, 97 (20), and 57 (20). 
63 Crude GC/MS data for 2.66 (Method: 30°C, hold for two min; ramp at 20°C/min for 14 min, hold 
at 310°C for five min) tR = 9.34 min; m/z 282 (<5, M+), 267/269 (100, M+ - Me), 211/213 (80), 
169/171 (40), 155/157 (40), 97 (30), and 57 (20). 
64 Crude GC/MS data for 2.67 (Method: 50°C, hold for two min; ramp at 20°C/min for 10 min, hold 
at 250°C for three min) tR = 9.34 min; m/z 246 (5), M+), 231 (20, M+ - Me), 173 (20, M+ - OtBu), 
133 (40), and 117 (100). 
65 Alternatively, attempts to synthesize 1,3,2-azaoxasilinanes by treating 3-amino-1-propanol with 
di-t-butoxydichlorosilane again led to a disappointing mixture of products in the GC/MS trace. 
None of the products could be reliably assigned as a cyclized, non-chlorinated substrate. 
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Scheme 2-13. Failed attempts to synthesize of cyclic aminotrialkoxysilanes. 
 
 
 
3. Control Experiments. Discouraged by these unsatisfying results, a 
series of controls were designed to elucidate the cause of the failed reactions in 
Scheme 2-14. First, to determine if the long silicon-heteroatom bonds in the 
potential product(s) was somehow untenable, di-t-butoxydichlorosilane was 
treated with ethylene glycol (2.68) and, in a separate reaction, 1,3-propanediol 
(2.70). The data obtained via GC/MS analysis of these reactions confirmed the 
synthesis of the five- and six-membered rings (2.6966 and 2.71,67 respectively), 
as has been previously reported (Scheme 2-15).40 Confident that established 
cyclic silicate ester chemistry was not only feasible but also achievable in my 
hands, the extreme steric bulk of the dichlorosilane was next hypothesized as the 
limiting factor. 
 
???????????????????????????????????????? ????????????????????
66 Crude GC/MS data for 2.68 (Method: Method: 30°C, hold for 1.5 min; ramp at 27°C/min for 13 
min, hold at 300°C for 1.5 min) tR = 9.07 min; m/z 219 (40, M+ - Me) and 163 (100, M+ - OtBu). 
67 Crude GC/MS data for 2.70 (Method: 50°C, hold for two min; ramp at 20°C/min for 10 min, hold 
at 250°C for three min) tR = 5.05 min; m/z 233 (40, M+ - Me), 177 (100), and 119 (20). 
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Scheme 2-14. The first generation of control experiments: synthesis of cyclic 
tetraalkoxysilanes. 
 
 
To fully eliminate the steric congestion induced by the t-butoxy 
substituents as the reason for the lack of observed cyclization, sterically 
constrained aminotrialkoxysilane model systems were designed as further control 
experiments. These systems were analogous to the previous (single) report of 
dimethylaminotri-t-butoxysilane that was obtained pure upon distillation.68 
Specifically, in the control experiments reported here, benzylamino-i-propoxy-di-t-
butoxysilane (2.73) and benzylamino-tri-t-butoxysilane (2.72) were envisioned. 
Analysis of GC/MS data during both experiments confirmed the synthesis of 
2.7369 and 2.72, respectively (Scheme 2-15). This result, coupled with the 
synthesis of 2.69 and 2.71, firmly established that steric congestion is not the 
cause of the failed reactions described in Scheme 2-13.  
 
 
 
 
???????????????????????????????????????? ????????????????????
68 Ismail, V. R. M. Herstellung von Tertiarbutoxy-(halogenphenoxy)-silanen. XIV. Z. anorg. allg. 
Chem. 1969, 371, 23–31. 
69 Crude GC/MS data for 2.73 (Method: Method: 30°C, hold for 1.5 min; ramp at 27°C/min for 13 
min, hold at 300°C for 1.5 min) tR = 12.46 min; m/z 339 (40, M+), 324 (50, M+  - Me), 282 (100, M+  
- tBu), 268 (20), 226 (60), 184 (30), 139 (30),  and 91 (20, Bn+). 
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Scheme 2-15. Second generation of control experiments: synthesis of sterically 
encumbered (di)aminoalkoxysilanes. 
 
 
Two final tests were designed to lend guidance to the stability of the 
potential aminosilane products. First, the stability of 2.72 was tested by 
subjecting it to purification via MPLC. Compound 2.72 was isolated in low yields 
from the chromatographic experiment, and resubjecting the pure compound to a 
short silica plug returned ca. 97% of the submitted material. Second, the 
presumably more labile bis(benzylamino)di-t-butoxysilane (2.74) was designed,  
synthesized, and successfully filtered through a silica plug (Scheme 2-16).70 
Stability of both of these compounds to silica gel is unusual compared to other 
amino-silicate esters that are typically used crude or purified by distillation. These 
results, (namely, the observation of a presumably more labile aminosilane 
species such as 2.74) suggest that, if cyclic compounds such as 2.64 and 2.67 
were the primary product of their respective reactions, they would be observed.  
Taken as a whole, the above results further suggest that neither extreme 
lability nor steric hindrance is the likely source of the undesired outcomes in 
Scheme 2-14. Further experimentation with, for example, a di-i-
???????????????????????????????????????? ????????????????????
70 Crude GC/MS data for 2.73 (Method: 50°C, hold for two min; ramp at 20°C/min for 10 min, hold 
at 250°C for three min) tR = 5.05 min; m/z 386 (20, M+), 371 (10, M+ - Me), 329 (20, M+ - tBu), 313 
(5, M+ - OtBu), 295 (80, M+ - Bn), 273 (30), 257 (10), 239 (40), 183 (100), 168 (30), 139 (40), 106 
(30), and 91 (30, Bn+). 
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propyldichlorosilane could yield a less sterically hindered cyclic 1,3,2-
azaoxsilolane, but the increased lability of the compound would probably render 
it non-isolable. Nonetheless, the ability to synthesize and (as discussed next) 
readily hydrolyze these silicate esters opens possibilities to the use of silicate 
esters as labile amine protecting groups.  
4. Trialkoxy Silicate Esters as Labile Amine Protecting Groups. Silyl-based 
protecting groups (trialkylsilylamines) have not received extensive use in 
synthesis due to their high reactivity to moisture.61 However, a few such 
examples of have shown that the use of sterically hindered silyl protecting groups 
hold promise. Notably, reacting t-butyldiphenylchlorosilane (TBDPS-Cl) with a 
wide scope of primary amines gave high yields of the desired silylamines. Further 
encouraging, these protecting groups were stable to chromatography and 
hydrolytic conditions, and the Si-N bond could be cleaved by treatment with 80% 
acetic acid or pyridine-HF.71 Recently, a yet more hindered silyl protecting group, 
the di-tert-butylisobutylsilyl (BIBS) group, has been reported.72 This strategy 
allows the protection of primary amines and subsequent purification via flash 
chromatography in high (typically, > 90%) yields. Also noteworthy, in both of 
these literature reports,  secondary amines were found to be unreactive under 
these conditions72 (although addition of carbon dioxide allows for formation of the 
protected carbamate73).  
 Only one reported use of a protecting group strategy involving a 
trialkoxysilane was found in the literature. In this case, the published graphical 
scheme depicts the use of a triisopropoxysilane [NSi(OiPr)3] as a nitrogen 
???????????????????????????????????????? ????????????????????
71 Overman, L. E.; Okazako, M. E.; Mishra, P. tert-Butyldipenylsilylamines: A Useful Protecting 
Group for Primary Amines. Tet. Lett. 1986, 27, 4391–4394. 
72 Liang, H.; Hu, L.; Corey, E. J. Di-tert-butylisobutylsilyl, Another Useful Protecting Group. Org. 
Lett. 2011, 13, 4120–4123. 
73 Lipshutz, B. H.; Papa, P.; Keith, J. M. Triisopropylsiloxycarbonyl (“Tsoc”): A New Protecting 
Group for 1° and 2° Amines. J. Org. Chem. 1999, 64, 3792–3793. 
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protecting group, but ambiguity remains regarding the true chemical compound. 
The text refers to the protecting group as a traditional “triisopropylsilyl” (as 
opposed to a “triisopropoxysilyl” as depicted in the scheme) group. Further 
complicating matters, the article contains minimal characterization or proof of 
constitution related to the compound.74  
Given the relatively limited development of silicon-based nitrogen 
protecting groups, tri-t-butoxysilyls were envisioned as novel, labile protecting 
groups for amines. Thus, the purified 2.72 was dissolved in a co-solvent mixture 
of deionized water:acetonitrile (5:95) and monitored via GC/MS methodology in 
an effort to test for stability. Consistent with the previously noted lability of the 
attempted prodrug models, a rapid hydrolysis was observed (t1/2 < 2 h) in these 
neutral conditions. Furthermore, dissolving 2.72 in ethyl acetate saturated with 
water yielded complete cleavage of the Si-N bond in less than 24 hours.  
The potential utility of silicate ester protecting groups was further 
expanded by the discovery that, for the first time, unbranched secondary amines 
(diethylamine, 2.75) could be successfully silylated with sterically encumbered 
silyl reagents to yield 2.7675 (Scheme 2-16). Notably, similar reaction conditions 
failed to provide the silylated analog when TBDPS-Cl was used as the silylating 
agent. Competition studies that subjected 2.75 to equal molar quantities of 
SiCl(OtBu)3 and TBDPS-Cl yielded exclusively 2.76. Presumably, the ability of 
the SiCl(OtBu)3 reagent  to successfully functionalize these more hindered 
systems in cases were TBDPS-Cl and BIBS-OTf failed is the result of the longer 
???????????????????????????????????????? ????????????????????
74 Tao, M.; Park, C. H.; Bihovsky, R.; Wells, G. J.; Husten, J.; Ator, M. A.; Hudkins, R. L. 
Synthesis and Structure-Activity Relationships of Novel Poly(ADP-ribose) Polymerase-1 
Inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 938–942. 
75 Crude GC/MS data for 2.76 (Method: 50°C, hold for two min; ramp at 20°C/min for six min, hold 
at 170°C for six min) tR = 9.44 min; m/z 319 (5, M+), 304 (100, M+  - Me), 248 (20), 192 (20), and 
136 (20). 
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Si-O bond, thus providing a less crowded and more readily functionalized silicon 
center. 
Scheme 2-16. Synthesis of a secondary aminotri-t-butoxysilane 2.76. 
 
 
Attempts to expand silicate ester chemistry to branched secondary amines 
(e.g., diisopropylamine) were, however, unsuccessful. Nonetheless, the 
synthesis of both primary and unbranched secondary amino silicate esters and 
the purification of a subset of these compounds via column chromatography is 
highly advantageous to their development as protecting groups.  These 
preliminary studies have established the labile nature that accounts for rapid 
hydrolysis under neutral conditions and warrant further development of the 
general concepts described here.76 These attractive features open the possibility 
to their use as a new class of protecting groups that may be removed under 
exceedingly mild co-solvent conditions. 
 
6.  Conclusions. 
 The work described in Chapter 2 has established silicate esters as a 
viable promoiety. Both physical (i.e., hydrophobic character) and chemical (i.e., 
rate of hydrolysis) characteristics can be controlled, largely independently, 
through the choice of the sacrificial substituents. Under acid-catalyzed 
conditions, all but the most sterically hinder of these silicate ester prodrug models 
???????????????????????????????????????? ????????????????????
76 Development of hindered amonotrialkoxysilanes is continuing in collaboration with the 
laboratory of Prof. Michael Wentzel, Augsburg College, Minneapolis, MN. 
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cleanly return the parent compound(s). The principals developed within this 
chapter have been applied, with varying degrees of success, to specific model 
systems that are designed to mimic a variety of drug molecules containing 
aliphatic hydroxyls, aryl hydroxyls, phosphonic acids, and amines. With the 
guiding data regarding the rate of silicate ester hydrolysis trends now 
established, it is logical to advance these concepts to therapeutically relevant 
prodrugs. 
 
7.  Experimental Section. 
Tetramethyl orthosilicate, tetraethyl orthosilicate, and menthol were 
purchased and used as received. Silicon tetrachloride was purchased and 
transferred to a Schlenk flask for storage. Tetraisopropyl orthosilicate and 
triethoxychlorosilane were purchased and used as received. Estradiol was 
purchased and used as received. Hydrocortisone was purchased and used as 
received. n-Butanol, n-hexanol, n-octanol, i-propanol, and t-butanol were dried 
over activated 3 or 4 Å molecular sieves overnight. Tetra-n-butoxysilane,31 tetra-
n-hexoxysilane,31,32 and tetra-n-octoxysilane,32 tri-n-butoxychlorosilane,77 tri-n-
octyloxychlorosilane,78 tri-i-propoxychlorosilane,79 and di-t-butoxydichlorosilane32 
were synthesized according to literature precedent. Tri-t-butoxychlorosilane was 
either purchased or prepared according to literature precedent.80 
???????????????????????????????????????? ????????????????????
77 Gerrard, W.; Jones, J. V. Stability of Isomeric Butoxysilanes with Respect to Silicon 
Tetrachloride and Hydrogen Chloride. J. Chem. Soc. 1952, 1690–1693. 
78 Gerrard, W.; Howe, B. K. The Behaviour of 1:1:1:3:3:3-hexachloropropan-2-ol with Inorganic 
Non-Metal Halides. J. Chem. Soc. 1955, 505–510. 
79 Chappelow, C. C.; Elliot, R. L.; Goodwin, J. T. The Phenylation and Methylation of 
Alkoxychlorosilanes. J. Org. Chem. 1960, 25, 435–439. 
80 Pedlow, G. W.; Miner, C. S. Tertiary-Alkoxy Chlorosilanes. U.S. Patent 2,566,957, September 
4, 1951. 
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Triethylamine and pyridine were purchased and purified by distillation over 
CaH2. Tetrahydrofuran was purchased and dried by being passed through an 
activated alumina column. Ethanol (anhydrous) was further dried by storing 
overnight over activated 3Å molecular sieves. Ethyl acetate (ACS grade) was 
and hexanes (ACS grade) were used as received. The d6-acetone and d-
chloroform were dried over activated 3Å molecular sieves overnight. D2O was 
purchased and used as received.  
Medium pressure liquid chromatography (MPLC) purifications were 
performed using columns dry-packed with ca. 25-35 µm silica gel. The MPLC 
apparatus was pressurized with a chromatography pump. Compound detection 
was performed by using a UV absorbance detector at 254 nm and a differential 
refractometer in series. All thin layer chromatography (TLC) data were collected 
on glass-backed plates coated with F-254 indicator. Visualization was completed 
via UV-light and/or staining with phosphomolybdic acid (PMA). 1H NMR spectra 
were taken on a 500 MHz (1H) instrument. All 1H characterization spectra were 
taken in CDCl3 and chemical shifts (δ) are referenced to tetramethylsilane at δ = 
0.00. All 13C NMR characterization spectra were taken in CDCl3 on either a 125 
MHz (13C) or a 75 MHz (13C) instrument and referenced to CHCl3 at δ = 77.23. 
The following abbreviations are used to describe the NMR signals: s (singlet), d 
(doublet), t (triplet), q (quartet), sept (septet), m (multiplet), br (broad), and app 
(apparent). Coupling constants (J) are reported in Hz. Infrared spectra were 
recorded using an FT-IR instrument. All samples were collected in attenuated 
total reflectance (ATR) mode as thin films on a germanium window. Melting point 
data were collected on a hot stage and are uncorrected. High resolution mass 
spectra were collected on a BioTOF II (ESI-TOF) instrument using poly(ethylene 
glycol) (PEG) or poly(propylene glycol) (PPG) as an internal standard. 
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Triethoxy (1R,2S,5R)-2-isopropyl-5-methylcyclohexoxysilane (2.25). To an 
oven-dried 5 mL culture tube containing a stir bar, menthol (98.0 mg,  0.628 
mmol, 1.0 equiv) was added. This was dissolved in 3 mL of dry THF. Distilled 
pyridine (60 µL, 0.742 mmol, 1.2 equiv) and triethoxychlorosilane (150 µL, 0.764 
mmol 1.2 equiv) were added. Immediately, a white precipitate formed. The vessel 
was closed with a Teflon®-lined culture tube and allowed to stir for 0.5 h while 
being monitored by GC/MS. The reaction mixture was diluted with a 1:1 mixture 
of hexanes:ethyl acetate (EtOAc), filtered through Celite®, concentrated under 
reduced pressure, and redissolved in a minimal amount of 49:1 hexanes:EtOAc. 
If a slurry resulted, this was filtered prior to being loaded onto a silica gel column. 
Purification by MPLC was performed using 49:1 hexanes:EtOAc as the eluent to 
yield the title silicate (165 mg, 82.3%) as a colorless oil. 
1H NMR (500 MHz, CDCl3): δ 3.84 [q, J = 7.0 Hz, 6H, OSi(OCH2CH3)3], 3.67 
(ddd, J = 4.3, 10.5, 10.5 Hz, 1H, SiOCH), 2.23 [dsept, J = 2.6, 7.0 Hz, 1H, 
(CH3)2CH], 2.02 (m, 1H, SiOCHCHACHE), 1.64-1.56 [m, 2H, 
(CH3)2CHCHCHACHECHACHE], 1.40 (ddddq, J = 3.5, 3.5, 11.6, 11.6, 6.7, 1H, 
CH3CH), 1.23 [t, J = 7.0 Hz, 9H, OSi(OCH2CH3)3], 1.19 (dddd, J = 3, 3, 10, 12 
Hz, 1H, (CH3)2CHCH), 1.05 (ddd, J = 10.5, 12.0, 12.0 Hz, 1H, SiOCHCHAHE), 
0.95 [dddd, J = 3.0, 12.3, 12.3, 12.3 Hz, 1H, (CH3)2CHCHCHAHE], 0.90 (d, J = 
6.5 Hz, 3H, CH3CH), 0.89 (d, J = 7.1 Hz, 3H, CH3CHCH), 0.83 (dddd, J = 3.2, 
12.4, 12.4, 12.4 Hz, 1H, (CH3)2CHCHCH2CHACHE), and  0.77 (d, J = 6.9 Hz, 3H, 
CH3CHCH). 
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13C NMR (75 MHz, CDCl3): δ 73.3, 59.3, 49.9, 44.8, 34.7, 31.8, 25.5, 22.9, 22.4, 
21.4, 18.3, and 15.8. 
HRMS (ESI) Calc’d for C16H34NaO4Si+ (M + Na+): 341.2119, found 341.2114. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for three min) tR = 7.75 min; m/z 318 (5, M+), 303 (10. M+-Me), 233 (100), 
181 (10), and 138 (20). 
IR (thin film) 2956, 2923, 1456, 1392, 1294, 1168, 1102, 1082, 1002, 963, 883, 
829, and 791. 
 
 
 
Tri-n-butoxy (1R,2S,5R)-2-isopropyl-5-methylcyclohexoxysilane (2.26). To 
an oven dried 5 mL culture tube containing a stir bar, menthol (177.5 mg, 1.14 
mmol, 1 equiv) was added. This was dissolved in 3 mL of dry THF. Distilled 
pyridine (0.11 mL, 1.37 mmol, 1.2 equiv) and a 2.5:1 mixture of 
SiCl(OnBu)3:Si(OnBu)4 [533 mg 1.37 mmol of SiCl(OnBu)3, 1.2 equiv] were added. 
Immediately, a white precipitate formed. The vessel was closed with a Teflon®-
lined cap and the mixture was allowed to stir for 16 h. The slurry was filtered 
through Celite®, concentrated under reduced pressure, and redissolved in a 
minimal amount of 49:1 hexanes:EtOAc. If a slurry resulted, this was filtered prior 
to being loaded onto a silica gel column. Purification by MPLC led to two 
overlapping peaks, and the pure title product was obtained by taking the front of 
the faster eluting substance, yielding the title silicate (180.3 mg, 68.6%) as a 
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colorless oil. The remainder of the peak corresponded to the Si(OnBu)4 (1H NMR) 
present in the starting silylating reagent. 
1H NMR (500 MHz, CDCl3): δ 3.76 [t, J = 6.7 Hz, 6H, OSi(OCH2CH2)3], 3.66 
(ddd, J = 4.4, 10.5, 10.5 Hz, 1H, SiOCH), 2.24 [dsept, J = 2.7, 7.0 Hz, 1H 
(CH3)2CH], 2.05-2.00 (m, 1H, SiOCHCHACHE), 1.66-1.56 [m, 2H, 
(CH3)2CHCHCHACHECHACHE], 1.56 [tt, J = 6.6, 7.0 Hz, 6H, Si(OCH2CH2)3], 
1.37-1.28 [tq, J = 7, 7 Hz, 6H, Si(OCH2CH2CH2CH3)3 and m, 1H, CH3CH), 1.19 
[dddd, J = 3.0, 4.6, 9.9, 12.2 Hz, 1H, (CH3)2CHCH], 1.04 [ddd, J = 10.5, 12.0, 
12.0 Hz, 1H, SiOCHCHAHE), 1.00-0.90 (m, 1H, (CH3)2CHCHCHAHE], 0.92 [t, J = 
7.4 Hz, 9H, Si(OCH2CH2CH2CH3)3], 0.90 (d, J = 6.5 Hz, 3H, CH3), 0.89 [d, J = 
7.1 Hz, 3H, CH3], 0.85 [dddd, J = 3.5, 12.0, 12.0, 12.0 Hz, 1H, 
(CH3)2CHCHCH2CHACHE], and 0.77 (d, J = 6.9 Hz, 3H, CH3). 
13C NMR (75 MHz, CDCl3): δ 73.4, 63.3, 49.9, 44.9, 34.7, 34.6, 31.9, 25.5, 23.0, 
22.5, 21.4, 19.1, 15.9, and 14.1. 
HRMS (ESI) Calc’d for C22H46NaO4Si+ (M + Na+): 425.3058, found 425.3082. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for three min) tR = 10.12 min; m/z 402 (10, M+), 359 (20. M+-CH2CH2CH3), 
317 (100), 265 (30), and 138 (40). 
IR (thin film) 2957, 2931, 2873, 1456, 1383, 1235, 1151, 1089, 1051, 989, 938, 
895, 832, 802, and 734. 
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Tri-n-octyloxy (1R,2S,5R)-2-isopropyl-5-methylcyclohexoxysilane (2.27). 
Menthol (342 mg, 2.19 mmol, 1 equiv) was added to an oven-dried 12 mL culture 
tube containing a stir bar. This was dissolved in 10 mL of dry THF. Distilled 
pyridine (0.22 mL, 2.74 mmol, 1.25 equiv) and a 1:0.55 mixture of 
SiCl(OnOct)3:Si(OnOct)4 [1.79 g, 2.19 mmol, 1.0 equiv of SiCl(OnOct)3] were 
added. Immediately, a white precipitate formed. The vessel was closed with a 
Teflon®-lined cap and allowed to stir for 2 h. The reaction mixture was filtered 
through a paper filter to remove the pyridinium chloride salt, concentrated under 
reduced pressure, and redissolved in a minimal amount of 99:1 hexanes:EtOAc. 
If a slurry resulted, this was filtered prior to being loaded onto a silica gel column. 
Purification by MPLC provided two overlapping peaks, and the pure title product 
was obtained by taking the front of the faster eluting substance, yielding the title 
silicate (858 mg, 68.6%) as a colorless oil. The remainder of the peak 
corresponded to the Si(OnOct)4 (1H NMR) present in the starting silylating 
reagent. 
1H NMR (500 MHz, CDCl3): δ 3.74 [t, J = 6.6 Hz, 6H, OSi(OCH2CH2)3], 3.66 
(ddd, J = 4.3, 10.5, 10.5 Hz, 1H, SiOCH), 2.22 [dsept, J = 2.6, 7.0 Hz, 1H 
(CH3)2CH], 2.02 (m, 1H, SiOCHCHACHE), 1.68-1.50 [m, 8H, 
(CH3)2CHCHCHACHECHACHE and Si(OCH2CH2CH2)3], 1.40-1.10 {m, 32H, 
CH3CH, (CH3)2CHCH, and Si[OCH2CH2(CH2)5CH3]3}, 1.03 (ddd, J = 10.5, 12.0, 
12.0 Hz, 1H, SiOCHCHAHE), 0.99-0.83 {m,17H, Si[O(CH2)7CH3]3, 
(CH3)2CHCHCH2CHACHE, (CH3)2CHCHCH2CHAHE, CH3, and CH3}, and 0.76 (d, 
J = 6.9 Hz, 3H, CH3). 
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13C NMR (75 MHz, CDCl3): δ 73.4, 63.7, 49.9, 44.9, 34.7, 32.6, 32.1, 31.9, 29.62, 
29.59, 26.0, 25.5, 23.0, 22.9, 22.5, 21.4, 15.9, and 14.3. 
HRMS (ESI) Calc’d for C34H74NO4Si+ (M + NH4+): 588.5382, found 588.5376. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 12 min, hold at 
250 °C for seven min) tR = 14.23 min; m/z 570/571 (10, M+), 527 (10), 486 (100), 
433 (30), and 138 (40). 
IR (thin film) 2953, 2924, 2855, 1458, 1380, 1095, 1054, 1002, 936, 888, 836, 
807, and 725. 
 
 
 
Tri-i-propoxy (1R,2S,5R)-2-isopropyl-5-methylcyclohexoxysilane (2.28). 
Menthol (71.6 mg, 0.458 mmol, 1 equiv) was added to an oven-dried 12 mL 
culture tube containing a stir bar. This was dissolved in 2 mL of dry THF. Distilled 
pyridine (55 µL, 0.687 mmol, 1.5 equiv) and a 2.9:1 mixture of 
SiCl(OiPr)3:Si(OiPr)4 [206 mg, 0.620mmol, 1.4 equiv of SiCl(OiPr)3] were added.  
Immediately, a white precipitate formed. The reaction vessel was closed with a 
Teflon®-lined cap and monitored by GC/MS. After 2 h, no starting material 
remained, and the reaction mixture was filtered through Celite® to remove the 
pyridinium chloride salt, concentrated under reduced pressure, and redissolved 
in a minimal amount of 99:1 hexanes:EtOAc. If a slurry resulted, this was filtered 
prior to being loaded onto a silica gel column. Purification by MPLC was 
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performed using 99:1 hexanes:EtOAc as the eluent to yield the title silicate (133 
mg, 0.369 mmol, 80.7%) as a colorless oil.  
1H NMR (500 MHz, CDCl3): δ 4.22 [sept, J = 6.1 Hz, 3H, OSiOCH(CH3)2], 3.66 
(ddd, J = 4.3, 10.5, 10.5 Hz, 1H, SiOCH), 2.25 [dsept, J = 2.6, 7.0 Hz, 1H 
(CH3)2CH], 2.08-2.02 (m, 1H, SiOCHCHACHE), 1.65-1.55 [m, 2H, 
(CH3)2CHCHCHACHECHACHE], 1.38 (ddddq, J = 3, 3, 10, 12, 7 Hz, 1H, CH3CH), 
1.19 [d, J = 6.0 Hz, 18H, SiOCH(CH3)2], 1.02 (ddd J = 10, 12, 12 Hz, 1H, 
SiOCHCHAHE), 0.94 [dddd, J = 3.2, 12.8, 12.8, 12.8 Hz, 1H, 
(CH3)2CHCHCHAHE], 0.90 (d, J = 6.5 Hz, 3H, CH3), 0.89 (d, J = 7.1 Hz, 3H, CH3), 
0.81 [dddd, J = 3.2, 12.7, 12.7, 12.7 Hz, 1H, (CH3)2CHCHCH2CHACHE], and 0.76 
(d, J = 6.9 Hz, 3H, CH3). 
13C NMR (75 MHz, CDCl3): δ 73.3, 65.9, 50.0, 44.9, 34.8, 31.9, 25.6, 25.4, 23.0, 
22.5, 21.4, and 15.9. 
HRMS (ESI) Calcd for C19H40NaO4Si+ (M + Na+): 383.2588, found 383.2585. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for three min) tR = 7.32 min; m/z 360 (10, M+), 345 (40, M+-CH3), 275 
(100), and 138 (30). 
IR (thin film) 2971, 2924, 2872, 1455, 1380, 1371, 1172, 1120, 1085, 1042, 935, 
890, 825, 807, 769, 687, 649, 635, and 611. 
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Triethoxy p-tolyloxysilane (2.30). P-cresol (1.50 g, 13.9 mmol, 1 equiv) was 
dissolved in dry THF (60 mL) in a round bottom flask with a magnetic stir bar. 
Triethylamine (2.32 mL, 16.6 mmol, 1.2 equiv) and triethoxychlorosilane (3.27 
mL, 16.6 mmol, 1.2 equiv) were added to this solution. A white precipitate was 
immediately observed upon addition of the triethoxychlorosilane. The mixture 
was allowed to stir for 2 hours, after which the crude reaction mixture was 
centrifuged, the solution decanted, and the remaining solid was washed with dry 
THF (3x). The collected solution was concentrated under reduced pressure, and 
the crude product (2.36 g) was purified by flash column chromatography (SiO2, 
20:1 hexanes:EtOAc) to afford the title compound as a colorless oil (2.25 g, 8.3 
mmol, 60%).  
1H NMR (500 MHz, CDCl3): δ 7.04 (d, J = 8.5 Hz, 2H, CH3CCH), 6.91 (d, J = 8.5 
Hz, 2H, SiOCCH), 3.91 [q, J = 7.0 Hz, 6H, Si(OCH2CH3)3], 2.28 (s, 3H, 
CH3C6H4), and 1.24 [t, J = 8.0 Hz, 9H, Si(OCH2CH3)3]. 
13C NMR (125 MHz, CDCl3): δ 151.4, 131.2, 129.9, 119.0, 59.6, 20.6, and 18.0. 
HRMS (ESI) Calc’d for C13H22NaO4Si+ (M + Na+): 293.1180, found 293.1187. 
TLC (20:1 hexanes:EtOAc) Rf  = 0.40 
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3,17-Di-O-(Triethoxysilyl) estradiol (2.32).  Estradiol (50.0 mg, 0.184 mmol, 1 
equiv) was dissolved in 0.75 mL of dry THF in a 4 mL glass vial containing a stir 
bar. Triethylamine (100 µL, 0.72 mmol, 3.9 equiv) and triethoxychlorosilane (145 
µL, 0.74 mmol, 3.9 equiv) were added. The vessel was capped and allowed to 
stir overnight at ambient temperature. Incomplete conversion was noted by TLC; 
an additional aliquot of triethylamine (60 µL, 0.43 mmol, 2.3 equiv) and 
triethoxychlorosilane (80 µL, 0.41 mmol, 2.3 equiv) were added. The vial was 
again capped and stirred overnight. The reaction mixture was diluted with dry 
THF, the slurry centrifuged, the organic layer decanted, and the solution dried 
under reduced pressure. The product was redissolved in a minimal volume of 9:1 
hexanes:EtOAc and purified via flash column chromatography using 9:1 
hexanes:EtOAc as the eluent. A volatile contaminant was removed by high 
vacuum for 72 h, yielding the title compound (64.5 mg, 0.168 mmol, 91.3%) as a 
colorless oil. 
1H NMR (500 MHz, CDCl3)81: δ 7.15 (d, J = 8.5 Hz, 1H, H1), 6.79 (dd, J = 8.4, 2.6 
Hz, 1H, H2), 6.73 (d, J = 2.5 Hz, 1H, H4), 3.91 [overlapping q, J = 7.0 Hz, 6H, 
OSi(OCH2CH3)3 and d, 1H, H17], 3.86 [q, J = 7.0 Hz, 6H, OSi(OCH2CH3)3], 2.81, 
(m, 2H, H6α and H6β), 2.28 (ddd, J = 13.3, 7.0, 3.9 Hz, 1H, H11α), 2.17 (ddd, J = 
11.3, 11.3, 4.2 Hz, 1H, H9), 2.06 (m, 1H, H16β), 1.97 (ddd, J = 12.6, 3.2, 3.2 Hz, 
1H, H7β), 1.86 (dddd, J = 11.0, 8.0, 2.6, 2.6 Hz, 1H, H15α), 1.70-1.10 [m, 26H, 
???????????????????????????????????????? ????????????????????
81 1H NMR assignments were made with the assistance of: Ciuffreda, P.; Casati, S.; Manzocchi, 
A. Complete 1H and 13C NMR Spectral Assignment of 17-Hydroxy Epimeric Sterols with Planar A 
or A and B Rings. Magn. Reson. Chem. 2004, 42, 360–363. 
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H7α, H8, H11β, H12α, H12β, H14, H15β, H16α, OSi(OCH2CH3)3, 
OSi(OCH2CH3)3], and 0.79 (s, 3H, C18H3). 
13C NMR (75 MHz, CDCl3): δ 151.5, 138.1, 134.1, 126.4, 119.3, 116.5, 82.3, 
59.8, 59.4, 49.8, 44.3, 43.7, 39.0, 37.0, 30.5, 29.8, 27.4, 26.5, 23.3, 18.4, 18.3, 
and 11.5. 
HRMS (ESI) Calc’d for C30H52NaO8Si2 [M + Na]+ 619.3093, found 619.3098 
TLC Rf (1:1 hexanes:EtOAc) = 0.5.  
 
 
 
19-O-(Triethoxysilyl) hydrocortisone (2.34).  Hydrocortisone (53.3 mg, 0.147 
mmol, 1.0 equiv) was transferred to an oven-dried culture tube containing a stir 
bar. The hydrocortisone was dissolved with gentle heating in dry THF (1.0 mL). 
Pyridine (20 µL, 0.247 mmol, 1.7 equiv) and triethoxychlorosilane (40 µL, 0.204 
mmol, 1.4 equiv) were added by Wiretrol®. Immediately, a white precipitate was 
observed. The vessel was sealed with a Teflon®-lined cap, and the solution was 
stirred at room temperature while being monitored by TLC. After stirring for 3 h, 
the reaction mixture was diluted with hexanes:ethyl acetate (1:1), filtered through 
a short plug of Celite® to remove the pyridinium salt, concentrated under reduced 
pressure, and redissolved in a minimal amount of hexanes:ethyl acetate (1:1). If 
a slurry resulted, this was filtered prior to being loaded onto a silica gel column. 
Subsequent chromatography (SiO2, 1:1 hexanes: ethyl acetate) via medium 
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pressure liquid chromatography and concentration under reduced pressure 
yielded the title compound (65.2 mg, 0.124 mmol, 84.5%) as a colorless oil. 
1H NMR (500 MHz, CD3OD)82: δ δ 5.67 (s, 1H, H4), 4.91 (d, J = 18.7 Hz, 1H, 
H21a), 4.55 (d, J = 18.7 Hz, 1H, H21b), 4.40 (app q, J = 3.3 Hz, 1H, H11α), 3.88 
(q, J = 7.0 Hz, 6H, OSiOCH2CH3), 2.72 (ddd, J = 14.3, 11.1, 2.5 Hz, 1H, 16β), 
2.56 (dddd, J = 14.3, 14.3, 5.5, 1.9, 1H, H6β), 2.49 (ddd, J = 16.7, 13.6, 5.0 1H, 
H2β), 2.35-2.18 (m, 3H, H2α, H6α, and H1β), 2.10-1.99 (m, 3H, H8, H7β, and 
H12α), 1.88 (ddd, J = 13.5, 13.5, 4.4 Hz, 1H, H1α), 1.82-1.71 (m, 2H, H14 and 
H15α), 1.63 (dd, J = 13.6, 2.7 Hz, 1H, H12β), 1.50-1.34 (m, 5H, H16α, C19H3, 
and H15β), 1.23 [t, J = 7.0 Hz, 9H, OSi(OCH2CH3)3], 1.11 (dddd, J = 4, 11.5, 
11.5, 11.5 Hz, 1H, H7α), 1.00 (dd, J = 11.1, 3.3 Hz, 1H, H9), and 0.90 (s, 3H, 
C18H3). 
13C NMR (125 MHz, CDCl3): 206.0, 199.8, 172.5, 122.5,89.5, 68.6, 68.4, 59.7, 
56.2, 51.8, 47.7, 40.1, 39.4, 35.2, 34.0, 34.0, 32.9, 32.3, 31.6, 23.9, 21.2, 18.3, 
and 17.7. 
HRMS (ESI) Calc’d for C27H44NaO8Si [M + Na]+ 547.2698, found 547.2705. 
IR (thin film) 3450 (br), 2974, 2930, 1744, 1723, 1657, 1614, 1442, 1390, 1364, 
1271, 1232, 1165, 1104, 1079, 1007, 965, 947, 908, 865, 846, 793 and 736. 
TLC Rf (1:1 hexanes:EtOAc) = 0.55.  
 
 
???????????????????????????????????????? ????????????????????
82 1H NMR assignments were made with the assistance of: Kirk, D. N.; Toms, H. C.; Douglas, C.; 
White, K. A.; Smith, K. E.; Latif, S.; Hubbard, R. W. P. A Survey of the High-Field 1H NMR 
Spectra of the Steroid Hormones, their Hydroxylated Derivatives, and Related Compounds. J. 
Chem. Soc. Perkin Trans. 2 1990, 1567–1594.  
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19-O-(Tri-n-butoxysilyl) hydrocortisone (2.35). Hydrocortisone (44.0 mg, 
0.121 mmol, 1.0 equiv) was transferred to an oven-dried culture tube with a 
Teflon-lined cap and stir bar and dissolved in dry THF (2.0 mL). Pyridine (15 µL, 
0.185 mmol, 1.5 equiv) was added by Wiretrol.® A 1:1.05 mixture of tri-n-
butoxychlorosilane:tetra-n-butoxysilane (0.108 mg, 0.179 mmol, 1.5 equiv of tri-n-
butoxychlorosilane) was then added and a white precipitate was immediately 
observed. The culture tube was sealed and the solution was stirred at room 
temperature while being monitored by TLC. After stirring for 3 h, the reaction was 
diluted with a mixture of hexane:ethyl acetate (1:1), filtered through a short plug 
of Celite® to remove the pyridinium salt, concentrated under reduced pressure, 
and redissolved in a mixture of hexane:ethyl acetate (2:1). Subsequent 
chromatography (SiO2, 3:1 hexanes: ethyl acetate) via medium pressure liquid 
chromatography and drying under reduced pressure yielded the title compound 
as a colorless oil (60.4 mg, 0.096 mmol, 79.3%). 
1H NMR (500 MHz, CD3OD) 82: δ 5.66 (s, 1H, H4), 4.90 (d, J = 18.7 Hz, 1H, H21), 
4.54 (d, J = 18.7 Hz, 1H, H21), 4.40 (app. q, J = 3.3 Hz, 1H, H11α), 3.82 [t, J = 
6.5 Hz, 6H, OSi(OCH2CH2CH2CH3)3], 2.72 (ddd, J = 14.3, 11.1, 2.5 Hz, 1H, 16β), 
2.56 (dddd, J = 14.3, 14.3, 5.5, 1.8 Hz, 1H, H6β), 2.49 (ddd, J = 16.7, 13.7, 5.0 
Hz, 1H, H2β), 2.35-2.19 (m, 3H, H2α, H6α, and H1β), 2.11-2.01 (m, 3H, H8, H7β, 
and H12α), 1.88 (ddd, J = 13.5, 13.5, 4.5 Hz, 1H, H1α), 1.82-1.72 (m, 2H, H14 
and H15α), 1.62 (dd, J = 13.6, 2.7 Hz, 1H, H12β), 1.56 [tt, J = 6.6, 6.6 Hz, 6H, 
OSi(OCH2CH2CH2CH3)3], 1.47 (s, 3H, C19H3), 1.46-1.33 [m, 8H, H16α, H15β, 
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and OSi(OCH2CH2CH2CH3)3], 1.12 (m, 1H, H7α), 1.00 (dd, J = 11.1, 3.4 Hz, 1H, 
H9), 0.94 [t, J = 7.4 Hz, 9H, OSi(OCH2CH2CH2CH3)3], and 0.90 (s, 3H, C18H3). 
13C NMR (125 MHz, CDCl3): 208.5, 199.7, 172.5, 122.5, 89.5, 68.6, 68.5, 63.7, 
56.2, 51.8, 47.6, 40.2, 39.4, 35.2, 34.6, 34.0, 33.9, 32.9, 32.3, 31.6, 23.9, 21.2, 
19.0, 17.7, and 14.0. 
HRMS (ESI) Calc’d for C33H56NaO8Si [M + Na]+ 631.3637, found 631.3650. 
IR (thin film) 3475 (br), 2956, 2934, 2875, 1724, 1658, 1615, 1455, 1388, 1269, 
1233, 1091, 1042, 1008, 989, 945, 906, 864, 803, 763, 701, 637, and 623. 
TLC Rf (2:1 hexanes:EtOAc) = 0.35. 
 
 
 
19-O-(Tri-n-octyloxysilyl) hydrocortisone (2.36). Hydrocortisone (48.5 mg, 
0.134 mmol, 1.0 equiv) was transferred to an oven-dried culture tube with a 
Teflon-lined cap and stir bar and dissolved with gentle heating in dry THF (2.0 
mL). Pyridine (20 µL, 0.247 mmol, 1.8 equiv) was added by Wiretrol®. A 1.67:1 
mixture of tri-n-octyloxychlorosilane:tetra-n-octyloxysilane (0.165 mg, 0.212 
mmol, 1.6 equiv of tri-n-octyloxychlorosilane) was then added and a white 
precipitate was immediately observed. The culture tube was sealed and the 
solution was stirred at room temperature while being monitored by TLC. After 
stirring for 4 h, the reaction was diluted with a mixture of hexane:ethyl acetate 
(1:1), filtered through a short plug of Celite® to remove the pyridinium salt, 
concentrated under reduced pressure, and redissolved in a mixture of 
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hexane:ethyl acetate (3:1). Subsequent chromatography (SiO2, 3:1 hexanes: 
ethyl acetate) via medium pressure liquid chromatography and drying under 
reduced pressure yielded the title compound as a colorless oil (82.1 mg, 0.106 
mmol, 78.8%). 
1H NMR (500 MHz, CD3OD)82: δ 5.66 (s, 1H, H4), 4.89 (d, J = 18.7 Hz, 1H, H21), 
4.55 (d, J = 18.7 Hz, 1H, H21), 4.40 (app. q, J = 3.3 Hz, 1H, H11α), 3.81 {t, J = 
6.5 Hz, 6H, OSi[OCH2CH2(CH2)5CH3]3}, 2.72 (ddd, J = 14.3, 11.1, 2.5 Hz, 1H, 
16β), 2.56 (dddd, J = 14.3, 14.3, 5.5, 1.8 Hz, 1H, H6β), 2.50 (ddd, J = 16.7, 13.7, 
5.0 Hz, 1H, H2β), 2.35-2.19 (m, 3H, H2α, H6α, and H1β), 2.12-2.00 (m, 3H, H8, 
H7β, and H12α), 1.87 (ddd, J = 13.5, 13.5, 4.4 Hz, 1H, H1α), 1.82-1.72 (m, 2H, 
H14, and H15α), 1.63 (dd, J = 13.6, 2.7 Hz, 1H, H12β), 1.58 {tt, J = 6.6, 6.6 Hz, 
6H, OSi[OCH2CH2(CH2)5CH3]3}, 1.50-1.25 {m,35H, H16α, C19H3, H15β, and 
OSi[OCH2CH2(CH2)5CH3]3}, 1.12 (br dddd, J = 13.7, 13.7, 13.7, 4.4 Hz, 1H, H7α), 
1.00 (dd, J = 11.1, 3.4 Hz, 1H, H9), and 0.94-0.88 {overlapping s, 3H, C18H3 and 
t, J = 6.9 Hz, 9H, OSi[OCH2CH2(CH2)5CH3]3}. 
13C NMR (125 MHz, CDCl3): 208.5, 199.6, 172.4, 122.5, 89.5, 68.6, 68.5, 64.1, 
56.2, 51.8, 47.7, 40.3, 39.4, 35.2, 34.0, 33.9, 32.9, 32.5, 32.3, 32.0, 31.6, 29.6, 
29.5, 25.9, 24.0, 22.8, 21.2, 17.8, and 14.3. 
HRMS (ESI) Calc’d for C45H80NaO8Si [M + Na]+ 799.5515, found 799.5564. 
IR (thin film) 3400 (br), 2926, 2855, 1724, 1659, 1615, 1459, 1389, 1347, 1271, 
1232, 1183, 1096, 1059, 1006, 986, 907, 865, 813, 762, 742 and 725. 
TLC Rf (3:1 hexanes:EtOAc) = 0.35.  
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Tri-t-butoxyacetoxysilane (2.46).  To an oven-dried culture tube with stir bar, 
0.2980 g (1.127 mmol, 1 equiv) of tri-tert-butoxysilanol was added. This was then 
dissolved in 5 mL of dry THF. Next, 0.30 mL of acetic anhydride (3.18 mmol, 2.8 
equiv) followed by 0.010 g of DMAP (0.082 mmol, 0.073 equiv).  The reaction 
was sealed with a Teflon-lined, heated to 60 °C in an oil bath, and monitored by 
GC-MS. After 72 h, the volatile organic compounds were removed under 
concentrated under reduced pressure, and the residue redissolved in a mixture 
of 99:1 hexanes:EtOAc. The dissolved residue was split into two portions and 
purified sequentially by MPLC in 99:1 hexanes:EtOAc. The product was 
concentrated under reduced pressure to yield 0.1605 g (0.525 mmol, 46.5%) of 
the pure title product as a colorless oil.  
1H NMR (500 MHz, CDCl3): δ 2.09 [s, 3H, SiOC(O)CH3] and 1.33 {s, 27H, 
Si[OC(CH3)3]3}. 
LRMS (ESI) Calc’d for C14H30NaO5Si+ (M +  Na+): 329.2, found 329.2. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for three min) tR = 5.21 min; m/z 291 (20, M+-CH3), 233 [60, M+-OC(CH3)], 
177 (30), and 121 (100). 
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Ethoxy-tri-(1R,2S,5R)-2-isopropyl-5-methylcyclohexoxysilane (2.48). 
Trimenthyloxychlorosilane39 (166.2 mg, 0.306 mmol, 1 equiv) was added to an 
oven-dried 5 mL culture tube containing a stir bar and then dissolved in 3 mL of 
dry THF. Distilled pyridine (0.25 mL, 3.06 mmol, 10 equiv) and anhydrous 
ethanol, which had been dried over activated 3Å molecular sieves (0.18 mL, 3.06 
mmol, 10 equiv), were added. A white precipitate quickly formed. The reaction 
vessel was sealed with a Teflon®-lined cap, the reaction mixture was stirred at 
room temperature, and the reaction progress was monitored by GC/MS. After 0.5 
h no starting material remained, and the reaction slurry was filtered through a 
plug of glass wool to remove the pyridinium salt, concentrated under reduced 
pressure, and redissolved in a minimal amount of hexanes. If a slurry resulted, 
this was filtered prior to being loaded onto a silica gel column. Purification by 
MPLC using pure hexanes as the eluent yielded 0.0125 g of tetramenthyloxy 
orthosilicate and, in a later eluting fraction, the pure title product (113.6 mg, 0.211 
mmol, 69.0%) as a colorless oil.  
1H NMR (500 MHz, CDCl3): δ 3.816 (dq, J = 10.1, 7.0 Hz, 1H, SiOCHaHbCH3), 
3.809 (dq, J = 10.2, 7.0 Hz, 1H, SiOCHaHbCH3), 3.67 [ddd, J = 4.3, 10.4, 10.4 
Hz, 3H, Si(OCH)3], 2.26 {dsept, J = 2.6, 7.1 Hz, 3H [(CH3)2CH]3}, 2.10-2.01 [m, 
3H, Si(OCHCHACHE)3], 1.67-1.54 {m, 6H, [(CH3)2CHCHCHACHECHACHE]3}, 1.36 
[ddddq, J = 3.5, 3.5, 12, 12, 7 Hz, 3H, (CH3CH)3], 1.23 (t, J = 7.0 Hz, 3H, 
SiOCH2CH3), 1.23-1.12 {m, 3H [(CH3)2CHCH]3}, 1.02 {ddd, J = 10.7, 12.1, 12.1 
Hz, 3H, Si[OCHCHAHE]3}, 0.94 {dddd, J  = 3, 12, 12, 12 Hz, 3H, 
[(CH3)2CHCHCHAHE]3}, 0.90 [d, J = 6.5 Hz, 9H, (CH3)3], 0.89 [d, J = 7.1 Hz, 9H, 
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(CH3)3], 0.88-0.76 {m, 3H, [(CH3)2CHCHCH2CHAHE]3}, and 0.75 [d, J = 6.9 Hz, 
9H, (CH3)3]. 
13C NMR (75 MHz, CDCl3): δ 73.4, 59.0, 50.0, 45.0, 34.8, 31.9, 25.4, 22.9, 22.5, 
21.5, 18.3, and 15.8. 
HRMS (ESI) Calc’d for C32H62NaO4Si+ (M + Na+): 561.4310 found 561.4292. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for three min) tR = 12.16 min; m/z 538 (40, M+), 523 (10. M+-Me), 453 
(100), 399 (90), 315 (20), 261 (20), and 138 (60). 
IR (thin film) 2953, 2921, 2870, 1455, 1387, 1371, 1280, 1155, 1101, 1083, 1070, 
1052, 1002, 980, 963,939, 889, 831, 804, and 757. 
 
 
 
Tri-(1R,2S,5R)-2-isopropyl-5-methylcyclohexoxyacetoxysilane (2.49). 
Trimenthyloxychlorosilane39 (226.3 mg, 0.428 mmol, 1 equiv) was added to an 
oven-dried 5 mL culture tube containing a stir bar and dissolved in 5 mL of dry 
THF. Distilled pyridine (0.34 mL, 4.20 mmol, 10 equiv) and glacial acetic acid 
(0.24 mL, 4.19 mmol, 10 equiv) were added. Within minutes, a white precipitate 
formed. The vessel was sealed with a Teflon®-lined cap and monitored by 
GC/MS. After 4 h, no starting material remained, and the reaction was filtered 
through a plug of glass wool to remove the pyridinium salt, concentrated under 
reduced pressure, and redissolved in a minimal amount of 49:1 hexanes:EtOAc. 
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If a slurry resulted, this was filtered prior to being loaded onto a silica gel column. 
Purification by MPLC was completed using 49:1 hexanes:EtOAc as the eluent. 
The product was concentrated under reduced pressure to yield 0.0133 g of 
tetramenthyloxy orthosilicate and, in a later eluting fraction, the pure title product 
(139.2 mg, 0.252 mmol, 58.9%) as a colorless oil.  
1H NMR (500 MHz, CDCl3): δ 3.68 [ddd, J = 4.3, 10.5, 10.5 Hz, 3H, Si(OCH)3], 
2.23 {dsept, J = 2.3, 6.8 Hz, 3H [(CH3)2CH]3}, 2.10-2.01 [m, 3H, 
Si(OCHCHACHE)3], 2.07 [s, 3H, C(O)CH3], 1.67-1.56 {m, 6H, 
[(CH3)2CHCHCHACHECHACHE]3}, 1.37 [ddddq, J = 3, 3, 12, 12, 7 Hz, 3H, 
(CH3CH)3], 1.18 {dddd, J = 3.1, 4.6, 9.9, 12.2 Hz, 3H [(CH3)2CHCH]3}, 1.05 [ddd, 
J = 10.5, 12.1, 12.1 Hz, 3H, Si(OCHCHAHE)3], 0.95 {dddd, J = 2.8, 12.5, 12.5, 
12.5 Hz, 3H, [(CH3)2CHCHCHAHE]3}, 0.90 [d, J = 6.5 Hz, 9H, (CH3)3], 0.89 [d, J = 
7.1 Hz, 9H, (CH3)3], 0.83 {dddd, J = 3.1, 12.7, 12.7, 12.7 Hz, 3H, 
[(CH3)2CHCHCH2CHAHE]3}, and 0.76 [d, J = 6.9 Hz, 9H, (CH3)3]. 
13C NMR (75 MHz, CDCl3): δ 169.4, 74.2, 49.8, 44.7, 34.6, 31.8, 25.4, 23.0, 22.9, 
22.4, 21.4, and 15.9. 
HRMS (ESI) Calc’d for C32H62NaO5Si+ (M + Na+): 575.4102 found 575.4144. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 12 min, hold at 
290 °C for seven min) tR = 14.59 min; m/z 509 (100), 425 (10), 371 (20), and 139 
(40). 
IR (thin film) 2955, 2925, 2871, 1740, 1455, 1370, 1248, 1181, 1086, 1054, 1020, 
1004, 946, 893, 833, 794, 768, 749, and 715. 
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Tri-(1R,2S,5R)-2-isopropyl-5-methylcyclohexoxypivaloxysilane (2.50). 
Trimenthyloxychlorosilane39 (227.2 mg, 0.429 mmol, 1 equiv) was added to an 
oven-dried 5 mL culture tube containing a stir bar and dissolved in 5 mL of dry 
THF. Distilled pyridine (0.34 mL, 4.20 mmol, 10 equiv) and pivalic acid (437 mg, 
4.29 mmol, 10 equiv) were added. Within minutes, a white precipitate formed. 
The reaction was sealed with a Teflon®-lined cap, stirred at room temperature, 
and monitored by GC/MS. After 5 h, no starting material remained, and the 
reaction was filtered through a plug of glass wool to remove the pyridinium salt, 
concentrated under reduced pressure, and redissolved in a minimal amount of 
99:1 hexanes:EtOAc. If a slurry resulted, this was filtered prior to being loaded 
onto a silica gel column. Purification by MPLC was completed using 99:1 
hexanes:EtOAc as the eluent to yield the title product (137.9 mg, 0.232 mmol, 
54.1%) as a colorless oil.    
1H NMR (300 MHz, CDCl3): δ 3.77 [ddd, J = 4.3, 10.5, 10.5 Hz, 3H, Si(OCH)3], 
2.22 {dsept, J = 2.4, 7.0 Hz, 3H, [(CH3)2CH]3}, 2.10-2.00 [br m, 3H, 
Si(OCHCHACHE)3], 1.68-1.52 {m, 6H, [(CH3)2CHCHCHACHECHACHE]3}, 1.44-
1.27 [br m, 3H, (CH3CH)3], 1.23-1.12 {m, 3H [(CH3)2CHCH]3}, 1.21 [s, 9H, 
SiOC(O)C(CH3)3], 1.04 [ddd, J = 10.6, 12.0, 12.0 Hz, 6H, Si(OCHCHAHE)3], 0.95 
{dddd, J = 3.2, 12.2, 12.2, 12.2 Hz, 3H, [(CH3)2CHCHCHAHE]3}, 0.89 [d, J = 6.5 
Hz, 9H, (CH3)3], 0.88 [d, J = 7.0 Hz, 9H, (CH3)3], 0.89-0.74 {m, 3H, 
[(CH3)2CHCHCH2CHACHE]3}, and 0.74 [d, J = 6.9 Hz, 9H, (CH3)3]. 
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13C NMR (75 MHz, CDCl3): δ 177.1, 74.2, 49.8, 44.7, 39.7, 34.7, 31.8, 27.3, 25.5, 
23.0, 22.4, 21.4, and 16.0. 
HRMS (ESI) Calc’d for C32H62NaO4Si+ (M + Na+): 617.4572 found 617.4572. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 12 min, hold at 
290 °C for seven min) tR = 13.35 min; m/z 493 (10), 455 (30), 317 (30), 301 (20), 
179 (30), 163 (100), and 137 (20). 
IR (thin film) 2954, 2923, 2871, 1727, 1456, 1370, 1291, 1236, 1175, 1101, 1086, 
1054, 1003, 941, 905, 893, 831, 827, 813, and 730. 
 
 
An alternative, one-pot procedure for the synthesis of 2.49 and 2.50. An 
oven-dried two-neck round bottom flask fitted with an oven-dried addition funnel 
and stir bar was purged with dry N2. To this vessel, dry THF was added followed 
by the transfer of SiCl4 via a dried, glass syringe. Menthol (3.1-3.4 equiv) and 
pyridine (3.1-3.4 equiv) were co-dissolved in dry THF and transferred to the 
closed addition funnel. The solution of menthol/pyridine was added dropwise to 
the solution of SiCl4. The mixture was allowed to stir overnight. A final THF 
solution consisting of an excess of the carboxylic acid and pyridine (equimolar 
amounts) was prepared and transferred to the addition funnel, again allowing the 
solution to add to the bulk reaction dropwise. The reaction was again stirred at 
room temperature overnight. The reaction was filtered through a paper filter to 
remove the pyridinium salt, concentrated under reduced pressure, and 
redissolved in a mixture of hexanes and EtOAc. The product was then purified by 
MPLC with a mixture of hexanes and EtOAc as the mobile phase. 
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Di-t-butoxy-(1R,2S,5R)-2-isopropyl-5-methylcyclohexoxychlorosilane (2.52). 
An oven-dried 100 mL, 3-neck round bottom flask with an attached addition 
funnel and containing a magnetic stir bar was purged with N2 (g). To this 
apparatus, 15 mL of dry THF was added followed by the addition of SiCl4 (0.50 
mL, 4.36 mmol, 1.0 equiv) in an dry, air-tight glass syringe. Pyridine (1.1 mL, 
13.6 mmol, 3.1 equiv) was co-dissolved with t-butanol (1.3 mL, 13.6 mmol, 3.1 
equiv) in 10 mL of dry THF and transferred to the addition funnel. The solution of 
pyridine and t-butanol was added dropwise over the course of ca. 15 minutes to 
the solution of SiCl4 at room temperature. The reaction was monitored by 
GC/MS. After stirring at room temperature for 20 h under N2, a solution of 
pyridine (50 µL, 0.654 mmol, 1.5 equiv)  and menthol (0.101 g, 0.654 mmol, 1.5 
equiv) co-dissolved in 10 mL of dry THF was added dropwise over the course of 
ca. five minutes. The reaction mixture was stirred for an additional 22 h overnight 
at room temperature. The reaction mixture was filtered through a paper filter, 
concentrated under reduced pressure, and redissolved in a minimal amount of 
99:1 hexanes:ethyl acetate. If a slurry resulted, this was filtered prior to being 
loaded onto a silica gel column. Purification by MPLC using 99:1 hexanes:ethyl 
acetate as the eluent yielded the title compound (0.510 g, 1.40 mmol, 32%) as a 
colorless oil. 
1H NMR (500 MHz, CDCl3): δ 3.74 (ddd, J = 4.3, 10.4, 10.4 Hz, 1H, SiOCH), 2.24 
[dsept, J = 2.6, 7.1 Hz, 1H (CH3)2CH], 2.15-2.10 (m, 1H, SiOCHCHACHE), 1.66-
1.57 [m, 2H, (CH3)2CHCHCHACHECHACHE], 1.44-1.28 (m, 1H, CH3CH), 1.354 [s, 
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9H, SiOC(CH3)], 1.350 [s, 9H, OSiOC(CH3)], 1.20 [dddd, J = 2.5, 2.5, 10.1, 12.6 
Hz, 1H (CH3)2CHCH], 1.04 [ddd, J = 10.6, 12.2, 12.2 Hz, 1H, SiOCHCHAHE], 
0.95 [dddd, J = 3.1, 12.7, 12.7, 12.7 Hz, 1H, (CH3)2CHCHCHAHE], 0.90 (d, J = 
6.5 Hz, 3H, CH3), 0.89 (d, J = 7.1 Hz, 3H, CH3), 0.82 [dddd, J = 3.3, 12.4, 12.4, 
12.4 Hz, 1H, (CH3)2CHCHCH2CHACHE], and 0.77 (d, J = 6.9 Hz, 3H, CH3). 
13C NMR (75 MHz, CDCl3): δ 75.4, 75.3, 74.6, 49.8, 44.4, 34.7, 31.8, 31.4, 31.4, 
25.4, 22.9, 22.5, 21.4, and 16.0. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for five min) tR = 8.42 min; m/z 364/366 (5, M+), 349/351 (60, M+ - Me), 
279/281 (100), 223 (20), 155 (100), and 81 (90). 
IR (thin film) 2976, 2956, 2930, 2871, 1456, 1390, 1367, 1244, 1184, 1078, 1031, 
1003, 935, 883, 832, 800, and 760. 
 
 
 
Di-t-butoxyethoxy-(1R,2S,5R)-2-isopropyl-5-methylcyclohexoxysilane 
(2.53). Di-t-butoxychloro((2-isopropyl-5-methylcyclohexyl)oxy)silane (200. mg, 
0.549 mmol, 1 equiv) was added to an oven-dried 5 mL culture tube containing a 
stir bar, and dissolved in a premixed solution of pyridine (0.20 mL, 2.5 mmol, 4.5 
equiv) and anhdrous ethanol (0.16 mL, 2.8 mmol, 5.1 equiv) in 5.5 mL of dry 
THF. The reaction vessel was sealed with a Teflon®-lined cap and stirred at room 
temperature. A white precipitate was observed after stirring under the sealed 
tube for 60 h, at which time the reaction mixture was decanted to remove the 
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pyridinium salt, concentrated under reduced pressure, and redissolved in a 
minimal amount of 49:1 hexanes:EtOAc. If a slurry resulted, this was filtered prior 
to being loaded onto a silica gel column.  The solution was filtered through glass 
wool, and purfied by MPLC using 49:1 hexanes:EtOAc as the eluent. The 
product was concentrated under reduced pressure to yield the title product (133 
mg, 0.355 mmol, 64.7%) as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ 3.78 (q, J = 7.0 Hz, 2H, SiOCH2CH3) 3.64 (ddd, J = 
4.3, 10.5, 10.5 Hz, 1H, SiOCH), 2.30 [dsept, J = 2.7, 7.0 Hz, 1H (CH3)2CH], 2.13-
2.06 (m, 1H, SiOCHCHACHE), 1.65-1.55 [m, 2H,(CH3)2CHCHCHACHECHACHE], 
1.38 (ddddq, J = 3.1, 3.1, 11.9, 11.9, 6.7 Hz, 1H, CH3CH ), 1.31 [s, 18H, 
SiOC(CH3)3 and SiOC(CH3)3], 1.20 (t, J = 7.0 Hz, 3H, SiOCH2CH3), 1.16 [dddd, J 
= 3.0, 3.0, 10.2, 12.9 Hz, 1H (CH3)2CHCH], 1.01 [ddd, J = 10.7, 12.2, 12.2 Hz, 
1H, SiOCHCHAHE), 0.96, [dddd, J = 3.2, 12.8, 12.8, 12.8 Hz, 1H, 
(CH3)2CHCHCHAHE], 0.89 (d, J = 6.6 Hz, 3H, CH3), 0.88 (d, J = 7.1 Hz, 3H, CH3), 
0.81 [dddd, J = 3.2, 12.5, 12.5, 12.5 Hz, 1H, (CH3)2CHCHCH2CHACHE], and 0.77 
(d, J = 7.0 Hz, 3H, CH3). 
13C NMR (125 MHz, CDCl3): δ 73.0, 72.6, 72.5, 56.6, 49.8, 44.6, 34.6, 31.7, 31.4, 
31.3, 25.1, 22.7, 22.4, 21.3, 18.1, and 15.6. 
HRMS (ESI) Calc’d for C20H40NaO4Si+ (M + Na+): 397.2745 found 397.2746. 
IR (thin film) 2972, 2922, 2871, 1455, 1388, 1365, 1242, 1191, 1062, 1029, 1001, 
959, 882, 832, 815, 757, and 703. 
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Di-t-butoxy-(1R,2S,5R)-2-isopropyl-5-methylcyclohexoxyacetoxysilane 
(2.54). Di-t-butoxychloro((2-isopropyl-5-methylcyclohexyl)oxy)silane (96.4 mg, 
0.264 mmol, 1 equiv) was added to an oven-dried 5 mL culture tube containing a 
stir bar and dissolved in 1.0 mL of dry THF. Pyridine (0.21 mL, 2.6 mmol, 10 
equiv) and glacial acetic acid (0.15 mL, 2.6 mmol, 10 equiv) were added. The 
reaction vessel was sealed with a Teflon®-lined cap and stirred at room 
temperature. A white precipitate was formed after stirring for 16 h. The reaction 
was decanted to remove the pyridinium salt, concentrated under reduced 
pressure, and redissolved in a minimal amount of 99:1 hexanes:EtOAc, upon 
which a white precipitate formed immediately. The solution was filtered through 
glass wool, and purification by MPLC was completed using 99:1 hexanes:EtOAc 
followed 19:1 hexanes:EtOAc as the eleuents. The product was concentrated 
under reduced pressure to yield the title product (73.9 mg, 72.0%) as a colorless 
oil.  
1H NMR (300 MHz, CDCl3): δ 3.76 (ddd, J = 4.4, 10.5, 10.5 Hz, 1H, SiOCH), 2.26 
[dsept, J = 2.4, 7.0 Hz, 1H (CH3)2CH], 2.12-2.04 (m, 1H, SiOCHCHACHE), 2.09 
(s, 3H, COCH3), 1.67-1.52 [m, 2H, (CH3)2CHCHCHACHECHACHE], 1.46-1.35 (m, 
1H, CH3CH), 1.33 [s, 9H, SiOC(CH3)], 1.32 [s, 9H, SiOC(CH3)], 1.18 [dddd, J = 
2.7, 2.7, 10.3, 12.7 Hz, 1H (CH3)2CHCH], 1.02 (ddd, J = 10.5, 12.0, 12.0 Hz, 1H, 
SiOCHCHACHE), 0.91 [dddd, J = 2.9, 12.0, 12.0, 12.0 Hz, 1H, 
(CH3)2CHCHCHAHE], 0.90 (d, J = 6.4 Hz, 9H, CH3), 0.89 (d, J = 7.1 Hz, 9H, CH3), 
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0.85 [dddd, J = 3.0, 11.9, 11.9, 11.9 Hz, 1H, (CH3)2CHCHCH2CHAHE], and 0.76 
[d, J = 6.9 Hz, 9H, CH3). 
13C NMR (125 MHz, CDCl3): δ 168.6, 74.4, 74.3, 74.1, 49.9, 44.6, 34.7, 31.8, 
31.4, 31.4, 25.4, 23.4, 22.9, 22.5, 21.4, and 15.9. 
HRMS (ESI) Calc’d for C20H40NaO5Si+ (M + Na+): 411.2537 found 411.2529. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 13 min, hold at 
310 °C for seven min) tR = 8.18 min; m/z 373 (10, M+ - Me), 315 (50, M+ - OtBu), 
275 (20), 233 (20), 177 (20), and 121 (100). 
IR (thin film) 2975, 2955, 2928, 2871, 1740, 1456, 1389, 1367, 1245, 1194, 1079, 
1020, 944, 884, 834, 804, and 737. 
 
 
 
Di-t-butoxy-(1R,2S,5R)-2-isopropyl-5-methylcyclohexoxypropionoxysilane 
(2.55). Di-t-butoxychloro((2-isopropyl-5-methylcyclohexyl)oxy)silane (85.0 mg, 
0.233 mmol, 1 equiv) was added to an oven-dried 5 mL culture tube containing a 
stir bar and dissolved in 1.0 mL of dry THF. Pyridine (0.19 mL, 2.3 mmol, 10 
equiv) and propanoic acid (0.17 mL, 2.3 mmol, 10 equiv) were added. The 
reaction vessel was capped with a Teflon®-lined cap and stirred at room 
temperature. After stirring for 22 h, a white precipitate was observed. The 
reaction was decanted to remove the pyridinium salt, concentrated under 
reduced pressure, and redissolved in a minimal amount of 19:1 hexanes:EtOAc. 
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The slurry was filtered through glass wool, and purification by MPLC was 
completed by using 19:1 hexanes:EtOAc as the eluent. The product was 
concentrated under reduced pressure to yield the title product (81.6 mg, 90.2%) 
as a colorless oil. 
1H NMR (500 MHz, CDCl3): δ 3.76 (ddd, J = 4.3, 10.5, 10.5 Hz, 1H, SiOCH), 2.35 
[q, J = 7.5 Hz, 2H, SiOC(O)CH2CH3], 2.26 [dsept, J = 2.6, 7.0 Hz, 1H (CH3)2CH], 
2.11-2.05 (m, 1H, SiOCHCHACHE), 1.66-1.56 [m, 
2H,(CH3)2CHCHCHACHECHACHE], 1.38 (ddddq, J = 3.1, 3.1, 8.5, 8.5, 6.8 Hz, 
1H, CH3CH ), 1.33 [s, 9H, SiOC(CH3)3], 1.32 [s, 9H, SiOC(CH3)3], 1.18 [dddd, J = 
3.1, 3.1, 10.4, 12.9 Hz, 1H (CH3)2CHCH], 1.13 [t, J = 7.5 Hz, 3H, 
SiOC(O)CH2CH3], 1.02 (ddd, J = 10.6, 12.2, 12.2 Hz, 1H, SiOCHCHACHE), 0.94 
(dddd, J = 3.1, 12.7, 12.7, 12.7 Hz, 1H, (CH3)2CHCHCHAHE], 0.90 (d, J = 6.6 Hz, 
3H, CH3), 0.89 (d, J = 7.1 Hz, 3H, CH3), 0.81 (dddd, J = 3.2, 12.3, 12.3, 12.3 Hz, 
1H, (CH3)2CHCHCH2CHAHE], and 0.76 (d, J = 6.9 Hz, 3H, CH3). 
13C NMR (75 MHz, CDCl3): δ 172.4, 74.25, 74.22, 74.1, 49.9, 44.6, 34.7, 31.8, 
31.4 (x2), 29.7, 25.3, 22.8, 22.5, 21.4, and 15.9. 
HRMS (ESI) Calc’d for C21H42NaO5Si+ (M + Na+): 425.2694 found 425.2702. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 13 min, hold at 
310 °C for seven min) tR = 8.54 min; m/z 387 (5, M+ - Me), 329 (60, M+ - OtBu), 
289 (20), 247 (20), 191 (10), and 135 (100). 
IR (thin film) 2975, 2956, 2926, 2871, 1738, 1459, 1389, 1366, 1243, 1182, 1079, 
1031, 1001, 935, 895, 835, 804, 756, and 703. 
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Di (tri-t-butoxysilyl) phenyl phosphonic acid (2.67). Phenylphosphonic acid 
(81.7 mg, 0.517 mmol, 1 equiv) was suspended in a 1:1 mixture of dry THF and 
dry pyridine (1 mL total volume) in a 5 mL, oven-dried culture tube with a stir bar. 
The suspension was stirred for 10 mins, in which time the solution became 
homogenous. The purified tri-t-butoxychlorosilane (0.4262 g, 1.51 mmol, 2.9 
equiv) was added and immediately a white precipitate was observed. The culture 
tube was capped and allowed to stir for 4 h. The crude material was passed 
through a short Celite® plug and passed through a silica plug. Concentration 
under reduced pressure and redissolution in a mixture of 9:1 hexanes:EtOAc and 
subsequent purification by two MPLC columns in 9:1 hexanes:EtOAc. An 
unsymmetrical MPLC peak was noted. The title compound was obtained pure as 
a white solid. (116.5 mg, 34.7%) 
1H NMR (500 MHz, CDCl3): δ 7.93 (ddd, J = 1.3, 8.3, 14.4 Hz, 2H, o-Ar), 7.46 
(ttd, J = 1.3, 1.3, 7.5 Hz, 1H,  p-Ar), 7.40 (ddd, J = 4.2, 7.6, 7.6 Hz, 2H, m-Ar), 
and 1.27 [s, 54H, SiOC(CH3)3]. 
13C NMR (125 MHz, CDCl3): δ 132.7 (J = 196.8 Hz), 132.3 (J = 10.7 Hz), 131.2 
(J = 3.2 Hz), 127.5 (J = 15.7 Hz), 73.9, and 31.4. 
HRMS (ESI) Calc’d for C30H60O9PSi2+ (M + H+):651.3508, found 651.3512. 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for three min) tR = 11.23 min; m/z 577 (100, M+ -OtBu), 521 (10), and 279 
(30). 
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LC/MS (Method: C8 column, gradient 50-98% methanol content over two min, 
then isocratic at 98% methanol content for 13 min, DAD 215 nm, 254 nm, 300 
nm, and 350 nm, MW 121-1000, MM-ES+APCI Positive and MM-ES+APCI 
Negative) tR = 13.9 min (M-H+ 651.1). 
IR (thin film) 2976, 1473, 1391, 1367, 1264, 1245, 1187, 1135, 1074, 1030, 998, 
910, 837, 812, and 734. 
 
 
 
Benzylamino-tri-t-butoxysilane (2.78): Tri-t-butoxychlorosilane (200 µL, 0.71 
mmol, 1.0 equiv) was transferred to an oven-dried culture tube with a Teflon-lined 
cap and stir bar and dissolved in dry THF (2.0 mL). Pyridine (100 µL, 1.24 mmol, 
1.75 equiv) was added by Wiretrol®. Dry benzylamine (120 µL, 1.10 mmol, 1.55 
equiv) was then added, and a white precipitate was observed in seconds. The 
culture tube was sealed and the solution was stirred at room temperature while 
being monitored by GC/MS. After stirring for 40 m, the tri-t-butoxychlorosilane 
was > 90% consumed. After a total of 75 m, the reaction was diluted with 
hexanes (3 mL), filtered through a short plug of Celite®, concentrated under 
reduced pressure, and redissolved in a mixture of hexane:ethyl acetate (99:1). 
Silica chromatography (SiO2, 99:1 hexanes: ethyl acetate) via medium pressure 
liquid chromatography and drying under reduced pressure yielded the title 
compound as a colorless oil (39.6 mg, 0.11 mmol, 15.8%). 
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1H NMR (300 MHz, CDCl3): δ 7.40 (dd, J = 7.4, 2.1 Hz, 2H, CH2-o-Ph), 7.30 (dd, 
J = 7.6, 7.1 Hz, 2H, CH2-m-Ph), 7.20 (tt, J = 7.2, 2.3 Hz, 2H, CH2-p-Ph), 3.97 (s, 
2H, CH2Ph), and 1.31 {s, 27H, SiO[C(CH3)3]3}. 
13C NMR (75 MHz, CDCl3): 128.3, 127.5, 126.4, 72.4, 45.9, and 31.7. 
HRMS (ESI) Calc’d for C19H36NO3Si [M + H]+ 354.2459, found 354.2467. 
IR (thin film) 2974, 2930, 2870, 1495, 1471, 1454, 1388, 1364, 1240, 1191, 1054, 
1027, 909, 828, 786, and 739. 
GC/MS (Method: 30 °C, hold for two min; ramp at 20 °C/min for 14 min, hold at 
310 °C for five min) tR = 12.70 min; m/z 353 (25, M+), 338 (40, M+ - Me), 296 
(100, M+ - tBu), 282 (10), 240 (30), 184 (70), 168 (40), 139 (30), 91 (20), and 77 
(10). 
 
 
General procedure for the hydrolysis studies of 2.25-2.28. The silicate ester 
(0.016 mmol) was dissolved in 900 µL of d6-acetone. To this homogenous 
solution, 100 µL of a 9:1 v/v solution of D2O : TFA was added, and the solution 
was vigorously mixed. The 1H NMR spectra were recorded (16 transients) on a 
500 MHz instrument at multiple time points over the course of multiple half-lives. 
The study was conducted at ambient temperature (ca. 22.5 °C ± 1.0 °C). To 
judge the extent of conversion, the H1 resonances in the menthyl moiety of the 
starting material menthyl silicate and product menthol were integrated in a 
baseline-corrected NMR spectrum using MestRe-C® software. The relative 
integration values were used to determine the extent of hydrolysis. Data from 
three replications were plotted on a semi-log scale to determine the kobs values 
that were then converted to the krel data as presented. Errors are defined as the 
standard deviation of the three trials. 
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Chapter 3  
Synthesis and Development of  
Silicate Ester Prodrugs of Paclitaxel. 
 
1. Introduction. 
Use of a prodrug that has altered the physical, chemical, and/or biological 
characteristics (e.g., metabolic stability, solubility, or pharmacokinetics) of a drug 
is a widely known tactic.83,84 Most commonly, a prodrug is formed by a strategic 
chemical modification of the drug structure to impart advantageous physical, 
chemical, and/or biological properties. The prodrug is often therapeutically inert 
prior to activation by an in vivo chemical event (e.g., either chemical or metabolic 
hydrolysis, oxidation, or reduction) to regenerate the active agent. This concept 
of temporarily masking a property that is restored following a subsequent 
chemical cleavage event – not dissimilar to that of protecting group use in 
synthetic chemistry – has been widely applied to therapeutically relevant 
drugs,85,86 including the antitumor agent paclitaxel (PTX, 1.01).87 
???????????????????????????????????????? ????????????????????
83 Stella, V. J. A Case for Prodrugs. In Prodrugs. Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; 
Oliyai, R.; Maag, H.; Tilley, J. W., eds. Springer Science: New York, 2007, 3–33. 
84 Stella, V. J. Prodrugs as Therapeutics. Expert Opin. Ther. Patents, 2004, 14, 277–280. 
85 Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons Learned from Marketed and 
Investigational Prodrugs. J. Med. Chem. 2004, 47, 2393–2404.  
86 Testa, B. Prodrug Research: Futile or Fertile? Biochem. Pharmacol. 2004, 68, 2097–2106. 
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2. The Silicate Ester Prodrug Strategy.88 
1. Silicate Esters as Prodrugs. This fundamentally new prodrug strategy 
(Figure 3-1) is novel. As this concept was initially conceived and undertaken, the 
application of silicate esters as prodrugs was unprecedented,5,13,18 leading to an 
inherently “high risk, high reward” scenario that necessitated extensive work on 
multiple model systems (described in Chapter 2). The results from these proof-of-
principle studies led to the conclusion that silicate esters hold significant promise 
as a promoiety with strong potential to finely control physical and chemical 
properties. 
Figure 3-1. The silicate prodrug strategy: modification of a hydroxyl group in the 
drug with a trialkoxychlorosilane generates the (labile) silicate prodrug, which, 
following administration, undergoes hydrolysis to return the free drug along with 
alcohol and orthosilicic acid byproducts. 
 
 
The innovative silicate ester prodrug design is predicated upon the 
hypothesis that a hydrolytically-labile orthosilicate ester (i.e., a tetraalkoxysilane) 
is an enabling platform. In principle, any drug with a derivitizable hydroxyl group 
(c.f., “Drug” in Figure 3-1) can be modified with an electrophilic silylating agent, 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ????????????????????
87 Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel Prodrugs: Toward Smarter Delivery of 
Anticancer Agents. J. Med. Chem. 2006, 49, 7253–7269. 
88 Wohl, A. R.; Kalscheuer, S.; Lee, H. S.; Han, J.; McCormick, A.; Macosko, C. W.; Panyam, J.; 
Hoye, T. R. A Silicate Ester Prodrug Strategy and in vivo Efficacy of Paclitaxel Prodrug-loaded 
Nanoparticles. J. Am. Chem. Soc., submitted. 
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such as a trialkoxychlorosilane,89 resulting in a silicate ester prodrug (c.f., 
“Prodrug” in Figure 3-1). Hydrolytic cleavage catalyzed by a weak acid returns 
the parent drug while simultaneously liberating three equivalents of the sacrificial 
alcohol and orthosilicic acid (2.08). This basic strategy is attractive for both its 
simplicity as well as its general applicability to a variety of drug molecules  
2. Toxicological Profile of Orthosilicic Acid. Orthosilicic acid [a.k.a., silicic 
acid, Si(OH)4, compound 2.08] is an unavoidable byproduct of the prodrug 
cleavage depicted in Figure 3-1. Given the intended application of these 
prodrugs, it is prudent to preemptively consider the biological profile of Si(OH)4 
and its oligomers. Notably, orthosilicic acid (and oligomers thereof) are, in fact, 
present in humans; we excrete such species at a rate of approximately 75 
mg/day.90,91  
Significant toxicological issues from the use of silicate prodrugs are not 
anticipated, and numerous studies on biological silicon support this assertion. For 
example, the degradation of cross-linked microparticles of dialkoxydialkysilanes 
demonstrated no toxicity at concentrations up to 100 µg/mL in HeLa or SKOV3 
cells.17  Additionally, implanted medical devices constructed from elemental 
silicon metal (Si°) are approved by the Food and Drug Administration (FDA). 
These materials are known to oxidatively degrade to silicic acids, and no 
significant detrimental effects have been reported.47,92 Another study showed that 
a multi-gram charge of glass shards implanted subdermally in the back of a 
???????????????????????????????????????? ????????????????????
89 Corriu R. J. P.; Granier M.; Lanneau G. F. Synthesis and Reactivity of 
Bis(triethoxysilyl)methane, Tris(triethoxysilyl)methane and Some Derivatives. 1998 J. Organomet. 
Chem. 562, 79–88. 
90 Gitelman, H. J.; Alderman, F.; Perry, S. J. Renal Hnadling of Silicon in Normals and Patients 
with Renal Insufficiency. Kidney Int. 1992, 42, 957–959.   
91 Marco-Franco, J. E.; Torres, V. E.; Nixon, D. E.; Wilson, D. M; James, E. M.; Bergstrahl, E J.; 
McCarthy, J. T. Oxalate, Silicon, and Vanadium in Acquired Cystic Kidney Disease. Clin. Nephrol. 
1991, 35, 52–58. 
92 Lai, W.; Garino, J.; Flaitz, C.; Ducheyne, P. Excretion of Resorption Products from Bioactive 
Glass Impanted in Rabbit Muscle. J. Biomed. Mater. Res. Part A 2005, 75A, 398–407. 
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rabbit was cleared over a period of several months by hydrolytic breakdown to 
(and excretion of) Si(OH)4.92 Furthermore, “no toxicity was observed” upon 
treatment of rat neuronal cells with silicic acid at concentrations up to 100µM,93 
and studies where human subjects orally ingested aqueous silicic acid noted 
excretion within 24 h.90,91  
Despite this ample (albeit somewhat indirect) evidence for the in vitro and 
in vivo safety of orthosilicic acid and its oligomers, a control experiment was 
designed in collaboration with Stephen Kalscheuer, a graduate student in the 
laboratory of Prof. Jayanth Panyam (Department of Pharmaceutics, University of 
Minnesota) to further establish the safety of the byproducts of these degraded 
silicate prodrugs.94 In this study, tetraethoxysilane (2.07) and 
triethoxymenthoxysilane (2.25) were subjected to an in vitro cytotoxicity assay. 
MDA-MB-231 cells were treated with a solution of either 2.07 or 2.25 dissolved in 
dimethyl sulfoxide (DMSO) and compared to control cells that were exposed only 
to pure DMSO. After 48 hours, the cells were treated with 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphyenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) to 
assess the viability of the cell culture.95 In all cases (up to 10 µM concentrations 
of the silanes), cell viability was greater than 90% of the untreated control (Figure 
3-2). Generally, the results of the model silicate ester treatments and the control 
were the same within error, further demonstrating the in vitro safety of the 
prodrug degradation byproducts. 
???????????????????????????????????????? ????????????????????
93 Mayne, A. H.; Bayliss, S. C.; Barr, P. Tobin, M.; Buckberry, L. D. Biologically Interfaced Porous 
Silicon Devices. Phys. Status Solidi A – Appl. Res. 2000, 182, 505–513. 
94 Kalscheuer, S.; Panyam, J. University of Minnesota, Minneapolis, MN. Personal 
communication, 2012. 
95 Cory, A. H.; Owen, T. C.; Barltrop, J. A.; Cory, J. G. Use of an Aqueous Soluble 
Tetrazolium/Formazan Assay for Cell Growth Assays in Culture. Cancer Comm. 1991, 3, 207–
212. 
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Figure 3-2. The cell viability of two representative silicate ester prodrug models 
[tetraethoxysilane (2.07), blue and triethoxymenthoxysilane (2.25), red] was 
found to be similar to the control groups at all concentrations examined.94  
 
Error bars represent ± the standard deviation (SD) of the data. 
 
3. Paclitaxel (PTX).  
1. A Brief Overview of Clinical Formulations of Paclitaxel. Paclitaxel96 
(PTX, c.f. Scheme 1-1, 1.01), the most famous natural product of the taxane 
???????????????????????????????????????? ????????????????????
96 Originally, compound 1.01 was named “taxol,” leading to the still persistent confusion over the 
name of the drug molecule (i.e., taxol with a lower case “t”) vs. the drug formulation (i.e., Taxol® 
with an upper case “T”). Historically, it was found after the name taxol was in widespread use, 
Taxol® was a previously trademarked name of a minor drug. By the time this came to be common 
knowledge, “taxol” was already widely recognized by the general public as a “miracle drug.” To 
maintain the positive publicity that had already been garnered by this molecule, Bristol-Meyers 
Squibb (BMS), the eventual commercial producer and marketer of this chemotherapeutic, 
purchased the legal rights to the name Taxol® during commercialization. Thus, the chemical entity 
was renamed “paclitaxel” to attempt to alleviate further confusion and to reserve the name Taxol® 
for the clinical formulation of paclitaxel in Cremophor EL® (CrEL®).  For a more detailed history 
and commentary on this subject, see Kingston, D. G. I. The Shape of Things to Come: Structural 
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family, was originally isolated from the bark of the Pacific Yew tree. After its 
structure was elucidated,97 Horwitz and co-workers discovered that PTX induced 
cell death by the inhibition of tubulin depolymerization during cellular division – a 
mode of action unique at its time of discovery.98 PTX continues to draw 
considerable interest due to its highly desirable anticancer efficacy.99 However, 
despite promising cytotoxicity, it is too hydrophobic to be merely dissolved in, for 
instance, a saline solution and administered by traditional clinical routes [e.g., 
intravenous (IV) delivery]. Therefore, significant effort has been expended over 
the course of decades toward devising methods to formulate PTX for clinical use. 
Most often, this is done by employing the use of an excipient.  
In Taxol®, the most widely used commercial drug formulation of PTX, 
Cremophor EL® (CrEL®, a 1:1 (v/v) mixture of polyethoxylated castor oil and 
absolute ethanol)100 is used as an emulsification agent to effectively solubilize 
PTX. Previously, CrEL® has been safely used to formulate a wide variety of other 
drugs, including other antineoplastics, sedatives, and immunosuppressant. In 
these cases, the small volume (typically, only a few milliliters) of CrEL® that was 
necessarily administered had minimal side effects.101 In the Taxol® formulation, 
however, especially high loads of CrEL® are required for successful 
administration (specifically, Taxol® contains only 1.14 wt% of PTX and a typical 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ????????????????????
and Synthetic Studies of Taxol and Related Compounds. Phytochemistry 2007, 68, 1844–1854 
and references therein. 
97 Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant Antitumor Agents. VI. The 
Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from Taxus brevifolia. 
J. Am. Chem. Soc. 1971, 2325–2327. 
98 Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of Microtubule Assembly in vitro By Taxol. 
Nature 1979, 277, 665–667. 
99 Wang, Y.-F.; Shi, Q.-W.; Dong, M.; Kiyota, H.; Gu, Y.-C.; Cong, B. Natural Taxanes: 
Developments Since 1828. Chem. Rev. 2011, 111, 7652–7709. 
100  U.S. Food and Drug Administration. TAXOL® (paclitaxel) INJECTION.  2007.  
101 ten Tije, A. J.; Verweij, J.; Loos, W. L.; Sparreboom, A. Pharmacological Effects of 
Formulation Vehicles: Implications for Cancer Therapy. Clin. Pharmacokinet. 2003, 42, 665–685. 
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dose is composed of ca. 25 mL of CrEL®). Unfortunately, at these high levels, 
pharmacologically and biologically of CrEL® is particularly dangerous. This 
onerous biological activity hindered the early development of Taxol®, with a 
dramatic example of two deaths that were attributed to the dosed CrEL.® 
Thankfully, this issue has been mitigated by a 24 hour infusion protocol.102 Even 
today, however, a subpopulation of patients receiving Taxol® chemotherapy still 
experience significant, undesirable side effects, including, among others, serious 
acute hypersensitivity and peripheral neurotoxicity.101,103,104  
Accordingly, significant efforts have been devoted to eliminating the use of 
CrEL® by replacement with a more benign adjuvant. These have included studies 
of formulations based on nanoparticles, liposomes, emulsions, and micelles.103 It 
is beyond the scope of this (or any) thesis to comprehensively review all of these 
cases. Most notably, Abraxane® is a drug formulation of PTX that has been 
developed, earned FDA-approval, and brought to the market.  It eliminates CrEL® 
and its associated hypersensitivity105,106 by formulating PTX in human serum 
albumin at a much higher loading level than in Taxol® (Abraxane® is administered 
as approximately 10 wt% PTX).107 In addition to eliminating the CrEL®-induced 
side effects, the efficacy of Abraxane® may be improved by its proposed ability to 
???????????????????????????????????????? ????????????????????
102 Wiernik, P. H.; Schwartz, E. L.; Einzig, A.; Strauman, J. J.; Lipton, R. B.; Dutcher, J. P. Phase I 
Trial of Taxol Given as a 24-Hour Infusion Every 21 Days: Responses Observed in Metastatic 
Melanoma. J. Clin. Oncol. 1987, 5, 1232–1239. 
103 Hennenfent, K. L.; Govindan, R. New Formulations of Taxol: A Review. Old Wine in a New 
Bottle? Ann. Oncol. 2006, 17, 735–749 and references therein. 
104 Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The Drawbacks and 
Advantages of Vehicle Selection for Drug Formulation. Eur. J. Cancer 2001, 37, 1590–1598. 
105 Scripture, C. D.; Figg, W. D.; Sparreboom, A.  Paclitaxel Chemotherapy: From Empiricism to a 
Mechanism-Based Formulation Strategy.  Ther. Clin. Risk Manag.  2005, 1, 107–114. 
106 Sparreboom, A.; Baker, S. D.; Verweij, J.  Paclitaxel Repackaged in an Albumin-Stabilized 
Nanoparticle: Handy or Just Dandy?  J. Clin. Oncol.  2005, 23, 7765–7767. 
107 U.S. Food and Drug Administration. ABRAXANE™ for Injectable Suspension (paclitaxel 
protein-bound particles for injectable suspension) (albumin-bound). 2005. 
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uniquely target the albumin-specific gp60 receptors that are prolific on tumors.108 
However, the use of Abraxane® remains limited due to its high financial costs and 
its failure to increase the survival time of “first-line” cancer patients (i.e., those 
that have not yet received chemotherapy).109 Thus, it is currently approved only 
for “second-line” metastatic breast cancer patients (i.e., those patients that have 
been ineffectively treated with well-established chemotherapeutics).110  
2. Selected, Relevant Pre-Clinical Formulations of Paclitaxel. Another 
noteworthy effort that aims to eliminate CrEL® from PTX-containing 
chemotherapeutics is the relatively recent development of Genexol-PM®. This 
formulation utilizes poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-PLA) to 
create micelles containing PTX trapped in the hydrophobic micellular core. The 
inventors of this work claim loading levels of 16.7111 to 25 wt% PTX.112 These 
drug-loaded micelles are then lyophilized and redispersed in a 5% dextrose 
solution prior to administration. Genexol-PM® has shown considerable promise 
for the treatment of breast cancer, and it has completed Phase II clinical trials,113 
although it has not yet achieved full FDA-approval.  
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Evaluation of Polymeric Micellar Paclitaxel Formulation: Toxicity and Efficacy. J. Control. Release 
2001, 72, 191–202. 
112 Hangal-Joshi, R.; Gore, A. Y.; Rubinfeld, J.; Shrotriya, R. Paclitaxel Formulation. U.S. Patent 
6,538,020, August 1, 2002. 
113 Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, C. S.; Kim, S.-B.; Rha, S. Y.; Lee, M. Y.; 
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A second, recently reported formulation tactic for PTX was used to create 
Nanotax®.114 This innovation is notable in that it consists solely of PTX – no 
excipient is needed. This achievement is realized by spraying small droplets of 
an organic solvent containing dissolved PTX into supercritical carbon dioxide. 
Upon evaporation of the solvent, the resulting precipitated PTX microcrystal is 
approximately 600-700 nm.114 Administration of the Nanotax® suspension has 
shown preliminary promise in mouse in vivo tumor models115 and Phase I 
studies.116 
3. Docetaxel and its Formulation as Taxotere®. An additional on-the-
market taxane drug is significant. Docetaxel (3.01 in Figure 3-3) has been 
incorporated with polysorbate 80 (i.e., Tween 80®, 3.02 in Figure 3-3) to create 
Taxotere®.117,118 The structure of docetaxel varies subtly from PTX (the C3’ 
benzoyl amide is replaced by a C3’ boc carbamate and the C10 acetate in PTX is 
a hydroxyl in docetaxel), and it is slightly more water-soluble than PTX. The 
administration of docetaxel as Taxotere® eliminates the need for CrEL®, leading 
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Formulation of Paclitasel, in Patients with Metastatic Breast Cancer. Breast Cancer Res. Treat. 
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114 Niu, F.; Roby, K. F.; Rajewski, R. A.; Decedue, C.; Subramaniam, B. Paclitaxel Nanoparticles: 
Production Using Compressed CO2 as Antisolvent: Characterization and Animal Studies. In 
Polymeric Drug Delivery II; Svenson, S., ed. American Chemical Society: Washington, D. C., 
2006, 262–277. 
115 Roby, K. F.; Niu, F.;  Rajewski, R. A.; Decedue, C.; Subramaniam, B.; Terranova, P. F. 
Syngenic Mouse Model of Epithelial Ovarian Cancer: Effects of Nanoparticle Paclitaxel, 
Nanotax®. Adv. Exp. Med. Biol. 2008, 622, 169–181. 
116 Axiak, S. M.; Selting, K. A.; Decedue, C. J.; Henry, C. J.; Tate, D.; Howell, J.; Bilof, K. J.; Kim, 
D. Y. Phase I Does Escalation Study of Nanoparticulate Paclitaxel (CTI 52010) in Normal Dogs. 
Int. J. Nanomedicine 2011, 6, 2205–2212. 
117 Crown, J. Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical 
Experience. Oncologist 2004, 9, 24–32.  
118 Bernstein, B. Docetaxel as an Alternative to Paclitaxel after Acute Hypersensitivity Reactions. 
Ann. Pharmacother. 2000, 34, 1332–1335. 
Chapter 3 Silicate Ester Prodrugs of Paclitaxel? 
?
???
?
to minimal hypersensitivity in patients; however, neurotoxicity and poor drug 
distribution/clearance are still reported.119,120 
Figure 3-3. The chemical structures of the components of Taxotere® – docetaxel 
3.01 and Tween 80® 3.02. 
 
 
4. Hydrophilic Derivatives of PTX. Beyond improving PTX-containing 
chemotherapeutic formulations solely by improving the excipient load and 
properties, structural modifications of PTX have also been considered. Various 
PTX [and other taxane-based (e.g., docetaxel)] prodrugs and drug conjugates 
have been explored, in part with an eye toward identification of a bioactive agent 
that might no longer require the use of any formulation agent. Typically, these 
efforts have centered on increasing the hydrophilicity of the parent taxane, 
thereby improving its classical solubility parameters.87 For example, a non-
inclusive list of PTX prodrugs includes phosphate ester prodrugs,121,122 amino 
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acid conjugates,123 succinates,124 and sugar conjugates.125 Further efforts have 
been directed toward covalent conjugation of PTX to macromolecules such as 
poly(ethylene glycol),126,127,128 polysaccharides,129 and poly(amino acids).130 All of 
these compounds have been synthesized in attempts to increase the aqueous 
solubility of PTX. 
5. Hydrophobic Derivatives of PTX. Conversely (and, perhaps, ironically), 
the use of PTX prodrugs that are more hydrophobic than PTX itself has also 
been explored. The motivating hypothesis is that such prodrugs can be more 
efficiently loaded into the hydrophobic regions of the various encapsulating 
vehicles, thereby reducing the overall amount of excipient. Examples of such 
hydrophobic derivatives include modification of PTX as a steroidal (cholesterol) 
carbonate,131 phospholipid,132 fullerene,133 α-bromo fatty ester,134 or as a fatty 
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Complete Regression of Well-Established Tumors using a Novel Water-Soluble Poly(ʟ-glutamic 
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Formulation for a Lipophilic Paclitaxel Prodrug. Pharm. Res. 2004, 21, 2153–2157. 
Chapter 3 Silicate Ester Prodrugs of Paclitaxel? 
?
???
?
ester derivatives.8,135,136 Most notably, however, is the conjugation of 
docosahexaenoate (DHA) via ester bond formation at the C2’ hydroxyl to give a 
new DHA-PTX drug conjugate (3.03, Figure 3-4).137  3.03 has been studied in 
Phase III clinical trials.138  
Figure 3-4. The chemical structure of the DHA ester of PTX (3.03).  
 
All of these hydrophobic derivatives have demonstrated notably higher 
load levels within drug delivery vehicles. However, the PTX derivatives 
demonstrated lower (or no) in vitro activity at equimolar concentration vis-à-vis 
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132 Ansell, S. Lipophilic Drug Derivatives for Use in Liposomes. U.S. Patent 5,534,499, July 9, 
1996. 
133 Zakharian, T. Y.; Seryshev, A.; Sitharaman, B.; Gilbert, B. E.; Knight, V.; Wilson, L. J. A 
Fullerene-Paclitaxel Chemotherapeutic: Synthesis, Characterization and Study of Biological 
Activity in Tissue Culture. J. Am. Chem. Soc. 2005, 127, 12508–12509. 
134 Ali, S.; Ahmad, I.; Peters, A.; Masters, G.; Minchey, S.; Janoff, A. S.; Mayhew, E. Hydrolyzable 
Hydrophobic Taxanes: Synthesis and Anticancer Activities. Anti-Cancer Drugs 2001, 12, 117–
128. 
135 Lundberg, B. B.; Risovic, V.; Ramaswamy, M.; Wasan, K. M. A Lipophilic Pacltaxel Derivative 
Incorporated in a Lipid Emulsion for Parenteral Administration. J. Control. Release 2003, 86, 93–
100. 
136 Rodrigues, D. C.; Maria, D. A.; Fernandes, D. C.; Valduga, C. J.; Couto, R. D.; Ibanez, O. C. 
M.; Maranhao, R. C. Improvement of Paclitaxel Therapeutic Index by Derivatization and 
Association to a Cholesterol-Rich Microemulsion: in vitro and in vivo Studies. Cancer Chemother. 
Pharmacol. 2005, 55, 565–576. 
137 Bradley, M. O.; Webb, N. L.; Anthony, F. H.; Devanesan, P.; Witman, P. A.; Hemamalini, S.; 
Chander, M. C.; Baker, S. D.; He, L.; Horwitz, S. B.; Swindell, C. S. Tumor Targeting by Covalent 
Conjugation of a Natural Fatty Acid to Paclitaxel. Clin. Cancer Res. 2001, 7, 3229–3238. 
138 Bedikian, A. Y.; DeConti, R. C.; Conry, R.; Agarwala, S.; Papadopoulos, N.; Kim, K. B.; 
Ernstoff, M. Phase 3 Study of Docosahexaenoic Acid-Paclitaxel Versus Dacarbazine in Patients 
with Metastatic Malignant Melanoma. Ann. Oncol. 2011, 22, 787–793. 
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PTX against cancer cell lines,8,131,137 despite their higher loading capacity into 
encapsulating vehicles. Formulation of the PTX-DHA conjugate 3.03, for 
instance, is able to be formulated using ca. 20% less CrEL® than is required for 
PTX. Promising behavior in in vivo studies has been further observed, allowing 
the advancement of the DHA ester to a Phase III human clinical trial under the 
trade name of Taxoprexin®, but has not yet been FDA-approved or 
marketed.138,139  
These encouraging indications have further motivated our interest in the 
development of the novel silicate prodrug strategy introduced above, specifically 
in the context of (and as a forerunner to) PTX prodrug therapy. We aim to 
demonstrate the ability to control both the extent of hydrophobicity and the 
hydrolysis rate of a series of PTX-silicate prodrug candidates analogous to the 
alkoxy silicate ester models described in Chapter 2. We further note that this 
strategy has considerable potential for general applicability to many other 
prodrugs beyond PTX – as is detailed in sections 3.4 and 3.5. 
6. PTX Silicate Prodrug Design and Synthesis of Tetraalkoxy PTX Silicate 
Prodrugs.140 A suite of PTX silicate ester prodrugs 3.04-3.12 (Figure 3-5) was 
selected for study and synthesized in moderate to high yields. The members of 
this family differed in their i) hydrophobicity (e.g., 3.04 vs. 3.05), ii) anticipated 
hydrolytic lability based on steric differences (e.g., 3.04 vs. 3.06 vs. 3.07), iii) and 
sites of the silylated hydroxyl group (e.g., 3.04 vs. 3.08 vs. 3.11). The rationale 
for each of these systematic changes is described hereafter. 
???????????????????????????????????????? ????????????????????
139 Harries, M.; O’Donnell, A.; Scurr, M.; Reade, S.; Cole, C.; Judson, I.; Greystoke, A.; Twelves, 
C.; Kaye, S. Phase I/II study of DHA-Paclitaxel in Combination with Carboplatin in Patients with 
Advanced Malignant Solid Tumours. Br. J. Cancer 2004, 91, 1651–1655. 
140 Hoye, T. R.; Wohl, A. W.; Macosko, C. W.; Panyam, J. Silicate Prodrugs and Nanoparticles. 
U.S. Patent Application PCT/US2012/040247, May 31, 2012. This application claims priority to a 
provisional application filed on May 31, 2011. 
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Figure 3-5. The chemical structure of selected mono- and bis- trialkoxy silicate 
ester prodrugs of PTX.  
 
 
The differences in aliphatic chain length (e.g., 3.04 vs. 3.05) of the PTX 
silicate esters could yield three significant advantages. First, and most obviously, 
the differing hydrophobicities imparted from the sacrificial alkoxy substituents will 
lead to varied solubility in water. This, in turn, will likely affect the loading levels, 
encapsulation efficiencies, and/or stability of prodrug-loaded nanoparticles 
produced from the FNP process.8 Secondly, delivery of a highly nonpolar has the 
potential to result in improved cellular uptake8,131 and prolonged retention in the 
lipophilic portion of the cell wall prior to hydrolysis. This may, in turn, provide an 
improved cell kill. Additionally, inclusion of oily hydrocarbon side chains (e.g., n-
octyl as in 3.08) could minimize or eliminate the crystallinity of the silicate 
prodrug in the nanoparticle core – thereby favorably altering the drug release 
profile by depressing the initial “burst” release of the drug.141,142 
Variations in the steric bulk of the alkoxy substituents (e.g., 3.04 vs. 3.06 
vs. 3.07) build upon the well-established trends detailed in Chapter 2. While the 
???????????????????????????????????????? ????????????????????
141 Kim, I.-S.; Kim, S.-H. Development of a Polymeric Nanoparticulate Drug Delivery System: In 
vitro Characterization of Nanoparticles based on Sugar-Containing Particles. Int. J. Pharm. 2002, 
245, 67–73. 
142 Gӧrner, T.; Gref, R.; Michenot, D.; Sommer, F.; Tran, M. N.; Dellacherie, E. Lidocaine-loaded 
Biodegradable Nanospheres. I. Optimization of the Drug Incorporation into the Polymer Matrix. J. 
Control. Release 1999, 57, 259–268. 
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hydrolysis rate trends have been well-established in fully solvated model 
systems, the absolute hydrolysis rate of a prodrug encapsulated within a 
nanoparticle is difficult, if not impossible, to predict. Thus, prodrugs that will 
hydrolyze at substantially different rates (due to varying steric bulk and varying 
leaving group ability) were prepared and tested in IC50 studies. Feedback from 
these concurrent biological assays performed by our collaborators Stephen 
Kalscheuer and Prof. Jayanth Panyam will be crucial to the selection of prodrug 
with an acceptable rate of hydrolysis.   
Finally, the prodrugs were designed considering the literature precedent 
that the C2’-hydroxyl of PTX is both the most reactive of the three hydroxyls as 
well as critical to the bioactivity of the drug.143  The vast majority of true prodrugs 
(i.e., those for which there is evidence for formation of PTX after administration) 
functionalize PTX at this C2’ site.87 Alternatively, the C7-hydroxyl is also 
reasonably reactive, and the biological activity of PTX is less sensitive to minor 
alterations at this site. Such C7 derivatives often exhibit efficacy similar to the 
parent PTX, but many of the PTX conjugates at this position fail to provide 
convincing evidence of the true structure of the bioactive agent.87 The C1 
hydroxyl is generally inert to typical reaction conditions. Therefore, this family of 
PTX silicates (e.g., 3.04 vs. 3.08 vs. 3.11) conscientiously includes mono-
substituted prodrugs at either the C2’ and C7 positions as well as bis-silylated 
silicate prodrugs to further examine these issues. 
 
 
 
 
???????????????????????????????????????? ????????????????????
143 Zhu, Q.; Guo, Z.; Huang, N.; Wang, M.; Chu, F. Comparative Molecular Field Analysis of a 
Series of Paclitaxel Analogs. J. Med. Chem. 1997, 40, 4319–4328. 
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Scheme 3-1. Synthesis of the silicate prodrugs of PTX. Conditions: (a) 
SiCl(OR1)3, NEt3, THF. (b) i) SiCl2(OtBu)2, py, THF; ii) EtOH, py. (c) SiCl(OR)3, 
py, THF. (d) d6-acetone, D2O, TFA (90:9:1 v/v/v). Yields of chromatographed 
product: 3.04 (91%); 3.05 (81%); 3.06 (65%); 3.07 (84%); 3.08 (85%); 3.09 
(77%); 3.10 (67%) 3.11 (91%, brsm); and 3.12 (66%, brsm). brsm = based on 
recovered starting material. 
 
 
 
 Each compound was synthesized from PTX as outlined in Scheme 3-1. 
The 2’-triethoxy (3.04), 2’-trioctyloxy (3.05), and 2’-tri-i-propoxy (3.06) PTX 
silicates were synthesized via treatment with triethylamine (TEA) and the 
appropriate trialkoxychlorosilane. Subjecting PTX to tri-t-butoxychlorosilane in the 
presence of either TEA or pyridine led to no evidence of conversion to the 
desired 2’-tri-t-butoxy PTX silicate. (A similar observation has been made by my 
colleague in the Hoye labs, Andrew Michel, when using docetaxel as the taxane 
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substituent.144) Thus, the di-t-butoxyethoxy PTX silicate (3.07) was synthesized 
by treatment with the di-t-butoxydichlorosilane and pyridine. The reaction 
progress was followed by 1H NMR spectroscopy, and, upon observing complete 
consumption of PTX, a 100-fold excess of ethanol was added, yielding 
compound 3.07. 
Treating PTX with a stoichiometric excess (i.e., > two equivalents) of a 
trialkoxychlorosilane in the presence of TEA failed to provide any notable [via thin 
layer chromatography, (TLC)] conversion to the 2’,7-bis PTX silicate esters. 
Fortunately, optimization of the amine base led to the desired bis-silylation. 
Replacing TEA with the less basic but more nucleophilic pyridine as the amine 
base leads to high conversion of PTX to the bis-silicate esters. In this way, the 
2’,7-bis(triethoxy) (3.08), 2’,7-bis(tri-n-octyloxy) (3.09), and 2’,7-bis(tri-i-propoxy) 
(3.10) were successfully accessed.   
Finally, 3.08 and 3.09 were treated with TFA in a mixed d6-acetone/D2O 
co-solvent (precisely the same as the hydrolysis conditions utilized in the kinetic 
experiments; refer to sections 2.2.3 or 3.3.7). The selective degradation of the 
C2’ silicate ester was monitored by in situ 1H NMR spectroscopy. After ca. 2 half-
lives were observed, the reactions were quenched with a saturated NaHCO3 
solution, extracted, and purified from the starting material and PTX, resulting in 
reasonable yields of the 7-triethoxy (3.11) and 7-tri-n-octyloxy (3.12) PTX 
silicates. 
7. PTX Tetraalkoxy Silicate Prodrug Hydrolysis Studies. As in the models 
studies described in Chapter 2, 1H NMR spectroscopy was again used to 
establish relative hydrolysis rates and trends thereof for compounds 3.04-3.12. 
Using the previously established “standard hydrolysis conditions” (c.f., section 
2.2.3), each prodrug was dissolved in a solution of d6-acetone, D2O, and TFA in 
???????????????????????????????????????? ????????????????????
144 Michel, A. University of Minnesota, Minneapolis, MN. Personal communication, 2012. 
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a 90:9:1 ratio (v/v/v). Resonances of, e.g., H2’ in the reactant silicate vs. product 
carbinol were monitored. None of the partially hydrolyzed silanol intermediates 
arising from the tetraalkoxy silicates were observed in these compounds, 
reinforcing that the initial hydrolysis event (i.e., cleavage of the first Si–OR bond) 
is the rate-limiting step in the hydrolysis.  
Table 3-1. The hydrolysis rates of the PTX silicate prodrugs relative to that of the 
slowest (3.07). 
Prodrug at C2’   at C7 
  t1/2  kobs  krel a t1/2  kobs krel a 
  (min)  (10-3 s-1)  (min)  (10-3 s-1)   
 3.04 4.0 ± 1.3 3.1 ± 0.9 2200 ± 600 n/a b n/a n/a 
 3.05 12 ± 1 0.10 ± .04 710 ± 30 n/a n/a n/a 
 3.06 120 ± 10 0.097 ± 0.006 69 ± 4 n/a n/a n/a 
 3.07 1200 ± 100 0.0014 ± 0.0001 1.0 ± 0.1 n/a n/a n/a 
 3.08 4.6 ± 0.1 2.5 ± 0.1 1800 ± 100 33 ± 2 0.35 ± 0.02 250 ± 10 c 
 3.09 18 ± 1 0.64 ± 0.01 460 ±10 200 ± 10 0.058 ± 0.004 41 ± 3 d 
 3.10 n.d. e n.d. n.d. n.d. n.d. ca. 50 f 
 3.11 n/a n/a n/a 31 ± 1 0.38 ± 0.01 270 ± 10 
 3.12 n/a n/a n/a 150 ± 10 .077 ± .005 55 ± 3  
 a The krel values displayed in Table3-1 are referenced such that the most 
slowly-hydrolyzing prodrug, 3.07, krel = 1.  
 b n/a = not applicable 
 c The rate of hydrolysis of in situ generated 3.07 to PTX.  
 d The rate of hydrolysis of in situ generated 3.08 to PTX. 
 e n.d. = not determined  
 f The rate of hydrolysis of in situ generated of 7-O-(tri-i-propoxysilyl)paclitaxel 
to PTX was not rigorously established because it was not a candidate for 
biological studies described in section 3.3.8. 
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As anticipated, the results (Table 3-1) show that increasing the steric bulk 
of the silicate prodrug slows its hydrolysis rate. The krel values (here, referenced 
to the most slowly hydrolyzed prodrug, 3.07) differ by > 2000-fold between the 
extremes of the 2’-triethyl PTX-silicate 3.04 to the hindered 2’-di-t-butylethyl PTX-
silicate 3.07. The hydrolysis rates for 3.04 and 3.05 were similar (krel of a factor of 
ca. 3), demonstrating that the hydrophobicity of the PTX silicate can be 
significantly increased with only a small change in the relative hydrolysis rate. 
(This result is in line with expectations derived from the menthol-based silane 
model systems in section 2.3.1.) As a group, prodrugs bearing the silicate at C7 
hydrolyzed ca. 10x slower than those at C2’.  
It is interesting to note that the absolute rate of hydrolysis in the PTX-
based silicate ester prodrugs was faster than predicted from the menthol models. 
Specifically, TEOS 2.07 and triethoxymenthoxysilane 2.25 were found to exhibit 
kobs values of 3.7 ± 0.2 s-1 and 0.67 ± 0.04 s-1, respectively. In contrast, the kobs 
value measured for the related secondary, PTX-based triethoxy silicate 3.04 was 
3.1 ± 0.9 s-1. An analysis based purely upon steric bulk would suggest that 2.25, 
consisting of a branched secondary hydroxyl, would be a more reasonable model 
for 3.04.  
Previous, related work has shown that a nucleophilic primary amine at the 
C3’ position in isotaxel (3.13) is able to rapidly (t1/2 = 15 min at pH = 7.4) induce 
an O-N acyl migration.145,146 The hydrolysis rate variance from the menthol model 
in our PTX silicate prodrugs may be attributed to similar nucleophilic capabilities 
of the C3’ amide, generating a transient, highly activated tetravalent silicon 
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145 Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sohma, Y.; Kumura, T.; Kiso, Y. A Novel 
Approach of Water-Soluble Paclitaxel Prodrug with No Auxiliary and no Byproduct: Design and 
Synthesis of Isotaxel. J. Med. Chem. 2003, 46, 3782–3784. 
146 Sohma, Y.; Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sasaki, M.; Kimura, T.; Kiso, Y. O-N 
Intramolecular Acyl Migration Reaction in the Development of Prodrugs and the Synthesis of 
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moiety (i.e., 3.14 in Scheme 3-2) to substitute the first alkoxy substituent. This 
potential, short-lived intermediate may then be consumed by water more rapidly 
than originally anticipated.   
Scheme 3-2. O-N Acyl transfer of isotaxel (3.13) and the postulated, related 
participation of the benzoyl amide functioning as an activator (3.14) of the rapid 
silicate hydrolysis.  
 
 
However, despite differences from the expected (but ultimately 
inconsequential) absolute rate, the observed trends were quite comparable to 
those measured for the menthol-containing silicate ester models (Table 3-2). For 
example, the bis-trialkoxy PTX silicates 3.08, 3.09, and 3.10 were compared with 
the analogous menthol models 2.25, 2.27, and 2.28 (ethyl, n-octyl, and i-propyl, 
respectively). When the krel values of all compounds were referenced to the 
respective parent triethoxy silicate ester, the PTX trends aligned well with the 
patterns found in the menthoxy silicate ester models. In addition to further 
validating the model work performed in Chapter 2, the desired generality of these 
trends was supported by the closely related patterns observed for both C2’ and 
C7 silicates. 
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Table 3-2. A comparison of observed hydrolysis rates of the PTX silicate 
prodrugs and the menthoxytrialkoxysilanes. 
 Menthoxy  PTX at C2’ at C7 
 Silicate krel a Silicate krel b krel c 
 ________ ___________ ___ ______________________ 
 2.25 1.0 ± 0.06 3.08 1.0 ± 0.06 1.0 ± 0.06 
 2.27 0.22 ± 0.01 3.09 0.22 ± 0.01 0.17 ± 0.01 
 2.28 0.084 ± 0.004 3.06 / 3.10 d 0.033 ± 0.002 ca. 0.028 
 a The rate of hydrolysis referenced to krel = 1 for 2.25.  
 b The rate of hydrolysis referenced to krel = 1 for the C2’ silicate of 3.08.  
 c The rate of hydrolysis referenced to krel = 1 for the C7 silicate of 3.08.  
 d The krel for the C2’ silicate is taken from the mono-silicate 3.06 and the krel 
for the C7 silicate is taken from the bis-silicate 3.10.  
 
8. Acyloxy-Containing PTX Silicate Prodrug Design and Synthesis. 
Encouraged by the reliable translation of the menthoxy silicate ester models, I 
aimed to apply the principles delineated in section 2.3.4 and synthesize PTX 
silicate esters that were yet more labile than 3.04. Thus, the expansion of the 
acyloxy-containing silicate esters was applied to the design of a rapidly 
hydrolyzing PTX analog. Anticipating a highly labile compound, t-butoxy groups 
were chosen as the sacrificial alkoxies during this prodrug development. An initial 
attempt to pre-form the acetoxy-di-t-butoxychlorosilane in situ followed by 
addition of PTX was unsuccessful. However, following a strategy similar to the 
synthesis of 3.07, PTX was treated with di-t-butoxydichlorosilane, leading to the 
successful formation of intermediate 3.15 (Scheme 3-3).147 It was often 
necessary to add an excess of acetic acid and pyridine prior to quantitative 
???????????????????????????????????????? ????????????????????
147 Analysis of crude 1H NMR data demonstrated a characteristic shift of the C2’ methine from a 
doublet (δ = 4.78) to a pair of diastereotopic doublets (δ = 5.03 and 5.01 in an ca. 3:2 ratio) 
assigned to 3.14. 
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conversion of PTX to 3.15 (due to the observation of a byproduct148 in the crude 
1H NMR spectrum), the major product was isolated in a moderate yield after 
MPLC chromatography. Spectroscopic and mass analysis confirmed this 
compound as the desired PTX silicate ester prodrugs 3.16.  
Interestingly, compound 3.18 was isolated (in low yield) when the crude 
reagent di-t-butoxydichlorosilane (i.e., a sample still containing unreacted t-
butanol) was used during attempts to synthesize 3.15 (Scheme 3-3). As 
previously discussed, attempts to synthesize 3.18 by treatment of PTX with tri-t-
butoxychlorosilane, even at elevated temperatures and large reagent excesses, 
led to no evidence of conversion to 3.18. (Similar observations have been made 
with docetaxel.144) The origin of this apparent discrepancy is not clear — both 
PTX and t-butanol are bulky substituents leading to highly hindered 
chlorosilanes. It is difficult to imagine a scenario in which there is a notable 
difference in substitution at the silicon center. Further efforts toward the synthesis 
of 3.18 were not pursued, as 3.07 could be synthesized reliably to serve as a 
“slowly hydrolyzing” PTX prodrug in biological studies.149  
An analogous strategy was exploited to synthesize a presumably more 
stable acyloxy silicate, 3.19 (Scheme 3-3). Pivalic acid was used in place of 
acetic acid, but in situ analysis by 1H NMR of the preformed chlorosilane 3.15 
showed a significantly slower rate of incorporation. The reaction was sufficiently 
slow (Table 3-3) such that hydrolysis of 3.15 by adventitious water was 
competitive with acyl substitution. Thus, the reaction was stopped prior to full 
conversion, and the desired PTX silicate 3.17 was isolated only in a low yield. 
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148 This byproduct was later found to be the PTX-containing di-t-butoxysilanol 3.18, confirmed by 
the HR-MS and the independent synthesis of 3.18. 
149 Subjecting 3.17 to the “standard hydrolysis conditions” led to a t1/2 > 400 h, at which point the 
experiment was discontinued.  
Chapter 3 Silicate Ester Prodrugs of Paclitaxel? 
?
????
?
Scheme 3-3. The synthetic route used to access the acyloxy-di-t-butoxy PTX 
silicate ester prodrugs 3.16 and 3.17 and the unexpected byproduct 3.18. 
 
 
 
Table 3-3. A correlation of time and conversion of PTX acyloxy silicate prodrugs. 
 Prodrug Substituent Time Conversion 
   (h) (%)  
 
 3.07 Ethoxy 72 > 99 
 3.16 Acetoxy 24 85  
 3.17 Pivaloxy 120 20  
  
 
9. PTX Acyloxy Silicate Prodrug Hydrolysis Studies. 1H NMR spectroscopy 
and the extensively used hydrolytic conditions [90:9:1 d6-acetone:D2O:TFA 
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(v/v/v)] were again employed to study the degradation of 3.16. The krel, as 
defined by the degradation of the parent compound 3.16 and referenced to 3.07, 
was found to be 240 ± 10 (t1/2 = 35 ± 2 mins). This is a significantly faster 
hydrolysis than that observed for 3.07 (a prodrug of similar steric bulk), but, 
unfortunately, still slower than the triethoxy PTX silicate 3.04.  
Perhaps the most interesting experimental result during the hydrolysis of 
3.16 was the detection of a long-lived intermediate (Figure 3-6). This 
intermediate was found to be sufficiently stable, allowing isolation via MPLC and, 
subsequently, full characterization. This work led to the identification of the 
intermediate it as the PTX-silanol 3.19 (Scheme 3-4). (The observation of a 
silanol is not unprecedented – recall that an intermediate silanol was detected in 
the hydrolysis of the highly hindered silicate ester model 2.58.) The pure silanol 
3.19 was subjected to identical hydrolysis conditions, and the krel value (relative 
to 3.07 as krel = 1) was measured to be 4.8 ± 0.2 (t1/2 = 250 ± 10 mins).  
Scheme 3-4. The hydrolysis of 3.16 to a stable, isolable silanol intermediate 3.19 
that reverts to free PTX upon further exposure to the hydrolytic conditions.  
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Figure 3-6. Representative 1H NMR spectra showing the hydrolysis of starting 
material 3.16 (H2’ resonance most downfield, ?) to stable intermediate 3.19 (H2’ 
resonance center, ?) and subsequent hydrolysis of 3.19 to free PTX 1.01 (H2’ 
resonance most upfield, ?).  
 
 
 
These observations led to limited analysis of the more stable (and thus 
more slowly hydrolyzing) pivalate derivative 3.17. In the case of 3.17, the rate 
limiting step of the hydrolysis could be either cleavage of the initial Si-O-acyl or 
the hydrolysis of silanol 3.19. Regardless, compound 3.17 would ultimately prove 
to be ineffective as a “more rapidly hydrolyzing prodrug,” as both 3.17 and 3.19 
would hydrolyze significantly more slowly than 3.04. If more rapidly hydrolyzing 
silicate prodrugs were deemed necessary, future work could incorporate i-
propoxy rather than t-butoxy substituents, opening the possibility of faster 
hydrolysis and reasonable stability to chromatography. This work has not yet 
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been pursued, however, due to feedback from concurrent biological studies 
detailed in the upcoming section 3.3.11. Briefly, these studies indicate that 
numerous trialkoxy PTX silicates hydrolyze at sufficiently fast rates, thereby 
diminishing motivation for the optimization of acyloxy-containing PTX silicate 
prodrugs. 
10. Mechanistic Studies of the Hydrolysis of 3.16. During the hydrolysis of 
3.16, the initial bond cleavage of the Si-O-acyl was not the rate limiting step. This 
led to the unique (among the other PTX-prodrugs) formation of a PTX-based 
silanol, 3.19. While the formation of an intermediate is decidedly negative from 
an application viewpoint, [the FDA would require safety data to be obtained 
separately for all intermediate(s)] the stability of 3.19 allows us to address an 
important scientific question. Namely, are the acyloxysilanes more rapidly 
hydrolyzed because the acyl group is a better leaving group or because there is 
a less sterically congested, electrophilic carbonyl carbon available to the 
nucleophilic water?  
While the SN2 nature of tetraalkoxy silicate ester substitution is well 
accepted,27 the stereochemical result of acyloxysilanes is considerably less 
studied. Minimally, precedent exists to suggest nucleophilic attack selectively at 
the electrophilic carbonyl is favored over direct substitution at silicon in specific, 
sterically constrained examples. Notably, Eaborn and co-workers have reported 
exclusive acyl-oxygen fission in the methanolysis of extremely hindered trisyl 
derivatives of trialkylacetoxysilanes.150 If this result held true in the case of 3.16, 
the mechanism of hydrolysis could proceed through a mechanism other than an 
SN2 mechanism. 
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150 Damja, R. I.; Eaborn, C.; Saxena, A. K. Acyl-Oxygen Fission in Reactions of Oragnosilicon 
Carboxylates with Sodium Methoxide in Methanol. J. Chem. Soc. Perkin Trans. II 1985, 2, 597–
598. 
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Defining the mechanism of hydrolysis in our PTX system (i.e., 3.16) was 
deemed critical to the rational design of future silicate ester prodrugs – not just in 
the specific case of PTX silicate esters but also for the development of this 
strategy more generally. Thus, isolation of the silanol intermediate 3.19 was 
undertaken to aid in the identification of the atomic location of the nucleophilic 
substitution. Namely, if substitution occurs directly at silicon (blue dashed arrow, 
Figure 3-7), the lability of the silicate ester is controlled at least primarily by the 
steric bulk and leaving group ability of the substituents. However, it is plausible 
that the accelerated rate of hydrolysis is the result of water attacking the 
electrophilic carbonyl in the acyloxy substituent (red solid arrow, Figure 3-7), 
resulting in cleavage of the O-acyl bond as the first step in the hydrolysis.  
Figure 3-7. The potential modes of nucleophilic attack in the acyloxy-containing 
PTX silicate ester prodrug 3.16 include direct displacement at the silicon (solid 
blue arrow) or the electrophilic carbonyl (dashed red arrow).  
 
 
 
The possible results described above in Figure 3-7 may be distinguished 
by a properly controlled isotopic labeling study. In this vein, the mechanistic study 
was conducting by partially hydrolyzing 3.16 in the presence of O18-labeled water 
(Scheme 3-5). Such conditions resulted in isolation (via MPLC) of solely the 18O-
labeled silanol 3.20 (as determined by ESI-HRMS). While such results are 
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strongly indicative of direct substitution of water at silicon, this single result fails 
to rule out post-hydrolysis exchange of 16O and 18O. Therefore, as an additional 
control, pure 3.20 was resubjected to the reaction conditions containing 16O 
water to test for hydroxyl exchange. Gratifyingly, even after submitting 3.20 to an 
identical acid catalyst load for an identical amount of time, only 3.20 and PTX 
(1.01) were obtained upon purification.  
Scheme 3-5. The hydrolysis of 3.16 in the presence of 18O-labeled water 
resulted in the exclusive formation of the 18O-labeled PTX silanols 3.20.  
 
 
 
In the specific context of PTX prodrugs, 3.16 hydrolyzed at a faster rate 
than the analogous di-t-butoxyethoxy PTX silicate 3.07, but its measured kobs 
value was still considerably slower than several of the other prodrug consisting of 
less hindered alkoxies (i.e., 3.04). However, potential exists for yet faster 
hydrolyzing prodrugs to be synthesized by, for instance, incorporating i-propoxy 
rather than t-butoxy alkoxy substituents. These compounds were not further 
pursued because ongoing biological studies (see section 3.3.10) indicated that 
linear, aliphatic prodrugs such as 3.04, 3.05, and 3.08 were hydrolyzing at 
sufficiently fast rates in in vitro studies to maintain drug efficacy. In a broader 
sense, these results offer convincing evidence of direct nucleophilic substitution 
of water at silicon. The leaving group ability, rather than inclusion of an 
electrophilic carbonyl, is the key to the generation of rapidly hydrolyzed prodrugs. 
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This information will instruct the design of potential, future, labile silicate prodrugs 
of other active agents.  
11. PTX Silicate Prodrug in Vitro Cytotoxicity Studies.88,151 A subset of 
PTX silicate prodrugs (3.04, 3.05, 3.06, 3.07, 3.08, 3.11, and 3.12) were selected 
for in vitro cell cytotoxicity assays during a productive collaboration with the 
group of Prof. Jayanth Panyam. Stephen Kalscheuer, a student in the Panyam 
group, grew and plated MDA-MB-231 cells prior to treatment with DMSO 
solutions of varying concentrations of a PTX silicate prodrug. Following an 
incubation period of 48 hours, the cells were treated with a solution of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent. Viable cells 
are known to reduce MTT, and absorbance measurements taken at 490 nm are 
reliably correlated to the number of viable cells.152  
The IC50 results are summarized in Table 3-4. Generally, the faster 
hydrolyzing prodrugs 3.04, 3.05, 3.06, 3.08, and 3.11 all exhibited IC50 values 
statistically equivalent to the parent PTX compound.  Prodrug 3.07 which 
hydrolyzes exceedingly slowly was found to have significantly decreased 
efficacy. Comparatively, prodrugs 3.04-3.06 and 3.08, all of which hydrolyze at 
much faster relative rates than 3.07, demonstrated IC50 values statistically 
equivalent to that of the free PTX. 
Interestingly, silylation at the less sensitive C7 position, as in prodrugs 
3.11 and 3.12 gave differing results. The faster hydrolyzing prodrug 3.11 resulted 
in a statistically equal cytotoxicity value as PTX. However, the more slowly 
hydrolyzing and marginally bulkier silicate, 3.12, demonstrated a significantly 
diminished cytotoxic effect. Given this result, we found that we were unable to 
???????????????????????????????????????? ????????????????????
151 These IC50 cytotoxicity studies were performed by Stephen Kalscheuer. Kalscheuer, S. 
University of Minnesota, Minneapolis, MN. Personal communication, 2012. 
152 Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to 
Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55–63. 
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infinitely increase the lipophilicity of the prodrug at the at the C7 position while 
retaining sufficient efficacy. Presumably, the reported biological tolerance at this 
site is, as are all parameters, relative. Clearly, the rate of hydrolysis back to the 
parent drug needs to be considered at both the C2’ and C7 hydroxyls. 
Table 3-4.151 The measured cytotoxicity of PTX and PTX silicate prodrugs in 
MDA-MB-231 cells.a 
 Compound IC50 (nM) b 
 ______________ _______________ 
 PTX (1.01) 23.6(± 9.8) 
 3.04 23.0 (± 10.7) 
 3.05 35.6 (± 19.4) 
 3.06 24.5 (± 12.7) 
 3.07     8140.   (± 1320) 
 3.08 74.4 (± 35.0) 
 3.11 21.4 (± 12.5) 
 3.12 540.   (± 113)  
 a The cell viability was measured after 48 h. 
 b The data are reported as the mean (± SD).   
 
12. Summary and Future Work. The development of PTX-based silicate 
prodrugs has validated the tetraalkoxysilane models used in Chapter 2 and 
yielded significant advances toward a novel prodrug family. A series of prodrugs 
of varying hydrophobicity and hydrolytic lability has been synthesized, purified, 
and hydrolyzed. IC50 values for a subset of seven were measured in the labs of 
our collaborator, Prof. Paynyam,151 and the outcomes were correlated with the 
prodrug rate of hydrolysis. These experiments resulted in the identification of five 
prodrugs that displayed cytotoxicity equivalent to the parent PTX. Consideration 
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of many relevant factors – ease of synthesis and handling, hydrophobic 
character, rate of hydrolysis, cytotoxicity, and nature of the byproducts – led to 
the selection of PTX prodrug 3.08 to be formulated into nanoparticles via flash 
nanoprecipitation. These prodrug-loaded nanoparticles were utilized in 
collaborative in vivo mouse model studies, described in Chapter 5. 
 
4. Curcumin.  
1. Introduction. Curcumin (1.04), the yellow/orange natural product derived 
from turmeric, has long been viewed as a potential therapeutic.153 Prominently 
featured among a host of potential health benefits is its use as a preventative 
chemotherapeutic. These aspirations center on the antioxidant prospects of this 
highly conjugated molecule. However, practical application of 1.04 has been 
limited by, among other issues, low bioavailability. The low bioavailability 
frequently observed in treatments of 1.04 results largely from the known 
glucuronidation of an aryl hydroxyl (occurring via UDP-glucuronosyltransferase 
activity154) upon oral administration to yield species such as 3.21 (Scheme 3-6). 
Additionally, action by reductases (occurring upon intravenous or intraperitoneal 
administration) gives undesired degradation to a variety of products of the form of 
3.22 (Scheme 3-6).153,155 
 
 
???????????????????????????????????????? ????????????????????
153 Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Bioavailability of Curcumin: 
Problems and Promises. Mol. Pharm. 2007, 4, 807–818. 
154 Hoehle, S. I.; Pfeiffer, E.; Metzler, M. Glucuronidation of Curcuminoids by Human Microsomal 
and Recombinant UDP-Glucuronosyltransferases. Mol. Nutr. Food Res. 2007, 51, 932–938. 
155 Pan, M.-H.; Huang, T.-M.; Lin, J.-K. Biotransformation of Curcumin through Reduction and 
Glucoronidation in Mice. Drug Metab. Dispos. .1998, 27, 486–494. 
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Scheme 3-6. Two of the known degradation pathways to which curcumin is 
susceptible: Glucuronidation to yield 3.21 and reduction to yield 3.22.  
 
 
 
2. Efforts toward a Curcumin Silicate Ester. The silicate prodrug strategy 
was applied to curcumin to modify its biochemical properties. We hypothesized 
that silylation of the phenols may render these functional groups unreactive 
toward in vivo biological glucuronidation following oral administration. 
Additionally, recent results have suggested that, while curcumin has been 
efficiently encapsulated within chitosan/Tween 20 microparticles, there is an 
extremely rapid release of the drug (ca. 40% released within five mins and full 
release in less than 2 h).156 Thus, as an added benefit, formation of silicate ester 
prodrugs would allow control of the release kinetics from future formulations.  
Strongly motivated by these factors, initial attempts to synthesize the bis-
triethoxy curcumin prodrug 3.23 were undertaken, resulted in low yields. This is 
likely the result of in situ oxidation that was qualitatively observed by the 
considerable darkening of the reaction solution. This minor complication could be 
easily avoided by carefully minimizing the reaction time. Controlling this variable, 
the bis-triethoxy and bis-tri-i-propoxy curcumin silicate prodrugs (3.24 and 3.26, 
???????????????????????????????????????? ????????????????????
156 O’Toole, M. G.; Henderson, R. M.; Soucy, P. A.; Fasciotto, B. H.; Hoblitzell, P. J.; Keynton, R. 
S.; Ehringer, W. D.; Gobin, A. S. Curcumin Encapsulation in Sub-Micron Chitosan/Tween 20 
Particles. Biomacromolecules, 2012, 13, 2309–2314. 
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respectively) were readily synthesized by treating curcumin with the appropriate 
trialkoxychlorosilane and pyridine (Scheme 3-7). The purification of these 
compounds was mildly problematic, in that the starting curcumin was only ca. 
94% pure. The contaminant, the monomethoxy derivative 3.23, was silylated, 
giving 3.25 or 3.27. These undesired byproducts were found to elute during silica 
chromatography with retention times similar to that of the desired, bis-silylated 
prodrugs. The only solution found to this complication was to take only specific 
fractions from the purifications, allowing isolation of the pure products, albeit in 
depressed yields. 
Scheme 3-7. The synthesis of the bis-triethoxy and bis-i-isopropoxy curcumin 
silicate prodrugs 3.24 and 3.26. The monomethoxy byproducts 3.25 and 3.27 co-
eluted with the desired products. 
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3. General Results of Collaborative Biological Assays.157 The biological 
assays involving prodrugs 3.24 and 3.26 were again performed in collaboration 
with Prof. Jayanth Panyam. Curcumin silicates 3.24 and 3.26 were given to Alex 
Grill, another graduate student studying in the Panyam labs, for further testing. 
Briefly, 3.24 was found to be far too labile, hydrolyzing in DMSO during 
preparation for biological assays.157 To our delight, prodrug 3.26 remained stable 
during experimentation and prevented glucuronidation during the in vitro assays. 
Thus, Alex Grill formulated 3.26 and injected the mixture into a live animal model. 
While glucuronidation was not observed in vivo, neither 3.26 nor free curcumin 
was detected after circulation.157 This observation suggests that, while 
conjugation to a silicate ester prevented glucuronidation, the curcumin was likely 
shunted to a secondary metabolic pathway via reductase and/or dehydrogenase 
activity.155,158 Given these disappointing results and no obvious strategy to 
minimize a secondary metabolic pathway, efforts toward curcumin silicate 
prodrugs were suspended.  
 
5. Conclusions.  
The silicate ester prodrug strategy has been applied to three 
fundamentally diverse hydroxyl environments in two different drugs: paclitaxel 
(two secondary alkyl hydroxyls) and curcumin (a phenol). The paclitaxel silicate 
ester prodrugs have been extensively developed, with efforts yielding a suite of 
prodrugs that vary in both their hydrophobic character and rate of hydrolysis. All 
but the most slowly hydrolyzing of this family demonstrated cytotoxicity 
???????????????????????????????????????? ????????????????????
157 These biological experiments were performed by Alex Grill. Grill, A. University of Minnesota, 
Minneapolis, MN. Personal communication, 2011. 
158 Ireson, C. R.; Jones, D. J. L.; Orr, S.; Coughtrie, M. W. H.; Boocock, D. J.; Williams, M. L.; 
Farmer, P. B.; Steward, W. P.; Gescher, A. J. Metabolism of the Cancer Chemopreventive Agent 
Curcumin in Human and Rat Intestine. Cancer Epidemiol. Biomarkers Prevent. 2002, 11, 105–
111. 
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equivalent to that of underivitized paclitaxel. This work has led to the selection of 
a 2’,7-Di-O-(triethoxysilyl)paclitaxel silicate prodrug (3.08) for work in formulation 
studies and subsequent in vivo work in animal models, as detailed in Chapter 5. 
Furthermore, the synthesis of the di-t-butoxyacetoxy paclitaxel silicate ester 
uniquely led to the observation of a stable di-t-butoxy paclitaxel silanol during 
hydrolysis. The mechanism of hydrolysis for these species was determined via 
18O-labeling studies to be direct SN2 substitution at the silicon atom (rather than 
nucleophilic attack at the electrophilic carbonyl). 
Additional efforts to expand the silicate ester prodrug strategy beyond 
paclitaxel resulted in the synthesis of curcumin-based silicate prodrugs. The 
curcumin silicates were successfully designed to prevent glucuronidation, but the 
bioavailability of the drug remained low in preliminary in vivo experiments. This 
observation is likely due to degradation via a secondary metabolic pathway. 
Taken together, these applications of the general silicate ester prodrug strategy 
further confirm that this novel idea is both general and effective. Further 
exploitation of this concept to alter the physical, chemical, and/or biological 
properties of additional drugs could advance its utility to yet more active agents.  
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6. Experimental Section.  
 
2’-O-(Triethoxysilyl)paclitaxel (3.04)159. Paclitaxel (55.3 mg, 0.0648 mmol, 1.0 
equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube fitted with 
a Teflon-lined cap and magnetic stir bar. Triethylamine (20 µL, 0.130 mmol, 2.0 
equiv) was added by Wiretrol®. Chlorotriethoxysilane (25 µL, 0.0127 mmol, 2.0 
equiv) was then added, and a white precipitate was immediately observed. The 
culture tube was sealed and the suspension was allowed to stir for 1 hour at 
room temperature. The reaction slurry was diluted with a mixture of hexanes 
:EtOAc (1:1) and filtered through a short plug of Celite® to remove the 
triethylammonium salt. The filtrate was concentrated under reduced pressure, 
and the residue redissolved in a mixture of hexanes:EtOAc (1:1). 
Chromatography (SiO2, 1:1 hexanes:EtOAc) via MPLC yielded the title 
compound as a white, crystalline solid (59.6 mg, 0.0587 mmol, 90.6%). If 
necessary, residual EtOAc was removed by storage under high vacuum for ≥ 
24h. 
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.5, 1.3 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.5, 1.2 Hz, 1H, C2O2C-p-
Ph, 1H), 7.56-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.36 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.29 (tt, J = 6.5, 2.2 Hz, 1H, C3’-p-
Ph), 7.19 (d, J = 8.6 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.24 (br dd, J = 9, 9 Hz, 
???????????????????????????????????????? ????????????????????
159 1H NMR assignments were made with the consideration of Oyama, M.; Itokawa, H. Physical 
Methods for Identification of the Structures of Taxoids. In Taxus: The Genus Taxus. Itokawa, H.; 
Lee, K.?H., Eds. Taylor & Francis, Inc: New York, 2003, 32; 79?133. 
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1H, H13), 5.72 (dd, J = 8.5, 3.2 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 1H, H2), 4.97 
(dd, J = 9.4, 2.0 Hz, 1H, H5), 4.96 (d, J = 3.3 Hz, 1H, H2’), 4.43 (ddd, J = 10.9, 
6.4, 4.5 Hz, 1H, H7), 4.32 (d, J = 8.5 Hz, 1H, H20α), 4.20 (d, J = 8.5 Hz, 1H, 
H20β), 3.80 (d, J = 7.2 Hz, 1H, H3), 3.71 [q, J = 7.0 Hz, 6H, C2’OSi(OCH2CH3)3], 
2.56 (ddd, J = 14.7, 9.6, 6.5 Hz, 1H, H6α), 2.45 (s, 3H, C4OAc), 2.44 (br s, 1H, 
C7OH), 2.32 (dd, J = 15.4, 9.4, Hz, 1H, H14α), 2.24 (s, 3H, C10OAc), 2.08 (dd, J 
= 15.2, 8.8 Hz, 1H, H14β), 1.90 (d, J = 1.2 Hz, 3H, C18H3), 1.89 (ddd, J = 14.5, 
11.0, 2.4 Hz, 1H, H6β), 1.68 (s, 3H, C19H3), 1.64 (br s, 1H, C1OH), 1.24 (s, 3H, 
C17H3), 1.15 [t, J = 7.0 Hz, 9H, C2’OSi(OCH2CH3)3], and 1.13 (s, 3H, C16H3). 
13C NMR (75 MHz, CDCl3): δ 204.0, 171.6, 171.0, 170.1, 167.3, 167.2, 143.0, 
138.2, 134.2, 133.9, 132.9, 132.0, 130.4, 129.3, 128.9 (x2), 128.8, 128.2, 127.3, 
126.8, 84.6, 81.2, 79.3, 76.7, 75.8, 75.3, 75.1, 72.3, 71.5, 59.7, 58.7, 55.6, 45.7, 
43.4, 35.7, 35.6, 27.0, 23.0, 22.4, 21.1, 18.2, 14.9, and 9.8.  
HRMS (ESI) Calc’d for C53H65NNaO17Si [M + Na]+ 1038.3914, found 1038.3942. 
IR (thin film) 3500 (br), 2977, 2898, 1744, 1730, 1636, 1580, 1540, 1487, 1452, 
1371, 1314, 1268, 1240, 1170, 1145, 1078, 1025, 978, 908, 854, 797, and 710 
cm-1. 
mp = 131-134 °C. 
TLC Rf (1:1 Hexanes:EtOAc) = 0.45.  
 
 
2-O-(Tri-n-octyloxysilyl)paclitaxel (3.05). Paclitaxel (76.0 mg, 0.0890 mmol, 
1.0 equiv) was dissolved in dry THF (1.5 mL) in an oven-dried culture tube fitted 
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with a Teflon-lined cap and magnetic stir bar. Triethylamine (60 µL, 0.430 mmol, 
4.8 equiv) was added by Wiretrol®. A 1.67:1 mixture of tri-n-
octyloxychlorosilane:tetra-n-octyloxysilane (0.200 mg, 0.257 mmol, 2.9 equiv of 
tri-n-octyloxychlorosilane) was added and a white precipitate was immediately 
observed. The culture tube was sealed and the suspension was allowed to stir 
for 22 h at room temperature. The reaction slurry was diluted with a mixture of 
hexanes:EtOAc (1:1), the slurry filtered through a short plug of Celite® to remove 
the triethylammonium salt, the filtrate concentrated under reduced pressure, and 
the residue redissolved in a mixture of hexanes:EtOAc (2:1). Chromatography 
(SiO2, 2:1 hexanes:EtOAc) via MPLC yielded the title compound as a white, 
crystalline solid (91.5 mg, 0.0721 mmol, 81.0%). If necessary, residual EtOAc 
was removed by storage under high vacuum for ≥ 24 h. 
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.5, 1.5 Hz, 2H, C2O2C-o-Ph), 7.77 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-p-
Ph), 7.55-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.35 (m, 6H, C3’-
o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.28 (tt, J = 6.9, 1.7 Hz, 1H, C3’-p-Ph), 
7.19 (d, J = 8.6 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.25 (br dd, J = 9, 9 Hz, 1H, 
H13), 5.72 (dd, J = 8.6, 3.2 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 1H, H2), 4.97 (dd, J 
= 9.8, 2.1 Hz, 1H, H5), 4.96 (d, J = 3.2 Hz, 1H, H2’), 4.44 (ddd, J = 10.9, 6.7, 4.2 
Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.3 Hz, 1H, H20β), 3.80 
(d, J = 7.1 Hz, 1H, H3), 3.61 {t, J = 6.8 Hz, 6H, C2’OSi[OCH2(CH2)6CH3]3}, 2.56 
(ddd, J = 14.8, 9.6, 6.6 Hz, 1H, H6α), 2.47 (d, J = 4.1 Hz, 1H, C7OH), 2.44 (s, 
3H, C4OAc), 2.32 (dd, J = 15.4, 9.4 Hz, 1H, H14α), 2.24 (s, 3H, C10OAc), 2.07 
(dd, J = 15.4, 8.8 Hz, 1H, H14β), 1.89 (d, J = 1.4 Hz, 3H, C18H3), 1.89 (m, 1H, 
H6β), 1.68 (s, 3H, C19H3), 1.65 (br s, 1H, C1OH), 1.48 [tt, J = 6.9, 6.9 Hz, 6H, 
C2’OSi(OCH2CH2(CH2)5CH3)3], 1.32-1.22 {m, 33H, C2’OSi[OCH2CH2(CH2)5CH3]3 
and C17H3}, 1.13 (s, 3H, C16H3), and 0.88 {t, J = 6.9 Hz, 9H, 
C2’OSi[OCH2CH2(CH2)5CH3]3}. 
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13C NMR (75 MHz, CDCl3): δ 204.0, 171.5, 170.9, 170.1, 167.2, 167.2, 143.0, 
138.3, 134.3, 133.9, 132.9, 132.0, 130.4, 129.3, 128.9 (x2), 128.8, 128.1, 127.3, 
126.8, 84.7, 81.2, 79.3, 76.6, 75.8, 75.3, 74.9, 72.4, 71.4, 64.1, 58.7, 55.5, 45.7, 
43.4, 35.8, 35.7, 32.4, 32.0, 29.54, 29.52, 27.0, 25.8, 23.0, 22.9, 22.4, 21.1, 14.9, 
14.3, and 9.8. 
HRMS (ESI) Calc’d for C71H101NNaO17Si [M + Na]+ 1290.6731; found 1290.6749. 
IR (thin film) 2926, 2855, 1730, 1665, 1643, 1602, 1581, 1518, 1484, 1453, 1371, 
1312, 1271, 1240, 1174, 1094, 1025, 985, 926, 907, 851, 801, 777, and 711 cm-
1. 
mp = 60-63 °C.  
TLC Rf (3:1 Hexanes:EtOAc) = 0.15. 
 
 
2’-O-(Tri-i-propoxysilyl)paclitaxel (3.06). Paclitaxel (38.8 mg, 0.0454 mmol, 1.0 
equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube fitted with 
a Teflon-lined cap and magnetic stir bar. Triethylamine (25 µL, 0.179 mmol, 3.9 
equiv) was added by Wiretrol®. A 2.9:1 mixture of tri-i-propoxychlorosilane:tetra-i-
propoxysilane (0.155 mg, 0.132 mmol, 2.9 equiv of tri-i-propoxychlorosilane) was 
added. The culture tube was sealed and a white precipitate was observed within 
minutes. The suspension was stirred at room temperature for 48 hours and the 
cloudy, heterogeneous reaction mixture was noted to be slightly yellowed. The 
suspension was diluted with a mixture of hexanes:EtOAc (1:1), the slurry filtered 
through a short plug of Celite® to remove the triethylammonium salt, the filtrate 
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concentrated under reduced pressure, and the residue redissolved in a mixture 
of hexanes:EtOAc (1:1). Chromatography (SiO2, 1:1 hexanes:ethyl acetate) via 
MPLC yielded the title compound as a white, crystalline solid (31.1 mg, 0.0294 
mmol, 64.7%). If necessary, residual EtOAc was removed by storage under high 
vacuum for ≥ 24h. 
1H NMR (500 MHz, CDCl3): δ 8.11 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.79 
(dd, J = 8.4, 1.3 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.6, 1.3 Hz, 1H, C2O2C-p-
Ph, 1H), 7.55-7.47 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.44-7.35 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.27 (tt, J = 7.0, 1.7 Hz, 1H, C3’-p-
Ph), 7.17 (d, J = 8.5 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.19 (br dd, J = 9, 9 Hz, 
1H, H13), 5.69 (dd, J = 8.5, 3.6 Hz, 1H, H3’), 5.68 (d, J = 6.7 Hz, 1H, H2), 4.98 
(d, J = 3.6 Hz, 1H, H2’), 4.96 (dd, J = 9.7, 2.4 Hz, 1H, H5), 4.44 (ddd, J = 10.9, 
6.6, 4.1 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.4 Hz, 1H, 
H20β), 4.13 {sept, J = 6.1 Hz, 3H, C2’OSi[OCH(CH3)2]3}, 3.80 (d, J = 7.1 Hz, 1H, 
H3), 2.56 (ddd, J = 14.8, 9.8, 6.6 Hz, 1H, H6α), 2.47 (d, J = 4.1 Hz, 1H, C7OH), 
2.42 (s, 3H, C4OAc), 2.29 (dd, J = 15.4, 9.4 Hz, 1H, H14α), 2.24 (s, 3H, 
C10OAc), 2.06 (dd, J = 15.4, 8.9 Hz, 1H, H14β), 1.91 (d, J = 1.4 Hz, 3H, C18H3), 
1.88 (ddd, J = 14.3, 11.0, 2.4 Hz, 1H, H6β), 1.76 (br s, 1H, C1OH), 1.68 (s, 3H, 
C19H3), 1.23 (s, 3H, C17H3), 1.15 {d, J = 6.1 Hz, 9H, 
C2’OSi[OCH(CH3)a(CH3)b]3}, 1.12 {d, J = 6.1 Hz, 9H, 
C2’OSi[OCH(CH3)a(CH3)b]3}, and 1.12 (s, 3H, C16H3). 
13C NMR (125 MHz, CDCl3): δ 204.1, 171.5, 171.1, 170.1, 167.3, 167.2, 143.1, 
138.3, 134.4, 133.9, 132.9, 131.9, 130.4, 129.4, 128.9 (x2), 128.8, 128.1, 127.3, 
127.0, 84.7, 81.2, 79.3, 76.7, 75.9, 75.3, 74.9, 72.3, 71.5, 66.7, 58.7, 55.8, 45.7, 
43.4, 35.8, 35.7, 27.0, 25.44, 25.42, 23.0, 22.4, 21.1, 15.2, and 9.8. 
HRMS (ESI) Calc’d for C56H71NNaO17Si [M + Na]+ 1080.4383; found 1080.4380. 
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IR (thin film) 3500 (br), 2974, 2934, 1729, 1666, 1603, 1583, 1515, 1485, 1452, 
1371, 1313, 1269, 1241, 1174, 1114, 1052, 985, 897, 850, 800, 773, and 712 
cm-1. 
mp = 126-129 °C. 
TLC Rf (1:1 Hexanes:EtOAc) = 0.45. 
 
 
2’-O-(Ethoxydi-t-butoxysilyl)paclitaxel (3.07).  Paclitaxel (49.3 mg, 0.0577 
mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube 
with a Teflon-lined cap and magnetic stir bar. Pyridine (0.12 mL, 1.48 mmol, 26 
equiv) was added by syringe. A distilled sample of di-t-butoxydichlorosilane 
(0.349 mg, 1.42 mmol, 25 equiv) was added by Wiretrol®. The culture tube was 
sealed and the solution was allowed to stir at room temperature. A small amount 
of a white precipitate was observed after ca. 30 minutes, and the reaction mixture 
was noted to be cloudy and heterogeneous after stirring for 6 hours. To the 
suspension, pyridine was again added (0.47 mL, 5.81 mmol, 100 equiv). 
Immediately afterward, anhydrous ethanol (dried overnight over 3Å molecular 
sieves, 0.68 mL, 11.7 mmol, 200 equiv) was added. The mixture was allowed to 
stir for one additional hour at room temperature. Analysis of the crude mixture 
was completed by removing a 0.1 mL aliquot of the reaction solution, removing 
the volatile components under reduced pressure, and analyzing the crude 1H 
NMR spectrum. The results indicated that the reaction was complete. The 
remainder of the reaction suspension was diluted with a mixture of 
hexanes:EtOAc (1:1), the slurry filtered through a short plug of Celite® to remove 
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the pyridinium salt, the filtrate concentrated under reduced pressure, and the 
residue redissolved in a mixture of hexanes:EtOAc (2:1). Chromatography (SiO2, 
2:1 hexanes:EtOAc) via MPLC yielded the title compound as a white, crystalline 
solid (52.0 mg, 0.0485 mmol, 84.1%). If necessary, residual EtOAc was removed 
by storage under high vacuum for ≥ 24h. 
1H NMR (500 MHz, CDCl3): δ 8.11 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.79 
(dd, J = 8.4, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-p-
Ph, 1H), 7.56-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.45-7.33 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.30-7.22 (m, 1H, C3’-p-Ph), 7.15 (d, 
J = 8.4 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.18 (br dd, J = 9, 9 Hz, 1H, H13), 
5.68 (d, J = 7.2 Hz, 1H, H2), 5.66 (dd, J = 8.3, 3.6 Hz, 1H, H3’), 5.01 (d, J = 3.6 
Hz, 1H, H2’), 4.97 (dd, J = 9.7, 2.3 Hz, 1H, H5), 4.44 (ddd, J = 10.8, 6.6, 4.1 Hz, 
1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.19 (d, J = 8.4 Hz, 1H, H20β), 3.79 (d, J 
= 7.0 Hz, 1H, H3), 3.64 (q, J = 7.0 Hz, 2H, C2’OSiOCH2CH3), 2.56 (ddd, J = 
14.8, 9.7, 6.6 Hz, 1H, H6α), 2.45 (d, J = 4.1 Hz, 1H, C7OH), 2.41 (s, 3H, 
C4OAc), 2.28 (dd, J = 15.4, 9.4, Hz, 1H, H14α), 2.24 (s, 3H, C10OAc), 2.05 (dd, 
J = 15.3, 9.0 Hz, 1H, H14β), 1.90 (d, J = 1.4 Hz, 3H, C18H3), 1.88 (ddd, J = 14.4, 
11.1, 2.5 Hz, 1H, H6β), 1.68 (s, 4H, C1OH and C19H3), 1.26 (s, 9H, 
C2’OSiOC(CH3)2], 1.25 (s, 9H, C2’OSiOC(CH3)2], 1.23 (s, 3H, C17H3), and 1.13 
(overlapping t, J = 7.0 Hz, 3H, C2’OSiCH2CH3 and s, 3H, C16H3). 
13C NMR (125 MHz, CDCl3): δ 204.1, 171.5, 171.0, 170.0, 167.3, 167.2, 143.1, 
138.4, 134.4, 133.9, 132.8, 131.9, 130.4, 129.4, 128.90, 128.89, 128.8, 128.1, 
127.3, 127.0, 84.7, 81.2, 79.3, 76.6, 75.9, 75.3, 74.9, 73.99, 73.98, 72.3, 71.4, 
59.3, 58.7, 55.8, 45.7, 43.4, 35.8, 35.7, 31.41, 31.38, 27.0, 22.9, 22.3, 21.1, 18.2, 
15.1, and 9.8.  
IR (thin film) 3500 (br), 2976, 2936, 1726, 1665, 1603, 1582, 1514, 1485, 1452, 
1389, 1368, 1312, 1270, 1242, 1179, 1128, 1069, 1025, 981, 909, 853, 821, 800, 
775, 733, and 711 cm-1. 
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HRMS (ESI) Calc’d for C57H73NNaO17Si [M + Na]+ 1094.4540; found 1094.4579. 
mp = 130-134 °C.  
TLC Rf (2:1 Hexanes:EtOAc) = 0.2. 
 
 
2’,7-Di-O-(Triethoxysilyl)paclitaxel (3.08). Paclitaxel (58.0 mg, 0.0679 mmol, 
1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube fitted 
with a Teflon-lined cap and a stir bar. Pyridine (25 µL, 0.309 mmol, 4.5 equiv) 
was added by Wiretrol®. Chlorotriethoxysilane (50 µL, 0.255 mmol, 3.8 equiv) 
was added, and a white precipitate was immediately observed. The suspension 
was allowed to stir for 2 hours at room temperature and then diluted with 
hexanes:EtOAc (1:1). The slurry was filtered through a short plug of Celite® to 
remove the pyridinium salt, and the filtrate concentrated under reduced pressure. 
The residue was purified by MPLC (SiO2, 2:1 hexanes:EtOAc) to yield 2a as a 
white crystalline solid (68.0 mg, 0.058 mmol, 85%). If necessary, residual EtOAc 
was removed by storage under high vacuum for ≥ 24 h. 
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.5 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.5, 1.5 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.5, 1.0 Hz, 1H, C2O2C-p-
Ph, 1H), 7.54-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.44-7.36 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.29 (tt, J = 7.0, 1.5 Hz, 1H, C3’-p-
Ph), 7.20 (d, J = 8.5 Hz, 1H, C3’NH), 6.58 (s, 1H, H10), 6.18 (br dd, J = 9, 9 Hz, 
1H, H13), 5.72 (dd, J = 8.5, 3.0 Hz, 1H, H3’), 5.71 (d, J = 6.5 Hz, 1H, H2), 4.98 
(d, J = 3.0 Hz, 1H, 2’H), 4.96 (dd, J = 10.0, 2.0 Hz, 1H, H5), 4.62 (dd, J = 10.5, 
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6.7 Hz, 1H, H7), 4.31 (d, J = 8.5 Hz, 1H, H20α), 4.20 (d, J = 8.5 Hz, 1H, H20β), 
3.85 (d, J = 7.0 Hz, 1H, H3), 3.76 [q, J = 7.0 Hz, 6H, C7OSi(OCH2CH3)3], 3.71 [q, 
J = 7.0 Hz, 6H, C2’OSi(OCH2CH3)3], 2.66 (ddd, J = 14.5, 9.5, 6.5 Hz, 1H, H6α), 
2.45 (s, 3H, C4OAc), 2.33 (dd, J = 15.4, 9.4Hz, 1H, H14α), 2.15 (s, 3H, 
C10OAc),2.08 (d, J = 1.5 Hz, 3H, C18H3), 2.07 (dd, J = 15.1, 9.0 Hz, 1H, H14β), 
1.96 (ddd, J = 14.5, 10.8, 2.2 Hz, 1H, H6β), 1.73 (s, 3H, C19H3), 1.65 (br s, 1H, 
C1OH), 1.23 (s, 3H, C17H3), 1.19 [t, J = 7.0 Hz, 9H, C7OSi(OCH2CH3)3], 1.17 (s, 
3H, C16H3), and 1.15 [t, J = 7.0 Hz, 9H, C2’OSi(OCH2CH3)3].  
13C NMR (75 MHz, CDCl3): δ 202.6, 171.0, 169.8, 169.0, 167.3, 167.2, 141.0, 
138.2, 134.3, 133.9, 133.3, 132.0, 130.4, 129.4, 128.9, 128.8, 128.7, 128.1, 
127.3, 126.8, 84.5, 81.2, 78.9, 76.7, 75.9, 75.02, 74.99, 72.1, 71.6, 59.7, 59.5, 
58.3, 55.5, 46.9, 43.4, 36.5, 35.5, 26.7, 23.0, 21.4, 21.0, 18.0 (x2), 14.2, and 
10.4. 
HRMS (ESI) Calc’d for C59H79NNaO20Si2 [M + Na]+ 1200.4626, found 1200.4631. 
IR (thin film) 3500 (br), 2976, 2928, 2896, 1744, 1725, 1644, 1603, 1580, 1541, 
1486, 1451, 1370, 1314, 1268, 1238, 1169, 1098, 1080, 1027, 969, 891, 842, 
795, and 708 cm-1. 
mp = 121-123 °C.  
TLC Rf (2:1 Hexanes:EtOAc) = 0.4. 
 
 
2’,7-Di-O-(Tri-n-octyloxysilyl)paclitaxel (3.09). Paclitaxel (57.8 mg, 0.0677 
mmol, 1.0 equiv) was dissolved in dry THF (1.5 mL) in an oven-dried culture tube 
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fitted with a Teflon-lined cap and magnetic stir bar. Pyridine (25 µL, 0.309 mmol, 
4.6 equiv) was added by Wiretrol®. A 1.67:1 mixture of tri-n-
octyloxychlorosilane:tetra-n-octyloxysilane (0.155 mg, 0.199 mmol, 2.9 equiv of 
tri-n-octyloxychlorosilane) was added, and formation of a white precipitate was 
immediately observed. The culture tube was sealed and the suspension was 
allowed to stir for 5 h at room temperature. The reaction mixture was diluted with 
a mixture of hexanes:EtOAc (1:1), and the slurry filtered through a short plug of 
Celite® to remove the pyridinium salt. The filtrate was concentrated under 
reduced pressure, and the residue purified by MPLC (SiO2, 9:1 hexanes:EtOAc) 
to yield 2b as a viscous oil (88.1 mg, 0.0523 mmol, 77.3%). Additional elution in 
hexanes:EtOAc (2:1) yielded 1b (1.7 mg, 0.0013mmol, 2.0 %). If necessary, 
residual EtOAc was removed from 2b by storage under high vacuum for ≥ 24 h. 
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.6, 1.4 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.6, 1.5 Hz, 2H, C3’NHCO-o-Ph), 7.60 (tt, J = 7.4, 1.2 Hz, 1H, C2O2C-p-
Ph, 1H), 7.54-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.44-7.35 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.28 (tt, J = 7.2, 1.3 Hz, 1H, C3’-p-
Ph), 7.22 (d, J = 8.7 Hz, 1H, C3’NH), 6.55 (s, 1H, H10), 6.23 (br dd, J = 10, 9 Hz, 
1H, H13), 5.74 (dd, J = 8.6, 3.0 Hz, 1H, H3’), 5.70 (d, J = 7.1 Hz, 1H, H2), 4.99 
(d, J = 3.0 Hz, 1H, 2’H), 4.94 (dd, J = 9.7, 1.9 Hz, 1H, H5), 4.61 (dd, J = 10.6, 6.8 
Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.4 Hz, 1H, H20β), 3.86 
(d, J = 7.0 Hz, 1H, H3), 3.67 {t, J = 6.7 Hz, 6H, C7OSi[OCH2(CH2)6CH3]3}, 3.61 {t, 
J = 6.7 Hz, 6H, C2’OSi[OCH2(CH2)6CH3]3}, 2.65 (ddd, J = 14.7, 9.7, 6.8 Hz, 1H, 
H6α), 2.45 (s, 3H, C4OAc), 2.33 (dd, J = 15.3, 9.4 Hz, 1H, H14α) 2.13 (s, 3H, 
C10OAc), ), 2.06 (d, J = 1.2 Hz, 3H, C18H3), 2.09-2.02 (m, 1H, H14β), 1.96 (ddd, 
J = 14.5, 10.8, 2.2 Hz, 1H, H6β), 1.73 (s, 3H, C19H3), 1.66 (br s, 1H, C1OH), 
1.56-1.44 {m, 12H, C2’OSi[OCH2CH2(CH2)5CH3]3  and 
C7OSi[OCH2CH2(CH2)5CH3]3}, 1.34-1.21 {m, 63H, C17H3, 
C2’OSi[OCH2CH2(CH2)5CH3]3, and C7OSi[OCH2CH2(CH2)5CH3]3}, 1.17 (s, 3H, 
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C16H3), and 0.88 {overlapping t’s, J = 6.8 Hz, 18H, C2’OSi[OCH2CH2(CH2)5CH3]3 
and C7OSi[OCH2CH2(CH2)5CH3]3}. 
13C NMR (75 MHz, CDCl3): δ 202.4, 170.9, 169.8, 168.7, 167.3, 167.2, 140.9, 
138.3, 134.3, 133.8, 133.3, 131.9, 130.4, 129.4, 128.91, 128.89, 128.8, 128.1, 
127.3, 126.8, 84.6, 81.2, 79.0, 76.8, 75.8, 75.1, 74.9, 72.0, 71.5, 64.1, 63.9, 58.3, 
55.5, 46.8, 43.5, 36.6, 35.6, 32.5, 32.4, 32.1, 32.0, 29.6, 29.63, 29.60, 29.57, 
26.7, 25.92, 25.89, 23.0, 22.91, 22.90, 21.6, 21.1, 14.3 (x2), 14.1, and 10.4. 
HRMS (ESI) Calc’d for C95H151NNaO20Si2 [M + Na]+ 1705.0260; found 
1705.0228. 
IR (thin film) 3500 (br), 2927, 2856, 1728, 1741, 1721, 1634, 1580, 1545, 1456, 
1371, 1315, 1270, 1239, 1174, 1095, 1028, 989, 968, 924, 893, 843, 779, and 
709 cm-1. 
TLC Rf (3:1 Hexanes:EtOAc) = 0.55. 
 
 
 
2’,7-Di-O-(Tri-i-propoxysilyl)paclitaxel (3.10). Paclitaxel (30.1 mg, 0.0352 
mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube 
fitted with a Teflon-lined cap and magnetic stir bar. Pyridine (15 µL, 0.185 mmol, 
5.3 equiv) was added by Wiretrol®. A 3.5:1 mixture of tri-i-
propoxychlorosilane:tetra-i-propoxysilane (0.0424 mg, 0.134 mmol, 2.9 equiv of 
tri-i-propoxychlorosilane) was added. The culture tube was sealed and a white 
precipitate was observed within minutes. The suspension was stirred at room 
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temperature for 18 hours. The suspension was directly filtered through a short 
plug of Celite® to remove the triethylammonium salt, the filtrate concentrated 
under reduced pressure, and the residue redissolved in a mixture of 
hexanes:EtOAc (2:1). Chromatography (SiO2, 2:1 hexanes:ethyl acetate) via 
MPLC yielded the title compound as a white, crystalline solid (29.8 mg, 0.0236 
mmol, 67.0%). If necessary, residual EtOAc was removed by storage under high 
vacuum for ≥ 24h. 
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.5 Hz, 2H, C2O2C-o-Ph), 7.80 
(dd, J = 8.4, 1.5 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.4, 1.7 Hz, 1H, C2O2C-p-
Ph, 1H), 7.55-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.34 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.29-7.24 (m, 1H, C3’-p-Ph), 7.17 (d, 
J = 8.4 Hz, 1H, C3’NH), 6.53 (s, 1H, H10), 6.14 (br dd, J = 9, 9 Hz, 1H, H13), 
5.70 (d, J = 7.3 Hz, 1H, H2), 5.67 (dd, J = 8.4, 3.6 Hz, 1H, H3’), 5.00 (d, J = 3.6 
Hz, 1H, H2’), 4.96 (dd, J = 9.4, 2.0 Hz, 1H, H5), 4.61 (dd, J = 10.7, 6.7, Hz, 1H, 
H7), 4.31 (d, J = 8.8 Hz, 1H, H20α), 4.19 (d, J = 8.6 Hz, 1H, H20β), 4.13 and 
4.12 {overlapping septs, J = 6.2 Hz, 6H, C2’OSi[OCH(CH3)2]3 and 
C7OSi[OCH(CH3)2]3}, 3.85 (d, J = 7.4 Hz, 1H, H3), 2.68 (ddd, J = 14.7, 9.7, 6.8 
Hz, 1H, H6α), 2.41 (s, 3H, C4OAc), 2.30 (dd, J = 15.1, 9.3 Hz, 1H, H14α), 2.14 
(s, 3H, C10OAc), 2.10 (d, J = 1.2 Hz, 3H, C18H3), 2.03 (dd, J = 15.7, 9.5 Hz, 1H, 
H14β), 1.95 (ddd, J = 14.6, 10.9, 2.2 Hz, 1H, H6β), 1.72 (s, 3H, C19H3), 1.61 (br 
s, 1H, C1OH), 1.23 (m, 3H, C17H3), 1.18-1.10 {m, 39H, 
C2’OSi[OCH(CH3)a(CH3)b]3}, C2’OSi[OCH(CH3)a(CH3)b]3, 
C7OSi[OCH(CH3)a(CH3)b]3}, C7OSi[OCH(CH3)a(CH3)b]3, and C16H3}. 
13C NMR (125 MHz, CDCl3): δ 202.6, 171.1, 169.6, 168.9, 167.3, 167.2, 141.2, 
138.4, 134.4, 133.8, 133.3, 131.9, 130.4, 129.5, 128.9 (x2), 128.8, 128.1, 127.3, 
127.0, 84.6, 81.2, 80.0, 76.8, 75.9, 75.2, 74.9, 72.3, 71.7, 66.6, 66.2, 58.3, 55.9, 
46.8, 43.5, 36.7, 35.5, 26.8,25.5, 25.4, 25.4, 25.4, 23.0, 21.5, 21.1, 14.7, 10.5  
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HRMS (ESI) Calc’d for C65H91NNaO20Si2 [M + Na]+ 1284.5565, found 1284.5563  
IR (thin film) 3500 (br), 2973, 2933, 1725, 1671, 1603, 1582, 1512, 1484, 1452, 
1371, 1313, 1267, 1238, 1173, 1116, 1047, 989, 893, 839, 767, and 711. 
MP = 108-113°C  
TLC Rf (2:1 Hexanes:EtOAc) = 0.55  
 
 
7-O-(Triethoxysilyl)paclitaxel (3.11). Bis-silicate ester 3.08 (99.5 mg, 0.0845 
mmol, 1.0 equiv) was dissolved in d6-acetone (1.8 mL, dried over 3Å molecular 
sieves) in an NMR tube. A 9:1 mixture of D2O:TFA was added (200 µL) and the 
reaction progress was monitored by 1H NMR spectroscopy. After eight minutes at 
21.4 °C, the mixture was transferred into saturated aqueous NaHCO3 (2 mL). 
This mixture was extracted with CH2Cl2 (3 x 5 mL). The combined organic 
extracts were dried over MgSO4. and concentrated under reduced pressure. The 
residue was purified by MPLC (SiO2, 2:1 hexanes:EtOAc) to provide recovered 
starting material 2a (27.3 mg, 0.0232 mmol, 27.4%). Additional elution in 1:1 
hexanes:EtOAc gave the title compound as a white, crystalline solid [56.9 mg, 
0.0560 mmol, 66.3% (91.4% brsm)]. If necessary, residual EtOAc was removed 
by storage under high vacuum for ≥ 24 h. 
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.3 Hz, 2H, C2O2C-o-Ph), 7.75 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 7.5, 1.2 Hz, 1H, C2O2C-p-
Ph, 1H), 7.53-7.46 (m, 5H, C2O2C-m-Ph, C3’NHCO-p-Ph, and C3’-o-Ph,), 7.43-
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7.37 (m, 4H, C3’-m-Ph and C3’NHCO-m-Ph), 7.34 (tt, J = 7.3, 1.2 Hz, 1H, C3’-p-
Ph), 7.09 (d, J = 9.0 Hz, 1H, C3’NH), 6.56 (s, 1H, H10), 6.18 (br dd, J = 9, 9 Hz, 
1H, H13), 5.80 (dd, J = 6.9, 2.5 Hz, 1H, H3’), 5.69 (d, J = 6.9 Hz, 1H, H2), 4.93 
(dd, J = 9.6, 1.7 Hz, 1H, H5), 4.78 (dd, J = 4.9, 2.7 Hz, 1H, 2’H), 4.57 (dd, J = 
10.5, 6.9 Hz, 1H, H7), 4.30 (d, J = 8.4 Hz, 1H, H20α), 4.19 (dd, J = 8.3, 0.9 Hz, 
1H, H20β), 3.83 (d, J = 6.9 Hz, 1H, H3), 3.76 [q, J = 7.0 Hz, 6H, 
C7OSi(OCH2CH3)3], 3.69 (br s, 1H, C2’OH), 2.65 (ddd, J = 14.7, 9.7, 6.9 Hz, 1H, 
H6α), 2.37 (s, 3H, C4OAc), 2.35-2.25 (m, 2H, H14α and H14β), 2.15 (s, 3H, 
C10OAc), 1.95 (ddd, J =14.6, 10.7, 2.1 Hz, 1H, H6β), 1.93 (d, J = 1.3 Hz, 3H, 
C18H3), 1.76 (br s, 1H, C1OH), 1.73 (s, 3H, C19H3), 1.23 (s, 3H, C17H3), 1.19 [t, 
J = 7.0 Hz, 9H, C7OSi(OCH2CH3)3], and 1.16 (s, 3H, C16H3). 
13C NMR (125 MHz, CDCl3): δ 202.4, 172.6, 170.4, 169.0, 167.2, 167.1, 140.1, 
138.2, 133.9, 133.8, 132.1, 130.3, 129.4, 129.1, 128.89, 128.87, 128.5, 127.3, 
127.24, 127.23, 84.4, 81.5, 78.8, 76.8, 76.1, 74.8, 73.4, 72.5, 72.1, 59.5, 58.6, 
55.0, 47.0, 43.4, 36.7, 35.6, 26.8, 22.9, 21.1, 21.0, 18.2, 14.5, and 10.3. 
HRMS (ESI) Calc’d for C53H65NNaO17Si [M + Na]+ 1038.3914, found 1038.3914. 
IR (thin film) 3500 (br), 2975, 2898, 1724, 1653, 1602, 1580, 1515, 1485, 1451, 
1394, 1370, 1314, 1266, 1240, 1172, 1079, 1025, 969, 913, 888, 839, 797, and 
712 cm-1. 
mp = 141-146 °C.  
TLC Rf (1:1 Hexanes:EtOAc) = 0.5. 
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7-O-(Tri-n-octyloxysilyl)paclitaxel (3.12). Bis-silicate ester 3.09 (88.1 mg, 
0.0523 mmol, 1.0 equiv) was dissolved in d6-acetone (1.8 mL, dried over 3Å 
molecular sieves) in an NMR tube. A 9:1 mixture of D2O:TFA was added (200 
µL) and the solution became white and cloudy. Upon vigorous mixing for 30 
seconds, the mixture became homogeneous and transparent. The hydrolysis 
progress was monitored by 1H NMR spectroscopy. After 30 minutes at room 
temperature, the solution was transferred into saturated aqueous NaHCO3 (2 
mL). This mixture was extracted with CH2Cl2 (3 x 5 mL). The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by MPLC (SiO2, 3:1 hexanes:EtOAc) to provide recovered 
2b (12.9 mg, 0.0076 mmol, 27.4%). Additional elution in 2:1 hexanes:EtOAc 
gave the title compound as a crystalline solid [37.3 mg, 0.0294 mmol, 56.2% 
(65.7% brsm)]. If necessary, residual EtOAc was removed by storage under high 
vacuum for ≥ 24 h. 
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.3 Hz, 2H, C2O2C-o-Ph), 7.75 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-p-
Ph, 1H), 7.53-7.47 (m, 5H, C2O2C-m-Ph, C3’NHCO-p-Ph, and C3’-o-Ph,), 7.43-
7.38 (m, 4H, C3’-m-Ph and C3’NHCO-m-Ph), 7.34 (tt, J = 7.2, 1.3 Hz, 1H, C3’-p-
Ph), 7.06 (d, J = 9.0 Hz, 1H, C3’NH), 6.53 (s, 1H, H10), 6.17 (br dd, J = 9, 9 Hz, 
1H, H13), 5.81 (dd, J = 6.8, 2.4 Hz, 1H, H3’), 5.68 (d, J = 6.9 Hz, 1H, H2), 4.92 
(dd, J = 9.6, 1.8 Hz, 1H, H5), 4.78 (dd, J = 4.8, 2.6 Hz, 1H, 2’H), 4.56 (dd, J = 
6.7, 10.5 Hz, 1H, H7), 4.29 (d, J = 8.3 Hz, 1H, H20α), 4.19 (d, J = 8.5 Hz, 1H, 
H20β), 3.83 (d, J = 7.0 Hz, 1H, H3), 3.66 {t, J = 6.7 Hz, 6H, 
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C7OSi[OCH2(CH2)6CH3]3}, 3.60 (d, J = 4.9 Hz, 1H, C2’OH), 2.64 (ddd, J = 14.7, 
9.7, 6.9 Hz, 1H, H6α), 2.37 (s, 3H, C4OAc), 2.34-2.27 (m, 2H, H14α and H14β), 
2.14 (s, 3H, C10OAc), 1.97-1.90 (m, 4H, H6β and C18H3), 1.74-1.70 (m, 4H, 
C1OH and C19H3), 1.52 {tt, J = 6.8, 6.8 Hz, 6H, C7OSi[OCH2CH2(CH2)5CH3]3}, 
1.34-1.22 {m, 33H, C17H3 and C7OSi[OCH2CH2(CH2)5CH3]3}, 1.16 (s, 3H, 
C16H3), and 0.88 {t, J = 6.8 Hz, 9H, C7OSi[OCH2CH2(CH2)5CH3]3}. 
13C NMR (125 MHz, CDCl3): δ 202.2, 172.7, 170.3, 168.8, 167.2, 167.0, 140.0, 
138.3, 133.93, 133.89, 132.1, 130.4, 129.4, 129.1, 128.9 (x3), 128.5, 127.3, 
127.2, 84.5, 81.5, 78.8, 76.8, 76.0, 74.9, 73.3, 72.1, 63.9, 58.6, 54.9, 47.0, 43.4, 
36.6, 35.6, 32.5, 32.1, 29.62, 29.57, 26.8, 25.9, 22.91, 22.88, 21.1, 21.0, 14.5, 
14.3, and 10.3. 
HRMS (ESI) Calc’d for C71H101NNaO17Si [M + Na]+ 1290.6731; found 1290.6738. 
IR (thin film) 3500 (br), 2926, 2855, 1732, 1710, 1673, 1602, 1582, 1452, 1396, 
1370, 1317, 1281, 1269, 1241, 1179, 1093, 1025, 988, 968, 890, 844, 809, and 
712 cm-1. 
mp = 69-73 °C. 
TLC Rf (2:1 Hexanes:EtOAc) =0.4. 
 
 
2’-O-(Di-t-butoxyacetoxysilyl)paclitaxel (3.16).  Paclitaxel (33.5 mg, 0.0392 
mmol, 1.0 equiv) was dissolved in THF (1.0 mL, dried by distillation from 
sodium/benzophenone) in an oven-dried culture tube with a Teflon-lined cap and 
magnetic stir bar. Pyridine (50 µL, 0.618 mmol, 16 equiv) was added by 
Chapter 3 Silicate Ester Prodrugs of Paclitaxel? 
?
????
?
Wiretrol®. A distilled sample of di-t-butoxydichlorosilane (0.0524 mg, 0.214 mmol, 
5.5 equiv) was added by Wiretrol®. The culture tube was sealed and the solution 
was allowed to stir at room temperature for 24 hours. The reaction mixture was 
noted to be cloudy and heterogeneous after stirring overnight. To the 
suspension, pyridine was again added (50 µL, 0.618 mmol, 16 equiv). 
Immediately afterward, glacial acetic acid (50 µL, 0.873 mmol, 22 equiv) was 
added. The mixture was allowed to stir for an additional 24 hours at room 
temperature. The reaction suspension was diluted with EtOAc, the slurry filtered 
through a short plug of Celite® to remove the pyridinium salt, the filtrate 
concentrated under reduced pressure, and the residue redissolved in a mixture 
of hexanes:EtOAc (2:1). Chromatography (SiO2, 2:1 hexanes:EtOAc) via MPLC 
yielded the title compound (28.0 mg, 0.0258 mmol, 65.8%). If necessary, residual 
EtOAc was removed by storage under high vacuum for ≥ 24h. 
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.81 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.63 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-p-
Ph), 7.54 (t, J = 7.9 Hz, 2H, C2O2C-m-Ph), 7.48 (tt, J = 7.4, 1.9 Hz, 1H, 
C3’NHCO-p-Ph), 7.43-7.34 (m, 6H, C3’-o-Ph, C3’-m-Ph, and C3’NHCO-m-Ph), 
7.30-7.21 (m, 2H, C3’-p-Ph and C3’NH), 6.28 (s, 1H, H10), 6.13 (br dd, J = 9, 9 
Hz, 1H, H13), 5.69 (dd, J = 8.5, 3.9 Hz, 1H, H3’), 5.66 (d, J = 7.2 Hz, 1H, H2), 
5.19 (d, J = 4.0 Hz, 1H, H2’), 4.96 (dd, J = 9.6, 2.1 Hz, 1H, H5), 4.44 (ddd, J = 
10.8, 6.4, 4.3 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.3 Hz, 
1H, H20β), 3.79 (d, J = 7.0 Hz, 1H, H3), 2.56 (ddd, J = 14.9, 9.9, 6.6 Hz, 1H, 
H6α), 2.45 (overlapping m, 1H, C7OH and s, 3H, C4OAc), 2.30-2.18 (overlapping 
m, 1H, H14α and s, 3H, C10OAc), 1.97-1.84 (m, 8H, H14β, C18H3, SiOAc, and 
H6β), 1.67 (s, 3H, C19H3), 1.61 (s, 1H, C1OH), 1.30 (s, 9H, C2’OSiOC(CH3)2], 
1.26 (overlapping s, 9H, C2’OSiOC(CH3)2], 1.22 (s, 3H, C17H3), and 1.12 (s, 3H, 
C16H3). 
Chapter 3 Silicate Ester Prodrugs of Paclitaxel? 
?
????
?
13C NMR (75 MHz, CDCl3): δ 204.1, 171.6, 170.9, 170.2, 167.2, 167.1, 143.2, 
138.2, 134.4, 133.9, 132.7, 131.8, 130.4, 129.4, 128.92, 128.85, 128.7, 128.1, 
127.4, 127.1, 84.7, 81.1, 79.3, 76.6, 75.9, 75.4, 75.31, 75.27 (x2), 72.3, 71.6, 
58.7, 56.1, 45.7, 43.3, 35.7 (x2), 31.34, 31.32, 26.9, 23.1, 22.9, 22.4, 21.1, 15.2, 
and 9.8.  
HRMS (ESI) Calc’d for C57H71NNaO18Si [M + Na]+ 1108.4333; found 1108.4360. 
 
 
2’-O-(Di-t-butoxypivaloxysilyl)paclitaxel (3.17).  Paclitaxel (30.0 mg, 0.0351 
mmol, 1.0 equiv) was dissolved in THF (1.0 mL) in an oven-dried culture tube 
with a Teflon-lined cap and magnetic stir bar. Pyridine (25 µL, 0.31 mmol, 8.8 
equiv) was added by Wiretrol®. A distilled sample of di-t-butoxydichlorosilane 
(0.050 mg, 0.20 mmol, 6 equiv) was added by Wiretrol®. The culture tube was 
sealed and the solution was allowed to stir at room temperature for 96 hours. 
Pyridine ((40 µL, 0.49 mmol, 14 equiv) and pivalic acid (48.0 mg, 0.470 mmol, 
13.4 equiv) were co-dissolved in dry THF (1 mL), and the solution was added in a 
single portion to the reaction vesicle., The mixture was allowed to stir for an 
additional 24 hours at room temperature. An aliquot of the reaction mixture was 
removed, concentrated to dryness under reduced pressure, and analyzed by 
crude 1H NMR spectroscopy. Analysis showed that ca. 10% conversion to 3.16. 
The remainder of the reaction slurry was heated to 60 °C and stirred for 18 
hours. A second aliquot of the reaction mixture was removed, concentrated to 
dryness under reduced pressure, and analyzed by crude 1H NMR spectroscopy. 
Analysis showed an ca. 1:1:2 mixture of 3.17:PTX:PTX-2’OSi(OtBu)2Cl. The 
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reaction was capped and allowed to stir at 60 °C for an additional 24 hours. A 
third aliquot of the reaction mixture was removed, concentrated to dryness under 
reduced pressure, and analyzed by crude 1H NMR spectroscopy. The results 
showed no further conversion of the chlorosilane to 3.16 and a larger resonance 
corresponding to PTX. The remainder of the reaction suspension was diluted 
with EtOAc, the slurry filtered through a short plug of Celite® to remove the 
pyridinium salt, the filtrate concentrated under reduced pressure, and the residue 
redissolved in a mixture of hexanes:EtOAc (2:1). Chromatography (SiO2, 2:1 
hexanes:EtOAc) via MPLC yielded the title compound (4.8 mg, 0.0043 mmol, 
12%). If necessary, residual EtOAc was removed by storage under high vacuum 
for ≥ 24h. 
1H NMR (500 MHz, CDCl3)160: δ 8.12 (dd, J = 8.6, 1.4 Hz, 2H, C2O2C-o-Ph), 7.80 
(dd, J = 8.2, 1.1 Hz, 2H, C3’NHCO-o-Ph), 7.60 (br tt, J = 7, 1 Hz, 1H, C2O2C-p-
Ph), 7.54-7.35 (m, 9H, C2O2C-m-Ph, C3’NHCO-p-Ph, C3’-o-Ph, C3’-m-Ph, and 
C3’NHCO-m-Ph), 7.31 (t, J = 7.0 Hz, 1H, C3’-p-Ph), 7.07 (d, J = 9.3 Hz, 1H, 
C3’NH), 6.28 (s, 1H, H10), 6.22 (br dd, J = 9, 8 Hz, 1H, H13), 5.82 (dd, J = 9.0, 
2.5 Hz, 1H, H3’), 5.68 (d, J = 7.5 Hz, 1H, H2), 5.20 (d, J = 2.4 Hz, 1H, H2’), 4.96 
(dd, J = 9.3, 2.2 Hz, 1H, H5), 4.44 (br m, 1H, H7), 4.30 (d, J = 8.8 Hz, 1H, H20α), 
4.20 (d, J = 8.6 Hz, 1H, H20β), 3.80 (d, J = 6.9 Hz, 1H, H3), 2.56 (ddd, J = 14.4, 
9.7, 6.3 Hz, 1H, H6α), 2.45 (overlapping m, 1H, C7OH and s, 3H, C4OAc), 2.37 
(dd, J = 14.8, 8.5 Hz, 1H, H14α), 2.25 (s, 3H, C10OAc), 1.97-1.84 (overlapping 
m, 1H, H14β and s, 3H, C18H3), 1.68 (overlapping m, 1H, H6β and s, 3H, 
C19H3), 1.59 (br s, 1H, C1OH), 1.33 [s, 9H, C2’OSiOC(CH3)2], 1.32 [s, 9H, 
C2’OSiOC(O)C(CH3)3], 1.31 [s, 9H, C2’OSiOC(CH3)2],, 1.22 (s, 3H, C17H3), and 
1.13 (s, 3H, C16H3).   
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PTX-2’OSi(OtBu)32’-O-(Tri-t-butoxyacetoxysilyl)paclitaxel (3.18).  Paclitaxel 
(49.8 mg, 0.0583 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-
dried culture tube with a Teflon-lined cap and magnetic stir bar. A 1.0 mL aliquot 
containing ca. 0.40 mL of SiCl4 (2.6 mmol), 0.84 mL of pyridine (10. mmol), and 
0.73 mL of t-butanol (7.6 mmol) in THF (pre-mixed for 24 h) was added crude to 
the reaction vessel.  The culture tube was sealed and the solution was allowed to 
stir at room temperature overnight. To the suspension, pyridine was again added 
(50 µL, 0.62 mmol, 13 equiv). Immediately afterward, glacial acetic acid (50 µL, 
0.87 mmol, 24 equiv) was added. The mixture was allowed to stir for an 
additional 48 hours at room temperature. The reaction suspension was diluted 
with EtOAc, the slurry filtered through a short plug of Celite® to remove the 
pyridinium salt, the filtrate concentrated under reduced pressure, and the residue 
redissolved in a mixture of hexanes:EtOAc (2:1). Chromatography (SiO2, 2:1 
hexanes:EtOAc) via MPLC yielded 3.18 (11.2 mg, 0.0107 mmol, 18.4%) and, in 
the second fraction to elute 3.15 (23.0 mg, 0.0212 mmol, 36.3%), and finally, in 
the third fraction to elute, 3.17 (8.6 mg, 0.0078 mmol, 13.4%). If necessary, 
residual EtOAc was removed by storage under high vacuum for ≥ 24h. 
For 3.18: 
1H NMR (500 MHz, CDCl3)160: δ 8.11 (dd, J = 8.8, 1.7 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.8, 1.8 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 7.3, 1.2 Hz, 1H, C2O2C-p-
Ph, 1H), 7.56-7.34 (m, 9H, C2O2C-m-Ph, C3’NHCO-p-Ph, C3’-o-Ph, C3’-m-Ph, 
???????????????????????????????????????? ????????????????????
160 Minor impurities were noted in the alkyl region of this product. 
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and C3’NHCO-m-Ph), 7.30-7.24 (m, 1H, C3’-p-Ph), 7.05 (d, J = 8.5 Hz, 1H, 
C3’NH), 6.29 (s, 1H, H10), 6.17 (br dd, J = 9, 9 Hz, 1H, H13), 5.74-5.66 (m, 2H, 
H2 and H3’), 5.16 (d, J = 2.9 Hz, 1H, H2’), 4.97 (dd, J = 9.2, 2.3 Hz, 1H, H5), 
4.45 (app br dd, J = 11, 6 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J 
= 8.6 Hz, 1H, H20β), 3.80 (d, J = 7.0 Hz, 1H, H3), 2.57 (ddd, J = 15.2, 9.9, 6.7 
Hz, 1H, H6α), 2.47 (br d, J = 4 Hz, 1H, C7OH), 2.42 (s, 3H, C4OAc), 2.32 (dd, J 
= 15.9, 9.6, Hz, 1H, H14α), 2.25 (s, 3H, C10OAc), 2.17 (br dd, J = 14, 5 Hz, 1H, 
H14β), 1.93 (br d, J = 1 Hz, 3H, C18H3), 1.89 (br m, 1H, H6β), 1.78 (br s, 1H 
C1OH), 1.68 (s, 3H, C19H3), 1.24 {overlapping s, 27H, C2’OSi[OC(CH3)]3 and s, 
3H, C17H3}, and 1.13 (s, 3H, C16H3).  
13C NMR (125 MHz, CDCl3): δ 204.1, 171.6, 171.1, 170.1, 167.4, 167.2, 143.2, 
138.3, 134.5, 133.9, 132.8, 131.9, 130.4, 129.4, 128.97, 128.95, 128.8, 128.0, 
127.3, 126.9, 84.7, 81.2, 79.3, 76.7, 75.9, 75.3, 74.2, 73.9, 72.4, 71.4, 58.7, 55.5, 
45.7, 43.4, 36.0, 35.7, 31.4, 27.0, 23.0, 22.4, 21.1, 15.3, and 9.8.  
IR (thin film) 3500 (br), 2973, 2929, 1729, 1670, 1511, 1483, 1452, 1389, 1367, 
1268, 1242, 1183, 1124, 1069, 1025, 985, 835, 800, 758, and 711 cm-1. 
HRMS (ESI) Calc’d for C59H77NNaO17Si [M + Na]+ 1122.4853; found 1122.4901 
mp = 134-138°C.  
For 3.19: 
1H NMR (500 MHz, d6-acetone): δ 8.13 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 
7.89 (dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.69 (tt, J = 7.3, 1.3 Hz, 1H, 
C2O2C-p-Ph), 7.63-7.26 (m, 10H, C2O2C-m-Ph, C3’NHCO-p-Ph, C3’-o-Ph, C3’-
m-Ph, C3’NHCO-m-Ph, and C3’-p-Ph), 6.41 (s, 1H, H10), 6.16 (br dd, J = 9, 9 
Hz, 1H, H13), 5.72-5.68 (m, 2H, H3’ and H2), 5.08 (d, J = 5.5 Hz, 1H, H2’), 4.97 
(dd, J = 9.8, 2.0 Hz, 1H, H5), 4.41 (dd, J = 10.7, 6.5 Hz, 1H, H7), 4.17 (d, J = 8.2 
Hz, 1H, H20α), 4.15 (d, J = 8.1 Hz, 1H, H20β), 3.85 (d, J = 6.9 Hz, 1H, H3), 2.57-
2.31 (m, 5H, H6α, C4OAc, and H14α), 2.16 (s, 3H, C10OAc), 2.0-1.9 (m, 4H, 
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H14β, and C18H3), 1.78 (ddd, J = 14.0, 10.8, 2.3 Hz, 1H,  H6β), 1.66 (s, 3H, 
C19H3), 1.30 (s, 9H, C2’OSiOC(CH3)2], 1.28 (s, 9H, C2’OSiOC(CH3)2], 1.21 (s, 
3H, C17H3), and 1.18 (s, 3H, C16H3). 
HRMS (ESI) Calc’d for C57H71NNaO18Si [M + Na]+ 1066.4227; found 1066.4251 
 
 
2’-O-(Di-t-butoxysilanol)paclitaxel (3.20).  Compound 3.16 (10.4 mg, 0.0096 
mmol, 1 equiv) was dissolved in THF (0.45 mL, dried by distillation from 
sodium/benzophenone) and to this solution 18O-labeled water (50 µL) was 
added. The solution was sealed with a Teflon-lined cap and allowed to stir at 
room temperature for two hours. The solution was diluted with 5 mL of CDCl3 
(dried over 3Å molecular sieves) and dried over magnesium sulfate. The solution 
was filtered, concentrated under reduced pressure, and analyzed by ESI HR-MS.  
HRMS (ESI) Calc’d for C57H71NNaO1718OSi [M + Na]+ 1068.4269; found 
1068.4267 
Approximately half of the recovered silanol 3.20 was dissolved in THF (0.45 mL, 
dried by distillation from sodium/benzophenone) and water (50 µL) was added. 
The solution was sealed with a Teflon-lined cap and allowed to stir at room 
temperature for two hours. The solution was diluted with 5 mL of CDCl3 (dried 
over 3Å molecular sieves) and dried over magnesium sulfate. The solution was 
filtered, concentrated under reduced pressure, and analyzed by ESI HR-MS.  
Chapter 3 Silicate Ester Prodrugs of Paclitaxel? 
?
????
?
HRMS (ESI) Calc’d for C57H71NNaO1718OSi [M + Na]+ 1068.4269; found 
1068.4281 
 
 
Di-O-(Triethoxysilyl)curcumin (3.24). Curcumin (≥94% purity as received, 19.7 
mg, 0.0535 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried 
culture tube fitted with a Teflon-lined cap and a stir bar. Pyridine (20 µL, 0.25 
mmol, 4.6 equiv) was added by Wiretrol®. Chlorotriethoxysilane (50 µL, 0.26 
mmol, 4.8 equiv) was added, and a white precipitate was immediately observed. 
The suspension was observed to be cloudy and orange, and it was allowed to stir 
for 15 minutes at room temperature, at which time it was diluted with ca. 5 mL of 
dry THF. The slurry was filtered through a short plug of Celite® to remove the 
pyridinium salt, and the filtrate concentrated under reduced pressure. The 
residue was redissolved in hexanes:EtOAc (9:1), filtered through a plug of glass 
wool, and purified by MPLC (SiO2, 9:1 hexanes:EtOAc) to yield the 
monomethoxy byproduct as an orange solid (ca. 2 mg). In a second, slightly 
overlapping fraction, the desired product 3.23 was eluted. Yield of the pure 3.23 
(22.0 mg, 0.0318, 59.4%) was achieved by discarding fractions containing the 
co-eluted byproduct and 3.23. If necessary, residual EtOAc was removed by 
storage under high vacuum for ≥ 24 h. 
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1H NMR of 3.24 (500 MHz, CDCl3): δ 7.60 (d, J = 15.8, Hz, 2H, Hd), 7.10-7.03 (m, 
6H, Ha, Hb, and Hc), 6.51 (d, J = 15.8, Hz, 2H, He), 5.82 (s, 1H, Hf), 3.93 [q, J = 
7.0 Hz, 12H, OSi(OCH2CH3)3 and OSi(OCH2CH3)3], 3.89 (s, 6H, OCH3), and 1.24 
[t, J = 7.0 Hz, 18H, OSi(OCH2CH3)3 and OSi(OCH2CH3)3]. 
1H NMR of 3.25 (500 MHz, CDCl3): δ 7.62 (d, J = 15.8, Hz, 1H, Hd’), 7.60 (d, J = 
15.7, Hz, 1H, Hd), 7.47 (d, J = 8.6 Hz, 2H, Ha’) 7.10-7.02 (m, 5H, Ha, Hb, Hc, and 
Hb’), 6.511 (d, J = 15.8, Hz, 1H, He’), 6.507 (d, J = 15.8, Hz, 1H, He), 5.80 (s, 1H, 
Hf), 3.93 [q, J = 7.0 Hz, 12H, OSi(OCH2CH3)3 and OSi(OCH2CH3)3], 3.89 (s, 3H, 
OCH3), 1.26 and 1.24 [overlapping t’s, J = 7.0 Hz, 18H, OSi(OCH2CH3)3 and 
OSi(OCH2CH3)3]. 
 
 
Di-O-(Tri-i-propoxysilyl)curcumin (3.26). Curcumin (≥94% purity as received, 
17.2 mg, 0.0467 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-
dried culture tube fitted with a Teflon-lined cap and a stir bar. Pyridine (15 µL, 
0.25 mmol, 4.0 equiv) was added by Wiretrol®. An approximately 3:1 mixture of 
tri-i-propoxychlorosilane:tetra-i-propoxysilane (0.0472 mg, 0.14 mmol, 3 equiv of 
tri-i-propoxychlorosilane) was added. The orange solution gradually became 
cloudy while it stirred for 3.5 hours at room temperature. The suspension was 
diluted with dry THF, the slurry filtered through a short plug of Celite® to remove 
the pyridinium salt, and the filtrate concentrated under reduced pressure. The 
residue was redissolved in hexanes:EtOAc (99:1), filtered through a plug of glass 
wool, and subjected to MPLC (SiO2, 99:1 hexanes:EtOAc) to remove the tetra-i-
propoxysilane byproduct. The solvent mixture was changed (3:1 hexanes:EtOAc) 
to yield 3.24 contaminated with a column impurity. In a second MPLC 
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experiment, the impure 3.24 was subjected to MPLC (19:1 hexanes:EtOAc), to 
yield of the pure 3.24 (7.8 mg, 0.0129, 27.6%). If necessary, residual EtOAc was 
removed by storage under high vacuum for ≥ 24 h. 
1H NMR (500 MHz, CDCl3): δ 7.60 (d, J = 15.8, Hz, 2H, Hd), 7.10-7.05 (m, 6H, 
Ha, Hb, and Hc), 6.50 (d, J = 15.8, Hz, 2H, He), 5.81 (s, 1H, Hf), 4.34 {sept, J = 6.1 
Hz, 6H, [OSi(OCH(CH3)2]3 and [OSi(OCH(CH3)2]3}, 3.87 (s, 6H, OCH3), and 1.22 
{d, J = 6.1 Hz, 18H, OSi[OCH(CH3)2]3 and OSi[OCH(CH3)2]3}. 
 
 
A representative, general experimental procedure for the PTX silicate 
prodrug hydrolysis studies The PTX silicate prodrug was dissolved in 900 µL 
of d6-acetone. To this homogenous solution, 100 µL of a 9:1 v/v solution of 
D2O:TFA was added, and the solution was vigorously mixed. The 1H NMR 
spectra were taken (16 transients) on a 500 MHz Varian instrument at multiple 
time points over the course of more than three half-lives. The study was 
conducted at room temperature (rt = 22.5 °C ± 1.0 °C). Upon completion of the 
study, the H2’ and/or H7 methine resonances were integrated in a baseline-
corrected NMR spectrum using MestRe-C® software. The relative integration 
values were used to determine the extent of hydrolysis. Data from three 
replications were plotted on a semi-log scale to determine the kobs values that 
were then converted to the krel data as presented (Table 3-1), where the rate of 
the most slowly hydrolyzed prodrug (3.07) is taken to be krel = 1.0. Errors are 
defined as the standard deviation of the three trials. 
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Chapter 4  
A Strategy for Control of “Random” 
Copolymerization of Lactide and 
Glycolide: Application to the Synthesis of 
PEG -b-PLGA Block Copolymers Having 
Narrow Polydispersity. 
 
Efforts toward the development of a random copolymerization of glycolide 
and lactide were motivated by the need for acceptably hydrophobic, non-
crystalline, and biocompatible block copolymers for use in the FNP experiments. 
Toward that end, Dr. Haitao Qian initiated research designed to synthesis PEG-
b-PLGA block copolymers having varying molecular weights and lactide to 
glycolide ratios. In the course of his studies, he adapted work originally published 
by the Waymouth, Hedrick, and co-workers detailing the use of 1,8-
diazabicyclo[5.4.0]-undec-7-ene (DBU) as a catalyst for the polymerization of, 
among other lactones, lactide.161 Dr. Qian’s work applying this literature 
precedent to the copolymerization of lactide and glycolide included: i) the 
determination of the DBU-catalyzed polymerization kinetics of lactide and 
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161 Lohmeijer, B. G. G.; Pratt, R. C.; Leibfarth, F.; Logan, J. W.; Long, D. A.; Dove, A. P.; 
Nederberg, F.; Choi, J.; Wade, C.; Waymouth, R. M.; Hedrick, J. L. Guanidine and Amidine 
Organo-Catalysts for Ring-Opening Polymerization of Cyclic Esters. Macromolecules 2006, 39, 
8574–8583. 
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glycolide, ii) the synthesis of PEG-b-PLA and PEG-b-PLGA block copolymers via 
Method A (see section 4.4.3), and iii) the measurement of the extent of 
randomization in the PLGA backbone via 13C NMR spectroscopy.  
As Dr. Qian prepared to leave the Hoye lab to accept a new position, the 
research progress of the polyesterification project was gradually transferred to 
my responsibility.  Working with Dr. Qian, I repeated a number of his experiments 
and subsequently began to advance the project goals. In doing so, I made 
experimental contributions, including: i) the optimization of the Method B (see 
section 4.4.4) to render the synthesis of PEG-b-PLA and PEG-b-PLGA block 
copolymers more efficient and convenient, ii) the synthesis of the high molecular 
weight PEG-b-PLGAs (with the help of an undergraduate student, Jordan Crow, 
under my direction), iii) the demonstration of the proof of principle of PEG-b-
PLGA polymerizations with high lactide consumption, and iv) the SEC/MALS 
characterization of a subset of polymers. In addition to these experimental 
efforts, I took a primary role in analyzing the data, compiling the experimental 
results and analysis for publication, and writing/editing the Macromolecules 
manuscript. These joint, collaborative efforts were crucial to the project’s success 
and eventual publication of this research.162 
 
 
The following sections (Chapter 4) are reprinted (adapted) with permission from 
Qian, H.; Wohl, A. R.; Crow, J. T.; Macosko, C. W.; Hoye, T. R. A Strategy for 
Control of “Random” Copolymerization of Lactide and Glycolide: Application to 
Synthesis of PEG-b-PLGA Block Polymers Having Narrow Dispersity. 
Macromolecules, 2011, 44, 7132-7140. Copyright 2011 American Chemical 
Society. 
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1. Introduction. 
Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable copolymer that is 
also acceptable for use in a variety of biomedical applications. Typically, a 
random PLGA polymer is synthesized in a bulk batch polymerization using a tin-
based catalyst at high temperatures. This methodology results in relatively broad 
polydispersity indexes (PDIs) due to transesterification, and the polymer product 
is often discolored.  We report here the use of 1,8-diazabicyclo[5.4.0]-undec-7-
ene (DBU), a known, effective, and convenient organocatalyst for the ring-
opening polymerization of cyclic esters, to synthesize random copolymers of 
lactide and glycolide.  The polymerization kinetics of the homo- and 
copolymerizations of lactide and glycolide were explored via NMR spectroscopy. 
A novel strategy that employs a controlled addition of the more reactive glycolide 
monomer to a solution containing the lactide monomer, the poly(ethylene glycol) 
(PEG) macroinitiator, and DBU catalyst was developed.  Using this tactic (semi-
batch polymerization), we synthesized a series of block copolymers that 
exhibited excellent correlation of the expected and observed molecular weights 
and possessed narrow PDIs. We also measured the thermal properties of these 
block copolymers and observed trends based on the composition of the block 
copolymer.  We also explored the need for experimental rigor in several aspects 
of the preparations and have identified a set of convenient reaction conditions 
that provide polymer products that retain the aforementioned desirable 
characteristics. These polymerizations proceed rapidly at room temperature and 
without the need for tin-based catalysts to provide PEG-b-PLGAs suitable for use 
in biomedical investigations.   
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2. Lactide and Glycolide Polyester Synthesis Background. 
Polyesters synthesized from ring-opening polymerization (ROP) of cyclic 
ester163 monomers [lactones and dilactones (diolides)] have found wide 
application in the fields of drug delivery (microparticles, nanoparticles, or 
micelles),164 tissue engineering (sutures and other biodegradable implants),165,166 
medical devices,167 and single-use plastics168 because of their biocompatibility 
and biodegradability. The most extensively studied of these polyesters are 
poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA), the homopolymer 
of lactide (4.01) or random copolymer of 4.01 and glycolide (4.02), 
respectively.169,170 Tin(II) octoate is widely used as a catalyst for the synthesis of 
PLA or PLGA.171 However, tin-based catalysts are less than ideal from both 
chemical [e.g., broad polydispersities (PDIs)] and biological (e.g., toxicity) 
perspectives, especially in the synthesis of the more readily transesterified 
PLGAs.   
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163 Jerome, C.; Lecomte, P. Recent Advances in the Synthesis of Aliphatic Polyesters by Ring-
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169 Chu, C. C. Biodegradable Polymeric Biomaterials: an Updated Overview. In Biomaterials; 
Wong, J. Y., Bronzino, J. D. CRC Press: Boca Raton, FL, 2007; 6/1–6/22.  
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171 Stjerndahl, A.; Wistrand, A. F.; Albertsson, A. C. Industrial Utilization of Tin-Initiated 
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Biomacromolecules 2007, 8, 937–940. 
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The importance of PLGA microstructure has been demonstrated in a study 
of polyester hydrolytic degradation by Meyer and coworkers.172 They 
demonstrated that microspheres made from PLGA copolymers having alternating 
lactic and glycolic acid units [from condensation polymerization of (S)-2-(2-
hydroxyacetoxy)propanoic acid monomer] undergo chain scission ca. two times 
more slowly than those prepared from PLGA copolymers containing longer 
blocks of lactic and glycolic units. The observed difference in degradation rates 
was attributed to the difference in the rate of nucleophilic attach at the less 
sterically hindered glycolic carbonyls present in the blocks of glycolic repeat 
units. 
Controlled homopolymerization of glycolide (4.02) is challenging because 
of the low solubility of both the monomer and resulting poly(glycolic acid) (PGA) 
homopolymer (or block copolymers) in common organic solvents. 
Copolymerization of glycolide (4.02) and lactide (4.01) provides an effective way 
to modify the chemical and physical properties of these polyesters for various 
applications, and PLGAs that comprise up to a 1:1 ratio of lactic to glycolic units 
are of practical interest.9 Dong et al. developed a strategy for obtaining PLGA 
with exactly a 1:1 molar ratio of lactic to glycolic acid by polymerizing 3-
methylglycolide (tin(II) octoate).173 These polymerizations were shown to proceed 
with high monomer conversion and typical PDIs of 1.6-1.7. However, we are 
unaware of any protocols for random copolymerization of glycolide (4.02) and 
lactide (4.01) that produce PLGAs having well-controlled molecular weights and 
narrow PDIs while minimizing the sequence length of the lactic and glycolic 
repeat units. This largely reflects differences in reactivity and solubility of these 
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172 Li, J.; Stayshich, R. M.; Meyer, T. Y. Exploiting Sequence to Control the Hydrolysis Behavior of 
Biodegradable PLGA Copolymers. J. Am. Chem. Soc. 2011, 133, 6910–6913. 
173 Dong, C.-M.; Qiu, K.-Y.; Gu, Z.-W.; Feng, X.-D. Synthesis of Poly(D,L-lactic acid-alt-glycolic 
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two monomers.174 Thus, simple use of equimolar charges of glycolide (4.02) and 
lactide (4.01) results in polymers containing long glycolic blocks (at least in the 
absence of chain transfer). This adversely affects the solubility and PDI of the 
copolymer. Melt copolymerization of glycolide (4.02) and lactide (4.01) has often 
been used to prepare PLGA with high glycolic content. Under these conditions in 
situ transesterification of the polymer both randomizes the sequence and 
broadens the distribution of the PLGA.9 During our attempts to synthesize PEG-
b-PLGAs using Sn(II)-catalysis, we observed PDI values greater than 1.7 and 
significant discoloration of the resulting PLGA copolymer. Thus, we felt there was 
room for improvement in the methods for preparation of well-defined PLGAs.  
In addition to tin(II) octoate, other metal-containing catalysts have been 
studied for the ROP of lactide (4.01), glycolide (4.02), ring strained lactones, and 
cyclic carbonates. These include zinc or aluminum alkoxides9,175,176,177,178 and 
rare earth metal compounds.175,178,179,180,181 Some of these catalysts also raise 
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health safety concerns. Enzymatic ROP of lactones, lactide (4.01), and glycolide 
(4.02) has also been studied to address concerns about possible toxicity of 
heavy metal catalysts and initiators.182  
A decade ago the first organocatalytic ROP of lactide (4.01) was reported, 
using 4-dimethylaminopyridine (DMAP) and pyrrolidinopyridine as catalysts.183 
This was followed by the investigation of several other classes of organic small 
molecules as more potent catalysts for ROP of lactide (4.01) and lactones. 
Among these, N-heterocyclic carbenes,184 phosphines,185 phosphazenes,186 and 
amidines and guanidines161 have been demonstrated to have unique properties 
that influence the synthesis of polyesters from different monomers. Many of 
these allow for better control of molecular weight and molecular weight 
distribution; some show enhanced functional group compatibility.  
Here we report a strategy for the successful controlled “random” 
copolymerization (Scheme 4-1) of glycolide (4.02) and a racemic mixture of D- 
and L-lactide [50:50 R,R-4.01 and S,S-4.01, which we will refer to as (±)-4.01] 
using poly(ethylene glycol) monomethyl ether (4.03, mPEG-OH) as a 
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macroinitiator. The resulting amphiphilic mPEG-b-PLGA block copolymers (4.04) 
have well-controlled molecular weights (MWs) and MW distributions. The 
resulting poly(ethylene glycol) (PEG)-containing amphiphilic block copolymers 
(BCPs) of PLA and PLGA have practical applications in drug delivery 
systems.187,188,189 Specifically, they can be used to formulate aqueous 
dispersions of hydrogels or nanoparticles. The use of well-defined PEG-b-PLAs 
and/or PEG-b-PLGAs to fabricate drug-containing nanoparticles may lead to 
more precise control of size, degradability, thermal properties (Tm and Tg), and 
release profiles in these applications.  
Scheme 4-1. The co-polymerization of rac-lactide [(±)-4.01] and glycolide (4.02) 
yields the PEG-b-PLGA block copolymer 4.04.  
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3. Shorthand Designation of the Polymer Nomenclature. 
PEGx-PLyA is used to designate our PEG-b-PLA diblock copolymers and 
PEGx-PLyGzA is used for PEG-b-PLGA. PEG is used interchangeably with 
poly(ethyele oxide) (PEO) due to the prevalent use of the PEG nomenclature in 
the biological sciences. PEGx-PLyA has a PEG block with the number average 
molecular weight (Mn) of x kilodaltons and a lactic acid (LA) block with the 
average MW of y kilodaltons. Similarly, PEGx-PLyGzA has a PEG block with the 
average MW of x kilodaltons and a lactic-co-glycolic acid (LGA) block comprising 
LA and GA of y and z kilodaltons, respectively. PEGx-PLLyA refers to a PEG-b-
PLA polymer in which pure L-lactide (i.e., S,S-4.01) was used rather than (±)-
4.01. Essential data for each of the polymer samples prepared in this study are 
presented in Table 4-1.  
 
4. Methods for PEG-b-PLA and PEG-b-PLGA Synthesis. 
1. Method A for PEG-b-PLA Synthesis. The following reaction mixture was 
prepared in a controlled atmosphere (N2) glove box. To a solution of rac-lactide 
[(±)-4.01, 100 mg, 0.694 mmol] and mPEG-OH (4.03, 5K) (100 mg, 0.02 mmol) in 
1 mL of chloroform was added DBU [1 mg, 1 mol% relative to (±)-4.01] in a 
screw-capped glass reaction vessel (e.g., culture tube). The solution was 
removed from the glove box and stirred for 1 h. The vessel was opened, 
hydrochloric acid (1N) was added immediately, and the mixture was washed with 
water and brine. The polymer was precipitated by dropwise addition of the 
chloroform solution with stirring into excess isopropanol. Solvent was removed 
from the resulting suspension of white polymer by either filtration or decantation, 
and the polymer was dried under vacuum at 50 °C overnight.  
2. Method B for PEG-b-PLA Synthesis. The following reaction mixture was 
prepared under ambient atmosphere in a fume hood. A solution of mPEG-OH 
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(4.03) in dry CH2Cl2 (0.5 g mL-1) was dried over 3 Å molecular sieves overnight. 
A portion of this solution (2.0 mL) was added to a solution of rac-lactide [(±)-4.01] 
in 8 mL of dry CH2Cl2 in an oven-dried, screw-capped glass reaction vessel. DBU 
was added (10 µL) and the reaction vessel was tightly capped. The resulting 
solution was stirred for 1 h, and benzoic acid (150 mg) was added. This solution 
was concentrated to approximately 30% of the original volume and then added 
dropwise with stirring into excess isopropanol. Solvent was removed from the 
resulting suspension of white polymer by either filtration or decantation, and the 
polymer was dried under vacuum at 50 °C overnight. 
3. Method A for PEG-b-PLGA Synthesis. The following operations were 
performed in a controlled atmosphere (N2) glove box. i) mPEG-OH (4.03, 5K, 150 
mg) in CH2Cl2 (7 mL) together with a predetermined amount of rac-lactide [(±)-
4.01] were combined in a round-bottomed flask containing a magnetic stir bar 
and closed with a septum. ii) DBU was dissolved in CH2Cl2 at a concentration of 
11 µL mL-1 in a round-bottomed flask closed with a septum. iii) Glycolide (4.02) 
was dissolved in THF (2 mL) and taken up in a syringe. All three solutions i-iii) 
were removed from the glove box. Solution i) was vigorously stirred. Immediately 
after the addition of solution ii) (1 mL), solution iii) was infused into the reaction 
vessel via a syringe pump at the rate of 0.2 mL min-1. At the end of the infusion 
(10 min), solid benzoic acid (50 mg) was added to arrest the polymerization. The 
PEG-b-PLGA (4.04) was purified by precipitation twice into isopropanol from 
CH2Cl2 and dried at 50 °C under vacuum overnight.  
  4. Method B for PEG-b-PLGA Synthesis. The following three solutions 
were prepared in ambient atmosphere in a fume hood.  i) mPEG-OH (4.03, 5K, 
450 mg) was dissolved in CH2Cl2 (22 mL) together with a predetermined amount 
of rac-lactide [(±)-4.01] in an oven-dried round-bottomed flask containing a 
magnetic stir bar and closed with a septum. ii) DBU was dissolved in CH2Cl2 at a 
concentration of 16.7 µL mL-1 in a screw-capped vial. iii) Glycolide (4.02) was 
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dissolved in THF (6 mL) and taken up in a syringe. Solution i) was vigorously 
stirred. Immediately after the addition of solution ii) (2 mL), solution iii) was 
infused into the reaction vessel via a syringe pump at the rate of 0.6 mL min-1. At 
the end of the infusion (10 min), solid benzoic acid (150 mg) was added to arrest 
the polymerization. As above, the PEG-b-PLGA (4.04) was purified by 
precipitation twice into isopropanol from CH2Cl2 and dried at 50 °C under vacuum 
overnight.  
 
5. Synthesis of PEG-b-PLA. 
1. Introduction and Replication of Waymouth and Hedrick’s PLA 
Polymerization. DBU is an organic base of low nucleophilicity that has found wide 
application as a catalyst for transesterification-like reactions. Waymouth, Hedrick, 
et al. 161 have demonstrated that DBU and other superbases, such as 1,5,7-
triazabicyclo[4.4.0]dec-1-ene (TBD), catalyze ring-opening polymerization of 
lactide and other lactones. Moreover, these polymerizations occur in solution, at 
ambient temperature, and with impressive effectiveness to afford polyesters that 
have defined structure, controlled molecular weight, and controlled molecular 
weight distribution. Their findings that DBU is a less active catalyst than TBD 
[and thus more manageable for controlling undesired transesterification (chain 
transfer) during polymerization] prompted us to investigate its use for the 
preparation of PLGA moieties. Our interest in use of poly(ethylene oxide)-
containing, amphiphilic block copolymers for various drug delivery applications 
led us to target PEG-b-PLGAs. Hence, we selected mPEG-OH as the 
(macro)initiator in the work reported here. 
We used the Waymouth/Hedrick methodology161 first to prepare a series 
of PEG-b-PLA block copolymers using only lactide as the monomer. Thus, rac-
lactide [(±)-4.01] was polymerized using mPEG-OH (MW= 2K or 5K) as the 
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macroinitiator to afford PEG-b-PLA. When 1 mol% of DBU and monomer 
concentrations of ca. 0.5-2M were used for polymerization at room temperature, 
>95% monomer conversions were observed in less than 1 h. We prepared a 
series of mPEG-b-PLA diblock copolymers of different molecular weight ratios. 
Each had a small PDI (cf. entries 1-6, Table 4-1) and was monomodal. This is in 
accordance with the fact that DBU does not cause extensive transesterification of 
PLA on the time scale of lactide ROP.161 We observed (1H NMR spectroscopy) a 
preference for production of isotactic arrays in these DBU-catalyzed ROPs of 
rac-lactide [(±)-4.01]. Interestingly, this contrasts with the known syndiotactic 
preference when tin(II) octoate is used as the polymerization catalyst190 but is in 
agreement with the slight isotactic preference noted in TBD-catalyzed ROPs.161 
2. Tacticity Analysis of PEG-b-PLAs.  A representative 1H NMR spectrum 
of one of the PEG-b-PLAs (PEG5-PL10A) is shown in Figure 4-1. The tacticity of 
the PLA block can be judged from analysis of the methine proton resonances 
between δ = 5.10-5.25 ppm.190,191 The array of overlapped quartets centered at 
ca. 5.16 ppm arises from backbone methine protons flanked on both sides by a 
lactic acid moiety of the same configuration (isotactic,isotactic or i,i) while the 
array at ca. 5.21 ppm reflects flanking by one lactic acid moiety of the same and 
a second of opposite configuration (isotactic,syndiotactic, or i,s) . Racemic lactide 
[(±)-4.01] was used as the monomer for these ROPs. Since each monomer 
lactide in (±)-4.01 (R,R-4.01 or S,S-4.01) bears two lactic acid moieties of the 
same configuration, there are no individual lactic acid moieties in the PLA that 
are flanked on both sides by ones of opposite configuration (and thus there are 
no syndiotactic,syndiotactic, or s,s relationships). Arrays of similar quartets rather 
???????????????????????????????????????? ????????????????????
190 Thakur, K. A. M.; Kean, R. T.; Hall, E. S.; Kolstad, J. J.; Munson, E. J. Stereochemical Aspects 
of Lactide Stereo-Polymerization Investigated by 1H NMR: A Case of Changing Stereospecificity. 
Macromolecules 1998, 21, 1487–1497. 
191 Thillaye du Boullay, O.; Marchal, E.; Martin-Vaca, B.; Cossio, F. P.; Bourissou, D. An Activated 
Equivalent of Lactide toward Organocatalytic Ring-Opening Polymerization. J. Am. Chem. Soc. 
2006, 128, 16442–16443. 
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than a single discrete quartet are observed because of small influences on the 
precise chemical shifts from longer-range, relative configurational relationships. If 
the rates for homochiral (PLA-R with R,R-1 or PLA-S with S,S-1) vs. heterochiral 
(PLA-R with S,S-1 or PLA-S with R,R-1) propagation were identical, the intensity 
of each of the two multiplets at δ = 5.16 and 5.21 (proportional to the #i,i and #i,s, 
respectively) would be equal. The average sequence length (SL, the number of 
adjacent lactic acid moieties of the same configuration) is [(#i,i + #i,s)/(#i,s/2)],192 
and in this scenario SL would be 4. Since, instead, the ratio of these resonances 
is 3, the average SL is 8. Finally, from the SL, one can deduce the reactivity 
ratio193 (r) for homo- vs. heterochiral propagation events; namely, r = (SL-2)/2194 
or 3.  
 
 
 
 
 
 
 
 
???????????????????????????????????????? ????????????????????
192 Each run of i,i moieties is terminated at each of its ends by a i,s moiety; there are two i,s 
moieties per run; and the number of runs is one half the number of i,s moieties. The average 
sequence length in any sample is the total number of lactic acid units (#i,i + #i,s) divided by the 
total number of runs (#i,s/2). 
193 Hiemenz, P. C.; Lodge, T. P. Copolymers, Microstructure, and Stereoregularity. In Polymer 
Chemistry, 2nd Ed.; Taylor & Francis Group, LLC: Boca Raton, 2007, 1; 165–216. 
194 The reactivity ratio for a growing chain whose reactive terminal carbinol center has the R 
configuration is rPLA-R = (SL-2)/(2*[R,R-1]/[S,S-1]). Likewise, rPLA-S = (SL-2)/(2*[S,S-1]/[R,R-1]). 
Since (±)-1 was used here, [S,S-1]/[R,R-1] = 1 and rPLA-R = rPLA-S = r = (SL-2)/2. 
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Figure 4-1. 1H NMR spectrum of the PEG-b-PLA copolymer PEG5-PL10A (CDCl3)  
The ratio of the methine multiplets at ca. δ 5.16 and 5.21 ppm indicates that the 
DBU catalyst favors the formation of isotactic sequences with a 
homochiral/heterochiral reactivity ratio of 3 (see text). 
 
 
  
6. Synthesis of PEG-b-PLGA. 
1. Determining Glycolide to Lactide Reactivity Ratio during DBU-Catalyzed 
Polymerization. The organocatalyzed copolymerization of glycolide (4.02) with 
lactide (4.01) is challenging. The low solubility in common organic solvents of 
both the monomeric glycolide and, especially, growing polymers that have a high 
glycolyl content can make the experiment problematic. Additionally, glycolide is, 
of course, much more reactive than lactide.9,174 Thus, batch copolymerizations 
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that have equimolar ratios of the glycolide and lactide monomers result in the 
synthesis of long blocks of polyglycolide, further reducing polymer solubility 
during copolymerization (as previously observed for cationic polymerizations195). 
Consequently, we are unaware of reports that describe either 
homopolymerization or copolymerization of glycolide by organocatalysis. We 
were interested in determining the relative reactivity of glycolide and lactide in 
order to design an essentially “random” copolymerization protocol. 
Initial attempts to quantify the reactivity ratios of glycolide (4.01) and 
lactide (4.02) by subjecting a 1:1 mixture of the two monomers to mPEG-initiated, 
DBU-catalyzed polymerization followed by NMR analysis were only marginally 
successful. Instead of observing copolymerization of both monomers, we noted 
the rapid consumption of the glycolide monomer via ROP, while nearly all of the 
lactide remained intact. Thus, we were unable to directly measure the 
copolymerization reactivity ratio, but it was clear that the glycolide had 
polymerized significantly faster than the lactide.  
We then explored the relative reactivity of glycolide and lactide via parallel, 
independent homopolymerization experiments. Thus, analogous kinetic 
experiments utilizing lactide [(±)-4.01] vs. glycolide (4.02) were conducted, 
leading eventually to the following sets of conditions from which comparative 
reactivities could be assessed. For lactide, [mPEG2k] = 5.0mM and a ratio of [(±)-
4.01]:[mPEG2k]:[DBU] = 264:1:1.32 was used. For the more reactive glycolide, 
much lower catalyst and initial monomer concentrations were used—namely,  
[mPEG2k] = 5.1mM and the ratio of [4.02]:[mPEG2k]:[DBU] was 2.94:1:0.0022. In 
the case of glycolide (4.02), only polymers having short PGA blocks could be 
prepared because of solubility limitations of the oligomeric product. Waymouth 
and Hedrick have demonstrated that similar amidine-catalyzed ROPs (of 
???????????????????????????????????????? ????????????????????
195 Kricheldorf, H. R.; Kreiser, I. Polylactones, 11. Cationic Copolymerization of Glycolide with L,L-
Dilactide. Makromol. Chem. 1987, 188, 1861–1873. 
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valerolactone) show a first-order dependency on the monomer, alcohol initiator, 
and amine catalyst conentrations.161 We assumed that this would also be the 
case for lactide or glycolide polymerizations, which is reflected in the rate 
expression shown in equation 4-1. The concentration of propagating hydroxyl 
groups equals the concentration of alcohol initiator used and remains constant 
throughout the polymerization as does, of course, the concentration of DBU 
catalyst. Thus, we hypothesized the reaction to be pseudo first-order in 
monomer, since the apparent rate constant (kapp, eq 4-2) remains unchanged 
under a given set of conditions. This was then supported by observing linearity in 
the plots of ln[1/(1-x)] vs. time (x = monomer conversion) for both glycolide and 
lactide as shown in Figure 4-2A. 
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Figure 4-2. Lactide and glycolide homopolymerizations in CDCl3 solvent at 
ambient temperature (reaction progress measured by 1H NMR spectroscopic 
analysis) under the following conditions (cf. Table 4-1). For lactide [(±)-4.01]: 
{[mPEG2k] = 5.0mM; [(±)-4.01]0:[mPEG2k]:[DBU] = 264:1:1.32}; for glycolide 
(4.02): {[mPEG2k] = 5.1mM, [4.02]0:[mPEG2k]:[DBU] = 2.94:1:0.0066. Panel A: 
Plot of ln[1/(1-x)] vs. time (x = monomer conversion). Panel B: Experimentally 
observed (red) exponential decay of monomer concentration for lactide 
polymerization. The blue line denotes the approximate linear conversion during 
the first half-life of lactide consumption, which we then used to guide the choice 
of the (constant) rate of glycolide addition during subsequent syntheses of the 
PEG-b-PLGA copolymers. 
 
 
 
The apparent first-order rate constant (kapp, cf. eq 4-2) for each of these 
two pseudo-first order polymerizations is given in Table 4-1 (column 4). The third 
order rate constant (k) for each, calculated according to eq 4-1, is given in 
column 5. The ratio of this latter pair of rate constants is ca. 103, favoring the 
more reactive glycolide monomer. This is larger than the reported relative 
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reactivity of glycolide to lactide using tin(II) octoate at 200 °C, where the krel for 
these two monomers is 14:1.196  
Table 4-1. Rate constants for glycolide and lactide polymerization. 
 Monomer [mPEG2K ] [DBU] kappa kb  
  (mM) (mM) (s-1) (105 (L/mol)2 s-1)
  
 Lactide [(±)-1, 1.3M] 5.0 6.6 550 1.7 
 Glycolide (2, 15mM) 5.1 0.033 3100 1800  
 a Apparent rate constant of pseudo-first order ROP (cf. eq 4-2)  
 b Third order rate constant (cf. eq 4-1). 
 
The large difference in ROP reactivity of the two monomers reflects 
collective differences in steric hindrance of both the electrophilic monomer and 
the nucleophilic hydroxyl group of the propagating polymer chain in this pair of 
homopolymerizations.196 Knowledge of this reactivity difference guided our 
design of the following copolymerization experiments in which, of course, both 
monomers were simultaneously exposed to identical concentrations of catalyst 
and propagating hydroxyl groups. Thus, alteration of the relative amounts of each 
monomer was the obvious exploitable experimental variable.  
2. Initial PEG-b-PLGA Synthesis by Method A. One strategy for 
copolymerization of monomers with different propagation rate constants is to add 
the fast-reacting monomer continuously during the polymerization. In this 
???????????????????????????????????????? ????????????????????
196 Gilding, D. K.; Reed, A. M. Biodegradable Polymers for Use in Surgery – 
Polyglycolic/Poly(lactic acid) Homo-  and Copolymers: 1. Polymer 1979, 20, 1459–1464. 
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manner, the inherent reactivity imbalance is compensated by the fact that at any 
instant the slow-reacting monomer is in excess. We adopted this “semi-batch 
polymerization”197 strategy to target copolymers of lactide (4.01) and glycolide 
(4.02) having approximately equal composition by mass. We initiated 
polymerization of lactide with mPEG-OH, immediately (<1 sec) began addition of 
glycolide at a constant rate, set the glycolide addition to finish at the time 
required to reach ca. 50% conversion of the lactide, and quenched the reaction 
(by addition of excess benzoic acid161) immediately upon completion of glycolide 
addition. A control experiment demonstrated that pretreatment of mPEG-
OH/lactide with excess benzoic acid followed by addition of DBU did not result in 
polymerization. Because it was convenient to add glycolide at a constant rate, we 
approximated lactide consumption as if it were linear during its first half-life (see 
blue line in Figure 4-2B). In a typical run a solution containing [mPEG-OH] = 
4mM and [(±)-4.01]0 = 0.3M in anhydrous CH2Cl2 was charged to the reaction 
vessel. The DBU catalyst (1 mol% based on the amount of mPEG-OH) was 
injected to this rapidly stirred solution. Addition via syringe pump of a solution of 
glycolide (4.02, 0.5 equiv vs. the initial charge of lactide) was immediately (<1 
sec) begun. We judged the t1/2 for lactide consumption to ca. ten minutes under 
these conditions, which we therefore set as the glycolide addition time. The 
polymerization progress was immediately then arrested, and the excess 
unreacted lactide was removed by precipitation.  
The purified PEG-b-PLGA polymers were characterized by gel permeation 
chromatography (GPC) and NMR analyses. The 1H NMR spectrum of a typical 
product is shown in Figure 4-3. The small resonances for the carbinol protons f 
and for the methylene protons c at the linkage point between the PEG and PLGA 
blocks indicate that, again, the polymerization occurred with good functional 
???????????????????????????????????????? ????????????????????
197 Dotson, N. A.; Galván, R.; Laurence, R. L.; Tirrell, M. Reactor Configuration. In Polymerization 
Process Modeling; VCH Publishers, Inc.: New York, NY, 1996; 259–303. 
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fidelity. It can be inferred from this spectrum (i.e., from the integration ratio or 
resonances g to d) that we were able to achieve the targeted 50:50 mass ratio of 
glycolate to lactate reasonably well (cf., Tables 4-2 and 4-4). Finally, we judged 
from analysis of 13C NMR data that the glycolide and lactide monomers were 
incorporated into the PLGA blocks with nearly random monomer distributions 
(see sequence length discussion, below). 
Figure 4-3. 1H NMR spectrum of PEG-PLA block copolymer PEG5-PL5G5A 
obtained in CDCl3. 
 
 
3. Alternative PEG-b-PLGA Synthesis by Method B. We then explored 
whether less rigorous polymerization conditions, those described as Method B in 
the Experimental Section, would allow us to obtain polymers of comparable 
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quality and with similar levels of control, thereby reducing the time and effort 
necessary to complete a polymerization experiment vis-à-vis the more careful 
protocols of Method A. We compared the preparation of five polymers using both 
Methods A and B.  The results are given in Table 4-2 and demonstrate that in all 
cases, both methods yielded polymers having molecular weights and monomer 
ratios similarly close to the targets. Note that in several instances we judged that 
the copolymers made by Method B had slightly higher PDI values. Two of the 
polymerizations were carried out in triplicate, and the results were quite 
consistent among runs. Therefore, use of the less stringent Method B conditions 
did not adversely affect the process or product. 
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Table 4-2.  A comparison of polymers made by DBU-catalyzed ROP using 
Methods A vs. B. 
 Polymer Method Mn(PEG) Mn(PLGA)a Ratio a,b PDI c  
 (targeted)    LA : GA   
 PEG2-PL2A A 2K 2.16K 100 : 0 1.08  
 PEG 2-PL2A B 2K 2.03K 100 : 0 1.15  
 PEG 5-PL5A A 5K 5.62K 100 : 0 1.06  
 PEG 5-PL5A B 5K 5.09K 100 : 0 1.06  
 PEG 5-PL10A A 5K 10.8K 100 : 0 1.05  
 PEG 5-PL10A d B 5K 10.1–10.2K 100 : 0 1.08–1.09  
PEG 5-PL2.5G2.5A A 5K 4.90K 46 : 54 1.06 
PEG 5-PL2.5G2.5A B 5K 4.79K 50 : 50 1.05 
 PEG5-PL5G5A A 5K 10.4K 54 : 46 1.08  
 PEG 5-PL5G5A d B 5K 10.2–10.3K 52-54 : 46-48 1.09–1.17  
 a Results based on NMR spectroscopy198 
 b Mass ratio of the repeat units 
 c Results based on GPC measurements against a polystyrene standard 
 d Run in triplicate, giving the indicated ranges of values 
 
4. Molecular Weight Determination via SEC/MALS. To assess the 
accuracy of our determinations of Mn via 1H NMR spectroscopy, we further 
analyzed three polymers by SEC/MALS to determine the absolute molecular 
???????????????????????????????????????? ????????????????????
198 To assess the accuracy of determining Mn via 1H NMR spectroscopy, we analyzed three 
polymer samples by SEC/MALS to measure the absolute molecular weight each. The Mn values 
by these two approaches showed reasonably good agreement. 
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weight of the samples. The results are summarized in Table 4-3. The specific 
refractive index (dn/dc) of a polymer is a concentration-dependent value of the 
difference in the refractive index of a dilute solution of the polymer and the 
corresponding pure solvent. If we assume a 100% recovery of the polymeric 
sample through the SEC column, then the value we measured for the specific 
refractive index (dn/dc) for the PEG sample was lower than its known value. This 
results in an Mn value that is higher than expected (i.e., 5K for the mPEG–OH 
sample, entry 1) or measured (for the block copolymers in entries 2 and 3) via 1H 
NMR spectroscopy.  Specifically, if we assume 100% recovery in the analysis of 
the 5K PEG-OH (run as a control), the experimentally determined dn/dc value 
was only 0.055 mL/g and the calculated Mn was 6.0 K. However, when the 
reported dn/dc value for poly(ethylene oxide) in THF of 0.068 mL/g was used,199 
the Mn was determined to be 4.9K–in good agreement with the value reported by 
the supplier of this commercial sample. Presumably, sample loss during filtration 
prior to injection and/or during elution from the SEC column is responsible for the 
need to correct the data in this manner.   
Similarly, the observed dn/dc values for both the PEG-b-PLA and PEG-b-
PLGA samples were also lower than expected, resulting, again, in 
correspondingly high Mn values. In this case, the known dn/dc value in THF for 
PLA of 0.042 was used,199 for either the PLA block or as an approximation for the 
PLGA block. The weighted average of the dn/dc values for the PEG and 
polyester blocks were then used to calculate a dn/dc value for the block 
copolymer.200 Using this approach, satisfactory correlation was found between 
the corrected Mn values found via SEC/MALS and 1H NMR spectroscopy. 
???????????????????????????????????????? ????????????????????
199 Bandrup, J.; Immergut, E. H.; Grulke, E. A.; Abe, A.; Bloch, D. R. Polymer Handbook, 4th 
Edition, John Wiley & Sons, Inc. New York, 1999. 
200 Medrano, R.; Laguna, M. T. R.; Saiz, E.; Tarazona, M. P. Analysis of Copolymers of Styrene 
and Methyl Methacrylate using Size Exclusion Chromatography with Multiple Detection. Phys. 
Chem. Chem. Phys. 2003, 5, 151–157. 
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Table 4-3. A comparison of Mn values obtained via 1H NMR spectroscopy and 
SEC/MALS. 
 Polymer dn/dc (mL/g) Mn a dn/dc (mL/g) Mn Mn 
  (measured) (MALS) (literature) (MALS/corrected) (1H NMR) 
 PEG5-OH 0.055  6.0 K 0.068 4.9 K b 5.0 K 
PEG5-PL10A 0.042 19.0 K 0.051 15.5 K c 14.5 K 
PEG5-PL5G5A 0.031 24.2 K 0.051 14.7 K c 14.2 K 
 a Mn value assuming 100% recovery of the polymer sample during the SEC 
analysis. 
 b Mn value using the reported dn/dc value for PEG (0.068).199  
 c Mn value using a weighted average (0.33/0.67) for the reported dn/dc values 
for PEG (0.068) and PLA (0.042). 
 
5. Improvements to the Extent of Lactide Consumption during PEG-b-
PLGA Synthesis. Quenching the copolymerization at ca. 50% lactide conversion 
effectively establishes the proof of principle of the described semi-batch 
methodology. From a practical perspective, it likely would be advantageous to 
convert the lactide to a higher degree of polymerization.  We demonstrated proof 
of principle by polymerizing the lactide through three half-lives. To maintain a the 
near “random” lactyl to glycolyl distribution in the product, a total of 87.5 mol% of 
glycolide relative to lactide was added and the rate of its infusion was halved 
after each of the first and second half-times (i.e., after and 10 and 20 minutes 
with a total addition time of 30 minutes). In the experiment we targeted a PEG5-
PL4.38G4,38A polymer. A small aliquot was removed from the polymerization 
mixture after 10 and 20 minutes. They contained polymers with compositions that 
were measured to be PEG5-PL3.1G2.5A and PEG5-PL3.8G3.4A vs. the theoretical 
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PEG5-PL2,5G2.5A and PEG5-PL3.75G3.75A, respectively (1H NMR). The final sample 
of bulk polymer had a composition of PEG5-PL4.4G4.3A and a PDI of 1.19. While 
unoptimized, this experiment establishes the ability to achieve higher levels of 
lactide conversion while maintaining narrow polydispersities. 
6. High MW PEG-b-PLGA Synthesis. Because polyesters with high 
glycolate content are notorious for their limited solubility,201 we viewed it 
important to establish some of the limits of both the PEG and PLGA block sizes 
as well as the PLGA compositions that could be prepared using this new 
methodology. The results of these experiments are reported in entries 14-21 of 
Table 4-4.  It can be seen from entries 7-10 that we were able to consistently and 
reproducibly generate PEG-b-PLGAs having PLGA blocks of MW up to 10K. 
However, attempts to synthesize a 5K-15K PEG-b-PLGA (PEG5-PL7.5G7.5A Entry 
9) revealed a limitation. In this case, the reaction mixture became heterogeneous 
prior to conclusion of the polymerization and resulted in abnormally high lactic 
acid content. Presumably the inhomogeneity is the result of the growing glycolic 
acid content (total mass% of the block copolymer), which ultimately caused the 
polymer to become insoluble. Characterization of this sample showed that it 
possessed a PLGA block having a molecular weight lower than that targeted and 
an atypically broad PDI.  
 
 
 
 
 
???????????????????????????????????????? ????????????????????
201 Huffman, K. R.; Casey, D. J. Effect of Carboxyl End Groups on Polyglycolic Acid. J. Polym. 
Sci: Polym. Chem. Ed. 1985, 23, 1939–1954.  
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Table 4-4. Data for all block copolymers synthesized in this chapter.a   
entry Polymer Method Mn(PEG) Mn(PLGA) b Ratio c PDI d Tge Tme 
  (targeted)    LA : GA   (°C) (°C) 
 1 PEG2-PL2A A 2K 2.16K 100 : 0 1.08 ND 39.3 
 2 PEG2-PL5A A 2K 5.11K 100 : 0 1.07 1.6 ND 
 3 PEG5-PL2A A 5K 2.10K 100 : 0 1.04 ND 54.1 
 4 PEG5-PL5A A 5K 5.62K 100 : 0 1.06 ND 51.0 
 5 PEG5-PL10A A 5K 10.8K 100 : 0 1.05 1.8 ND 
 6 PEG5-PL15A A 5K 16.3K 100 : 0 1.07 16.1 ND 
 7 PEG5-PL2.5G2.5A A 5K 4.90K 46 : 54 1.06 -24.2 50.1 
 8 PEG5-PL5G5A  A 5K 10.4K 54 : 46 1.08 -4.8 ND 
 9 PEG5-PL7.5G7.5A A 5K 16.1K 58 : 42 1.13 7.5 ND 
 10 PEG5-PL7.5G7.5A B f 5K 13.5K 47 : 53 1.15 g -2.8 ND 
 11 PEG5-PLL5G5A  A 5K 9.43K 56 : 44 1.10 -6.1 ND 
 12 PEG 5-PL7.5G2.5A A 5K 8.44K 76 : 24 1.08 -12.9 ND 
 13 PEG5-PL15G5A B 5K 18.5K 77 : 23 1.65 h -0.8 ND 
 14 PEG10-PL2.5G2.5A B 10K 4.64K 53 : 47 1.04 ND 57.0 
 15 PEG10-PL5G5A B 10K 10.9K 54 : 46 1.04 -19.2 55.1 
 16 PEG10-PL7.5G7.5A B i 10K 15.7K 51 : 49 1.22 g -18.6 55.3 
 17 PEG10-PL10G10A B f 10K 16K 50 : 50 2.29 h -- -- 
 18 PEG10-PL3.75G1.25A B f,j 10K 4.30K 72 : 28 1.05 ND 56.5 
 19 PEG10-PL7.5G2.5A B f,j 10K 10.3K 78 : 22 1.05 ND 51.5 
 20PEG10-PL11.75G3.75A B f,j 10K 12.0K 71 : 29 1.07 -23.3 50.1 
 21 PEG10-PL15G5A g B f,j 10K 20.3K 77 : 23 1.39 -3.5 ND  
 a Grayed information is reproduced from Table 4-2 and included here for 
comparison within sets having the same PEG block size and same polyester 
composition 
 b Results based on NMR spectroscopy 
 c Results based on NMR spectroscopy and presented as the mass ratio of the 
repeat units 
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 d Results based on GPC measurements against a polystyrene standard 
 e Results obtained by DSC measurements (ND = none detected) 
 f Reaction performed at 8-fold lower concentration than Method B  
 g Minor asymmetric broadening noted in the GPC trace  
 h Asymmetric broadening noted in the GPC trace  
 i Reaction performed at 2-fold lower concentration than Method B 
 j The amounts of glycolide and lactide used were 0.5 and 1.5 times those used 
in Method B, in order to target a final 1:3 mass ratio within the PLGA block 
 
We then turned to a different strategy—the use of lower reaction 
concentration to improve product solubility as the PLGA blocks grew larger. 
Thus, performing the reaction 8-fold more dilute than in Method B allowed the 
synthesis of the 5K-15K PEG-b-PLGA (PEG5-PL7.5G7.5A, entry 10). However, 
that modification alone still fell short when we attempted to prepare the yet larger 
5K-20K analog (i.e., PEG5-PL10G10A); again heterogeneity prior to the end of the 
polymerization time was observed. Increasing solubility by use of a longer 10K 
PEG macroinitiator led to no substantial improvement (entry 17). However, we 
were finally able to prepare the 5K-20K PEG-b-PLGA PEG10-PL15G5A (entry 21, 
albeit with an atypically large PDI) by increasing the lactic acid content of the 
PLGA block to 75 wt%. From these experiments, we conclude that if one desires 
polymers having PLGA blocks with narrow PDIs,  the scope of the reported 
methodology is limited to the synthesis of PEG-b-PLGAs having PLGA block 
sizes of less than ca. 20K.  
7. Thermal Properties of the Block Copolymers. The melting and glass 
transition properties (Tg and Tm) of the PEG-b-PLA and PEG-b-PLGA block 
copolymers were measured by DSC and the results for each block copolymer are 
presented in Table 4-4. High molecular weight PEG homopolymer is highly 
crystalline (Tm ~ 63 °C). Consistent with this fact and as the data in Table 4-4 
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clearly show, every block copolymer sample containing a PEG block of greater 
than 40 wt% showed a melting exotherm at ca. 50 °C. This observation indicates 
that the polyether and polyester blocks in these samples are phase-separated 
(likely into lamellar phases) so that the PEG is able to crystallize.202 One example 
(entry 7 in Table 4-4) is shown in Figure 4-4A.  
The diblock copolymers with PEG blocks of less than 40 wt% show a 
single Tg but no evidence of a melting exotherm (e.g., Figure 4-4B, entry 8 in 
Table 4-4), suggesting that the polyether and polyester blocks are phase mixed. 
The Tg of PEG, PGA, and PLA homopolymers are approximately -40 °C, 35 °C, 
and 55 °C, respectively.196,203 The Tg values of the diblock copolymers with PEG 
fraction <0.4 follow a general trend that can be rationalized by the Fox equation; 
that is, the Tgs of these copolymers are correlated with the weighted average of 
the Tgs for each of the PEG, lactyl, and glycolyl components. This is also 
consistent with the interpretation that a PEG-b-PLGA copolymer with <40 wt% 
PEG is a single phase at room temperature.  
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202 Khandpur, A. K.; Förster, S.; Bates, F. S.; Hamley, I W.; Ryan, A. J.; Bras, W.; Almdal, K.; 
Mortensen, K. Polyisoprene-Polystyrene Diblock Copolymer Phase Diagram near the Order-
Disorder Transition. Macromolecules 1995, 28, 8796–8806. 
203 Bandrup, J.; Immergut, E. H.; Grulke, E. A.; Abe, A.; Bloch, D. R. Polymer Handbook, 4th 
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Figure 4-4. Representative DSC plots showing typical melting (A) and glass 
transition (B) behavior. 
 
 
A few additional general trends can be seen in the Tm and Tg data in Table 
4-4: i) increased MW of the polyether block tends to result in lower Tg values; ii) 
increased MW of the polyester block tends to result in higher Tg values; and iii) 
increased lactic (relative to glycolic) acid content in the polyester block tends to 
result in higher Tg values. These observations offer guidance for the design of 
PEG-b-PLGAs having compositions leading to specific thermal properties.  
8. Sequence Length of Monomer Units in the PLGAs. Because the 
chemical shifts of the ester carbonyl carbons are sensitive to subtle electronic 
differences, 13C NMR spectroscopy can be used to ascertain the average 
number of adjacent lactide (or glycolide) dyads in a PLGA backbone.195,204 The 
NMR spectral data for several PLGA samples (Table 4-5) were used to calculate 
sequence lengths of both LA and GA repeating units using equations 3 and 
???????????????????????????????????????? ????????????????????
204 Kricheldorf, H. R.; Mang, T.; Jonte, J. M. Polylactones. 1. Copolymerization of Glycolide and ε-
caprolactone. Macromolecules 1984, 17, 2173–2181. 
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4.174,205 Representative data for two of these, having a 50:50 vs. a 75:25 LA:GA 
composition, are shown in Figure 4-5. LL  and LG  are the average sequence 
lengths of both the lactyl and glycolyl repeat units, respectively; LLI , LGI , GGI , 
and GLI  are the signal intensities of the lactyl-lactyl, lactyl-glycolyl, glycolyl-
glycolyl and glycolyl-lactyl structures ( LGI should be equivalent to GLI  if the 
carbonyl resonances are equally sensitive). Good agreement was observed by 
comparing the ratio of lactide to glycolide sequence lengths deduced from this 
13C NMR analysis (LL /LG) to that observed by integration of the methine vs. 
methylene resonances of the backbone protons for lactic to glycolic units, which 
lends confidence to the reliability of the 13C NMR method.  
 
 
 
 
 
 
 
 
 
 
 
???????????????????????????????????????? ????????????????????
205 Grujpma, D. W.; Nijenhuis, A. J.; Pennings, A. J. Synthesis and Hydrolytic Degradation 
Behaviour of High-Molecular-Weight L-Lactide and Glycolide Copolymers. Polymer 1990, 31, 
2201–2206. 
Chapter 4 “Random” Coplymerization of Lactide and Glycolide? 
?
????
?
Figure 4-5. 13C NMR spectra (in hexafluoroisopropanol195,204) of two PEG-b-
PLGA block copolymers of different compositions. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 “Random” Coplymerization of Lactide and Glycolide? 
?
????
?
Table 4-5. Average sequence length of lactide ( LL ) and glycolide ( GL ) as 
measured by 13C vs. 1H NMR spectroscopies. 
  
 Entry Polymer LL  
a LG
a LL /LG
a LA/GAb 
  (Targeted) 
 1 PEG5-PL2.5G2.5A 3.68 5.31 40.9/59.1 40.3/59.7 
 2 PEG5-PL5G5A 4.57 4.31 51.5/48.5 48.8/51.2 
 3 PEG5-PL7.5G2.5A 7.73 3.00 72.0/28.0 71.7/28.3 
 4 PEG5-PLL5G5A 4.90 4.57 51.7/48.3 50.7/49.3 
 5 PEG5-PL7.5G7.5A 4.90 4.54 51.9/48.1 52.2/47.8  
 a Sequence lengths and their ratio calculated from 13C NMR results according 
to eq 4-3 and 4-4. 
 b Molar ratio of lactic to glycol units calculated from integration of 1H NMR 
data. 
 
The expectation value for each of the sequence lengths of both lactic and 
glycolic dyads for a truly random copolymerization of lactide and glycolide is 4.00 
(recall that each propagation event delivers two of the same acid backbone units 
since each monomer is dimeric).206 In the case of PEG5-PL5G5A (Table 4-5, entry 
???????????????????????????????????????? ????????????????????
206 Odian, G., Principles of Polymerization, 4th Edition, Wiley-Interscience, New York, 2004, p 
470.  
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2) the average sequence of the lactyl unit, LL , is 4.57 and of GL  is 4.31. These 
differences from the theoretical likely arise from some combination of the use of 
constant rather than a diminishing rate of addition of glycolide, error in the 
measured rate constant ratio, imperfect mixing, and inherent difference in cross 
reactivity ratios that attend each of four possible propagation partners. When the 
glycolide feed rate was decreased to obtain the PEG5-PL7.5G2.5A polymer, GL  
was observed to decrease to 3 while LL  increased to 7.73 (Table 4-5, entry 3). 
  
7. Collaborative Circulation Studies with Nanoparticles Comprised of 
Narrowly Dispersed PEG-b-PLGA and PEG-b-PLA BCPs.207 
Using the methodology described above, a series of PEG-b-PLGA and 
PEG-b-PLA BCPs were prepared and, in collaboration with Suzanne D’Addio 
and Prof. Robert Prud’homme (Department of Chemical Engineering, Princeton 
University) used to synthesize nanoparticles via FNP. Fine analysis and control 
of the PL(G)A MW, PLGA monomer ratio, and PLGA microstructure was 
necessary to systematically examine the effects of these parameters on 
nanoparticle stability and accurately compare them to nanoparticles made from 
either PEG-b-PS or PEG-b-PCL of varying MWs. 
Briefly, the result of this study suggested general guidelines for the design 
of stable, PEG-protected, drug-loaded nanoparticles. Characteristics to be 
considered are: i) the area ratio of PEG block vis-à-vis the hydrophobic block, ii) 
the hydrophobicity of the hydrophobic block relative to the PEG solvation energy, 
iii) the absolute MW of the PEG block, and iv) the physical state (i.e., crystalline 
???????????????????????????????????????? ????????????????????
207 D’Addio, S. M.; Saad, W.; Ansell, S. M.; Squiers, J. J.; Adamson, D.; Herrera-Alonso, M.; 
Wohl, A. R.; Hoye, T. R.; Macosko, C. W.; Mayer, L. D.; Vauthier, C.; Prud’homme, R. K. Effects 
of Block Copolymer Properties on Nanocarrier Protection from in vivo Clearance. J. Control. 
Release 2012, 162, 208–217. 
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vs. amorphous) of the hydrophobic block.207 In these studies, the PEG-b-PLA 
and PEG-b-PLGA synthesis methodology was used to control three of these 
critical parameters in the PLA/PLGA polyester blocks: i) absolute polyester MW 
and, correspondingly, its area ratio, ii) the hydrophobicity of the polyester block 
via control of both the absolute PLA/PLGA MW as well as the ratio of 
lactide:glycolide, and iii) the crystallinity of the polyester via incorporation of a 
“random” PLGA. These studies indicate the utility of the PLGA synthesis 
methodology described within Chapter 4. 
 
8. Conclusions. 
The high activity of DBU makes it a convenient catalyst for the synthesis 
of PEG-b-PLA block copolymers having well-controlled sizes and narrow 
distribution. To expand this chemistry to the synthesis of PEG-b-PLGAs, with a 
“random” PLGA copolymer block, we determined the reactivity ratio of 4.02:4.01 
to be approximately 1000:1 for glycolide (4.02) to lactide (4.01) in 
homopolymerizations. We developed a new, semi-batch PEG-b-PLGA synthesis 
strategy in which the continuous addition of glycolide approximated the 
conversion curve of lactide throughout its first half-life. This resulted in a 
convenient method for the preparation of PEG-b-PLGAs of various block sizes 
and monomer ratios. As a consequence of the controlled copolymerization of 
lactide and glycolide, MW, composition, sequence length and distribution (and 
therefore physical properties) of PEG-b-PLGA block copolymers could be easily 
manipulated for different applications. We determined that the limitation of this 
method was the synthesis of PLGA blocks with MW greater than 20K, likely due 
precipitation before completion of the polymerization. This strategy was found to 
give reproducible results, allowing the convenient preparation of PEG-b-PLGA 
block copolymers that could be useful in a variety of applications, including the 
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synthesis of well-defined BCPs for systematic studies of nanoparticle circulation 
behavior. The general principles explored here should be applicable to the 
copolymerization of glycolide and lactide with other less reactive lactones for the 
preparation of various copolymers.  
 
9. Experimental Section. 
 
General Materials. Rac-Lactide [(±)-4.01] was purchased from Altasorb 
was purified by recrystallization from toluene. L-Lactide (S,S-4.01) was 
purchased from Purac, recrystallized twice from toluene, and stored in a dry box. 
Glycolide (4.02) was purchased from Altasorb and was purified by 
recrystallization from dry THF. 1,8-Diazabicyclo[5.4.0]-undec-7-ene (DBU) was 
purchased from Sigma Aldrich, dried over calcium hydride, and distilled.  mPEG-
OH of molecular weight 2 and 5 kg mol-1 (K) was purchased from Aldrich and 10 
K from JenKem Technology. All polymerizations were conducted at ambient 
temperature.  
 
 
Method A for reagent and catalyst purification, storage, and handling 
(more rigorous). Chloroform was washed with water and distilled from 
phosphorus pentoxide. Dichloromethane (CH2Cl2) was first dried by being 
passed through an activated alumina column and then distilled from calcium 
hydride (CaH2). Tetrahydrofuran (THF) was first dried by being passed through 
an activated alumina column and then distilled from sodium and benzophenone. 
DBU was purified by distillation twice from CaH2. Lactides and glycolide were 
stored and handled in a controlled atmosphere dry box. mPEG-OHs were dried 
by azeotropic distillation with toluene at atmospheric pressure.  
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Method B for reagent and catalyst purification, storage, and handling 
(less rigorous). CH2Cl2 and THF were dried by passing through an activated 
alumina column. DBU was purified by one distillation from CaH2. Lactide and 
glycolide were stored in screw-capped containers under ambient lab atmosphere. 
mPEG-OHs were dried as a solution in dry dichloromethane and overnight over 
activated molecular sieves (4 Å) in an airtight culture tube. 
 
 
Polymer Characterization. 1H NMR spectra were obtained on a Varian 
VI-300, Varian VXR-300, or Varian VXR-500 spectrometer in CDCl3. Number-
average molecular weight was calculated by comparison of the ratio of the 
integrations of the methine and methylene signals of PLA and PGA residues vs. 
the methylene signal of PEG residues assuming the manufacturer-provided 
molecular weight of the mPEG–OH macroinitiator. For sequence analysis, 13C 
NMR spectra were obtained on a Varian 400 instrument at 100 MHz in 
hexafluoroisopropanol; a 45 degree pulse and a relaxation delay of 5 s were 
used. Size-exclusion chromatography (SEC) was performed on an Agilent 
Technologies 1100 series liquid chromatograph equipped with a Hewlett-Packard 
1047A refractive index detector. Chloroform was used as the mobile phase at an 
elution rate of 1 mL min-1. The instrument was operated at 35 °C using a series 
of three PLgel 5 µm Mixed-C columns (Polymer Laboratories) with molecular 
weight range of 0.4-400 K. PDIs are reported with respect to polystyrene 
standards having molecular weights ranging from 5 to 1000 K (Polymer 
Laboratories). Size-exclusion chromatography/multiangle light scattering 
(SEC/MALS) was performed using an Alltech 426 HPLC pump equipped with a 
Wyatt Technology Corporation Dawn DSP Laser photometer and an Optilab 
refractive index detector. Laser light scattering data were collected using a 633 
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nm wavelength at a 90° scattering angle. Tetrahydrofuran containing 1% 
tetramethylethylenediamine was used as the mobile phase at an elution rate of 1 
mL min-1. The instrument was operated at 25 °C using a series of three 
Phenomenex columns containing Phenogel 5 µm cross-linked styrene divinyl 
benzene with a molecular weight range of 5-500 K. The results were analyzed 
with ASTRA software.  Differential scanning calorimetry (DSC) was performed 
using a TA Instruments model Q1000 Differential Scanning Calorimeter that was 
calibrated using high purity indium at a heating rate of 10 °C min-1. Transitions 
were recorded during the second scan. 
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Chapter 5 
Studies on Silicate-Loaded Nanoparticles: 
Characterization, Structure, and 
Efficacy.  
 
1. Introduction. 
1. A Brief Discussion of Common Encapsulation Methodologies. General 
strategies to encapsulate drugs into polymeric and/or liposomal carriers have 
been rigorously explored over the last several decades. While a number of highly 
customized polymers have been synthesized exclusively for drug delivery 
applications, more often, common, easily prepared polymeric species are 
preferred for these applications. One chief example of a frequently used polymer 
is PLGA, which has been used to encapsulate drugs and/or prodrugs via a 
variety of formulation techniques, including single emulsions, double emulsions, 
coacervation, and spray drying.208  
Unfortunately, when these strategies are applied to encapsulate PTX, they 
frequently result in rather low drug loading levels. For example, PTX-loaded 
liposomes often contain exceptionally low PTX content (e.g., 3.4 wt%209 or 6.5 
???????????????????????????????????????? ????????????????????
208 Jain, R. A. The Manufacturing Techniques of Various Drug-Loaded Biodegradable 
Poly(lactide-co-glycolide) (PLGA) Devices. Biomaterials, 2000, 21, 2475–2490. 
209 Fetterly, G. J.; Straubinger, R. M. Pharmacokinetics of Paclitaxel?Containing Liposomes in 
Rats. AAPS PharmSci. 2003, 5, 90?100. 
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wt%210), with the remainder of the mass consisting of non-therapeutic 
excipient(s). Another example of PTX-loaded BCPs can be found in the  
construction of PTX-containing thin films of PEG and/or PLGA. Such efforts have 
resulted in encapsulation of up to 10 wt% PTX in PLGA films containing 
systematically varied PEG content.211  
Perhaps the most common tactic to load PTX into a polymeric excipient, 
however, is through the creation of micelles. The most clinically relevant example 
of this strategy is Genexol-PM®. Depending upon the publication referenced, 
16.7-25 wt% PTX loading in ca. 2k-2k PEG-b-PLA micelles has been 
claimed.111,112 Unfortunately, it is difficult to independently analyze either the 
micellar structure of these preparations or the loading levels since only 
formulation procedures are reported –detailed data to corroborate full 
encapsulation or particle size are not readily available.111,112  
In addition to Genexol-PM®, numerous other reports demonstrate that 
emulsion techniques are an exceedingly common strategy to encapsulate PTX 
into micelles consisting of PEG and PLA/PLGA.212,213 These reports describe 
achievement of a wide variety of loading levels of PTX, but these levels are 
generally below 15 wt%.214,215,216,217 These typical, relatively low loading levels 
???????????????????????????????????????? ????????????????????
210 Koudelka, S.; Turaneck-Knotigova, P.; Masek, J.; Korvasova, Z.; Skrbalova, M.; Plockova, J.; 
Bartheldyova, E.; Turanek, J. Liposomes with High Encapsulation Capacity for Paclitaxel: 
Preparation, Characterization, and in vivo Anticancer Effect. J. Pharm. Sci. 2010, 99, 2309–2319. 
211 Steele, T. W. J.; Huang, C. L.; Widjaja, E.; Boey, F. Y. C.; Loo, J. S. C.; Venkatraman, S. S.; 
The Effect of Polyethylene Glycol Strutcture on Paclitaxel Drug Release and Mechanical 
Properties of PLGA Thin Films. Acta Biomater. 2011, 7, 1973–1983. 
212 Quintanar-Guerrero, D.; Allѐmann, E.; Fessi, H.; Doelker, E. Preparation Techniques and 
Mechanisms of Fromation of Biodegradable Nanoparticles from Preformed Polymers. Drug Dev. 
Ind. Pharm. 1998, 24, 1113–1128. 
213 Torchilin, V. P. Micellar Nanocarriers: Pharmaceutical Perspectives. Pharm. Res. 2007, 24, 1–
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214 Chavanpatil, M. D.; Patil, Y.; Panyam, J. Susceptibility of Nanoparticle-Encapsulated 
Paclitaxel to P-glycoprotein-mediated Drug Efflux. Int. J. Pharm. 2006, 320, 150–156. 
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are likely a result of the encapsulation level reaching a maximum dictated by the 
thermodynamic (rather than kinetic) physical properties of the polymeric excipient 
and/or PTX small molecule.   
2. Flash Nanoprecipitation (FNP). As opposed to the emulsion and 
micellization processes, flash nanoprecipitation is a technique that is capable of 
kinetically entrapping hydrophobic solutes. This fundamentally different concept 
has demonstrated the ability to increase the maximum loading level of 
hydrophobic small molecules during development of the methodology.1 
Prud’homme and coworkers were the first to realize the potential of the FNP 
process as applied to drug delivery. Both the Prud’homme group and the 
Macosko/Hoye groups expanded the fundamental understanding of FNP by 
establishing several trends: i) relationships of jet diameters, chamber diameters, 
and outlet configurations to micromixing performance;2 ii) impact of matching the 
aggregation time of the polymer with the nucleation time of the hydrophobic 
solute;3 and iii) plateau effect of the nanoparticle size at sufficiently large 
Reynolds number.5 These (and other) principles were successfully used to 
encapsulate β-carotene as a model hydrophobic solute.5,218 Additionally, these 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ????????????????????
215 Patil, Y. B.; Toti, U. S.; Khdair, A.; Ma, L.; Panyam, J. Single-Step Surface Functionalization of 
Polymeric Nanoparticles for Targeted Drug Delivery. Biomaterials, 2009, 30, 859–866. 
216 Danhier, F.; Lecouturier, N.; Vroman, B.; Jѐrӧme, C.; Marchand-Brynaert, J.; Feron, O.; Prѐat, 
V. Paclitaxel-loaded PEGylated PLGA-based Nanoparticles: In vitro and in vivo Evaluation. J. 
Control. Release 2009, 133, 11–17. 
217 He, G.; Lwin, L.; Pan, J.; Venkatraman, S. ABA and BAB Type Triblock Copolymer of PEG 
and PLA: A Comparative Study of Drug Release Properties and “Stealth” Particle Characteristics. 
Int. J. Pharm. 2007, 334, 48–55. 
218 Johnson, B. K. Flash NanoPrecipitation of Organic Actives via Confined Micromixing and 
Block Copolymer Stabilization. Ph.D. Dissertation, Princeton University, Princeton, NJ, 2003, 1–
291. 
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trends were used more broadly to, for example, establish the ability to precipitate 
an in situ formed BCP via reactive flash nanoprecipitation.219 
Despite the high encapsulation efficiencies and solute loading levels (> 80 
wt% β-carotene) in model studies, weaknesses remained in the overall design. 
Namely, impingement mixing via the CIJ mixer required the use of equal volumes 
of the solvent and anti-solvent – a potentially limiting feature when attempting to 
reach supersaturation. Thus, the Prud’homme group advanced the FNP mixing 
science with the invention and development of the multi-inlet vortex (MIV) mixer.4 
This device consisted of four separate solvent streams that mix tangentially, 
allowing alterations in the mixing physics and the production of dispersions of 
varied solvent composition. While an effective device, especially for larger scale 
experiments, the capital costs of the apparatus, inconvenient set-up, and larger 
material requirements reduced the applicability to experiments that are material-
limited, such as those with high-value prodrug or end-functionalized BCPs. 
Thus, a collaborative effort between the Macosko group and Hoye group 
continued to advance the CIJ mixer design. This work led to the development of 
a confined impingement jet with dilution (CIJ-D)6 mixing FNP methodology 
(Figure 5-1; also, c.f. Figure 1-1). This simple, hand-operated apparatus allowed 
for: i) rapid creation and analysis of nanoparticles derived from new materials, ii) 
small material requirements, and iii) a post-impingement dilution stage to 
increase the range of co-solvent mixtures that could be accessed. Particles made 
from this CIJ-D method were shown to produce nanoparticles of similar size and 
stability as that of the MIVM, and thus the CIJ-D mixer served as a useful device 
for the screening of new materials (both silicate ester prodrugs and BCPs).6  
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Figure 5-1. The design and dimensions of the modified confined impingement jet 
mixer for flash nanoprecipitation.6 
 
 
 
With ample tools (i.e., silicate ester prodrugs and PEG-b-PLGA BCPs) 
and methodologies (i.e., FNP) customized for highly efficient encapsulation in 
hand, a notable scientific inquiry remained. Namely, will these modifications 
overcome the propensity of PTX to rapidly crystallize outside of a nanoparticle 
core? Furthermore, other tangential questions related to the creation of defined 
nanoparticles exist. For instance, since these are kinetically trapped particles, it 
is likely that they are less uniform than traditional micelles or liposomes – an 
assumption that is validated by the relatively large size distribution observed in 
both DLS and microscopy experiments.5 One can thus ask a number of pertinent 
questions regarding these nanostructures. Is the water soluble PEG block and 
hydrophobic PLGA block phase segregated or interspersed in the final 
nanoparticle? Is the silicate ester prodrug distributed uniformly throughout the 
polymer, highly localized in the nanoparticle core, or some blend of the two 
extremes? Is the PTX silicate ester amorphous or crystalline? What analytical 
techniques can we employ to attain data to answer such questions? 
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2. Studies of Model Silicate Ester-Loaded Nanoparticles. 
1. Behavior of PEG-b-PLA in Co-Solvents of Varying Aqueous Content. 
The power of NMR spectroscopic techniques is one of many options that provide 
insight into block copolymer self-assembly and micellization.220 Such studies 
have been conducted on a variety of BCPs, but the most pertinent and 
informative to the materials addressed in this thesis is the work by Davis and co-
workers on PEG-b-PLA. They have extensively detailed the behavior of 
micellized PEG-b-PLA (of a variety of MWs) BCPs via 1H NMR spectroscopy and 
correlated it with the particle sizes obtained from DLS.221 Briefly, they deduced 
that the traditional micellization technique that they employed (dissolution of the 
BCP in a water miscible organic solvent, slow addition of the two co-solvents, 
and finally, removal of the organic solvent) resulted in a miclle with a traditional 
core-shell structure. Notably, they observed significantly large PLA resonances 
(as judged relative to an internal standard) for low MW polyester blocks (< 3K). 
They interpreted this result as significant polymer mobility at these low MWs. In 
contrast to these findings, analogous resonances were not observed for BCPs 
with a PEG MW >6K.221 Additionally, quantitative integration of the PEG block 
suggested minimal penetration of the PEG chains into the micelle core, indicative 
of a solid-like PLA core.221,222 
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220 Riess, G. Micellization of Block Copolymers. Prog. Polym. Sci. 2003, 28, 1107–1170 and 
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While these excellent studies provide a wealth of information potentially 
applicable to our PEG-b-PLGA copolymers, a key difference (other than the use 
of a PLGA polyester block) remained. Unlike the thermodynamically-stable 
micelles formed in the Davis work, FNP-produced nanoparticles are kinetically 
trapped. Thus, the possibility for PEG entrapment within the core, extraneous 
PLGA corona material, or mobile PLGA chains within the core (potentially due to 
entrapped solvent) remained reasonable propositions. Understanding the 
structure of these nanoparticles is of fundamental scientific interest. Additionally, 
the physical state of the polyester block could provide key insights and guidance 
into the results of, for example, future drug release studies.223 
The initial experiment was a simple derivation of the Davis study221 – a 
5K-5K PEG-b-PLGA BCP was dissolved in d6-acetone (a precisely known 
concentration of methanol was included as an internal standard). D2O was 
progressively titrated into the solution and the proton NMR resonances 
attributable to the ethylene oxide, lactic, and glycolic repeat units were 
integrated. With the progressive addition of D2O, the PLGA resonances 
broadened significantly during the experiment, becoming unrecognizable at >50 
vol% D2O content (see Table 5-1). In contrast, the PEG-related proton resonance 
remained sharp, and its integration value remained essentially constant 
throughout the experiment (up to 90 vol% D2O).  
After successfully emulating the Davis work in the related PEG-b-PLGA 
system, the precipitation method was altered such that unloaded particles were 
prepared via FNP. Yet, even in the case of a kinetic arrest of particle growth, the 
results were essentially the same. After precipitation via FNP, the PLGA 
resonances were broadened such that they were indistinguishable from the 
???????????????????????????????????????? ????????????????????
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baseline, whereas the PEG resonances remained well-defined and integrated to 
the “full” value relative to the internal standard. Both of these sets of results are 
consistent with the Davis conclusion of a solubilized PEG corona and a solid-like 
PLGA core.221,222 
Table 5-1. The observed resonance integration for a PEG-b-PLGA BCP relative 
to an internal standard.   
Method D2O ethylene glycol glycolyl lactyl   
  content (%)a integration (%)b integration (%)b  integration (%)b 
 A c 0 100 100 100  
 A 20 99.5 82.1 96.1  
 A 33 98.9 65.9 d 92.8 d  
 A 50 95.7 17.9 d  48.8 d  
 A 75 99.6 n.o. e n.o.  
 A 90 94.2 n.o. n.o.   
 B f 0 100 100 100  
 B 90 88.5 n.o. n.o. 
 a The percent D2O content is relative to the d6-acetone content (v/v). 
 b The percent integration is presented as the percentage of the full solubilized 
(100% acetone) NMR sample relative to an internal standard 
 c  Method A consists of slow addition of the anti-solvent (water).  
 d The resonances were noted to be very broad.  
 e n.o. = not observed.  The resonances were too broad to reliably integrate.  
 f  Method B consists of mixing by FNP (CIJ-D).  
 
2. Tetra-n-butoxysilane-Loaded Nanoparticles: Analysis by DOSY NMR 
Methodologies. While analysis of nanocarrier contents via spectroscopic 
techniques is invariably difficult (the use of 1H NMR spectroscopy in conjunction 
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with a pH dependent chemical shift is a notable exception224), defining the size of 
macrostructures via spectroscopy and/or microscopy has realized substantially 
more success. The most common means encountered in the literature of 
measuring particle sizes on the nanometer scale is DLS. While this is typically 
effective for (near) monodisperse samples, rigorous analysis of DLS 
methodology as it is most commonly practiced, (i.e., with a single angle detector) 
fails to identify bimodal distributions. Typically, in these cases microscopic 
techniques [e.g., atomic force microscopy (AFM) scanning electron microscopy 
(SEM), or transmission electron microscopy (TEM)] are better able to provide a 
more accurate “snapshot” of mixtures containing a significant size 
distribution.5,225  
Even in these cases, however, there is no way to know the constitution of 
the particles containing only low atomic weight atoms – only the size is 
measured. In the case of our FNP-produced nanoparticles, one of the critical 
parameters is not just the size of the particles, but also their composition. 
Namely, is there a way to determine that the hydrophobic silicate was indeed 
encapsulated in a polymer-protected nanoparticle (rather than merely self-
aggregated)?  
We turned to advanced NMR techniques to gain further definition of both 
the nanoparticle size and composition.226 Specifically, we employed diffusion 
oriented spectroscopy (DOSY) to determine if the silicate esters were being 
???????????????????????????????????????? ????????????????????
224 Zhang, X.-M.; Patel, A. B.; de Graaf, R. A.; Behar, K. L. Determindation of Liposomal 
Encapsulation Efficiency Using Proton NMR Spectroscopy. Chem. Phys. Lipids 2004, 127, 113–
120. 
225 Hoo, C. M.; Starostin, N.; West, P.; Mecartney, M. L. A Comparison of Atomic Force 
Microscopy (AFM) and Dynamic Light Scattering (DLS) Methods to Characterize Nanoparticle 
Size Distributions. J. Nanopart. Res. 2008, 10, 89–96. 
226 Valentini, M.; Vaccaro, A.; Rehor, A.; Napoli, A.; Hubbell, J. A.; Tirelli, N. Diffusion NMR 
Spectroscopy for the Characterization of the Size and Interactions of Colloidal Matter: The Case 
of Vesicles and Nanoparticles. J. Am. Chem. Soc. 2004, 126, 2142–2147. 
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efficiently encapsulated within the BCP nanoparticle.227 A series of silicate esters 
were initially screened for these studies: tetra-n-butylsilane (2.11) 
tetraphytylsilane (2.14), tetramenthoxysilane (2.17) and the bis-triethoxy PTX 
silicate (3.08) were considered. Compounds 2.17 and 3.08 were quickly 
eliminated from consideration because these compounds were likely entrapped 
in the solid state within the solid PLGA core. Thus, the proton resonances from 
2.17 and 3.08 species were not observed. Fortunately, the oily silicate esters 
2.11 and 2.14 exhibited distinctive resonances that were easily discernible after 
FNP formulation. Silicate 2.11 was chosen over 2.14 for further study, however, 
because a small degree of water solubility in the model was desirable for control 
experiments involving non-polymer protected, self-aggregation of the 
tetraalkoxysilane in D2O. Successful completion of this control necessitates the 
ability to observe resonances associated with the model compound in pure D2O. 
Thus, 2.11 was subjected to FNP with a PEG-b-PLGA BCP using D2O/d6-
acetone as the co-solvents (9:1 v/v). The dispersion was analyzed by 1H and 
DOSY NMR spectroscopy after the addition of a water-soluble, small molecule 
internal standard (monomethoxy diethylene glycol). The internal standard served 
as a check for the diffusion coefficient (D) of a solubilized small molecule.  
The Stokes-Einstein equation is sometimes employed to determine 
absolute sizes of the particulate species. However, this equation is only valid if 
the substrate is a perfectly spherical particle that behaves identically to the 
standard in the given medium, and neither of these assumptions is rigorously 
true in the case of FNP-derived nanoparticles. Instead, we chose to focus on the 
differences of the diffusion coefficients (ΔD) that are observed in the silane 
resonances relative to the monomethoxy diethylene glycol standard. 
???????????????????????????????????????? ????????????????????
227 Garcia-Fuentes, M.; Torres, D.; Martin-Pastor, M.; Alonso, M. J. Application of NMR 
Spectroscopy to the Characterization of PEG-Stabilized Lipid Nanoparticles. Langmuir, 2004, 20, 
8839–8845. 
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Interestingly, comparison of the diffusion coefficients of the (presumably 
encapsulated) silane 2.11 and soluble monomethoxy diethylene glycol produced 
a ΔD = ca. 106 m2 s-1 (compare resonances ? and ? in Figure 5-2)! This large 
difference is consistent with incorporation of the tetraalkoxysilane into the much 
larger (and more slowly diffusing) nanoparticle. [The “smeared” resonances (?) 
are a frequent artifact from overlapping resonances of different diffusion 
coefficients and are disregarded in the analysis.228] To rule out simple 
aggregation of the silane 2.11 as the cause of the large ΔD, 2.11 was dissolved 
in a d6-acetone solution and added to D2O in the same concentration and solvent 
ratio. In this case, comparison to the internal standard yielded a ΔD = ca. 102 m2 
s-1 (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
???????????????????????????????????????? ????????????????????
228 Dr. Letitia Yao provided critical expertise and assistance during these DOSY NMR 
experiments. Yao, L. University of Minnesota, Minneapolis, MN. Personal communication, 2011. 
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Figure 5-2. DOSY spectrum showing the ΔD = 106 of the (presumably) 
encapsulated tetra-n-butylsilane (?, ?, and ?) as compared to the 
monomethoxy diethylene glycol (?) in D2O (?). 
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As evidenced by the ΔD of the non-polymer protected silane, it is likely 
that some aggregation of the silane exists in the absence of the BCP. However, 
aggregation only fails to account for the magnitude of the change in the diffusion 
coefficient. Coupling these diffusion coefficient results from DOSY 
measurements with qualitative observations (e.g., the apparent homogeneity of 
the FNP dispersion), it is highly probable that the silane is encapsulated within 
the nanoparticle. These qualitative observations are further expanded in the 
context of PTX silicates in section 5.3.2. While far from an “open and shut case,” 
the evidence remains consistent with the tentative conclusion expressed here.  
 
3. Selected Studies of PTX Silicate Prodrug-Loaded Nanoparticles. 
1. FNP Encapsulation of PTX and a PTX-Silicate in a PEG-b-PLGA 
Nanoparticle. Recall that FNP is an attractive technique for producing 
nanoparticles loaded with high levels of hydrophobic compounds, including 
pharmaceutically relevant agents. Co-precipitation of varying hydrophobes with 
an amphiphilic block copolymer (BCP) provides dispersions of kinetically 
protected NPs in the size range of 50-200 nm.2,3,6 However, attempts to 
incorporate PTX within a PEG-b-PCL BCP via FNP led to unstable NPs.7 The 
PTX is sufficiently hydrophilic that it quickly partitions out of the NP cores. The 
PTX crystallizes from the aqueous medium via Ostwald ripening. In the end 
result, the crystalline form of the drug acts as an infinite sink in a partitioning 
experiment, resulting in rapid loss of encapsulated drug from the nanoparticle 
core. This is ironic given that PTX is too hydrophobic to be formulated as an 
aqueous solution for conventional intravenous delivery. 
Working together with Dr. Zhengxi Zhu of the Macosko group, efforts 
toward the successful incorporation of the PTX silicates were initiated by altering 
the Saad experimental procedure7 by substituting a PEG-b-PLGA (2K-10K) as 
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the BCP. This reasonable control experiment was predicated on both repeating 
the previously described results in our hands, but also because the more 
amorphous PLGA polyester will potentially precipitate at a different rate and/or in 
an alternate morphology. Either of these outcomes could lead more efficient PTX 
encapsulation. Specifically, the FNP of 25 mg of both PTX and PEG-b-PLGA 
were impinged in the MIVM mixer [final ratio of THF:water was 5:95 (v/v)]. 
Immediately (i.e., one minute) after FNP-mixing, the suspension was 
homogeneous. Dr. Zhu prepared an SEM sample (Figure 5-3a) which visualized 
a broad dispersion of spherical particles. However, approximately 90 mins later, 
a significant change in the dispersion was noted. A white, crystalline precipitate 
was readily observed. Dr. Zhu’s subsequently prepared SEM (Figure 5-3b), 
confirmed the presence of micron-sized crystals.5  
With the instability of FNP-produced,l PTX-loaded nanoparticles 
reaffirmed, the focus of the study quickly shifted to incorporation of a PTX silicate 
in its place. Guided by its mosaic of prodrug characteristics (ease of synthesis 
and handling, hydrophobic character, rate of hydrolysis, cytotoxicity, and nature 
of the byproducts), we selected the bis-triethoxysilicate prodrug 3.08 for 
formulation into nanoparticles. Again in collaboration with Dr. Zhengxi Zhu, the 
first FNP experiment utilizing a PTX silicate was conducted. In this experiment, 
35 mg of 3.08 (an equimolar amount of PTX as used in the above experiment) 
and 25 mg of a 2K-10K PEG-b-PLGA were impinged in a MIV mixing device 
[final ratio of THF:water was again 5:95 (v/v)]. In this case, the dispersion was 
again initially homogeneous, but in this trial, only negligible changes in the 
measured particle size (ca. 100 nm by DLS) were observed over the course of 
several days. SEM images prepared by Dr. Zhu 90 minutes (Figure 5-3c and d) 
and eight days (Figure 5-3e) were virtually indistinguishable. Both images 
confirmed the qualitative observations and DLS measurements that indicated a 
moderately broad size range of spherical particles with no crystallization.5 
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Figure 5-3. The SEM images taken by Dr. Zhu from collaboratively formulated 
nanoparticles show (a) the kinetically trapped nanoparticles consisting of PEG-b-
PLGA and PTX one minute after formulation, (b) the crystal growth of PTX 90 
minutes after formulation, (c) the kinetically trapped nanoparticles consisting of 
PEG-b-PLGA and 3.08 90 minutes after formulation, (d) a magnified image of 
panel c, and (e) the maintained size and shape of the silicate-containing particles 
after eight days.5 
 
 
 
For convenience, future nanoprecipitation experiments were conducted on 
the CIJ-D mixer unless otherwise indicated. A cartoon depicting a representative 
FNP experiment is given (with typical amounts) in Figure 5-4 to yield PEG-b-
PLGA based nanoparticles loaded with PTX silicate 3.08 (hereafter, 3.08-NPs). 
While these results led to highly prodrug-loaded nanoparticles (up to 58 wt%), 
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the maximum loading level of these PTX silicate prodrugs within FNP-derived 
PEG-b-PLGA nanoparticles has yet to be defined.229  
Figure 5-4. A typical experiment that utilizes the CIJ-D mixer to impinge water 
against a THF solution containing 35 mg of the PTX silicate 3.08 in 25 mg of a 
5K-10K PEG-b-PLGA BCP co-dissolved. The final ratio of THF:H2O is 95:5. 
 
 
 
2. Qualitative Observations of PTX Silicate Aggregates and Nanoparticles. 
With one of the basic concepts (specifically, that the hydrophobicity of the silicate 
prodrug can be tailored to improve the nanoparticle stability) of the silicate 
prodrug strategy now practically applied, efforts turned toward understanding the 
nature of these kinetically trapped particles. Due largely to the absence of visible 
aggregation after FNP, full encapsulation of the PTX silicate in the nanoparticle 
was assumed. However, running a simple control experiment cast doubt on such 
an assumption. An FNP experiment in which only 3.08 (without a protective BCP 
present) was dissolved in the organic solvent did not lead to rapid formation of 
large aggregates. Instead, a cloudy but seemingly homogeneous suspension 
???????????????????????????????????????? ????????????????????
229 These studies are ongoing in collaboration with Ms. Jing Han and Prof. Christopher Macosko. 
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was attained (Figure 5-5a). Analyzing this mixture by DLS led to the 
measurement of larger, (ca. 200-300 nm) but still nano-sized, particles. 
Fortunately, rapid aggregation (in less than one min) was observed upon addition 
of 0.9 wt% NaCl (Figure 5-5d) – an observation consistent with “unprotected” 
drug aggregates in a solution of the same ionic strength as blood. In contrast, 
varying the ionic strength of the polymer-protected PTX silicate nanoparticles 
resulted in no visible changes in the nanoparticle size, even at extended times 
(Figure 5-5c and d).  
Figure 5-5. The photographs show a visual analysis of FNP mixing experiments 
of 3.08 in various conditions: (a) the impinged PTX silicate in H2O/THF, (b) the 
impinged PTX silicate in H2O/THF with 0.9 wt% NaCl added, (c) the impinged 
PEG-b-PLGA BCP and PTX silicate in H2O/THF, and (d) the impinged PEG-b-
PLGA BCP and PTX silicate in H2O/THF with 0.9 wt% NaCl added. 
 
 
 
3. NMR Studies of FNP-produced, PTX Silicate Loaded Nanoparticles. 
While the qualitative results discussed above provided data consistent with 
silicate prodrug encapsulation within the PEG-b-PLGA nanoparticles, more 
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quantitative and definitive experiments were desired. In other words, many 
questions still remained. For instance, a necessary step for future in vivo work 
requires complete removal of the solvents. However, this necessary freeze 
drying (i.e., lyophilization) step consisted of several experimental unknowns. 
Most important to these discussions, however, was determining if the PTX 
silicate survives the FNP and subsequent freeze drying procedure.  
This question was addressed by dissolving lyophilized, 3.08-loaded, PEG-
b-PLGA nanoparticles in a CDCl3 solution (Figure 5-6). This NMR spectrum 
provides convincing evidence that the PTX silicate survived intact, as judged by 
the readily observed, diagnostic resonances associated with the ethoxy groups at 
ppm = 3.76 and 3.71 (? in Figure 5-6). Integration of these resonances against 
the, e.g., aromatic and alkyl PTX-derived resonances demonstrated that minimal, 
if any, hydrolysis occurred during FNP and subsequent handling. Furthermore, 
integration of the ethoxy resonances vis-à-vis the polymer resonances (? in 
Figure 5-6) confirmed that the ratio of the silicate:polymer was within 
experimental error of the material used. Finally, THF-related resonances were 
not observed in the spectrum, confirming that the organic solvent is fully removed 
during the freeze-drying process. 
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Figure 5-6. The 1H NMR spectrum in CDCl3 of a lyophilized nanoparticle 
suspension shows resonances from the PTX silicate prodrug 3.08 (silicate ester 
ethoxy resonances labeled as ?) and PEG-b-PLGA BCP (all polymer 
resonances labeled as ?). 
 
 
 
4. Quantification of Encapsulated PTX Silicate by Differential Solubilities. 
While the 1H NMR results (c.f., Figure 5-6) confirm the overall constitution of the 
freeze dried powder, they fail to provide any information about the 
macrostructure of the nanoparticles. Essentially, the NMR spectrum tells us what 
is in the freeze dried powder but not where the silicate is located relative to the 
BCP. This is an especially critical point, given that previous work has suggested 
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that PTX itself partitions into the PEG component of PEG/PLGA thin films.230 
Therefore, further studies were designed to supplement the conclusions drawn 
from the qualitative observations in section 5.3.2. Understanding the distribution 
of the PTX silicate within the nanoparticle has implications for both the stability of 
the FNP particles and the hydrolysis/release rate of the prodrug/drug more 
generally.230,231 
Techniques to quantify encapsulated PTX that are reported in the 
literature rely almost exclusively on HPLC analysis of the nanoparticle contents 
and quantification against a standard curve. Unfortunately, “extracting” the PTX 
from PEG-b-PLGA particles in, for example, acetonitrile is ineffective because 
the BCP is readily soluble in this solvent. Thus, this strategy is capable of 
quantifying the total amount of PTX (or the PTX silicate prodrug) in the freeze 
dried powder, but it is insufficient to differentiate the total amount of encapsulated 
taxane from the total amount present. Furthermore, because the PTX silicate 
aggregates if the protecting polymer is not included, techniques (e.g., 
centrifugation) intended to separate the bigger particles from molecularily 
dissolved species were not anticipated to be effective. Instead, to better 
understand the amount of encapsulated PTX silicate, we employed a simple 
strategy exploiting the differential solubilities of PEG and the PTX silicate.  
Specifically, PEG homopolymers are minimally soluble in diethyl ether, 
whereas the PTX silicate prodrugs (including 3.08) are freely soluble. Thus, 
extracting an aqueous FNP suspension with multiple diethyl ether washes would, 
in principle, readily solubilize and remove any unprotected (i.e., non-
???????????????????????????????????????? ????????????????????
230 Kang, E.; Robinson, J.; Park, K.; Cheng, J.-X. Paclitaxel Distribution in Poly(ethylene glycol) / 
Poly(lactide-co-glycolide) Blends and its Release by Coherent Anti-Stokes Raman Scattering 
Microscopy. J. Control. Release 2007, 122, 261–268. 
231 Mu, L.; Teo, M. M.; Ning, H. Z.; Tan, C. S.; Feng, S. S. Novel Powder Formulations for 
Controlled Delivery of Poorly Soluble Anticancer Drug: Application and Investigation of TPGS and 
PEG in Spray-Dried Particulate System. J. Control. Release 2005, 103, 565–575. 
Chapter 5 Silicate Ester Loaded Nanoparticles? 
?
????
?
encapsulated) PTX silicate while the prodrug that is encapsulated within the BCP 
(with a solubilized PEG block) would reasonably be expected to remain 
entrapped in the nanoparticle core within the dispersion. Interestingly, 
investigation of this theory with a 3.08-NP resulted in less than 7% of 3.08 
recovered, even after multiple washes (Table 5-2). Conversely, washing FNP-
produced aggregates (i.e., non-encapsulated) of 3.08 yielded > 85% recovery of 
the PTX silicate (see Table 5-2). While again not overwhelming proof of 
encapsulation, these results provide strong corroboration for the high 
encapsulation efficiency of the PTX silicate prodrug in PEG-b-PLGA based 
nanoparticles. 
Table 5-2. The recovered PTX silicate from either polymer protected 
nanoparticles or prodrug aggregates derived from two different FNP experiments.   
 FNP Encapsulated  Recovered Recovered 
 Materials a Amount b 1H NMR c HPLC d   
  (mg) (mg) (mg)  
  
 3.08 + BCP 3.5 n.o. e 0.23  
 3.08 only 3.5 3.01 3.05  
 a The materials dissolved in THF during the FNP process. 
 b The mass of PTX silicate 3.08 that was dissolved in THF and subjected to 
FNP. 
 c  The amount of 3.08 that was quantified by 1H NMR relative to an internal 
standard of known quantity.  
 d The amount of 3.08 that was quantified by HPLC relative to a calibration 
curve of 3.08.  
 e n.o. = not observed.  The amount of the PTX prodrug was below the level of 
detection.  
 
Chapter 5 Silicate Ester Loaded Nanoparticles? 
?
????
?
5. Differential Scanning Calorimetry Studies of FNP-produced 
Nanoparticles. DSC techniques have been extensively employed for the general 
characterization of polymeric thermal behavior and phase transitions,193 including 
in Chapter 4 of this thesis.162 However, the use of DSC analysis in drug delivery 
vehicles is not viewed as standard, and it is decidedly less often utilized to 
answer important questions related to the macrostructure of drug delivery 
vehicles. Nonetheless, DSC studies on lipids232 and oil-in-water emulsions233 
have been conducted.  
While informative, these studies were on thermodynamically stable, rather 
than kinetically trapped, nanostructures. We, therefore, set out to determine if 
DSC could provide complementary data related to the structure and morphology 
of these nanoparticles. The first structure examined was the simplest – the FNP-
precipitated and subsequently freeze-dried 5K-10K PEG-b-PLGA BCP. Typically, 
DSC studies utilize the “second run” (i.e., the behavior of a polymer after a single 
heating/cooling cycle) of a DSC trace so that the polymer properties that are 
measured are independent of the polymer’s the thermal history. In the special 
case of a flash nanoprecipitated polymer, however, the “first run” is the most 
interesting – the handling history of the material and the induced morphological 
changes are the factors that we aim to probe. Interestingly, the “first run” DSC 
trace (Figure 5-7, black line) of the FNP-produced polymer exhibited a strong Tm 
of the crystalline PEG block at ca. 50 °C. This is a depressed melting transition 
temperature relative to the pure PEG homopolymer (which exhibited a Tm of ca. 
60 °C in a control experiment). This observation is consistent with incomplete 
???????????????????????????????????????? ????????????????????
232 Ali, H.; El-Sayed, K.; Sylvester, P. W.; Nazzal, S. Molecular Interaction and Localization of 
Tocotrienol-Rich Fraction (TRF) within the Matrices of Lipid Nanoparticles: Evidence Studied by 
Differential Scanning Calorimetry (DSC and Proton Nuclear Magnetic Resonance Spectroscopy 
(1H NMR). Colloids Surf., B. 2010, 77, 286–297. 
233 Essa, S.; Rabanel, J. M.; Hildgen, P. Effects of Polyethylene Glycol (PEG) Chain Organization 
on the Physicochemical Properties of Poly(ᴅ, L -lactide) (PLA) Based Nanoparticles. Eur. J. 
Pharm. Biopharm. 2010, 75, 96–106. 
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phase segregation. The Tg from the PLGA block was not as obvious in the trace, 
but it is conceivable that there is a weak, broad Tg transition at ca. 20 °C. While 
this value is less than what is predicted from the Fox equation (essentially, a 
mass weighting of the Tg values derived from the pure PLA and PGA 
homopolymers), this may be accounted for via a combination of the relatively low 
MW of the polyester block and the previously observed polyether/polyester 
mixing in other systems leading to polyester plasticization.234  
Interestingly, no recrystallization of the PEG was noted upon cooling 
(cooling trace omitted for clarity in Figure 5-7), and the “second run” DSC trace 
(Figure 5-7, gray line) exhibited a single Tg. This result was reproduced even 
when the polymer was cooled at an exceedingly slow rate (1 °C s-1), consistent 
with a thermodynamically stable, phase mixed system (and in contrast to PEG-
PʟLA BCPs235) observed in the polymer characterization studies reported in 
Chapter 4. Based upon these results, a reasonable conclusion is that the 
polymer blocks are largely, but not exclusively, phase segregated following FNP 
and lyophilization. This working knowledge further confirms the core-shell nature 
of these nanoparticles and may lead to further understanding of issues related to 
redispersion and drug release of these nanoparticles.    
 
 
 
 
 
???????????????????????????????????????? ????????????????????
234 Kulinski, Z.; Piorkowska, E.; Gadzinowska, K.; Stasiak, M. Plasticization of Poly(L-lactide with 
Poly(propylene glycol). Biomacromolecules, 2006, 7, 2128–2135. 
235 Lee, J. H.; Jho, J. Y. A Morphological Study of Semicrystalline Poly(ʟ-lactic acid-b-ethylene 
oxide-b-ʟ-lacitic acid) Triblock Copolymer. Macromolecules 2005, 38, 104–109. 
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Figure 5-7. The DSC trace of the FNP-precipitated and freeze-dried 5K-10K 
PEG-b-PLGA BCP shows a strong PEG Tm on the “first run” (black trace) 
indicative of significant phase segregation of the kinetically trapped nanoparticle 
and a single Tg on the “second run” (gray trace) that suggests a phase mixed 
state at equilibrium. 
 
 
 
With a basic understanding of the DSC behavior of the precipitated 
polymer, focus shifted to the analysis of 3.08-NP. An FNP experiment was 
conducted using typical mixing parameters (c.f., Figure 5-6) and lyophilized 
immediately after the nanoprecipitation. Due to the nature of the freeze dried 
powder [i.e., the high static charge as evidenced (albeit not explained) by the 
measured zeta potential5] only 0.8 mg of the fluffy white powder could be loaded 
into the experimental pan for analysis by DSC. Again, the “first run” was analyzed 
as the most informative (black line, Figure 5-8). In this case, there is again a 
strong, depressed PEG Tm at ca. 50 °C. Due to the small amount of material that 
was used, it is particularly difficult to postulate on the presence (or absence) of a 
PLGA Tg in this experiment. However, a more easily identifiable feature of this 
trace that was clearly unique to the PTX silicate-loaded nanoparticles was the 
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broad melting point centered at ca. 105 °C. I postulate that this endothermic peak 
is a result of an impure, crystalline melting transition of PTX silicate 3.08. (It is 
interesting to note that, upon heating 3.08-NPs to 250 °C, decomposition of, 
presumably, 3.08, was observed.) After cooling (trace not shown), a single Tg is 
again noted during the second heating cycle, a feature consistent with a well-
mixed, prodrug-loaded thin film (rather than a nanoparticle).  
Figure 5-8. The DSC trace of the FNP-precipitated and freeze-dried 
nanoparticles composed of PTX silicate 3.08 and 5K-10K PEG-b-PLGA BCP 
shows a strong PEG Tm and a broad melting point attributed to a depressed 
melting of 3.08 on the “first run” (black trace) and a single Tg associated with a 
phase-mixed film in the “second run” (gray line). 
 
 
 
6. Collaborative Cryo Transmission Electron Microscopy Studies of 3.08-
NPs.88,236 We collaborated with Han Seung Kim and Prof. Alon McCormick  
(Department of Chemical Engineering and Materials Science) to employ cryo-
TEM and obtain further definition of the nanoscopic structures of these particles. 
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236 The cryo-TEM images were obtained by Mr. Han Seung Lee, a member of Prof. Alon 
McCormick’s research group in Chemical Engineering and Materials Science. 
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Images like that shown in Figure 5-9a show the size-distribution and 
predominantly spherical nature of the loaded PEG-b-PLGA nanoparticles 
presumably loaded with PTX silicate 3.08. A subset of substantially smaller NPs, 
perhaps indicative of unloaded block-polymer, can also be seen; similar 
structures have been observed in a pluronics-based PTX NP system.237 The 
higher resolution micrographs in Figure 5-9b and Figure 5-9c suggest a core-
shell microstructure.237  
Figure 5-9. Cryo-TEM micrographs of nanoparticles loaded with PTX silicate 
3.08 (defocus parameter: -4 to -8 µm). (a) A low magnification image showing 
spherical NPs and their size distribution. (b) A higher magnification image of a 
portion of that field in which one can discern core-shell features. (c) An under 
focused image that emphasizes the core-shell nature of one particle. This particle 
is a prolate spheroid (long diameter is ca. 10% greater than the short). Only 
minor beam damage was observed during the under focused microscopy 
experiment. 
 
 
 
7. NMR Release Studies of 3.08-NPs. Given that the known bioactivity of 
PTX is critically dependent upon an unmodified C2’ hydroxyl,143 efforts were 
pursued to analyze the hydrolysis of prodrug 3.08 after FNP-loading into a PEG-
b-PLGA nanoparticle. Accordingly, a freeze-dried sample of these polymers was 
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237 Oh, K. S.; Song, J. Y.; Cho, S. H.; Lee, B. S.; Kim, S. Y.; Kim, K.; Jeon, H.; Kwon, I. C.; Yuk, 
S. H. Paclitaxel-loaded Pluronic Nanoparticles Formed by a Temperature-Induced Phase 
Transition for Cancer Therapy. J. Control. Release 2010, 148, 344–350. 
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redispersed in buffered D2O (pD = 6.4) at ambient temperature and an internal 
standard [methyl tert-butyl ether (MTBE)] was added. Since the low solubility of 
both the PTX silicate and PTX itself in water will render both species 
unobservable, the production of the water-soluble byproduct ethanol was 
observed during the experiment and quantified against the internal standard. 
In contrast to Ms. Jing Han’s collaborative dialysis studies that suggested 
nearly quantitative hydrolysis and release in several hours,238 the evolution of 
ethanol was markedly slower in these NMR experiments. After 162 h (ca. one 
week), only 25% of the maximum molar equivalents of ethanol (dashed line in 
Figure 5-10) was observed. Even if this quantity of ethanol was the result of 
exclusive hydrolysis at the C2’ position of 3.08, this result still accounts for only 
half of the molar quantity of ethanol that is expected (Figure 5-10). This 
observation is consistent with a nanostructure in which there is a large amount of 
the PTX silicate prodrug protected deep within the nanoparticle core. A delayed, 
prolonged release could prove beneficial during in vivo experiments by potentially 
subjecting a cancerous tumor to a more prolonged chemotherapeutic dose 
and/or minimizing undesirable side effects. 
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Figure 5-10. The graph depicts the evolution of ethanol in the hydrolysis of 
encapsulated 3.08. The dashed line represents the expected amount of ethanol 
upon complete hydrolysis of the PTX bis-silicate.  
 
 
 
4. Efficacy of the PTX Silicate Ester-Loaded Nanoparticles.88 
1. In vivo Efficacy Study of 3.08-NPs. The in vitro efficacy of the PTX 
silicate-loaded nanoparticles 3.08-NPs was next tested by Mr. Stephen 
Kalscheuer and Dr. Barath Guru in the lab of Prof. Jayanth Panyam (Department 
of Pharmaceutics). Briefly, his studies demonstrated that the efficacy of 3.08-NPs 
are statistically equivalent to clinical PTX formulations (Taxol® and 
Abraxane®).144,239 The in vivo efficacy of the 3.08-NPs was evaluated in mice 
carrying orthotopic MDA-MB-231 tumor xenografts. This cell line was stably 
transfected with luciferase to enable subsequent quantitative bioluminescence 
imaging of tumor growth. The prodrug-loaded particles were prepared by FNP 
and immediately lyophilized to remove THF and water. The resulting white 
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239 Guru, B. University of Minnesota, Minneapolis, MN. Personal communication, 2010. 
??
????
????
????
????
????
????
????
????
????
??
?? ??? ??? ??? ??? ???? ???? ???? ???? ???? ????
???
???
???
???
???
???
?? ??????
Chapter 5 Silicate Ester Loaded Nanoparticles? 
?
????
?
powder was then resuspended into a phosphate buffered saline (PBS) solution (1 
wt%, probe tip sonication) directly prior to injection into tumor-bearing animals.  
Three active PTX-based drug formulations were administered (n≥5 for 
each group): 3.08-NPs, PTX-CrEL® (formulated as in Taxol®), and Abraxane®. 
Equimolar quantities of PTX were used in each dosing regimen to enable 
comparison of the therapeutic response of 3.08-NP vis-à-vis the current clinical 
formulations of PTX. Non-drug loaded CrEL® and PEG-b-PLGA NP (hereafter, 
blank NPs) control groups were also included.  
Quantitative luminescence was used to determine therapeutic response. 
Luciferase-catalyzed oxidation of luciferin is an ATP-dependent reaction, and the 
intensity of the resulting photon emission is taken to be indicative of the number 
of viable grafted luc+ MDA-MB-231 cells at the primary tumor site.240 The relative 
antitumor efficacy of 3.08-NP, PTX-CrEL®, and Abraxane® was determined by 
photon flux from the primary tumor site via bioluminescence imaging. Luciferin 
was administered at 150 mg•kg-1 by i.p. injection on an every 8 day schedule. 
Each time point reflects the number of days following initiation of either PTX-
containing or control formulation dosing schedule. The images of the three 
animals in Figure 5-11a (one from each test PTX treatment group at the end of 
the experiment) are representative of the data provided by this quantitative 
luminescence assay. A full panel of images from one mouse from each treatment 
group at each of 5 time points (22 to 54 days post-treatment) is provided in 
Figure 5-11b.  
 
???????????????????????????????????????? ????????????????????
240 Jenkins, D. E.; Oei, Y.; Hornig, Y. S.; Yu, S.-F.; Dusich, J.; Purchio, T.; Contag, P. R. 
Bioluminescent Imaging (BLI) to Improve and Redefine Traditional Murine Models of Tumor 
Growth and Metastasis. Clin. Exp. Metastasis 2003, 20, 733–744. 
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Figure 5-11. A summary of the quantitative luminescence data (a) Luminescence 
images from one representative mouse from each of the three PTX-based 
treatments at the completion of the study and (b) luminescence images from one 
representative mouse from each time point. Images were autoscaled to insure 
uniformity. The pseudocolor scale represents photon flux [photons sec-1 (cm2)-1 
sr-1] from a defined region of interest at the primary tumor site. Red boxes 
indicate death of the animal.88 
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The data in Figure 5-12 summarize the luminescence response from all 
animals in a given test group at the indicated time points. Highlights are that 
treatment with each of 3.08-NPs, PTX-CrEL®, and Abraxane® showed significant 
inhibition of tumor growth relative to the controls and that all three of 3.08-NPs, 
PTX-CrEL®, and Abraxane® were statistically comparable in their protective 
capacity. Recall that the dosage of PTX or PTX prodrug was identical (50 µmol 
kg-1) for all treatment groups. 
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Figure 5-12. The mean luminescence quantitation is correlated with photon 
intensity from the primary tumor site was determined for ≥4 mice at each time 
point. CrEL® and blank NP groups are shown up to the time point preceding 
euthanasia or death of a majority of the group. “x” indicates too few surviving 
animals for meaningful data interpretation. Data are presented as mean ± S.D.88 
 
 
 
2. Toxicological Analysis of the in vivo Study. Because the wt% of prodrug 
in 3.08-NPs (47 ± 5 wt%) was considerably higher than that of PTX in PTX-
CrEL® (1.1%) or Abraxane® (10%), much lower amounts of excipient were 
administered to the animals receiving 3.08-NPs. Qualitatively, tail tissue near the 
injection site in the mice treated with CrEL® alone (control) or PTX-CrEL® were 
found to exhibit necrotic characteristics, suggesting significant toxic side effects 
from the CrEL® excipient.104 Upon conclusion of the luminescence study, a liver 
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and blood toxicology profile [aspartate transaminase (AST) and alanine 
transaminase (ALT) levels and %neutrophils vs. %lymphocytes] showed less 
pronounced toxicity in the mice receiving 3.08-NPs vis-à-vis PTX-CrEL® and 
Abraxane® Figure 5-13. This is at least consistent with the hypothesis that 3.08-
NPs is the source of lower levels of toxic agent over a longer duration by virtue of 
slow release of PTX from NPs.  
Figure 5-13. Hepatological and hematological data from animals treated with 
3.08-NP, PTX-CrEL®, and Abraxane®. (a) Measured AST levels. (b) Measured 
ALT levels. (c) Ratio of %Neutrophils to %Lymphocytes (Table 5-3). In all graphs, 
each diamond represents the value for an individual animal, the solid bar 
represents the mean value with error bars denoting ± S.D., and the dashed 
horizontal line represents the “expected” values for this strain of female mice, as 
provided by the supplier.241 For a and b n=4 (3.08-NP), n=6 (PTX-CrEL®), and 
n=5 (Abraxane®). For c n=3 for each group due to hemolysis of the blood 
samples during analysis. 
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at http://www.criver.com/en-
US/ProdServ/ByType/ResModOver/ResMod/Pages/NuNuNudeMouse.aspx (accessed May 31, 
2012). 
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Table 5-3. Toxicological data for the mice treated with 3.08-NP, PTX-CrEL®, and 
Abraxane®. 
 Treatment ALT AST Mean Cell  
  (U/L) (U/L) Hemoglobin (g•dL-1)  
 
 Expected a 51.3 (± 18.8) 119.4 (± 95.5) 30.4 (± 2.7)  
 3.08-NP 24.3 (± 9.0) 123.6 (± 61.1)  27.6 (± 0.6)  
 PTX-CrEL® 27.2 (± 3.8) 170.0 (± 69.2)  27.9 (± 3.3)  
 Abraxane® 89.0 (± 79.2) 361.6 (± 187.8)  30.5 (± 1.7)  
 
   
  Lymphocytes Neutrophils    
  (%) (%)    
 
 Expected 62.5 (± 10.3) 29.9 (± 8.4) 
 3.08-NP 59.7 (± 16.2) 32.0 (± 13.0) 
 PTX-CrEL® 43.7 (± 5.0) 46.7 (± 2.1) 
 Abraxane® 46.0 (± 21.1) 49.0 (± 23.5) 
 
 
 a Expected values for this strain of mouse, as provided by the vendor.241  
 
The bioluminescence imaging data (Figure 5-11a and b) also suggest that 
tumors in mice treated with 3.08-NPs were decellularized (i.e., less dense at the 
tumor core) relative to Abraxane®-and PTX-CrEL®-treated mice. Histologic 
assessment of tumors at the study endpoint [hematoxylin and eosin (H&E) as 
well as caspase-3 staining assays] showed a trend towards a larger central non-
viable core in the 3.08-NPs relative to the PTX-CrEL® and Abraxane® treatment 
groups (Figure 5-13). Again, this is suggestive of a prolonged release profile of 
PTX from 2a-NPs at the tumor site. Collectively, these in vivo results suggest 
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that prodrug- and dose-optimization studies should be performed with an eye 
toward further improving the therapeutic window of PTX silicate prodrug 
formulations. 
Figure 5-14. The representative histology images are from animals treated with 
(a-c) 3.08-NP; (a’-c’)PTX-CrEL®; and (a’’-c’’)Abraxane®. (a,a’,a’’) Hematoxylin 
and eosin (H&E) tumor periphery (10X) staining. (b,b’,b’’) Full tumor H&E staining 
(1X). (c,c’,c’’) Cleaved caspase-3 (1x) assays. The larger decellularized core and 
thinner cellular margin of mitotically active cells among these tumors suggests a 
greater (apoptotic) cytotoxic effect of 3.08-NPs compared to PTX-CrEL® or 
Abraxane®. 
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5. Conclusion. 
Nanoparticles derived from flash nanoprecipitation are unique from those 
that are made via more traditional (e.g., emulsion) techniques. A key difference is 
that FNP-derived particles are kinetically-trapped species, and thus traits 
commonly associated with thermodynamically stable nano carriers (e.g., micelles 
or liposomes) did not necessarily apply. A series of experiments were designed 
and conducted to further define the structure of these FNP-formulated 
nanoparticles. Analysis by 1H NMR spectroscopy, DOSY NMR spectroscopy, and 
DSC, studies, in addition to collaborative SEM and cryo-TEM provided valuable 
information on the organization (or disorganization) of both encapsulated silicates 
and the PEG-b-PLGA BCP. While it is difficult to know with certainty, the 
evidence obtained from these broadly diverse studies is consistent with a 
nanoparticle whose solid core is composed largely of the crystalline PTX silicate 
co-mixed with the PLGA block. The water-soluble PEG forms a corona that 
effectively prevents aggregation.  
The bis-ethoxy PTX silicate prodrug 3.08 was formulated via FNP to 
provide nanoparticles 3.08-NP, which contained very high levels (47 ± 5 wt%) of 
prodrug load. Tumor-bearing mouse models were dosed with three taxane-
containing agents, and quantitative luminescence was used to assess 
comparative in vivo antitumor efficacy. The 3.08-NPs were found to display 
similar effectiveness as the clinically used formulations PTX-CrEL® and 
Abraxane®. Importantly, liver and blood toxicology and histology studies showed 
that the 3.08-NP treatment group demonstrated minimal toxicity. Notably, the 
amount of excipient used in the 3.08-NP formulations is significantly lower than 
that in the PTX-CrEL® and Abraxane® drugs. Together, these results suggest 
that prodrug- and dose-optimization studies should be performed with an eye 
toward further improving the therapeutic window of PTX silicate prodrug 
formulations.  
Chapter 5 Silicate Ester Loaded Nanoparticles? 
?
????
?
6. Experimental Section. 
 
A Typical FNP Experiment to Synthesizes 3.08-NPs. Prodrug 3.08-
loaded nanoparticles were produced with a confined-impingement jet (CIJ) 
mixer.6 A 5K-10K PEG-b-PLGA polymer (25 mg) and prodrug 3.08 (35 mg) were 
dissolved in THF (2.5 mL) and impinged against 2.5 mL of DI water in the CIJ 
mixer over the course of 5 s. The resulting nanoparticle suspension was 
immediately diluted in 45 mL of DI water, resulting in a nanosuspension of 1.2 
mg/mL in a mixture of THF and DI water (5:95). This suspension was lyophilized 
and kept frozen at -80 ˚C until used. In preparation for injection into mice, the NP 
powder was redispersed in 0.9%NaCl (ca. 10 mg/mL, 1 wt%) while cooling in an 
ice bath using probe sonication at 20 kHz for five minutes. 
 
 
DOSY Parameters. DOSY NMR measurements were performed on a 300 
MHz Varian NMR spectrometry with the temperature unregulated at ambient 
temperature. The 1D 1H NMR experiment was run first (number of transients = 
16), calibrated at 90°, and the 1D 1H NMR experiment repeated. Parameters 
were obtained from the 1D experiment (pulse width = 17 ms, spectral width 
=2007.3 Hz, transmitter offset -628.4 Hz, and gain = 50) and applied to the 
DOSY experiment. A series of spectra were then obtained (with the diffusion time 
set to be 0.03 s) such that the final signals decayed to approximately 10% of their 
original intensity. The spectra were baseline-corrected and processed using the 
Varian-supplied software. 
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SEM Sample Preparation. SEM samples were prepared by Zhengxi Zhu 
as previously described.242   
 
 
Quantification of PTX Silicate from Nanoparticles. 3.08-NPs were 
prepared as described in section 5.6.1 and 3.08 aggregates were prepared by 
omitting the polymeric component but otherwise identically to the procedure in 
section 5.6.1. The THF/H2O sample was extracted with diethyl ether (x3), the 
organic washes were combined, the solution dried over MgSO4, and then 
concentrated under reduced pressure. The 1H NMR quantification was 
performed in CDCl3 with ethanol as the internal standard. The HPLC 
quantification was performed on a C-18 column (4.6 mm x 25 cm) with 5 µm 
packing and eluted with a 75:25 mixture of acetonitrile:water at a rate of one 
mL•min-1. The amount of 3.08 was quantified by measuring the UV absorbance 
at 228 nm and comparing to a standard curve.   
 
 
DSC Analysis of the Nanoparticles. Differential scanning calorimetry 
(DSC) was performed using a Discovery DSC that was calibrated using high 
purity indium. The samples were analyzed over a temperature range of -50 °C – 
150 °C due to decomposition of the PTX silicate prodrug at higher temperatures. 
Runs were conducted at a heating rate of 10 °C min-1 unless otherwise noted. 
Transitions of the nanoparticles were recorded during the first scan and 
compared to the transitions recorded during the second scan. 
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242 Zhu, Z.; Margulis-Goshen, K.; Magdassi, S.; Talmon, Y.; Macosko, C. W. Polyelectrolyte 
Stabilized Drug Nanoparticles via Flash Nanoprecipitation: A Model Study With β-Carotene. J. 
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Cryo-TEM Sample Preparation. A lacey carbon Cu grid (200-mesh) was 
glow-discharged in a vacuum evaporator at 70 mTorr (DV-502A) for 30 s. A 7.0 
µL portion of a fresh sample (i.e., one hour after FNP) of 3.08-NP was pipetted 
onto the carbon coated side of the grid at 22 °C in a Mark III Vitrobot chamber 
with a relative humidity of 100%. The sample was blotted with filter paper for five 
seconds and relaxed for three seconds before being submerged in liquid ethane. 
The vitrified sample was transferred to a Gatan 626 cryo-transfer unit (Gatan,) at 
-193 °C and characterized at -179 °C in a low-dose mode. A 120 kV FEI Tecnai 
Spirit BioTWIN was used and images were taken with Eagle™ 2k CCD camera . 
The images were processed with TEM Imaging and Analysis and Image J 
software. 
 
 
MDA-MB-231 Luciferase-positive Orthotopic Xenograft. Balb/c nu/nu 
immunocompromised female mice were purchased from Charles River Labs 
(strain code 088, Charles River Labs, Wilmington MA, USA). For xenograft 
studies, 7.5*105 MDA-MB-231 Luc+ cells were resuspended in 100 µL of 
Dulbecco’s phosphate buffered saline (DPBS) and mixed with an equal volume 
of matrigel. Subcutaneous injection to mammary pad 9 located near the left flank 
was performed with a 26-gauge needle attached to 0.5 cc syringe. Subcutaneous 
tumors reached >100 mm3 within three-four weeks.  
 
 
PTX-CrEL®, Abraxane®, and 3.08-NP injections. Once tumors had 
grown to 100 mm3, animals were randomly assigned to treatment groups. A 
dosing schedule of three sequential doses of either PTX-CrEL®, Abraxane®, or 
3.08-NP, each containing 40 mg•kg-1 of PTX equivalent, was given on days 0, 4, 
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and 8.  For PTX-CrEL® a 7.5 mg•mL-1 stock solution of PTX in CrEL®-ethanol 
(1:1 v/v) was prepared and diluted to the appropriate working concentration in 
0.9% NaCl. Abraxane® was diluted to the appropriate concentration in 0.9% 
NaCl. Calculation of the PTX-equivalent dosing for the prodrug-loaded PEG-b-
PLGA NPs (3.08-NP) took into consideration both the prodrug loading level (i.e., 
47 wt%) and the molecular weight of the prodrug. In all cases the final volume of 
agent administered (by tail vein injection using a 26 gauge needle) was 200 µL. 
Two control groups were also included. Mice in the first received a working 
dilution in 0.9%NaCl with an identical CrEL® concentration to that in the PTX-
CrEL® treatment. Mice in the second received blank (i.e., empty) PEG-b-PLGA 
nanoparticles, administered at an identical level to the amount of PEG-b-PLGA 
polymer administered as 3.08-NP. Animal body weights were monitored. Mice 
displaying ≥20% reduction in body weight, greater than 2000 mm3 tumor volume, 
or ulcerations of the tumor were euthanized. 
 
 
In Vivo Bioluminescence Measurements. Quantitation of luminescence 
was determined following i.p. administration, beginning at day 22 following initial 
dosing, of D-luciferin on an every 8-day schedule. Mice were anesthetized with 
2% inhalational isoflurane prior to whole animal luminescence imaging. 
Luminescence was monitored longitudinally for all mice. Luminescence 
quantitation was performed using the Xenogen IVIS® whole animal imaging 
system located in the Biomedical Image Processing Lab at the University of 
Minnesota. D-Luciferin stock solutions of 15 mg•mL-1 were prepared in PBS and 
stored at -70 °C until used. D-Luciferin was administered at 150 mg•kg-1 by i.p. 
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injection. A 15-minute delay between injection and imaging was used.243 
Photographic overlay images were obtained simultaneous to luminescence 
detection (30 s exposure). The region of interest was defined to contain all 
photon emission. Photon flux was calculated using Living Image Pro 4.2 
software). 
 
 
Histopathological, Hematological, and Hepatological Analyses. At the 
endpoint of the study, blood was collected by cardiac puncture from mice that 
had received an active PTX agent, and complete blood count analysis and 
hepatic profiling was performed by Marshfield Labs. Tumors were then excised 
and fixed in 10% buffered formalin phosphate for 48 hours. Tumors were washed 
and subsequently stored in 70% ethanol. Histology and immunohistochemistry in 
formalin-fixed tumors was performed with assistance from the Comparative 
Pathology shared resource, University of Minnesota Masonic Cancer Research 
Center. 
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Chapter 6  
Selective End-Functionalization of  
PEG -b-PLGA Block Copolymers. 
 
1. Introduction. 
 “High value” (e.g., customized, functionalized, and well-defined) polymers 
represent tremendous potential in a wide variety of fields in both academic as 
well as industrial environments. This belief was aptly summarized Hawker and 
Wooley in a recent review, as they stated  “Applications for advanced functional 
soft materials that possess precisely engineered properties and functional groups 
have been expanding significantly with the development of nanotechnology and 
the growing need to address resource, health, and energy issues.”244 As is the 
theme throughout this thesis, the aim of Chapter 6 is to develop a general 
strategy that can solve immediate, practical problems and be amenable to a wide 
variety of future uses. Specifically, the covalent conjugation of a targeting agent 
on the water-soluble polyether block could serve to selectively localize 
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244 Iha, R. K.; Wooley, K. L.; Nystrӧm, A. M.; Burke, D. J.; Kade, M. J.; Hawker, C. J. Applications 
of Orthogonal “Click” Chemistries in the Synthesis of Functional Soft Materials. Chem. Rev. 2009, 
109, 5620–5686. 
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nanoparticles in vivo.  In doing so, material of potentially tremendous value to 
both the fundamental scientific inquiries involving the nanoparticles as well as the 
overall efficacy of the drug delivery project would be created. Furthermore, these 
efforts will be directed toward the development of a general route toward 
selectively end-functionalized block polymers that could be expanded to include 
numerous other functional ligands and fluorescent imaging agents. 
 
2. A General Strategy toward a Common Polymeric Precursor. 
1. Generalized Route Design. The use of PEG-b-PLGA BCPs (i.e., those 
described in Chapter 4) to synthesize 3.08-NPs via FNP experiments generally 
produced particles that were ca. 100 nm in diameter.5 This size is generally 
advantageous for passive particle localization via the Enhanced Permeation and 
Retention (EPR) effect.245,246,247 This localization is an artifact of the “leaky” 
vasculature that results from the rapid angiogenesis of cancer tumors. Since 
these loose junctions occur primarily in a cancer tumor, a variable degree of 
passive but somewhat selective localization of nano-sized particles at a 
cancerous tumor is a generally accepted phenomenon. However, the range of 
particle sizes reported to be conducive to the EPR effect varies widely in the 
literature.248 Additionally, the EPR effect alone is unlikely to optimize localization 
???????????????????????????????????????? ????????????????????
245 Acharya, S.; Sahoo, S. K. PLGA Nanoparticles Containing Various Agents and Tumour 
Delivery by EPR Effect. Adv. Drug Deliver. Rev. 2011, 63, 170–183. 
246 Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and Target Systems for Cancer Therapy. 
Adv.Drug Delivery Rev. 2004, 56, 1649–1659. 
247 Maeda, H.; Sawa, T.; Konno, T. Mechanism of Tumor-Targeted Delivery of Macromolecular 
Drugs,Including the EPR Effect in Solid Tumor and Clinical Overview of the Prototype Polymeric 
DrumSMANCS. J. Control. Release 2001, 74, 47–61. 
248 Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an 
Emerging Platform for Cancer Therapy. Nature Nanotech. 2007, 2, 751–760. 
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of particles,especially so for tumors of small volume (i.e., < 100 mm3).249 
Potential improvements in both efficacy and safety of prodrug-loaded 
nanoparticles could be realized by including an active (e.g., ligand-based) 
targeting strategy,. 
As described in Chapter 5, PTX silicate-loaded PEG-b-PLGA BCPs 
demonstrated a statistically equivalent chemotherapeutic effect as compared to 
the clinical formulations of PTX, Taxol® and Abraxane®.88 While the efficacy of 
this 3.08-NP treatment may have been aided by the EPR effect, the pursuit of 
BCPs that display a targeting ligand (and thus function as more than a simple, 
biocompatible excipient) was viewed as especially promising for further improved 
efficacy. Therefore, BCPs functionalized with a biologically relevant small 
molecule or ligand to improve taxane delivery in future drug-loaded nanoparticle 
applications were desired. The advances made in highly efficient polymer 
functionalization (of both end groups and repeat units)244 and advances in the 
generation of a wide variety of nanomedicines that are conjugated to effective 
targeting ligands is particularly are examples of earlier work proving  this field to 
be a growing area of fertile research.250,251   
To achieve a targeted BCP, multiple options toward the synthesis of end-
differentiated BCPs have been previously reported. For example, end group 
differentiation of the commercially available and inexpensive dihydroxyl PEG 
homopolymers has been explored, but this strategy is greatly hindered by the 
generation of statistical mixtures of products and/or challenging separations and 
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250 Petros, R. A. & DeSimone, J. M. Strategies in the Design of Nanoparticles for Therapeutic 
Applications. Nat. Rev. Drug Discov. 2010, 9, 615–627. 
251 Betancourt, T.; Doiron, A.; Brannon-Peppas, L. Polymeric Nanoparticles for Tumor-Targeted 
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purifications.252 Conversely, numerous reports that detail the use of specific, 
functional initiators for the synthesis of PEO homopolymers have also been 
published.253 For instance, initiation of an ethylene oxide polymerization by allyl-
containing (for metathesis reactions)254,255 and cyano-containing (for reduction to 
a primary amine)256 have been synthesized. This strategy effectively produces 
PEO homopolymers with defined, differentiated end groups, but it suffers from a 
rather limited scope. Often, a new initiator and, correspondingly, a new PEO 
polymer is necessary for each unique conjugation reaction scheme.  
As has been thematic throughout this thesis, an approach that is practical 
and widely applicable to a variety of functionalization reactions and substrates 
was desired. A “PEG-protecting group” approach fit these criteria and was 
adapted to meet the challenging synthesis of these BCPs. To access these 
materials, a general strategy was designed that included the following features: i) 
independent functionalization of either the polyether or polyester terminus, ii) 
chemical reactions that are compatible with the hydrolytically-susceptible 
polyester block, iii) highly efficient end-functionalization reactions to maximize the 
incorporation of precious targeting ligands, and iv) strategic route design to allow 
access to multiple, functionalized block copolymers from a common, late-stage 
intermediate.  
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256 Nagasaki, Y.; Iijima, M.; Kato, M.; Kataoka, K. Primary Amino-Terminal Heterobifunctional 
Poly(ethylene oxide). Facile Synthesis of Poly(ethylene oxide) with a Primary Amino Group on 
One End and a Hydroxyl Group at the Other End. Bioconjugate Chem. 1995, 6, 702–704. 
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Given the extensive research already devoted to hydroxyl protecting group 
chemistry, multiple protecting groups have been considered to mask a PEO 
hydroxyl group. For instance, initiating an ethylene oxide polymerization with a 
potassium salt of an ethylene glycol tert-butyldimethyl (TBS) ether has been 
reported to successfully provide TBS-protected PEG homopolymers of narrow 
polydispersity and controlled molecular weights.257 However, subsequent work 
has identified difficulties arising from the in situ deprotection of the TBS group 
during the quench with an acidic resin. This, of course, leads to undesireable 
contamination by a significant amount of the PEO diol. 258 Additional reports of 
mono-tetrahydropyran (THP)-protected ethylene glycol initiators have also been 
utilized to synthesize monoTHP-protected PEOs.259 However, removal of the 
THP group is conducted with acidic methanol – conditions that are less optimal in 
a BCP with an incorporated PLGA block. 
In view of the above, a general route to a common polymeric intermediate 
(Scheme 6-1) was envisioned. This scheme began with initiation of the anionic 
polymerization of ethylene oxide 6.02 with mono-protected diol 6.01, in turn 
yielding mono-protected PEG homopolymer 6.03. Using 6.03 as a macroinitiator, 
the co-polymerization of lactide 4.01 and glycolide 4.02 via the previously 
established continuous addition methodology162 could be employed to yield the 
hydroxyl-terminated polyester block of 6.04. At this stage, the polyester could be 
functionalized selectively, by, for example, an esterification reaction. 
Alternatively, the polyester could be simply rendered inactive by acetylation, with 
???????????????????????????????????????? ????????????????????
257 Ito, K.; Hashimura, K.; Itsuno, S. Poly(ethylene oxide) Macromolecules. 8. Preparation and 
Polymerization of ω-Hydroxypoly(ethylene oxide) Macromonomers. Macromolecules 1991, 24, 
3977–3981. 
258 Reed, N. N,; Janda, K. D. A One-Step Synthesis of Monoprotected Polyethylene Glycol 
Ethers. J. Org. Chem. 2000, 65, 5843–5845. 
259 Hiki, S.; Kataoka, K. Versatile and Selective Synthesis of “Click Chemistry” Compatible 
Heterobifunctional Poly(ethylene glycol)s Possessing Azide and Alkyne Functionalities. 
Bioconjugate Chem. 2010, 21, 248–254. 
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either route giving a BCP of the general form 6.05. From this intermediate, the 
deprotection at the PEG terminus would yield BCP 6.06 that displays a primary 
hydroxyl. This readily-diversified functional group could be manipulated by a 
variety of amenable to chemical reactions, including, among others, substitutions, 
esterifications, and oxidations. 
Scheme 6-1. Schematic of the general strategy for selective end-
functionalization of the PEG-b-PLGA block copolymers. 
 
 
2. A Brief Description of Nomenclature. Within Chapter 6, it is critical that 
the end groups of all polymers be unambiguously defined. As in Chapter 4, PEG 
is used interchangeably with PEO for consistency with previous chapters and 
due to the prevalence of the PEG nomenclature in the biological sciences. The 
description of the BCP’s in text will use the general format of XXX-PEG-YYY, 
XXX-PEG-b-PLA-YYY, and XXX-PEG-b-PLGA-YYY. “XXX” will denote the 
terminus of the PEG block (always appearing on the left-hand side) while “YYY” 
will describe the terminus of the PLGA block (always appearing on the right-hand 
side). In the case of the symmetrical PEG homopolymers, the XXX and YYY end 
groups are used without regard for the left- or right-hand designation. As the 
absolute MW of the BCPs is not critical in this chapter, the block sizes are not 
specified in text, but, for completeness, are included parenthetically after the 
compound number in all schemes, with the PEG block size written first and 
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followed by the total MW of the polyester written second. For consistency, the 
described general format will read from left to write as the PEG then PLGA 
blocks, and this system will be used throughout the text.  
  
3. Synthesis of a Common, Derivitizable Intermediate: HO-PEG-b-PLGA-
OAc. 
1. Synthesis of BnO-PEG-OH. In line with one of the project goals (i.e., 
developing a methodology that is readily adaptable to a variety of compatible 
chemistries), a common, readily diversified intermediate analogous to 6.06 was 
sought. Efforts toward a polymeric intermediate were initiated by synthesizing the 
mono-benzyl-protected PEG 6.08 following the precedent of Janda and co-
workers (Scheme 6-2).258 2-(benzyloxy)ethanol 6.07 was utilized as to initiate the 
ethylene oxide polymerization. During this methodology, extreme care was taken 
in the drying of the reagents, monomer, and solvent to minimize the production of 
the PEG diol. Gratifyingly, SEC analysis of the precipitated product showed a 
narrow (PDI = 1.06), symmetrical, and monomodal peak during elution of 6.08, 
indicating nearly exclusive initiation by 6.07. Further analysis via 1H NMR 
spectroscopy resulted in confirmation of the product purity and determination of a 
Mn of 3,300 g mol-1.  
Scheme 6-2. Synthesis of a poly(ethylene glycol) mono benzyl ether. 
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2. Synthesis and Derivatization of the Polyester Block. With 6.08 (and 
other BnO-PEG-OH’s260 of differing MW) in hand, polymerizations of both a pure 
PLA block (6.09) and a “random” PLGA polyester (6.10) were completed 
(Scheme 6-3).162 Both polymerizations proceeded as expected – the targeted 
PLA and PLGA MWs were readily achieved using the techniques described in 
Chapter 4. With these mono-benzylated block polymers 6.09 and 6.10 
synthesized, the focus turned toward selectively functionalized of the 
hydrophobic polyester block via, for example, esterification reactions.  
Scheme 6-3. Synthesis of a PEG-b-PLA mono benzyl ether and PEG-b-PLGA 
mono benzyl ether. 
 
 
While functionalization of the polyester is ineffective for the incorporation 
of targeting ligands (the targeting agent would most likely be buried in the 
nanoparticle core and thus unable to interact with a cellular receptor), 
conjugation of a fluorescent imaging agent at the polyester end may be 
advantageous. Specifically, functionalization of PEG-b-PLA (as a model proxy for 
6.09) with the carboxylic acid-derivitized pyrene 6.11 has been quantitatively 
???????????????????????????????????????? ????????????????????
260 Additional samples (ca. 2K and 6K) were purchased at a later date from Adavanced Polymer 
Materials, Inc.  
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conjugated to the polyester block of a MeO-PEG-b-PLA-OH BCP (see Scheme 
6-4 for a representative example). The synthesis of 6.12 demonstrated the proof 
of principle and our ability to derivative the polyester block of these BCPs.  
Scheme 6-4. Representative esterifications of BnO-PEG-b-PLA-OH to a pyrene 
fluorophore. 
 
 
The practicality of pyrene-derivatized polymer 6.12 (and related analogs), 
is somewhat limited to applications other than those involving animal models. 
The maximum emission wavelength of pyrene is < 400 nm, significantly shorter 
than the ca. 600-800 nm wavelengths that are desired for quantitative in vivo 
work. Nonetheless, converting polymers such as 6.12 into bis-functionalized 
BCPs consisting of both a targeting and imaging agent could prove more 
innovative and useful in fundamental studies of nanoparticle formation and/or 
micellization.261  
Utilization toward a bis-functionalized BCP was explored by subjecting 
6.12 to debenzylation conditions to examine its stability under the deprotection 
conditions. These experiments led to extensive decomposition of the pyrene 
moiety. While benzylated analogs of 6.12 would likely prove ineffective for the 
synthesis of bis-derivatitized BCPs, the incorporation of a longer wavelength 
fluorophores (e.g., rhodamine dyes262) remains a possibility. These studies would 
???????????????????????????????????????? ????????????????????
261 Zhao, C.-L.; Winnik, M. A.; Riess, G.; Croucher, M. D. Fluorescence Probe Techniques Used 
to Study Micelle Formation in Water-Soluble Block Copolymers. Langmuir, 1990, 6, 514–516. 
262 Savic, R.; Luo, L.; Eisenberg, A.; Maysinger, D. Micellar Nanocontainers Distribute to Defined 
Cytoplasmic Organelles. Science 2009, 300, 615–618. 
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further benefit from the ability to accommodate in vivo and/or intracellular 
imaging in future studies. Regardless, these preliminary studies demonstrate 
unambiguously that terminal polyester hydroxyls are readily and quantitatively 
derivitizable. 
3. Acetylation of the Polyester block. In the pursuit of derivatized BCPs 
that display a targeting ligand at the water soluble polyether block, there was 
typically no need to functionalize the polyester terminus. To avoid competing 
reactions, simple acetylation of the polyester block was completed prior to 
debenzylation. Initial attempts to employ a one-pot procedure by quenching the 
polyesterification reaction with an excess of acetyl chloride were encouraging; 
the PDI measurements of these polymers remained narrow. However, future 
studies demonstrated that the end groups were not quantitatively acetylated.  
This problem became apparent after debenzylation of 6.10to give 6.06. 
Esterification of this polymer with, for example, 5-hexynoic acid gave an 
inseparable byproduct. 1H NMR analysis confirmed that the byproduct contained 
a second alkyne, with the structure later being identified as 6.13 (Figure 6-1). 
This was confirmed through the synthesis of multiple small molecule analogs and 
comparison of their 1H NMR resonances. The esterification of a second hexyne 
ester on the PLGA end was finally confirmed by an independent synthesis of 
6.14 and further correlation of the key 1H NMR resonances with the previously 
observed impurity. 
Figure 6-1. Structures of the bis-esterified byproduct 6.13 via independent 
synthesis and 1H NMR analysis of 6.14. 
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A two-step “polymerization-then-acetylation” procedure was instead 
employed. The polyesterification was halted by addition of benzoic acid as 
previously described,162 the polymer purified, and the acetylated to yield the ca. 
100% acetylated BnO-PEG-b-PLGA-OAc (6.15). It is worth noting that 
spectroscopic analysis via 1H NMR of these polymer end-groups is complicated 
by the varying ratios of lactic vs. glycolic terminated polymers, thereby leading to 
different integration nvalues of the resonances of the acetate CH3’s. This ratio 
changes with each polymer “batch,” and the characteristic ratios can be used as 
a tool to “track” aliquots that originate from the same polymerization. 
Polymer 6.15 (and other analogous polymers of varying MWs) was now 
primed for a selective deprotection of the PEG terminus. Indeed, placing the 
solution of 6.15 in a H2 gas atmosphere in the presence of catalytic palladium on 
carbon cleanly and quantitatively debenzylated the block copolymer to yield 
6.16.258 With gram-quantities of the versatile intermediate 6.16 in hand, attention 
was turned to the selective functionalization of the water soluble PEG block.  
Scheme 6-5. Sequential acetylation and debenzylation of a BnO-PEG-b-PLGA-
OH 6.10 to yield a HO-PEG-b-PLGA-OAc that may act as a common 
intermediate for further derivatization of the water-soluble polyether. 
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4. Attempts to Conjugate Biotin to HO-PEG-b-PLGA-OAc BCPs. 
1. Conjugation of Biotin via Esterification. Early efforts to add a discrete 
targeting molecule to the water-soluble, polyether terminus of PEG-b-PLGA 
BCPs first centered on an extensively studied ligand, biotin (3.17). Due to its 
exceptionally strong binding with avidin and streptavidin linkers [dissociation 
constant = ca. 10-15],263 biotin has been widely studied for many different uses. 
For example, it has been used as an affinity tag for protein identification in which 
exceedingly specific interactions are necessary.264 Relevant to nanoparticle-
based chemotherapy, biotin tagged therapies been exploited by conjugation of 
biotin to the surface of nanoparticles, thus inducing active targeting of breast 
cancer cells265 because breast cancer cells overexpress biotin receptors.266 
An (overly) simplistic approach was taken toward the first generation of 
biotin labeled PEG-b-PLGA BCPs. Treating 6.16 with an excess of 6.17 in the 
presence of EDCI and DMAP efficiently led to the near quantitative 
functionalization of the biotin-tagged BCP 6.18. However, despite the ease of 
synthesis, biological studies were not performed on (pro)drug-loaded 
nanoparticles consisting of polymer 6.18 due to concerns regarding the stability 
of the exposed ester bond in eventual in vivo work. Nonetheless, this work 
provided material that was easily characterized for use as a standard during the 
NMR characterization of future biotin-tagged particles. 
???????????????????????????????????????? ????????????????????
263 Laitinen, O. H.; Hytӧnen, V. P.; Nordlund, H. R.; Kulomaa, M. S. Genetically Engineered 
Avidins and Streptavidins. Cell Mol. Life Sci. 2006, 63, 2992–3017. 
264 Tashiro, E.; Imoto, M. Target Identification of Bioactive Compounds. Bioorg. Med. Chem. 
2012, 20, 1910–1921. 
265 Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-Mediated Simultaneous and Targeted 
Delivery of Paclitaxel and Tariquidar Overcomes Tumor Drug Resistance. J. Control. Rel. 2009, 
136, 21–29. 
266 Lee, E. S.; Na, K.; Bee, Y. H. Super pH-Sensitive Multifunctional Polymeric Micelle. Nano Lett. 
2005, 5, 325–329. 
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Scheme 6-6. Biotinylation of HO-PEG-b-PLGA-OAc 6.16 via esterification to 
yield 6.18. 
 
 
2. Attempts to Conjugate Biotin via an Amide Bond. In light of the 
potential, detrimental degradation of the biotin/PEG ester linkage during in vivo 
applications, a secondary, less direct route was explored. For example, 
biotinylated PEG-b-PLA BCPs were prepared by conjugation of an N-hydroxy-
succinimide (NHS)-activated biotin with a heterobifunctional α-hydroxy-ω-amine 
PEG block to form the amide-linked biotin. This species was then utilized as a 
macroinitiator for the polymerization of lactide to form the final product.267  
With this precedent, focus turned briefly from the synthesis of a biotin-
tagged BCP from common polymeric precursor 6.16 to the synthesis of a BnO-
PEG-NH2 polymer. To avoid unnecessarily consuming large amounts of the 
precious (and expensive) benzylated PEG 6.08, model work was performed 
utilizing MeO-PEG-OH 4.03 as a model system. Accordingly, 4.03 was treated 
with mesyl chloride to give 6.19. The purified product could then be redissolved 
in a saturated aqueous solution of ammonium hydroxide to produce 6.20 in high 
yield (Scheme 6-7).  
???????????????????????????????????????? ????????????????????
267 Salem, A. K.; Cannizzaro, S. M.; Davies, M. C.; Tendler, S. J. B.; Roberts, C. J.; Williams, P. 
M.; Shakesheff, K. M. Synthesis and Characterization of a Degradable Poly(lactic acid)-
Poly(ethylene glycol) Copolymer with Biotinylated End Groups. Biomacromolecules 2001, 2, 575–
580. 
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A similar route was employed to access the activated MsO-PEG-b-PLA-
OAc 6.21. While possibly counterintuitive, 6.21 was considered as a candidate 
for direct displacement of the mesylate by ammonia. I hypothesized that pre-
organization of the BCP in its nanoparticulate form may result in the rate of 
displacement of the mesylate being significantly faster than the diffusion of the 
water-soluble ammonia into the hydrophobic nanoparticle core. If this proved 
true, the end-group may be effectively functionalized with minimal degradation of 
the polyester core. Alas, this hypothesis proved to be incorrect, as treatment of a 
nanoparticle suspension of 6.21 resulted in rapid consumption of the PLA block 
(Scheme 6-7).  
Scheme 6-7. Synthesis of model polymer NH2-PEG-OMe 6.20 and attempted 
direct synthesis of NH2-PEG-b-PLA-OAc by displacement of 6.21. 
 
 
With the failure of the direct displacement of the mesylate-funtionalized, 
pre-organized PEG-b-PLA BCP, other means to biotinylate 6.08 were pursued. 
Treatment of 6.08 with mesyl chloride afforded the end-differentiated polymer 
6.22, and dissolution of this polymer in a saturated ammonium hydroxide solution 
cleanly yielded the α-benzoxy-ω-amine PEG (BnO-PEG-NH2) 6.23. 
Encouragingly, formation of the biotin amide also proceeded smoothly in the 
presence of the carbodiimide EDCI and DMAP, giving 6.24. However, the final 
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deprotection step proved problematic. Following literature precedent,268 6.24 was 
exposed to 10 wt% Pd/C (10 %) in a hydrogen atmosphere. Unfortunately, this 
led to only ca. 25% debenzylation of the polymer in three hours. Conversely, 
debenzylation of, for example, 6.09 and 6.10 were found to be fully deprotected 
under these conditions, likely a result of catalyst poisoning by the sulfide. Further 
disappointment was realized when subjecting 6.24 to the reduction conditions for 
prolonged time periods resulted in significant degradation of the biotin end group.  
Scheme 6-8. Synthesis of model polymer NH2-PEG-OMe 6.20, biotinylation, and 
attempted debenzylation of 6.23. 
 
 
Thus, an N3-PEG-b-PLGA-OAc 6.27 was next envisioned as an ideal 
monofunctional BCP. The azide functionality could be reduced under palladium-
catalyzed hydrogenation269 or Staudinger reduction conditions,270,271 revealing a 
???????????????????????????????????????? ????????????????????
268 Despras, G.; Robert, R.; Sendid, B.; Machez, E.; Poulain, D.; Mallet, J.-M. Biotin Sulfone 
Tagged Oligomannosides as Immunogens for Eliciting Antibodies against Specific Mannan 
Epitopes. Bioorg. Med. Chem. 2012, 20, 1817–1831. 
269 Newkome, G. R.; Kotta, K. K.; Mishra, A.; Moorefield, C. N. Synthesis of Water-Soluble Ester-
Terminated Dendrons and Dendrimers Containing Internal PEG Linkages. Macromolecules 2004, 
37, 8262–8268. 
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primary amine under conditions compatible with both the polyether and polyester 
blocks of the BCP. Furthermore, with the exploding popularity of Huisgen (i.e., 
“click”) cycloadditions in polymer chemistry and materials science,272 an azide-
tagged BCP was viewed as an attractive functional polymer target with extensive 
potential for functionalization. Again, initial studies employed the readily available 
monomethoxy PEG homopolymer as a model system. Accordingly, 6.19 was 
treated with an excess of sodium azide to give 6.25 in high conversion, as 
anticipated.273 
Scheme 6-9. Synthesis of model polymer N3-PEG-OMe 6.25. 
 
 
Accordingly, the treatment of HO-PEG-b-PLGA-OAc 6.21 with mesyl 
chloride readily produced 6.26 was unexpectedly problematic. Conversion to the 
mesylate functionalized BCP was irreproducible, and the rate was sluggish as 
compared to the PEG model system. Attempts to further explore the cause of 
these observations by measuring conversion with respect to time suggested a 
sudden (and currently inexplicable) halt to the reaction progress. For instance, 
temporal monitoring of the treatment of 6.26 with an excess of mesyl chloride 
and an amine base allowed, e.g., 40% conversion, at which point, additional 
???????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ??????????????????????????????????????? ????????????????????
270 Menger, F. M.; Zhang, H. Self-Adhesion among Phospholipid Vesicles. J. Am. Chem. Soc. 
2006, 128, 1414–1415. 
271 Ryu, J.-H.; Jang, C.-J.; Yoo, Y.-S.; Lim, S.-G.; Lee, M. Supramolecular Reactor in an Aqueous 
Environment: Aromatic Cross Suzuki Coupling Reaction at Room Temperature. J. Org. Chem. 
2005, 70, 8956–8962. 
272 Binder, W. H.; Sachsenhofer, R. “Click” Chemistry in Polymer and Materials Science. 
Macromol. Rapid Commun. 2007, 28, 15–54 and references therein. 
273 Opsteen, J. A.; van Hest, J. C. M. Modular Synthesis of Block Copolymers via Cycloaddition of 
Terminal Azide and Alkyne Functionalized Polymers. Chem. Commun. 2005, 57–59. 
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substitution was no longer observed. Surprisingly, additional reagents did not 
lead to further conversion over time.  
Unfortunately, a solution to this problematic and currently unexplained low 
conversion has remained elusive. It was deemed prudent to continue the line of 
experimentation with a BCP that is, typically, ca. 40-60% mesylated. This 
decision was made in part because it is not necessary to formulate a 
nanoparticle with a 100% end-capped BCP. Fortunately, conversion of 6.26 to 
the azide-tagged PEG-b-PLGA proceeded cleanly – the mesylate was 
quantitatively substituted with the azide nucleophile to yield 6.27.  
Scheme 6-10. Synthesis of N3-PEG-b-PLGA-OAc 6.27. 
 
 
With both the azido PEG model 6.25 and N3-PEG-b-PLGA-OAc BCP 6.27 
in hand, efforts were turned toward finding suitable reduction conditions to reveal 
the desired amino-terminated polymers. Preliminary reduction conditions were 
explored using model 6.25 in dry DCM and allowing it to stir at room temperature 
in the presence of Pd/C under a hydrogen atmosphere (Scheme 6-11). These 
conditions resulted in incomplete conversion after two hours, but conversion 
reached greater than 90% (as judged by the diminishing intensity of the 
methylene resonances assigned to those adjacent to the azide as in Figure 6-2) 
after 24 hours, yielding 6.28.  
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The identity of 6.28 necessitated added study because the methylene 
resonance observed at δ = 2.89 ppm in 6.20 formed via ammonia displacement 
of the mesylate was conspicuously absent in the spectra obtained from the 
purified polymer depicted in Scheme 6-11 (Figure 6-2). The identity of the 
polymer was confirmed by multiple control experiments. Treatment of the 
reduced and purified MeO-PEG-NH2 with an excess of acetyl chloride yielded the 
methyl amide 6.29. Correlation of the new amide resonance intensity to that of 
the menthoxy end-group allowed for quantitation of the amine functionality as > 
70%. To remove all doubt regarding the constitution of 6.28 (i.e., that the new 
singlet in the 1H NMR spectrum of 6.29 was not, in fact, simply an impurity), a 
carbodiimide amidification with octanoic acid experiment was run to obtain a 
product containing several new resonances in the 1H NMR spectrum of 6.30. 
Subjecting 6.31 (a PLA rather than PLGA polyester block) as a proxy for 6.27 to 
a 24 hour-long hydrogenation led to new, unassigned resonances in the polymer 
even after purification via standard precipitation techniques. 
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Scheme 6-11. The synthesis of NH2-PEG-OMe 6.28 from 6.25 was successful 
and confirmed by 1H NMR spectroscopic analysis of the analog amide, but 
subjecting BCP 6.31 to identical conditions lead to multiple byproducts. 
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Figure 6-2. The reduction of N3-PEG-OMe 6.25 (top black trace) to NH2-PEG-
OMe 6.28 (bottome blue trace) was successful. The identity of 6.28 was 
confirmed by derivatization to the methyl amide and subsequent 1H NMR 
spectroscopic analysis.  
 
 
 
Attention was next turned toward the Staudinger reduction as a means to 
reduce the BCP azide. Again, 6.25 functioned as a model system and a 
successful Staudinger reduction was completed (Scheme 6-12). Complications 
arose only in the purification of the product – removal of the triphenylphosphine 
oxide was problematic because it was not readily soluble in cold diethyl ether 
during the normal PEG precipitation procedure.  
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Fortunately, this hinderance was alleviated upon experimentation with the 
BCP. Subjecting 6.27 to standard Staudinger conditions provided encouraging 
initial results, and the purification proceeded to easily remove the 
triphenylphosphine oxide via precipitation in i-propanol. The analysis by 1H NMR 
spectroscopy showed a conspicuous disappearance of the azido methylene 
resonance (Figure 6-3). However, attempts to conclusively establish the amine 
functionality were disappointing. Treatment of 6.32 with either acetyl chloride to 
form the methyl amide or 3,5-bis(trifluoromethyl)benzaldehyde (BTBFA)274 to 
form an imine failed to producing convincing evidence of amine functionality. 
Scheme 6-12. The Staudinger reduction of NH2-PEG-OMe 6.28 was successful. 
Subjecting the block copolymer 6.31 to identical conditions led to multiple 
byproducts. 
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Chapter 6 End-Functionalized Block Copolymers? 
?
????
?
Figure 6-3. Analysis of the product of the reduction of N3-PEG-b-PLGA 6.31 by 
1H NMR spectroscopy showed a disappearance of the azide resonance. 
 
 
 
3. Conjugation of Biotin via a [3 + 2] Cycloaddition. Despite the anticipated 
ease, incontrovertible proof of the production and isolation of 6.32 remained 
elusive. Thus, efforts were shifted to the application of click chemistry in order to 
i) successfully conjugate biotin to a PEG-b-PLGA and ii) to develop expertise in 
polymer-based “click” chemistry to be used in future derivatizations. Previously, 
alkyne-tagged biotin molecules have been successfully prepared and conjugated 
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to magnetic nanoparticles275 and cellulosic films.276 At this time, experiments to 
successfully complete the [3 + 2] cycloaddition of a propargylated biotin276 and a 
N3-PEG-PLGA-OAc 6.27 are ongoing in collaboration with Mr. Andrew Michel. 
 
5. Conjugation of Mannose to HO-PEG-b-PLGA-OAc BCPs. 
1. Motivation. In concert with the stated objective of this chapter – namely, 
to synthesize a dearth of varied but useful end-functionalized BCPs from a 
common polymeric precursor – a mannose targeting agent was sought on the 
advice of Prof. Robert Prud’homme, a collaborator at Princeton University. 
Different from the majority of research in this thesis, which focuses on 
chemotherapeutic applications, mannose is thought to be particularly useful as a 
targeting agent in immunological (particularly tuberculosis) diseases. Mannose 
[and other (oligo)saccharides] have drawn increasing interest over the last two 
decades as landmark studies have shown key, selective sugar-protein 
complexes.277 Further motivation is found in recent studies that detail several key 
attractions for use of mannose in PEG-b-PLGA BCP-based formulations: i) a 
number of potential targets within the immune system are known,278 particularly 
in the mononuclear phagocyte system,279 making this a widely applicable 
concept, ii) binding to mannose receptors is known to induce endocytosis without 
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275 Lin, P.-C.; Ueng, S.-H.; Yu, S.-C.; Jan, M.-D.; Adak, A. K.; Yu, C.-C.; Lin, L.-C. Surface 
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receptor oligomerization,280 iii) conjugation to a PEG linker has been shown to 
increase receptor binding and correspondingly decrease nonspecific uptake,281 
and iv) sufficient ligand density is critical to effective binding and uptake.282 
Furthermore, motivation is found in recent reports of the effective targeting of 
nanoparticles that are mannosylated.283 Thus, such-mannose (MAN) capped 
MAN-PEG-b-PLGA polymers could readily find use in FNP-derived nanoparticles 
with interesting and varied drug delivery applications. 
2. Synthesis of an Alkyne-Functionalized BCP and Conjugation to 
Mannose via “Click” Chemistry. A combination of multiple reports of PEG-linked 
mannose derivatives synthesized via “click chemistry”284,285,286 and youthful 
ignorance of the prevalent esterase activity287 in vivo inspired the first foray into 
the field of mannose conjugation. In doing so, HO-PEG-b-PLGA-OAc 6.16 was 
readily converted in a single synthetic step to an alkyne-containing polymer 6.34 
via esterification with 5-hexynoic acid [treatment of mPEG-OH (4.03) with 5-
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280 Taylor, M. E.; Drickamer, K. Structural Requirements for High-Affinity Binding of Complex 
Ligands by the Macrophage Mannose Receptor. J. Bio. Chem. 1993, 268, 399–404. 
281 Engel, A.; Chatterjee, S. K.; Al-arifi, A.; Riemann, D.; Langner, J.; Nuhn, P. Influence of 
Spacer Length on Interaction of Mannosylated Liposomes with Human Phagocytic Cells. Pharm. 
Res. 2003, 20, 51–57. 
282 Yeeprae, W.; Kawakami, S.; Yamashita, F.; Hashida, M. Effect of Mannose Density on 
Mannose Receptor-Mediated Cellular Uptake of Mannosylated O/W Emulstions by Macrophages. 
J. Control. Release 2006, 114, 193–201. 
283 Mahajan, S.; Prashant, C. K.; Koul, V.; Choudhary, V.; Dinda, A. K. Receptor Specific 
Macrophage Targeting by Mannose-Conjugated Gelatin Nanoparticles: An in vitro and in vivo 
Study. Curr. Nanosci. 2010, 6, 413–421. 
284 Nagahori, N.; Nishimura, S.-I. Tailoring Glycopolymers: Controlling the Carbohydrate-Protein 
Interaction Based on Template Effects. Biomacromolecules 2001, 2, 22–24. 
285 Hotha, S.; Kashyap, S.; “Click Chemistry” Inspired Synthesis of pseudo-Oligosaccharides and 
Amino Acid Glycoconjugates. J. Org. Chem. 2006, 71, 364–367. 
286 Fernandez-Megia, E.; Novoa-Carballal, R.; Quio, E.; Riguera, R. Conjugation of Bioactive 
Ligands to PEG-Grated Chitosan at the Distal End of PEG. Biomacromolecules, 2007, 8, 833–
842. 
287 Berry, L. M.; Wollenberg, L.; Zhao, Z. Esterase Activities in the Blood, Liver and Intestine of 
Several Preclinical Species and Humans. Drug Metab. Lett. 2009, 3, 70–77. 
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hexynoic chloride was equally effective to produce the PEG homopolymer analog 
6.33288].  
Scheme 6-13. Esterification of a monomethoxy polyether block to the alkyne-
tagged 6.33 and 6.34. 
 
 
The azido mannose moiety 6.39 was synthesized as previously described 
(Scheme 6-14).284 Consistent with this previous report, mannose 6.35 was penta-
acetylated, after which the C2 acetate was selectively removed by treatment with 
benzyl amine, and the trichloroimidate of mannose (6.36) was formed of the 
trichloroimidate. An acid-catalyzed reaction with an azide-containing ethylene 
???????????????????????????????????????? ????????????????????
288 Synthesis of the mPEG-C(O)O(CH2)3CCH proceeded as expected and to high conversion. 
The key 1H NMR resonances (500 MHz, CDCl3): δ  4.24 [non-uniform t, J = 4.8 Hz, 2H, 
CH3O(CH2CH2O)mCH2CH2OC(O)CH2CH2CH2CCH], 3.65 [s, 455 H, 
CH3O(CH2CH2O)mCH2CH2OC(O)CH2CH2CH2CCH], 3.38 [s, 3H, 
CH3O(CH2CH2O)mCH2CH2OC(O)CH2CH2CH2CCH],  2.49 [t, J = 7.5 Hz, 3H 
CH3O(CH2CH2O)mCH2CH2OC(O)CH2CH2CH2CCH], 2.27 [dt, J = 7.0, 2.7 Hz, 2H, 
CH3O(CH2CH2O)mCH2CH2OC(O)CH2CH2CH2CCH], 1.98 [t, J = 2.6 Hz, 1H, 
CH3O(CH2CH2O)mCH2CH2OC(O)CH2CH2CH2CCH], and 1.85 [app pent, J = 7.1 Hz, 2H 
CH3O(CH2CH2O)mCH2CH2OC(O)CH2CH2CH2CCH]. 
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glycol oligomer {6.38, prepared from (2-[2-(2-chloroethoxy)ethoxy]ethanol) 6.37 
according to known precedent289} provided the acetylated mannose azide 6.39. 
Scheme 6-14. The precedented, synthetic route of azido mannose 6.39.284  
 
 
With both “click” chemistry partners (6.34 and 6.39) now in hand, attention 
turned to the strategic cyclization of the mannose azide and polymeric alkyne. As 
has been standard, the first such reactions were run not with the desired 
materials, but rather model systems were used. Specifically, 6.33 and 6.38 were 
selected for their i) ready synthetic accessibility, ii) conspicuous 1H NMR 
resonances in analysis, and iii) potential to provide insight into the chemical and 
spectroscopic properties of the desired system. In accordance with this plan, 
partners 6.33 and 6.38 were subjected to copper(I)-catalyzed Huisgen reaction 
conditions and, gratifyingly, strong evidence of the mannose-tagged azide 6.40 
was realized. In this case, the presence of the four remaining acetates (and their 
three proton singlet resonances) was useful in providing further evidence of the 
extent of conjugation. With this data in hand, the procedure was expanded to the 
cyclization of partners 6.33 and 6.39. Again, the reaction proceeded as expected. 
NMR analysis of product 6.41 demonstrated a significant shift of many of the 
???????????????????????????????????????? ????????????????????
289 Iyer, S. S.; Anderson, A. S.; Reed, S.; Swanson, B.; Schmidt, J. G. Synthesis of Orthogonal 
End Functinoaled Oligotheylene Glycols of Defined Lengths. Tetrahedron Lett. 2004, 45, 4285–
4288.  
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mannose-related resonances, presumably to ppm’s that coincide with the PEG 
backbone and a significant broadening of several other key resonances. This 
data proved useful in the analysis of the PEG-b-PLGA end functionalization 
reactions. 
Scheme 6-15. The synthesis of the mannose-labeled PEG model systems. 
 
 
Now armed with confidence and data regarding the NMR shifts of key 
spectroscopic resonances, the click chemistry was applied toward the synthesis 
of 6.43. In acknowledgement of the previous inconsistencies regarding the 
application of PEG model systems to the block copolymers, however, a final 
model system was designed prior to pursuit of 6.43. Accordingly, 6.34 and 6.38 
were cyclized to yield 6.42 (Scheme 6-16). Confidence in the success of this 
reaction (i.e., ca. 100% conversion) is attributable to the observance of several 
key resonances that were predicted by model 6.40 to be non-overlapping with 
the broad lactic and glycolic signals.  
Finally, the hexyne-terminated PEG-b-PLGA block copolymer 6.34 was 
subjected yo copper(I) conditions to conjugate it to the deacetylated mannose 
6.39 (Scheme 6-16). After the reaction and purification, analysis of the final 
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product was not trivial due to the number of small mannose resonances that 
overlapped with the much broader polymer peaks. However, relying particularly 
on model 6.41 as a guide, sufficient correlation to confidently conclude the 
cycloaddition occurred and ca. 25-50% conversion was obtained. 
Scheme 6-16. The synthesis of the mannose-labeled PEG-b-PLGA BCPs via a 
[3 + 2] cycloaddition of an azido mannose and hexyne-functionalized BCP. 
 
 
With the intent of synthesizing a biologically-relevant mannose tagged 
polymer for FNP, multiple routes to access a hexyne-functionalized polymer 
through the HO-PEG-b-PLGA-OAc 6.15 were explored. Unfortunately, treatment 
of 6.15 with either NaH/propargyl bromide nor a trichloroacetimidate/TMSOTf or 
TfOH resulted in efficient propargylation of 6.15. Instead, apparent 
decomposition of the block copolymer was observed. Both of these reactions 
were especially disappointing because reactions of the mPEG-OH model system 
were successful under both sets of conditions. Likely, the inability to fully dry the 
BCP and/or the presence of small amounts of adventitious water may have 
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resulted in minor hydrolysis in the polyester block, leading to a significant loss of 
material and concurrent broadening of the PDI.   
3. Synthesis of a Hexyne-Containing Mannose and Conjugation via “Click” 
Chemistry. While polymer 6.43 was not ultimately applicable from a biological 
perspective due to esterase activity,287 experiments with mannose-tagged 
models 6.40-6.43 provided hands-on experience during early efforts to utilize 
“click” chemistry in polymer end-functionalization. Furthermore, this work 
provided important clues regarding our ability to analyze block copolymer 
conjugation via standard 1H NMR spectroscopy.  
Attention was next turned to utilizing the previously described N3-PEG-b-
PLGA-OAc 6.25 and a hexyne-labeled mannose. Compounds such as the 
alkyne-tagged mannose 6.45 have been previously synthesized290 and utilized in 
click reactions to both PEG macromolecules291 and small molecules.285,292 
Access to the propargylated mannose moiety 6.45 was accomplished via penta-
acetylation of mannose 6.35 and treatment of this compound with propargyl 
alcohol in the presence of a strong acid, yielding 6.44. 6.44 could be subjected to 
strongly basic conditions, thereby giving 6.45 in a three step sequence (Scheme 
6-17).290  
 
 
 
???????????????????????????????????????? ????????????????????
290 Mereyala, H. B.; Gurrala, S. R. A Highly Diastereoselctive, Practical Synthesis of Allyl, 
Propargyl, 2,3,4,6-tetra-O-acetyl-β-ᴅ-gluco, β-ᴅ-galactopyranosides and Allyl, Propargyl, 
Heptaacetyl-β-ᴅ-lactosides. Carbohydr. Res. 1998, 307, 351–354. 
291 Wang, R.; Chen, G.-T.; Du, F.-S.; Li, Z.-C. Preparation and Aggregation Behavior of Mannose-
Terminated Poly(ethylene glycol)-b-poly(ʟ-leucine) in Water. Colloids Surf., B 2011, 85, 56–62. 
292 Kumar, K. K.; Kumar, R. M.; Subramanian, V.; Das, T. M. Expedient Synthesis of Coumarin-
Coupled Triazoles via ‘Click Chemistry’ Leading to the Formation of Coumarin-Triazole-Sugar 
Hybrids. Carbohydr. Res. 2010, 345, 2297–2304. 
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Scheme 6-17. The precedented synthesis of the hexyne mannose 6.45.290  
 
 
With 6.45 in hand, initial efforts once again centered on establishing the 
feasibility of click chemistry on an mPEG-OH model system. As in section 6.5.2, 
copper(I) catalysis was employed to couple 4.03 and 6.44 to confirm both the 
chemical methodology on these substrates and further confirm the shifts of the 
key resonances in the NMR spectrum. 6.46 was readily synthesized (Scheme 6-
18). Again, analysis of this 1H NMR spectrum suggested that analysis of a 
polyester-containing block copolymer would be far more challenging. Several 
diagnostic resonances of the mannose sugar were located at ppm values that 
are predicted to fall within the same range as the polyether resonances.  
Scheme 6-18. The cycloaddition of 6.25 and 6.45 gave the mannosylated PEG 
homopolymer 6.46. 
 
 
The azido functionalized PEG-PLGA BCP 6.31 was treated with a copper 
(I) source and the alkynylated mannose 6.45. The first experiments were run 
under reaction conditions utilizing equal volumes of water and THF as the 
reaction solvent, akin to those utilized in Scheme 6-16. ). Unfortunately, the 
small, one proton aromatic singlet of the triazole could not be convincingly 
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observed. This negative result may be attributable to a number of factors: the 
minimal amount of material, low signal-to-noise ratio, and previously observed 
broadness of this peak in CDCl3. However, there were encouraging changes in 
the 1H NMR spectrum of the product as well. Most notably, two resonances 
consistent with the (in this case, somewhat broadened) triplets assigned as the 
PEG methylenes that are α and β to the triazole (at δ = 4.56 and 3.87 ppm) are 
entirely consistent with model 6.46. The integrations of these resonances 
suggested that 20-25% of the BCP was mannose-functionalized – a 100% 
conversion after considering that the starting material, 6.31, was only 20% azide 
functionalized (owing to the difficulties in mesylation discussed previously in 
section 6.4.2  
Scheme 6-19. The [3 + 2] cycloaddition of 6.31 and 6.45 gave the mannosylated 
BCP 6.47. 
 
 
Attempts to obtain further proof of structure by treating 6.47 with large (> 
30 equiv) excess of acetic anhydride and pyridine did not yield an unambiguous 
result. Namely, while additional singlets were noted at ppm shifts consistent with 
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acetates, conversion was incomplete, likely owing to the significant dilution of 
polymeric solution. Regardless, evidence remains for successful [3 + 2] 
cycloaddition of 6.31 and 6.45. Further work involving a mannose derivative 
alkynylated with 3-butyn-1-ol has been initiated (to allow for additional resonance 
in the alkyl region to be monitored) and passed on to Mr. Andrew Michel for 
further work. While this conjugate would provide further evidence for the 
cyclization on the polymer end-group, it is likely that mannose-functionalized 
PEG-PLGA BCPs have been successfully accessed from the common precursor 
6.15. This result opens the possibility for the biological study of targeted 
nanoparticles of this BCP. 
 
6. Maleimide Conjugation to HO-PEG-b-PLGA-OAc BCPs via the 
Mitsunobu Reaction. 
1. Motivation and Literature Precedent. In addition to the azide/alkyne 
“click” chemistry that is discussed in sections 6.4 and 6.5, further diversity was 
sought in the materials applications of these end-functionalized polymers. After 
considering a number of functionalities associated with clean, high-yielding 
reactions, we settled upon the use of a maleimide (6.48, MAL) end group. This 
versatile chemical functionality is primarily employed in materials applications via 
the Diels-Alder [4 + 2] reaction as well as thiol conjugation to the α,β-
unsaturation.244 We sought to access a family of MAL-PEG-b-PLGA BCPs in 
order to eventually take advantage of its Michael-accepting properties, especially 
in applications that exploit the rapid conjugation of the thiol within cysteine 
residues of peptides and/or proteins for bioconjugation of targeting peptides.293 
Previously, maleimide has been incorporated into the polymer end groups 
in a variety of ways. For example, multiple highly cited reports have described 
???????????????????????????????????????? ????????????????????
293 Singh, R. A Sensitive Assay for Maleimide Groups. Bioconjugate Chem. 1994, 5, 348–351. 
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the use of a furan-protected, maleimide-terminated initiator (e.g., 6.49 or 6.50) to 
successfully synthesize poly(methyl methacrylate) (PMMA) macromolecules via 
atom transfer radical polymerization (ATRP)294,295 or poly(ethylene glycol) methyl 
ether acrylate via reversible-addition fragmentation transfer (RAFT) 
polymerization (Figure 6-4). Alternatively, polyacrylates that co-polymerize 
protected maleimide-containing monomers (e.g., 6.51) have been accessed via 
radical polymerization.296 
Figure 6-4. The structures of maleimide (6.48) and representative examples of a 
maleimide-functionalized ATRP initiator (6.49), RAFT initiator (6.50) and acrylate 
monomer (6.51). 
 
 
Specific to this thesis, the ability to display a maleimido group on the 
water-soluble PEG block of a BCP is critical to its successful implementation in 
the nanoparticle-based drug delivery systems described here. PEG 
homopolymers such as 4.03 have been derivatized with succinic acid and then 
esterified with a maleimide derivative to yield a PEG homopolymer that is end-
functionalized with an unprotected maleimide.297,298 [However, the use of a MAL-
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294 Durmaz, H.; Colakoglu, B.; Tunca, U.; Hizal, G. J. Preparation of Block Copolymers Via Diels 
Alder Reaction of Maleimide- and Anthracene-End Functionalized Polymers. J. Polym. Sci., Part 
A: Polym. Chem. 2006, 44, 1667–1675. 
295 Dag, A.; Durmaz, H.; Demir, E.; Hizai, G.; Tunca, U. Heterograft Copolymers via Double Click 
Reactions Using One-Pot Technique. J. Polym. Sci., Part A: Polym. Chem.2008, 46, 6969–6977. 
296 Kosif, I.; Park, E.-J.; Sanyal, R.; Sanyal, A. Fabrication of Maleimide Containing Thiol Reactive 
Hydrogels via Diels-Alder/Retro Diels-Alder Strategy. Macromolecules 2010, 43, 4140–4148. 
297 Durmaz, H.; Dag, A.; Altintas, O.; Erdogan, T.; Hizal, G.; Tunca, U. One Pot Synthesis of ABC 
Type Triblock Copolymers via in situ Click [3 + 2] and [4 + 2] Reactions. Macromolecules 2007, 
40, 191–198. 
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PEG-OH in the literature is frequently referenced as a commercially purchased 
commodity (rather than synthesized) from now-defunct companies as well.299,300] 
The work of Gao and co-workers, particularly, is noteworthy in that they used the 
heterobifunctional MAL-PEG-OH as a macroinitiator of caprolactone, generating 
a MAL-PEG-b-PCL that was utilized in the delivery of doxorubicin.  
Much more limited precedent is available for the selective end 
functionalization with maleimide. A notable example is an alternative synthesis of 
a MAL-PEG-b-PCL that was performed previously in the Hoye labs.301 This work 
synthesized the PEG-b-PCL block polymer via an esterification of a PCL acid 
chloride with a large (ca. 10-fold) excess of a PEG diol. The PCL-b-PEG-OH 
moiety could then be further functionalized with an acid chloride-containing 
maleimide derivative to yield the final MAL-PEG-b-PCL. This strategy served as 
a viable route to MAL-PEG-b-PCL’s of varying MWs, but it is still limited by the 
PEG-maleimide ester linkage – a chemical bond susceptible to esterase activity. 
 2. Maleimide Substitution under Mitsunobu Conditions. While the acid-
catalyzed reaction of an amine with maleic anhydride has been known for 
decades,302 interest in applying the Mitsunobu reaction303 to incorporate 
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298 Gacal, B.; Durmaz, H.; Tasdelen, M. A.; Hizal, G.; Tunca, U.; Yagel, Y.; Demirel, A. L. 
Anthracene-Maleimide-Based Diels-Alder “Click Chemistry” as a Novel Route to Graft 
Copolymers. Macromolecules 2006, 39, 5330–5336. 
299 Olivier, J.-C.; Huertas, R.; Lee, H. J.; Calon, F.; Pardridge, W. M. Synthesis of Pegylated 
Immunonanoparticles. Pharm. Res. 2002, 19, 1137–1143. 
300 Nasongkla, N.; Shuai, X.; Ai, H.; Weinberg, B. D.; Pink, J.; Boothman, D. A.; Gao, J. cRGD-
Functionalized Polymer Micelles for Targeted Doxorubicin Delivery. Angew. Chem., Int. Ed. 2004, 
116, 6483–6487. 
301 Ji, S.; Hoye, T. R.; Zhu, Z.; Macosko, C. W. Maleimide Functionalized Poly(ε-caprolactone)-b-
poly(ethylene glycol) (PCL-PEG-MAL) Nanoparticles: Formation and Thiol Conjugation. 
Macromol. Chem. Phys. 2009, 210, 823–831. 
302 Mehta, N. B.; Phillips, A. P.; Lui, F. F.; Brooks, R. E. Maleamic and Citraconamic Acids, Methyl 
Esters, and Imides. J. Org. Chem. 1960, 25, 1012–1015. 
303 Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and 
Transformation of Natural Products. Synthesis 1981 1–28. 
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maleimide has only been explored for the last ca. 20 years.304 These initial efforts 
by Walker yielded the Mitsunobu-derived maleimide compounds from activated 
primary alcohols in moderate yield.304 Especially relevant to the proposed PEG 
functionalization, when an ethylene glycol oligomer (n = 4, 6.53) was used as the 
alcohol, a reasonable (66%) yield was reported.304 Similar Mitsunobu reactions 
have been reported by others, with mixed results. For instance, utilization of 2-
methoxyethanol 6.52 has been reported to yield an approximately 70% yield of 
the maleimide-substituted Mitsunobu product.301 Conversely, others have 
reported the use of oligomeric ethylene glycols (n = 6, 6.54) providing low (ca. 
25%) yields under nearly identical conditions.305 The lone report of an attempt to 
activate a true PEG homopolymer 4.03 for displacement by maleimide resulted in 
minimal (ca. 10%) conversion.301 In this case, isolation of the pure maleimido 
functionalized polymer is not reported, likely owing to the difficulty associated 
with separation of starting material from product.  
Scheme 6-20. Previous efforts toward the Mitsunobu reaction of maleimide 
(6.48) and ethylene glycol oligomers (6.52-6.54) and polymers (4.03).301,304,305 
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304 Walker, M. A. The Mitsunobu Reaction: A Novel Method for the Synthesis of Bifunctional 
Maleimide Linkers. Tetrahedron Lett. 1994, 35, 665–668. 
305 Gill, H. S.; Tinianow, J. N.; Ogasawara, A.; Flores, J. E.; Vanderbilt, A. N.; Raab, H.; Scheer, 
J. M.; Vandlen, R.; Williams, S.-P.; Marik, J. A Modular Platform for the Rapid Site-Specific 
Radiolabelling of Proteins with 18F Exemplified by Quantitative Positron Emission Tomography of 
Human Epidermal Growth Factor Receptor 2. J. Med. Chem. 2009, 52, 5826–5825. 
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Table 6-1. Previously reported results of maleimide substitution under Mitsunobu 
reaction condtions with ethylene glycol oligomers and PEG.301,304,305   
 Starting Material n  R Product Yield 
  
 6.52 1 CH3 6.55 ca. 70%  
 6.53 4 CH3 6.56 66% 
 6.54 6 CCH 6.57 25% 
 4.03 110 CH3 6.58 ca. 10% 
  
 
Future optimization of Walker’s study utilized an excess of the primary 
alcohol substrate or inclusion of a “dummy” neo-pentyl alcohol (to render the 
unreacted betaine inactive, thereby minimizing the reaction between the betaine 
and the maleimide) to significantly improve the yields, now up to 92% in the case 
of primary alkyl alcohols.306 However, application of even these conditions to 
bifunctional oligomeric ethylene glycols (n = 3-6) resulted in disappointingly 
variable yields (25-68%).307 Given these results, Mitsunobu chemistry for the 
incorporation maleimide into a BCP is promising, but there remains room for 
improvement and optimization in these synthetic procedures.  
3. Mitsunobu Model Studies and Optimization of the Synthetic Procedure.  
In response to the apparent difficulties in reproducing the maleimide substitution 
with ethylene glycols under Mitsunobu conditions, the first goal of this project was 
???????????????????????????????????????? ????????????????????
306 Walker, M. A. A High Yielding Synthesis of N-alkyl Maleimides Using a Novel Modification of 
the Mitsunobu Reaction. J. Org. Chem. 1995, 60, 5352–5355. 
307 Warnecke, A.; Kratz, F. Maleimide-oligo(ethylene glycol) Derivative of Camptothecin as 
Albumin-Binding Prodrugs: Synthesis and Antitumor Efficacy. Bioconjugate Chem. 2003, 14, 
377–387. 
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to replicate the published results. The diethylene glycol monomethyl ether (6.59) 
was first tested under the Mitsunobu conditions containing neo-pentyl alcohol 
and diisopropyl azodicarboxylate (DIAD) rather than diethyl azodicarboxylate 
(DEAD), as per literature precedent.306 Accordingly, 6.59 was subjected to the 
neo-pentyl alcohol-containing Mitsunobu conditions, and GC/MS analysis of the 
crude reaction mixture provided convincing evidence of significant conversion to 
the substituted product 6.60. Encouraged by this first result, the extent of 
conversion was not rigorously analyzed by 1H NMR spectroscopy. Instead, a 
dried, 2K mPEG-OH polymer was subjected to identical reaction conditions. In 
the case of this (relatively small) macromolecule, however, the conversion was 
depressed to only 44% of the desired product 6.61. Further attempts to substitute 
a larger, 5K PEG homopolymer yielded an even further depressed conversion – 
approximately 15% of 6.62. 
 Dismayed by these progressively less desirable results, focus shifted 
away from incorporation of a dummy alcohol due to the less than ideal results of 
ethylene glycol oligomeric substrates reported.307  Reasoning that 100% 
maleimide incorporation was not critical in the final BCP application efforts were 
turned toward an excess of the desired alcohol.306 Taking (1.5 equivalents of) 
6.59 as a model system, the substitution of 6.59 was judged to be 72% (recall 
that the limiting reagent was not the alcohol – conversion of the alcohol was 
measured to be 48% crude). This result is well in line with the previously reported 
findings (66%304 and ca. 70%301).  
Once again encouraged by the prospect of the Mitsunobu chemistry, 1.1 
equivalents of the 5K PEG model system 4.03 was treated with 
triphenylphosphine, DIAD, and maleimide. Unfortunately, conversion of this 
reaction reverted back to the low levels (in this case, 26%) of conversion 
previously observed for the synthesis of 6.62. Interestingly, in this experiment, 
the reaction was noted to be slightly heterogeneous after addition of the 
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maleimide and stirring at -78 °C for ca. 10 min. This heterogeneity upon 
prolonged stirring after step i (Scheme 6-21) proved to be reproducible.  
Originally, I postulated that this observation was attributable to the PEG 
insolubility in an ethereal co-solvent (THF/DCM) mixture at a low temperature. In 
an attempt to overcome this, an additional volume of room temperature DCM 
was added to the reaction mixture upon observation of a white solid. Initially, this 
solvent addition appeared to correct the issue – the reaction again became 
homogeneous. However, upon further stirring at -78 °C, the white precipitate 
reappeared. A second addition of room temperature DCM once again resolvated 
the reactant, but again this proved to be only temporary. [As a control, a 
THF/DCM solution of 4.03 was prepared (at the same concentration as the 
reactions in Scheme 6-21) and cooled to -78 °C. In this case, however, the 
solution remained homogeneous indefinitely.] Upon the third addition of room 
temperature DCM, the dissolved maleimide was immediately added. Despite the 
decreased concentration of this reaction, a notable increase in the extent of 
conversion (55%) was noted upon analysis of the crude reaction. 
The hypothesis for the cause of the unanticipated insolubility was revised 
in light of the above results. Instead, the cause of the heterogeneity was thought 
to be a result of the cold temperature resulting in the insolubility of the PEG 
dioxaphosphorane intermediate rather than attributable to the co-solvent 
composition. The dissolution of the white precipitate in the experiment described 
above was instead the result of the solution warming from the room temperature 
solvent rather than increasing the DCM:THF solvent ratio. In accordance with this 
theory, the concentration of 4.03 was reduced and the temperature of the 
reaction was adjusted at step ii. After addition of the maleimide, the reaction was 
allowed to warm to -40 °C and stirred for 1 h. Satisfyingly, the reaction remained 
fully solvated throughout this incubation. Afterwards, the reaction was warmed to 
room temperature. 1H NMR spectroscopic analysis of the crude reaction mixture 
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provided evidence of a 60% conversion. While the Mitsunobu reaction of a 
dithiophenolmaleimide with PEG 4.03 has been reported in high (73%) yield,308 
this especially high conversion rate reported here is, to the best of my 
knowledge, unprecedented in a PEG/maleimide Mitsunobu reaction. 
Scheme 6-21. The optimization of Mitsunobu conditions for the reaction of 
maleimide (6.48) and diethylene glycol monomethyl ether (6.59) and PEG (4.03).  
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308 Given the limited discussion and spectroscopic data, it is difficult to judge the conversion 
(rather than the mass-based percent yield) of this reaction. See Schumacher, F. F.; Nobles, M.; 
Ryan, C. P.; Smith, M. E. B.; Tinker, A.; Caddick, S.; Baker, J. R. In Situ Maleimide Bridging of 
Disulfides and a New Approach to Protein PEGylation. Bioconjugate Chem. 2011, 22, 132–136.  
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Table 6-2. The optimization of the Mitsunobu reaction condtions for the 
substitution of ethylene glycol or PEG with maleimide.   
 Starting n  6.48 n-pentanol T t Product Conversion a 
 Material  (equiv) (equiv) (°C) (min)  (%) 
 6.59 2 1.0 0.5 -78 10 6.60 n.d.b  
 4.03 45 1.0 0.5 -78 10 6.61 44 
 4.03 110 0.5 1.0 -78 10 6.62 15 
 6.59 2 1.5 0 -78 10 6.60 48 c 
 4.03 110 1.1 0 -78 10 6.62 26 
 4.03 110 0.5 0 -78 to -40 60 6.62 60 
a Conversion based on 1H NMR analysis. 
b n.d. = not determined; product observed via GC/MS 
a 72% conversion based on limiting reagent. 
 
The final hurdle to declaring these model systems a rousing success was 
the need to purify the final product 6.62. It proved particularly difficult to remove 
the triphenylphosphine oxide from the PEG mixture – attempts to selectively 
precipitate the substituted PEG from the most frequently encountered solvents 
yielded little improvement in the purity. After extensive optimization, a multistep 
sequence of precipitations was established to effectively purify the maleimido-
functionalized polymer. In this procedure, the crude polymer was dissolved in 
EtOAc and added dropwise to an equal volume of hexanes pre-cooled to 0 °C, 
filtered, the solid redissolved in DCM, precipitated into isopropanol pre-cooled to 
0 °C, filtered, the solid redissolved in EtOAc and again added dropwise to an 
equal volume of hexanes pre-cooled to 0 °C and finally filtered for a third time. 
This resulted in the recovery of a pure, maleimide-substituted polymer. 
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4. Maleimide-Thiol Conjugation Model Studies.  With the maleimido-
functionalized 6.60 and 6.62 now in hand, control experiments were run to 
establish viability of thiol conjugation.309 In anticipation of future applications of 
amino-acid derived ligands, we aimed to establish our ability to conjugate the 
thiol of a cysteine ethyl ester (6.63) to 6.60, thereby forming the thioether 6.64. 
To our delight, addition of 1.1 equivalents of the cysteine ethyl ester to a D2O 
solution buffered at pD = 7.4 (note that it is pD rather than pH due to the 
deuterated buffer) resulted in > 85% conversion (as judged by 1H NMR analysis) 
to 6.64. The identity of this compound was further confirmed by the identification 
of the di/tri-deuterated species (the deuteration of the amine exchanged rapidly in 
methanol during analysis, and thus only two-three deuterium isotopes were 
detected) as the major peak in the LC-MS trace.310 
Scheme 6-22. The Michael addition of cysteine ethyl ester 6.63 to the maleimide 
model systems 6.60 and 6.62 in a buffered aqueous solvent resulted in 
significant conversion to the thiolated products 6.64 and 6.65. 
 
 
???????????????????????????????????????? ????????????????????
309 Veronese, F. M. Peptide and Protein PEGylation: A Review of Problems and Solutions. 
Biomaterials 2001, 22, 405–417 and references therein. 
310 Model 6.60 (17.5 mg, 0.088 mmol, 1 equiv) was co-dissolved with cysteine ethyl ester 
hydrochloride salt 6.68 (17.4 mg, 0.094 mmol, 1.1 equiv) in a buffered D2O solution (pD = 7.4) in 
a 3 mL vial with stir bar. The vessel was capped with a Teflon-lined cap and allowed to stir for 
overnight at rt. The product was analyzed crude and the major product was found to be 
6.69.LC/MS (Method: C18 column, gradient 50-100% methanol content MM-ES+APCI Positive 
and MM-ES+APCI Negative) tR = 1.8 min (M-H+ 349.0 and 350.0 for the di- and tri-deuterated 
species). 
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 Expanding these results to the PEG system, conversion to 6.65 was noted 
when 6.62 (30 % functionalized) was incubated with 12 equivalents of the 
cysteine ethyl ester for 18 hours. This encouraging result was judged by the 
observation of several new resonances in the 1H NMR spectrum: most notably a 
quartet at ppm = 4.27, two doublet of doublets at 3.01 and 2.99. Equally uplifting, 
the resonances associated with the α,β-unsaturation of the maleimide were no 
longer present. Encouraged by our ability to induce the thioether formation under 
mild, biologically compatible conditions, we proceeded forward with efforts 
toward the maleimido BCP. 
5. Initial Results of HO-PEG-b-PLGA-OAc Mitsunobu Reactions and 
Future Work.  With extensive and encouraging data in hand from the successful 
model systems, attention turned toward functionalization of the targeted system: 
the HO-PEG-b-PLGA-OAc BCP 6.16. Specifically, a 0.435 g sample of 6.16 was 
treated under the optimized conditions (Scheme 6-21, entry 6) in an attempt to 
access the maleimido BCP. Unfortunately, this first experiment resulted in no 
detectable maleimide substitution at the PEG terminus.  
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Scheme 6-23. The attempted application of the optimized Mitsunobu conditions 
to 6.16 resulted in none of the desired product.  
 
 
This disappointing failure could be most easily attributed to the small 
amount of material subjected to the reaction – 0.435 g of a 6K-12K BCP is only 
0.024 mmol. To put the reaction conditions in proper context, use of almost a half 
gram of the polymer starting material would initially seem sufficient, that is, until 
one realizes that a molar equivalent of water is only ca. 440 nL (yes, nanoliters!).  
Combining the unavoidable introduction of adventitious water with the previously 
described difficulties in completely drying PEG-b-PLGA BCPs, it is easy to 
understand how a small quantity of water could out-compete the poorly 
nucleophilic maleimide. Further complicating the practical difficulties of this 
transformation is the reduced molarity of this reaction. Specifically, the BCP was 
soluble to only 0.003 M – only one half the concentration of the successful PEG 
model systems. 
If maleimide substitution results with HO-PEG-b-PLGA-OAc from 
Mitsunobu conditions continue to be disappointing, alternatives exist. For 
instance, subjecting a BnO-PEG-OH species via a sequence of Mitsunobu 
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substitution with s furan-protected maleimide, debenzylation, and finally a retro 
Diels-Alder reaction to yield HO-PEG-MAL [commercial purchase of HO-PEG-
MAL is also an (expensive) option311]. The HO-PEG-MAL, with the maleimide in 
either its protected or unprotected form, may be used as a macroinitiator. This 
route is attractive as a second option because preliminary tests in which 6.60 
was incubated with DBU showed no decomposition over the time period of a 
normal PLGA polymerization (degradation of the small molecule to baseline 
material was noted after extended incubation). Thus, polyesterification of lactide 
and glycolide with MAL-PEG-OH could yield the MAL-PEG-PLGA-OH BCP. This 
polymer could then, in turn, be used as for thiol conjugation reactions. 
 
7. Conclusions. 
 Efforts to utilize the PEG-b-PLGA copolymer as a targeting or imaging 
agent (rather than merely as an excipient/carrier) in drug delivery applications are 
reported. Notably, an efficient and readily reproducible route to a common 
polymeric precursor of the BCP (HO-PEG-b-PLGA-OAc) has been established. 
Multiple chemical transformations on this entity have been examined by using 
mPEG-OH as a model substrate, but these results, surprisingly, did not translate 
well to the PEG-b-PLGA BCPs in all cases. This may be due to the add difficulty 
of drying and limited solubility (and correspondingly dilute reaction conditions) of 
the PEG-b-PLGA copolymer. Nonetheless, significant advances have been made 
through the synthesis of the N3-PEG-b-PLGA-OAc BCP, leading to the 
successful incorporation of a mannose targeting moiety. Additionally, significant 
effort has led to the optimization of Mitsunobu conditions for the synthesis of 
maleimido-functionalized PEG polymers. Further efforts toward applying this 
???????????????????????????????????????? ????????????????????
311 http://www.creativepegworks.com/heterobifunctional%20PEG.html accessed July 18th, 2012. 
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chemistry to the synthesis of a MAL-PEG-b-PLGA-OAc remains a strong 
possibility. 
 
8. Experimental Section.  
 
Mono benzyl ether poly(ethylene glycol) (6.08).258,312 To prepare for the 
polymerization of ethylene oxide, the following purifications were performed. 2-
(Benzyloxy)ethanol was distilled under N2 gas after stirring over CaH2, 
immediately transferred to an oven-dried Schlenk flask under N2 gas with a 
Teflon seal, and stored for future use. Potassium hydride (30 wt% dispersion in 
mineral oil) was washed with distilled hexanes (4x), dried under high vacuum, 
and transferred to a glove box for future use. Ethylene oxide (CAUTION: 
poisonous gas) was transferred to a flame-dried 2-neck flask that had been 
previously evacuated and back-filled with argon (3x) and cooled in an i-
propanol/dry ice bath. The liquid ethylene oxide was subjected to three freeze-
pump-thaw cycles and transferred to a flame dried flask containing neat butyl 
magnesium chloride and stirred for four hours at 0 °C. The drying procedure for 
ethylene oxide involving neat butyl magnesium chloride was repeated by 
transferring the ethylene oxide to another flask containing a fresh aliquot of the 
butyl magnesium chloride. The ethylene oxide was again stirred at 0 °C for four 
hours. Upon completion of the drying procedure, the ethylene oxide was 
transferred to a flame-dried Schlenk flask, and the flask was packed in solid dry 
ice to store the ethylene oxide for future use. THF was first passed through an 
???????????????????????????????????????? ????????????????????
312 This procedure was completed with the help of Mr. Ligeng Yin in the lab of Prof. Marc 
Hillmyer. Their expertise, assistance, and provision of materials are greatly appreciated. 
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alumina column directly into an oven-dried 2-neck flask containing neat butyl 
magnesium chloride and allowed to stir at room temperature for six hours. The 
THF was then transferred to a clean, flame-dried 1L flask under argon, subjected 
to three freeze-pump-thaw cycles, and stored under argon for future use.  
To complete the polymerization, a 1L, 5-neck round bottom flask fitted with a 
burette attachment, syringe attachment, and stir bar was heat under dynamic 
vacuum overnight. Following three fill-evacuate cycles, the argon-filled five-neck 
round bottom flask was transferred to a glove box. Inside the glove box, the pre-
dried THF (ca. 500 mL), 2-(benzyloxy)ethanol (0.61 mL, 4.3 mmol, 1.0 equiv), 
and KH (0.19 g, 4.8 mmol, 1.1 equiv) were added. The five-neck flask was 
removed from the glove box, returned to a fume food, and stirred for four hours. 
The burette containing the ethylene oxide monomer was attached while 
maintaining the ethylene oxide at 0 °C, and the tubing was flame dried. The 
monomer burette was removed from the ice bath and, with the stopcock to the 
five-neck flask open, inverted to added the ethylene oxide (21.5 g, 0.489 mol, 
114 equiv). After stirring for 24 hours at room temperature, the flask was opened 
and 8 g of Amberlyst-15 acidic resin was added and stirred for an additional two 
hours. Because the pH of the solution remained basic, dry i-propanol was 
acidified with concentrated HCl and added until a neutral pH was reached. The 
solution was then concentrated under reduced pressure, yielding a viscous, 
yellow oil that was precipitated in diethyl ether at 0 °C. After filtration, the title 
product was recovered as a white powder (10.44 g, 48.6%) with Mn = 3,300 g 
mol-1.  
1H NMR (500 MHz, DMSO): δ 7.37-7.26 (m, 5H, OCH2-o-Ph, OCH2-m-Ph, and 
OCH2-p-Ph), 4.58 [t, J = 5.6 Hz, 1H, BnO(CH2CH2O)nCH2CH2OH], 4.49 (s, 2H, 
OCH2Ph), and 3.51 [s, 332 H, BnO(CH2CH2O)nCH2CH2OH]. 
SEC (Polystyrene standards) PDI = 1.06. 
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Mono benzyl ether poly(ethylene glycol)-b-poly(lactic acid) (6.09). 
Representative procedure utilizing Method A from (see section 4.D.1); other 
PEG-b-PLA polymers have been prepared via Method B (see 4.D.2).  
The following reaction mixture was prepared in a controlled atmosphere (N2) 
glove box. To a solution of rac-lactide [(±)-4.01, 0.500 g, 3.47 mmol] and BnO-
PEG-OH (3.3K) (0.250 g, 0.076 mmol) in 5.5 mL of dichloromethane was added 
DBU [10 µL] in a screw-capped glass reaction vessel (e.g., culture tube). The 
solution was removed from the glove box and stirred for 1 h. The vessel was 
opened, hydrochloric acid (1N) was added immediately, and the mixture was 
washed with water and brine. The polymer was precipitated by dropwise addition 
of the chloroform solution with stirring into excess isopropanol. Solvent was 
removed from the resulting suspension of white polymer by decantation, and the 
polymer was dried under vacuum at 50 °C overnight, yielding the desired product 
as a white solid with Mn (PLA) = 6,700 g mol-1.  
1H NMR (500 MHz, CDCl3): δ 7.37-7.27 (m, 5H, OCH2-o-Ph, OCH2-m-Ph, and 
OCH2-p-Ph), 5.28-5.10 {m, 93H, BnO-PEG-
[OC(O)CH(CH3)]nOC(O)CH(CH3)OH}, 4.57 (s, 2H, OCH2Ph), 4.40-4.23 [m, 4H, 
BnO-PEG-OCH2CH2OC(O)CH(CH3)-PLA-C(O)CH(CH3)OH], 3.65 [s, 323 H, 
BnO-(CH2CH2O)nCH2CH2O-PLA], and 1.63-1.51 {m, 302 H, BnO-PEG-
[OC(O)CH(CH3)]nOC(O)CH(CH3)OH}. 
SEC (Polystyrene standards) PDI = 1.12. 
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Mono benzyl ether poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) 
(6.10). Representative procedure utilizing Method B from (see section 4.D.4); 
PEG-b-PLGA polymers of different MWs and lactic:glycolic ratios have also been 
prepared via Method B.  
The following three solutions were prepared in ambient atmosphere in a fume 
hood.  i) BnO-PEG-OH (3.3K, 450 mg) was dissolved in CH2Cl2 (21 mL) together 
with a predetermined amount of rac-lactide [(±)-4.01] in an oven-dried round-
bottomed flask containing a magnetic stir bar and closed with a septum. ii) DBU 
was dissolved in CH2Cl2 at a concentration of 16.7 µL mL-1 in a screw-capped 
vial. iii) Glycolide (4.02) was dissolved in THF (6 mL) and taken up in a syringe. 
Solution i) was vigorously stirred. Immediately after the addition of solution ii) (2 
mL), solution iii) was infused into the reaction vessel via a syringe pump at the 
rate of 0.6 mL min-1. At the end of the infusion (10 min), solid benzoic acid (150 
mg) was added to arrest the polymerization. The BnO-PEG-b-PLGA-OH (6.10) 
was purified by precipitation twice into isopropanol from CH2Cl2 and dried at 50 
°C under vacuum overnight yielding the desired product as a white solid with Mn 
(PLGA) = 9,000 g mol-1, ca. 60:40 lactic:glycolic ratio by mass. 
1H NMR (500 MHz, CDCl3): δ 7.37-7.27 (m, 5H, OCH2-o-Ph, OCH2-m-Ph, and 
OCH2-p-Ph), 5.29-5.12 {m, 78H, BnO-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]n}OH}, 
4.90-4.65 {m, 123H, BnO-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]n}OH}, 4.57 (s, 2H, 
OCH2Ph), 4.41-4.22 {m, 4H, BnO-PEG-OCH2CH2O-C(O)CH(R)-
{[OC(O)CH(CH3)]n[OC(O)CH2]n}-C(O)CH(R)OH}, 3.65 [s, 313 H, 
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BnO(CH2CH2O)nCH2CH2O-PLGA], and 1.61-1.44 {m, 239 H, BnO-PEG-
[OC(O)CH(CH3)]nOC(O)CH(CH3)OH}. 
SEC (Polystyrene standards) PDI = 1.12. 
 
 
Mono benzyl ether poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) 
mono 1-pyreneacetate (6.13). Polymer 6.09 (0.91 g, 0.061 mmol, 1 equiv) was 
transferred to an oven-dried culture tube with stir bar and dissolved in 5 mL of dry 
CH2Cl2. 1-Pyreneacetic acid (0.063 g, 0.242 mmol, 4 equiv), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.136 mg, 0.709 
mmol, 12 equiv), and 4-(dimethylamino)pyridine (0.018 g, 0.147 mmol, 2.4 equiv) 
were added sequentially. The reaction was sealed with a Teflon-lined cap and 
stirred for 48 hours. The reaction mixture was precipitated directly into i-propanol, 
decanted, and the solid dried under high vacuum at 50 °C overnight. A brown 
solid (0.710 g, 0.047 mmol, 78%) was obtained. 
1H NMR (500 MHz, CDCl3): δ 8.30-7.90 (m, 9H, CH2-Pyr), 5.25-5.11 {m, 133H, 
MeO-PEG-[OC(O)CH(CH3)]nOC(O)CH(CH3)OH}, 4.48-4.23 {m, 4H, MeO-PEG-
OCH2CH2OC(O)CH(CH3)[OC(O)CH(CH3)]nC(O)CH(CH3)OH}, 3.65 [s, 455 H, 
MeO(CH2CH2O)nCH2CH2O], 3.38 [s, 3H, CH3O(CH2CH2O)n-PLA], and 2.80 [s, 
2H, Pyr-CH2C(O)O]. 
6.13 (105 mg) was redissolved in 4 mL of a 3:1 mixture of CH2Cl2:EtOAc 
and transferred to a round bottom flask containing Pd/C (30 mg, 10% Pd) and a 
stir bar. The reaction mixture was flushed with N2 and subsequently purged with 
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H2. The reaction was allowed to stir under a hydrogen atmosphere for three 
hours. The reaction slurry was then filtered through celite, concentrated under 
reduced pressure, and precipitated into diethyl ether at 0 °C. 1H NMR 
spectroscopic analysis suggested decomposition of the pyrene moiety. 
 
 
Mono benzyl ether poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) 
mono acetate (6.15). Representative procedure; BnO-PEG-b-PLGA-OH 
polymers of different MWs and lactic:glycolic ratios have also been prepared via 
similar methodology.  
BnO-PEG-b-PLGA-OH 6.10 (4.61 g, 0.263 mmol, 1 equiv) was transferred to an 
oven-dried culture tube with a stir bar and dissolved in 20 mL of dry CH2Cl2. 
Pyridine (0.3 mL, 3.88 mmol, 15 equiv) and acetic anhydride (0.25 mL, 2.64 
mmol, 10 equiv) were added by syringe. The reaction was capped with a Teflon-
lined cap and allowed to stir at room temperature for 36 hours. After the reaction 
solution was then precipitated directly into ca. 250 mL of i-propanol at room 
temperature. Upon complete precipitation, the i-propanol was decanted, and the 
polymer was dried under high vacuum at 50 °C overnight, yielding the desired 
product as a white solid (4.16 g, 0.238 mmol, 90.2%) with ca. 100 % acetylation 
at the polyester terminus. 
1H NMR (500 MHz, CDCl3): δ 7.37-7.30 (m, 5H, OCH2-o-Ph, OCH2-m-Ph, and 
OCH2-p-Ph), 5.29-5.13 {m, 94H, BnO-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.91-4.62 {m, 164H, BnO-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.57 (s, 2H, OCH2Ph), 4.40-4.22 (m, 3-4H, 
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BnO-PEG-OCH2CH2-OC(O)CH(R)-PLGA-C(O)CH(R)OAc}, 3.65 [s, 545 H, 
BnO(CH2CH2O)mCH2CH2O-PLGA], 2.17 {overlapping s’s,  1.5H,313 BnO-PEG-
PLGA-C(O)CH2OC(O)CH3}, 2.13 {s,  1.5H,313 BnO-PEG-PLGA-
C(O)CH(CH3)OC(O)CH3}, and 1.62-1.50 {m, 304 H BnO-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc }. 
 
 
Poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) mono acetate (6.16). 
Representative procedure; BnO-PEG-b-PLGA-OH polymers of different MWs 
and lactic:glycolic ratios have also been prepared via similar methodology.  
BnO-PEG-b-PLGA-OAc 6.15 (4.16 g, 0.238 mmol, 1 equiv) was dissolved in 60 
mL of a 1:2 mixture of CH2Cl2:EtOAc. This homogeneous solution was 
transferred to an oven-dried round bottom flask containing a stir bar and 10 wt% 
palladium on carbon (0.452 g). The resulting slurry was mixture was flushed 
sequentially with N2 and then H2. The reaction was maintained under a H2 
atmosphere and allowed to stir for four hours. The reaction slurry was then 
filtered through celite and centrifuged for 20 hours. The supernatant was 
decanted from the black pellet that resulted from prolonged centrifugation, the 
supernatant was concentrated under reduced pressure, redissolved in CH2Cl2, 
and precipitated into ca. 225 mL of i-propanol at room temperature. Upon 
complete precipitation, the i-propanol was decanted, and the polymer was dried 
???????????????????????????????????????? ????????????????????
313 Two primary singlets (and associated minor peaks due to differing repeat unit and/or 
stereoisomer patterns at the end of the polyester) are observed in the 1H NMR spectrum. The 
total integration of these resonances in the fully acetylated BCP is 3H, although the ratio of the 
integrations varies by BCP batch. 
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under high vacuum at 50 °C overnight, yielding the desired product as an off-
white solid (4.15 g, 0.237 mmol, 99.5%) with ca. 100 % debenzylation at the 
polyether terminus. 
1H NMR (500 MHz, CDCl3): δ  5.28-5.12 {m, 89H, HO-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.92-4.64 {m, 158H, HO-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.38-4.22 (m, 3-4H, HO-PEG-
OCH2CH2OC(O)CH(R){[OC(O)CH(CH3)]n[OC(O)CH2]p}C(O)CH(R)OAc}, 3.65 [s, 
545 H, HO(CH2CH2O)mCH2CH2O-PLGA], 2.17 {overlapping s’s,  1.5H,313 HO-
PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}C(O)CH2OC(O)CH3}, 2.13 {s,  1.5H,313 HO-
PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}C(O)CH(CH3)OC(O)CH3}, and 1.62-1.50 
{m, 296 H HO-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc }. 
 
 
Mono biotin poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) acetate 
(6.18). HO-PEG-b-PLGA-OAc 6.16 (0.146 g, 0.0146 mmol, 1 equiv) was 
dissolved in 1.5 mL of dry CH2Cl2, and this homogeneous solution was 
transferred to an oven-dried culture tube with stir bar. Biotin was added (35.6 mg, 
0.146 mmol, 10 equiv), EDCI (28.0 mg, 0.146 mmol, 10 equiv), and DMAP (1.8 
mg, 0.0146 mmol, 1 equiv) were added sequentially. The reaction vessel was 
capped with a Teflon-lined cap and allowed to stir for 24 hours.  The reaction was 
then precipitated directly into i-propanol at room temperature, filtered over a 
glass frit, and dried under high vacuum at 50 °C overnight. 1H NMR 
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spectroscopic analysis determined that unreacted biotin likely was contaminating 
the sample. The polymer was redissolved in dichloromethane, filtered through a 
cotton plug, re-precipitated into i-propanol at room temperature, and again dried 
under high vacuum at 50 °C overnight, yielding the desired product as a white 
solid (0.088 g, 0.0088 mmol, 69.3%). 
1H NMR (500 MHz, CDCl3): δ  5.29-5.10 {m, 44H, Biotin-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.93-4.63 {m, 112H, Biotin-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.54-4.51 (m, 1H, Hg), 4.34-4.20 {m, 4-5H, 
Biotin-PEG-OCH2CH2-OC(O)CH(R)-PLGA-C(O)CH(R)OAc and Hf}, 3.65 [s, 300 
H, Biotin-(CH2CH2O)mCH2CH2O-PLGA], 3.19-3.15 (m, 1H, He), 2.93 (dd, J = 
12.9, 5.1 Hz, 1H, Hh), 2.74 (d, J = 12.9 Hz, 1H, Hh’), 2.37 (t, J = 7.3 Hz, 2H, Ha), 
2.22-2.17 [overlapping s’s,  1.5H,313 Biotin-PEG-PLGA-C(O)CH2OC(O)CH3 and 
Ha], 2.13 [s,  1.5H,313 Biotin-PEG-PLGA-C(O)CH(CH3)OC(O)CH3], and 1.62-1.50 
{m, 147 H Biotin-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc, Hb, Hc, and Hd}. 
 
 
Mono methyl ether poly(ethylene glycol) mesylate (6.19). MeO-PEG-OH 4.03 
(1.00 g, 0.200 mmol, 1 equiv) was dissolved in 5 mL of dry CH2Cl2, and allowed 
to sit over activated 3Å molecular sieves overnight. This homogeneous solution 
was then transferred to an oven-dried culture tube with stir bar, and pyridine (80 
µL, 0.989 mmol, 5 equiv) and methanesulphonyl chloride (75 µL, 0.969 mmol, 
4.8 equiv) were added sequentially. The reaction vessel was capped with a 
Teflon-lined cap and allowed to stir overnight.  The reaction was then precipitated 
directly into diethyl ether at 0 °C, filtered through a paper filter on a Buchner 
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funnel, and dried under house vacuum. The product was isolated as a white solid 
(0.697 g, 0.139 mmol, 69.7%). 
1H NMR (500 MHz, CDCl3): δ  4.39 [non-first order t, J = 4.4 Hz, 2H, MeO-PEG-
CH2CH2O-S(O)2CH3], 3.65 [s, 455 H, OMe-(CH2CH2O)mCH2CH2O-S(O)2CH3], 
3.38 [s, 3H, CH3O-PEG-CH2CH2O-S(O)2CH3], and 3.09 [s, 3H, CH3O-PEG-
CH2CH2O-S(O)2CH3]. 
 
 
Mono methyl ether poly(ethylene glycol) amine (6.20). MeO-PEG-OMs 6.19 
(0.780 g, 0.0156 mmol, 1 equiv) was dissolved in 4.0 mL of dry DMF, in an oven-
dried culture tube with stir bar. Sodium azide (0.101 g, 1.55 mmol, 10 equiv) was 
added and the originally water-white solution was noted to quickly turn to a 
yellow/brown tint. The reaction vessel was capped with a Teflon-lined cap and 
allowed to stir overnight.  The reaction was then precipitated directly into diethyl 
ether at 0 °C, filtered through a paper filter on a Buchner funnel, and dried under 
high vacuum for three hours at 80 °C and then under high vacuum at room 
temperature for 48 hours. The product was isolated as a slightly brown solid 
(0.680 g, 0.136 mmol, 87.2%). 
1H NMR (500 MHz, CDCl3): δ 3.65 [s, 455 H, OMe-(CH2CH2O)mCH2CH2O-NH2], 
3.38 [s, 3H, CH3O-PEG-NH2], 2.89 [t, J = 5.2 Hz, 2H, CH3O-PEG-CH2CH2O-
NH2],  and 1.9 [br s, 2H, CH3O-PEG-NH2]. 
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Mono methyl ether poly(ethylene glycol) azide (6.20). MeO-PEG-OMs 6.19 
(3.0 g, 0.60 mmol, 1 equiv) was dissolved in 20 mL of distilled water in an oven-
dried round bottom flask containing a stir bar and fitted with a condenser. The 
solution was buffered with NaHCO3 (ca. 150 mg), and the pH of the solution was 
measured to be eight. Sodium azide (0.078 g, 1.2 mmol, 2 equiv) was added and 
the solution was refluxed overnight. The reaction was extracted with 250 mL of 
DCM (x2), dried over MgSO4, the solid removed by filtration through a paper 
filter, and dried under reduced pressure. The residue was redissolved in DCM 
and precipitated into diethyl ether at 0 °C. The resulting white powder was dried 
high vacuum overnight The product was isolated as a white solid (2.21 g, 0.442 
mmol, 74%). 
1H NMR (500 MHz, CDCl3): δ 3.65 [s, 455 H, OMe-(CH2CH2O)mCH2CH2O-N3], 
3.40 [t, J = 5.1 Hz, 2H, CH3O-PEG-CH2CH2O-N3] and 3.38 [s, 3H, CH3O-PEG-
N3]. 
 
 
Mono benzyl ether poly(ethylene glycol) mesylate (6.22). BnO-PEG-OH 6.08 
(0.452 g, 0.137 mmol, 1 equiv) was dissolved in 2.0 mL of dry CH2Cl2, in an 
oven-dried 3 mL vial with stir bar. Pyridine was added (60 µL, 0.742 mmol, 5.4 
equiv) and methanesulphonyl chloride (50 µL, 0.646 mmol, 4.7 equiv) were 
added sequentially. The reaction vessel was capped with a Teflon-lined cap and 
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allowed to stir for 18 hours.  The reaction was then precipitated directly into 50 
mL of diethyl ether at 0 °C, filtered through a paper filter, and dried under house 
vacuum for three hours. The product was isolated as a white solid (0.407 g, 
0.123 mmol, 89.8%). 
1H NMR (500 MHz, CDCl3): δ 7.36-7.26 (m, 5H, o-Ph, m-Ph, p-Ph), 4.57 [s, 2H, 
PhCH2O-PEG-OTs], 4.39 [non-first order t, 2H, J = 4.5 Hz, PhCH2O-PEG-
CH2CH2O-S(O)2CH3], 3.65 [s, 455 H, BnO-(CH2CH2O)mCH2CH2O-OTs], and 3.07 
[s, J = 5.2 Hz, 3H, BnO-PEG-CH2CH2O-S(O)2CH3]. 
 
 
Mono benzyl ether poly(ethylene glycol) amine (6.22).  
BnO-PEG-OMs (0.892 g, 0.270 mmol, 1 equiv) was dissolved in 5 mL of distilled 
water, and this homogeneous solution was transferred to an oven-dried culture 
tube with stir bar. The solution was further diluted with 20 mL of an NH4OH (sat) 
aqueous solution. The reaction vessel was capped with a Teflon-lined cap and 
allowed to stir at room temperature for two days.  The aqueous solution was 
extracted with 100 mL of CH2Cl2 (x3), the extract dried over MgSO4, the solid 
removed via filtration, and the DCM solution concentrated under reduced 
pressure. The residue was redissolved in CH2Cl2 and precipitated into diethyl 
ether at 0 °C. The white solid was filtered through a paper filter and dried under 
house vacuum at room temperature for four days, yielding the desired product as 
a white solid (0.701 g, 0.212 mmol, 78.5%). 
1H NMR (500 MHz, CDCl3): δ 7.36-7.26 (m, 5H, o-Ph, m-Ph, p-Ph), 4.57 [s, 2H, 
PhCH2O-PEG-NH2], 3.65 [s, 300 H, BnO-(CH2CH2O)mCH2CH2-NH2], 2.89 [t, J = 
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5.2 Hz, 2H, BnO-PEG-OCH2CH2-NH2], and 1.9 [br s, 2H, BnO-
(CH2CH2O)mCH2CH2-NH2]. 
 
 
Mono benzyl ether poly(ethylene glycol) biotin (6.23). BnO-PEG-NH2 6.22 
(0.088 g, 0.029 mmol, 1 equiv) was dissolved in 0.5 mL of dry DMF (dried over 
3Å MS overnight), and this homogeneous solution was transferred to an oven-
dried vial with stir bar. In a separate, oven-dried culture tube with stir bar, biotin 
(17.9 mg, 0.072 mmol, 2.5 equiv), EDCI (11.2 mg, 0.058 mmol, 2 equiv), and 
DMAP (3.2 mg, 0.026 mmol, 0.9 equiv) were co-dissolved. The solution of 6.22 
was added, the reaction vessel was capped with a Teflon-lined cap and allowed 
to stir overnight.  The reaction was then diluted with 5 mL of distilled water, 
extracted three times with 20 mL of CH2Cl2, dried over MgSO4, concentrated 
under reduced pressure, redissolved in CH2Cl2, and finally precipitated into i-
propanol at 0 °C. The heterogeneous suspension was cooled further in a freezer 
for several hours, filtered, and dried under high vacuum at 50 °C overnight. 1H 
NMR spectroscopic analysis determined approximately 90% conversion in the 
isolated product, a white solid (0.013 g, 0.0043 mmol, 15%). 
1H NMR (500 MHz, CDCl3): δ 4.57 [s, 2H, PhCH2O-(CH2CH2O)mCH2CH2O-NH-
Biotin], 4.51 (br dd, J = 7, 6 Hz, 1H, Hg), 4.33 (br dd, J = 5, 4 Hz, 1H, Hf), 3.65 [s, 
300 H, BnO-(CH2CH2O)mCH2CH2O-NH-Biotin], 3.17 [m, 2H, BnO-
(CH2CH2O)mCH2CH2-NH-Biotin], 2.93 (dd, J = 12.9, 5.1 Hz, 1H, Hh), 2.74 (d, J = 
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12.9 Hz, 1H, Hh’), 2.22 (m, 2H, Ha), 1.72-1.62 (m, 4H, Hd and Hb), and 1.46 (ddt, 
xx Hz 2H, Hc). 
 
 
Tosyl poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) acetate (6.24). 
Representative procedure; HO-PEG-b-PLGA-OH and HO-PEG-b-PLA-OH 
polymers of different MWs and lactic:glycolic ratios have also been prepared via 
similar methodology.  
HO-PEG-b-PLGA-OAc 6.16 (3.6 g, 0.181 mmol, 1 equiv) was dissolved in 10 mL 
of dry CH2Cl2. This homogeneous solution was transferred to an oven-dried 
culture tube containing a stir bar. To the solution, pyridine (0.50 mL, 6.18 mmol, 
34 equiv) and mesyl chloride (0.47 mL, 6.07 mmol, 34 equiv) were added 
sequentially. The reaction was capped with a Teflon-lined cap and allowed to stir 
at room temperature for 24 hours. The slightly yellowed solution was then 
precipitated directly into i-propanol, the solvent decanted, and the solid polymer 
dried under high vacuum at 50 °C overnight, yielding the desired product as a 
white solid (2.25 g, 0.129 mmol, 71.3% recovery, ca. 35% yield) with ca. 40-50 % 
mesylation at the polyether terminus. 
1H NMR (500 MHz, CDCl3): δ  5.28-5.12 {m, 86H, MsO-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.92-4.64 {m, 162H, MsO-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.39 [non-uniform t, J = 4.4 Hz, 2H 
(integration of 1H due to 50% conversion), CH3S(O)2OCH2CH2O-PEG-PLGA-
OAc], 4.34-4.23 (m, 3-4H, MsO-PEG-OCH2CH2OC(O)CH(R)-PLGA-
C(O)CH(R)OAc}, 3.65 [s, 545 H, MsO-(CH2CH2O)mCH2CH2O-PLGA], 3.07 [s, 3H 
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(integration of 1H due to 50% conversion), CH3S(O)2O-PEG-PLGA-OAc], 2.17 
{overlapping s’s,  1.5H,313 MsO-PEG-PLGA-C(O)CH2OC(O)CH3}, 2.13 {s,  
1.5H,313 MsO-PEG-PLGA-C(O)CH(CH3)OC(O)CH3}, and 1.62-1.50 {m, 288 H 
MsO-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc }. 
 
 
Azido poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) acetate (6.25). 
Representative procedure; MsO-PEG-b-PLGA-OH and MsO-PEG-b-PLA-OH 
polymers of different MWs and lactic:glycolic ratios have also been prepared via 
similar methodology.  
MsO-PEG-b-PLGA-OAc 6.24 (1.65 g, 0.094 mmol, 1 equiv) was dissolved in 7 
mL of DMSO dried over activated 4Å sieves and transferred to an oven-dried 
culture tube containing a stir bar. Sodium azide (71 mg, 1.09 mmol, 12 equiv) 
was added. This homogeneous solution was capped with a Teflon-lined cap and 
slowly became tinted light orange as it stirred was at room temperature for 24 
hours. The slightly orange solution was then precipitated directly into i-propanol, 
the solvent decanted, and the solid polymer dried under high vacuum at 50 °C 
overnight, yielding the desired product (0.91 g, 0.052 mmol, 57.1%) with ca. 40-
50 % azide incorporation at the polyether terminus. 
1H NMR (500 MHz, CDCl3): δ 5.28-5.12 {m, 86H, N3-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.92-4.64 {m, 162H, N3-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.39 [non-uniform t, J = 4.4 Hz, 2H 
(integration of 1H due to 50% conversion), N3-CH2CH2O-PEG-PLGA-OAc], 4.34-
4.23 (m, 3-4H, N3-PEG-OCH2CH2OC(O)CH(R)-PLGA-C(O)CH(R)OAc}, 3.65 [s, 
Chapter 6 End-Functionalized Block Copolymers? 
?
????
?
545 H, N3-(CH2CH2O)mCH2CH2O-PLGA-OAc], 2.17 {overlapping s’s,  1.5H,313 
N3-PEG-PLGA-C(O)CH2OC(O)CH3}, 2.13 {s,  1.5H,313 N3-PEG-PLGA-
C(O)CH(CH3)OC(O)CH3}, and 1.62-1.50 {m, 288 N3-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc }. 
 
 
Mono methyl ether poly(ethylene glycol) amine (6.20). MeO-PEG-N3 6.25 
(0.180 g, 0.0360 mmol, 1 equiv) was dissolved with gentle heating in 10 mL of 
absolute ethanol, in a round bottom flask containing a stir bar and palladium on 
carbon (0.055 g). The flask was purged with N2 and subsequently purged with 
H2. After stirring under a hydrogen atmosphere for 24 hours, five mL of the 
solution was removed, filtered through Celite,® and precipitated directly into 
diethyl ether at 0 °C.  The solvent was decanted from the white solid and dried 
under vacuum. Analysis by 1H NMR spectroscopy showed a quantitative 
disappearance of the methylene resonance adjacent to the azide. 
1H NMR (500 MHz, CDCl3) matched the previously reported data. 
 
 
Mono methyl ether poly(ethylene glycol) methyl amide (6.29). MeO-PEG-NH2 
6.20 (0.045 g, 0.009 mmol, 1 equiv) was dissolved in 0.5 mL of CDCl3 in a 3mL 
vial containing a stir bar. Pyridine (12 µL, 0.148 mmol, 16.4 equiv) and acetyl 
chloride (10 µL, 0.141 mmol, 15.7 equiv) were added sequentially to the solution. 
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The reaction was capped and stirred overnight. Analysis of the crude 1H NMR 
spectrum was inconclusive. The CDCl3 solution was then precipitated into diethyl 
ether at 0 °C, the solvent decanted from the solute, and the isolated solid dried. 
The purified 1H NMR spectrum confirmed the absence of a methylene adjacent 
to an azide and the presence of an amide in the isolated, slightly yellow solid 
(0.012 g, 0.0024 mmol, 26.7%). 
1H NMR (500 MHz, CDCl3)314: δ 4.32 and 4.22 [non-first order t’s, J = 5 Hz, 2H 
total, OMe-(CH2CH2O)mCH2CH2-NHAc], 3.65 [s, 455 H, OMe-
(CH2CH2O)mCH2CH2-NHAc], 3.38 [s, 3H, CH3O-PEG-NHAc], and 2.08 [t, J = 5.2 
Hz, 3H, CH3O-PEG-NHC(O)CH3]. 
 
 
Mono methyl ether poly(ethylene glycol) octyl amide (6.30). MeO-PEG-NH2 
6.20 (0.045 g, 0.009 mmol, 1 equiv) was dissolved in 0.5 mL of CDCl3 in a 3mL 
vial containing a stir bar. In a separate vial, octanoic acid (20 µL, 0.126 mmol, 14 
equiv), EDCI (15 mg 0.078 mmol, 10 equiv), and DMAP (3 mg 0.025 mmol, 3 
equiv) were added co-dissolved in 0.5 mL of dry CDCl3. The two solutions were 
mixed and stirred overnight. Analysis of the crude 1H NMR spectrum was 
inconclusive. The CDCl3 solution was then precipitated into i-propanol at 0 °C, 
the solvent decanted from the solute, and the isolated solid dried. The purified 1H 
NMR spectrum confirmed the absence of a methylene adjacent to an azide and 
the presence of an amide in the isolated white solid. 
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314 The 1H NMR spectrum also exhibited resonances consistent with pyridine contamination.  
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1H NMR (500 MHz, CDCl3): δ 4.33 and 4.22 [non-first order t’s, J = 5 Hz, 2H 
total, OMe-PEG-CH2CH2-NHC(O)(CH2)6CH3], 3.65 [s, 455 H, OMe-
(CH2CH2O)mCH2CH2-NHC(O)(CH2)6CH3], 3.38 [s, 3H, CH3O-PEG-
NHC(O)(CH2)6CH3], 2.33 [t, J = 7.5 Hz, 2H, CH3O-PEG-NHC(O)CH2(CH2)5CH3], 
1.62 [app pent, J = 7.1 Hz, 2H, CH3O-PEG-NHC(O)CH2CH2(CH2)4CH3], 1.62 [m, 
8H, CH3O-PEG-NHC(O)CH2CH2(CH2)4CH3], and 0.88 [t, J = 6.6 Hz, 3H, CH3O-
PEG-NHC(O)(CH2)6CH3]. 
 
 
Mono methyl ether poly(ethylene glycol) amine (6.28). MeO-PEG-N3 6.25 (1.0 
g, 0.20 mmol, 1 equiv) was dissolved in seven mL of THF, in a culture tube 
containing a stir bar. Triphenylphosphine (0.262 g, 1.0 mmol, 5 equiv) and water 
(20 µL, 1.1 mmol, 11 equiv) were added sequentially to the polymer solution. The 
reaction was capped with a Teflon-lined cap and stirred overnight. The reaction 
was concentrated under reduced pressure, the residue redissolved in CH2Cl2, the 
solution precipitated into diethyl ether at 0 °C, and the solid filtered. 
Triphenylphosphine oxide was a noted contaminant, and so the polymer was 
redissolved in water, extracted with CH2Cl2 (x3), the organic phase washed with 
brine and then dried over MgSO4. The CH2Cl2 layer was then filtered through a 
paper filter, concentrated to a small volume under reduced pressure, and 
precipitated in diethyl ether at 0 °C. The isolated solid still retained 
triphenylphosphine oxide, and so the polymer was redissolved in CH2Cl2, 
precipitated into i-propanol, and cooled in a freezer. The liquid was decanted, 
and the solid dried under vacuum.  
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1H NMR (500 MHz, CDCl3) matched the previously reported data with a small 
amount of contaminating triphenylphosphine oxide. 
 
 
Mono 5-hexyne ester poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) 
acetate (6.33). HO-PEG-b-PLGA-OAc 6.16 (.114 g, 0.011 mmol, 1 equiv) was 
dissolved in one mL of dry CH2Cl2 in an oven-dried culture tube with stir bar. To 
this homogeneous solution, hexynoic acid (15 µL, 0.136 mmol, 12 equiv), EDCI 
(22 mg 0.114 mmol, 10 equiv), and DMAP were added. The reaction was sealed 
with a Teflon-lined cap and allowed to stir at room temperature overnight. The 
solution was then precipitated directly into i-propanol at room temperature, the 
solvent decanted, and the solid polymer dried under high vacuum at 50 °C 
overnight, yielding the desired product as a white solid (0.085 g, 0.0095 mmol, 
75% yield). Due to incomplete acetylation at the polyester terminus, the product 
was an ca. 2:1 mixture of 6.33:di-esterified compound 6.67. 
1H NMR (500 MHz, CDCl3): δ  5.29-5.10 {m, 53H, HCCCH2CH2CH2C(O)O-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.92-4.65 {m, 118H, 
HCCCH2CH2CH2C(O)O-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.34-4.23 
(m, 5H, HCCCH2CH2CH2C(O)O-CH2CH2O-PEG-OCH2CH2OC(O)CH(R)-PLGA-
Chapter 6 End-Functionalized Block Copolymers? 
?
????
?
C(O)CH(R)OAc}, 3.65 [s, 330 H, HCCCH2CH2CH2C(O)O(CH2CH2O)mCH2CH2O-
PLGA-OAc], 2.49 [t, J = 7.4 Hz, 3H HCCCH2CH2CH2C(O)O-PEG-PLGA-OAc], 
2.27 [dt, J = 6.9, 2.6 Hz, 2H, HCCCH2CH2CH2C(O)O-PEG-PLGA-OAc], 2.17 
{overlapping s’s,  1.3H,313 HCCCH2CH2CH2C(O)O-PEG-PLGA-OC(O)CH3}, 2.13 
[s,  1.7H,313 HCCCH2CH2CH2C(O)O-PEG-PLGA-OC(O)CH3], 1.98 [t, J = 2.6 Hz, 
1H, HCCCH2CH2CH2C(O)O-PEG-PLGA-OAc], and 1.85 [app pent, J = 7.2 Hz, 
2H HCCCH2CH2CH2C(O)O-PEG-PLGA-OAc], and 1.61-1.51 {m, 176 H, 
HCCCH2CH2CH2C(O)O-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}. 
 
 
Mono methyl ether poly(ethylene glycol) penta-acetate mannose (6.40).  
OMe-PEG-OC(O)CH2CH2CH2CCH 6.34 (0.080 g, 0.016 mmol, 1 equiv) was 
dissolved in 0.5 mL of dry THF in an oven-dried culture tube with stir bar. In a 
separate vial, 6.38 (7.5 mg, 0.015 mmol, 1 equiv) was dissolved in 0.5 mL of dry 
THF. The two solutions were combined. In a third vial, copper (II) sulfate 
pentahydrate (5 mg, 0.020 mmol, 1.3 equiv) and sodium ascorbate (25 mg 0.126 
mmol, 7.9 equiv) were dissolved in distilled water. The solutions were combined 
and sealed with a Teflon-lined cap and allowed to stir at room temperature for 14 
h.  The reaction was diluted with 10 mL of a 0.01 M EDTA aqueous solution, 
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extracted with 75 mL of DCM (3x), dried over MgSO4, and concentrated under 
reduced pressure, returning 58.6 mg of crude material. The residue was then 
precipitated into diethyl ether at 0 °C, the solid filtered through a paper filter, and 
the solid polymer dried under high vacuum at 50 °C overnight, yielding the 
desired product as a white solid (0.0125 g, 0.003 mmol, 75% conversion, 16% 
yield).  
1H NMR (500 MHz, CDCl3): δ 7.49 (s, 1H, H6’), 5.38-5.25 (m, 3H, H2, H3, and 
H4), 4.88 (d, J = 1.3 Hz, 1H, H1), 4.52 [t, J = 5.3 Hz, MeO-PEG-triazole-
CH2CH2O(CH2CH2O)2-mannose], 4.29 (dd, J = 12.2, 4.9 Hz, H6a), 4.23 (m, 2H, , 
MeO-PEG-triazole-(CH2CH2O)2CH2CH2O-mannose), 4.11 (dd, J = 12.2, 2.2 Hz, 
1H, H6b), 4.05 (m, 1H, H5), 3.65 [s, 461 H, mannose-triazole-(CH2CH2O)m-OMe], 
3.38 (s, 3H, CH3O-(CH2CH2O)m-triazole-mannose], 2.77 [t, J = 7.5 Hz, 2H, H4’], 
2.42 (t, J = 7.4 Hz, 2H, H2’), 2.16 (s, 3H, OC(O)CH3], 2.11 (s, 3H, OC(O)CH3], 
2.07-1.96 (m, 2H, H3’), 2.04 (s, 3H, OC(O)CH3], and 2.00 (s, 3H, OC(O)CH3]. 
 
 
Mono methyl ether poly(ethylene glycol) mannose (6.41). OMe-PEG-
OC(O)CH2CH2CH2CCH 6.34 (0.075 g, 0.015 mmol, 1 equiv) was dissolved in 1.0 
mL of dry THF in an oven-dried culture tube with stir bar. In a separate vial, 6.39 
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(5.1 mg, 0.015 mmol, 1 equiv) was dissolved in 0.5 mL of distilled water. The two 
solutions were combined. In a third vial, copper (II) sulfate pentahydrate (5 mg, 
0.020 mmol, 1.3 equiv) and sodium ascorbate (25 mg 0.126 mmol, 7.9 equiv) 
were dissolved in 0.5 mL of distilled water. The solutions were combined and 
sealed with a Teflon-lined cap and allowed to stir at room temperature for 
overnight. The reaction was extracted with 150 mL of DCM, dried over MgSO4, 
and concentrated under reduced pressure. The residue was then precipitated 
into diethyl ether at 0 °C, the solid filtered through a paper filter, and the solid 
polymer dried under vacuum. The residue was redissolved in DCM, washed with 
10 mL of a 0.01 M EDTA aqueous solution, and re-precipitated. 
1H NMR (500 MHz, CDCl3): δ 7.6 (br s, 1H, H6’), 4.54 [app br s, MeO-PEG-
triazole-CH2CH2O(CH2CH2O)2-mannose], 4.23 (br t, J = 5 Hz, 2H, MeO-PEG-
triazole-(CH2CH2O)2CH2CH2O-mannose), 3.65 [s, 468 H, MeO-(CH2CH2O)m-
triazole-mannose, H1, H2, H3, H4, H5, H6a, H6b], 3.38 (s, 3H, 
CH3O(CH2CH2O)m-triazole-mannose], 2.78 [app br s, 2H, H4’], 2.43 (br t, J = 6 
Hz, 2H, H2’), and 2.09-1.97 (br m, 2H, H3’). 
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Pentaacetate mannose poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) 
acetate (6.42). HCCCH2CH2CH2O(O)C-PEG-PLGA-OAc 6.33 (0.100 g, 0.010 
mmol, 1 equiv) was dissolved in 0.5 mL of dry THF in an oven-dried culture tube 
with stir bar. In a separate vial, 6.38 (7.5 mg, 0.015 mmol, 1.5 equiv) was 
dissolved in 0.5 mL of dry THF. The two solutions were combined. In a third vial, 
copper (II) sulfate pentahydrate (2.5 mg, 0.010 mmol, 1 equiv) and sodium 
ascorbate (20 mg 0.1 mmol, 10 equiv) were dissolved in distilled water. The 
solutions were combined and sealed with a Teflon-lined cap and allowed to stir at 
room temperature for overnight.  The reaction was diluted with 10 mL of a 0.01 M 
EDTA aqueous solution, extracted with 75 mL of DCM (3x), dried over MgSO4, 
and concentrated under reduced pressure. The residue was then precipitated 
into diethyl ether at 0 °C, the solid filtered through a paper filter, and the solid 
polymer dried under high vacuum at 50 °C overnight, yielding the desired product 
as a white solid (0.022 g, 0.002 mmol, > 90% conversion, 22% yield).  
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1H NMR (500 MHz, CDCl3):315 δ 7.49 (s, 1H, H6’), 5.35 (dd, J = 10, 4 Hz, 1H, 
H3), 5.32-5.08 {m, 43H, mannose-triazole-CH2CH2CH2C(O)O-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc, H2, and H4}, 4.91-4.65 {m, 95H, mannose-
triazole-CH2CH2CH2C(O)O-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc and H1}, 
4.52 [t, J = 5.0 Hz, mannose-(OCH2CH2)2OCH2CH2-triazole-CH2CH2CH2C(O)O-
PEG-PLGA-OAc], 4.34-4.23 (m, ca. 7H, mannose-OCH2CH2(OCH2CH2)2-
triazole-CH2CH2CH2C(O)O-PEG-OCH2CH2OC(O)CH(R)-PLGA-C(O)CH(R)OAc 
and H6a}, 4.11 (app br d, J = 12 Hz, 1H, H6b), 4.06 (m, 1H, H5), 3.65 [s, 336 H, - 
mannose-triazole-CH2CH2CH2C(O)O-(CH2CH2O)m-PLGA-OAc], 2.77 [t, J = 7.9 
Hz, 2H, H4’], 2.42 (t, J = 7.4 Hz, 2H, H2’), 2.17 {overlapping s’s,  1.3H,313 
mannose-triazole-CH2CH2CH2C(O)O-PEG-PLGA-OC(O)CH3}, 2.16 (s, 3H, 
OC(O)CH3], 2.13 [s,  1.7H,313 mannose-triazole-CH2CH2CH2C(O)O-PEG-PLGA-
OC(O)CH3], 2.11 (s, 3H, OC(O)CH3], 2.07-1.96 (m, 2H, H3’), 2.04 (s, 3H, 
OC(O)CH3], and 1.99 (s, 3H, OC(O)CH3]. 
 
 
???????????????????????????????????????? ????????????????????
315 Some contaimination was noted from a PEG-b-PLGA polymer bearing the alkyne at both the 
polyether and polyester termini. 
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Mannose poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) acetate (6.43). 
HCCCH2CH2CH2O(O)C-PEG-PLGA-OAc 6.33 (0.096 g, 0.0096 mmol, 1 equiv) 
was dissolved in 1.0 mL of dry THF in an oven-dried culture tube with stir bar. In 
a separate vial, 6.39 (8.0 mg, 0.021 mmol, 2.1 equiv) was dissolved in 1.0 mL of 
distilled water. The two solutions were combined. In a third vial, copper (II) 
sulfate pentahydrate (6.0 mg, 0.024 mmol, 2.5 equiv) and sodium ascorbate (47 
mg 0.24 mmol, 25 equiv) were added, and the culture tube was sealed with a 
Teflon-lined cap, wrapped in tinfoil, and allowed to stir at room temperature 
overnight.  The reaction was diluted with 2 mL of a 0.01 M EDTA aqueous 
solution, extracted with 100 mL of DCM (5x), dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was then precipitated into ca. 
25 mL of diethyl ether, but no obvious precipitate was noted. The cloudy 
suspension was centrifuged for one hour (4x), and the solid polymer recovered 
after each hour. The isolated solid material was observed to become whiter with 
each subsequent centrifuge procedure. The polymer was isolated (0.117 g, 
0.0117 mmol, ca. 25-50% conversion).  
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1H NMR (500 MHz, CDCl3): δ 7.55 (br s, 1H, H6’), 5.32-5.08 {m, 48H, mannose-
triazole-CH2CH2CH2C(O)O-PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.91-4.65 
{m, 110H, mannose-triazole-CH2CH2CH2C(O)O-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.52 [br t, J = 5 Hz, mannose-
(OCH2CH2)2OCH2CH2-triazole-CH2CH2CH2C(O)O-PEG-PLGA-OAc], 4.34-4.23 
(m, ca. 6H, mannose-OCH2CH2(OCH2CH2)2-triazole-CH2CH2CH2C(O)O-
(CH2CH2O)m-
OCH2CH2OC(O)CH(R){[OC(O)CH(CH3)]n[OC(O)CH2]p}C(O)CH(R)OAc}, 3.65 [s, 
343 H, -(CH2CH2O)m-, H1, H2, H3, H4, H5, H6a, and H6b], 2.77 [br t, J = 8 Hz, 
2H, H4’], 2.57-2.38 (m, 2H, H2’), 2.17 {overlapping s’s,  0.8H,313 PEG-PLGA-
OC(O)CH3}, 2.16 (s, 3H, OC(O)CH3], 2.13 [s,  2.2H,313 PEG-PLGA-OC(O)CH3], 
and 2.06-1.96 (m, 2H, H3’). 
 
 
Mono methyl ether poly(ethylene glycol) mannose (6.46). MeO-PEG-N3 6.25 
(0.175 g, 0.035 mmol, 1 equiv) was dissolved in 1.0 mL of dry DMSO in an oven-
dried culture tube with stir bar. Copper (II) sulfate pentahydrate (8.8 mg, 0.035 
mmol, 1 equiv) and ascorbic acid (32.9 mg, 0.187 mmol, 5 equiv) were added 
and observed to dissolve, resulting in a yellow solution. Crude 6.50 (62 mg 
crude) was dissolved in 0.5 mL of DMSO and added to the reaction solution. The 
culture tube was purged with nitrogen gas  and sealed with a Teflon-lined cap 
and allowed to stir at room temperature for 48 h. The reaction was filtered 
through glass wool precipitated into ca. 40 mL of iPrOH at 0 °C, the solid filtered 
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through a Buchner funnel, and the solid polymer dried under vacuum. The filtrate 
was centrifuged to yield an additional aliquot of the product, a white solid 
(0.1366g, 0.027 mmol, 78% yield, ca. 85% conversion). 
1H NMR (500 MHz, CDCl3): δ 7.84 (s, 1H, H6’), 4.97 (br s, 1H, H3), 4.82 (d, J = 
12.4 Hz, 1H, H2), 4.82 (d, J = 12.4 Hz, 1H, H4), 4.55 [br t, J = 4.7 Hz, 2H, 
CH3O(CH2CH2O)m-CH2CH2-triazole-CH2-mannose], 3.89 [t, J = 4.8 Hz, 2H, 
CH3O(CH2CH2O)m-CH2CH2-triazole-CH2-mannose], and 3.65 [s, 460 H, 
CH3O(CH2CH2O)m-CH2CH2-triazole-CH2-mannose, H6b, H1, H5], and 3.38 [s, 
3H, CH3O(CH2CH2O)m-CH2CH2-triazole-CH2-mannose]. 
 
 
Mannose poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) acetate (6.48). 
N3-PEG-PLGA-OAc 6.31 (0.152 g, 0.019 mmol, 1 equiv) was dissolved in 1.5 mL 
of dry THF in an oven-dried culture tube with stir bar. In a separate vial, 6.50 (ca. 
90 mg crude) was dissolved in 1.5 mL of distilled water. The two solutions were 
combined. copper (II) sulfate pentahydrate (2.4 mg, 0.001 mmol, 0.5 equiv) and 
ascorbic acid (9.4 mg 0.0475 mmol, 2.5 equiv) were added, and the culture tube 
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was sealed with a Teflon-lined cap, wrapped in tinfoil, and allowed to stir at room 
temperature overnight.  The reaction was concentrated under reduced pressure, 
extracted with dry DCM, and precipitated into ca. 30 mL of isopropanol. The 
cloudy suspension was centrifuged and the solid polymer recovered. The 
polymer was isolated (0.015 g, 0.002 mmol, 10%).  
1H NMR (500 MHz, CDCl3):316 δ 5.32-5.08 {m, 38H, mannose-CH2-triazole-PEG-
{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.91-4.65 {m, 62H, mannose-CH2-triazole-
PEG-{[OC(O)CH(CH3)]n[OC(O)CH2]p}OAc}, 4.56 [br t, J = 4 Hz, 2H (ca. 20% 
conversion), mannose-CH2-triazole-CH2CH2O-PEG-PLGA-OAc], 4.34-4.23 (m, 
ca. 3H, mannose-CH2-triazole-PEG-OC(O)CH(R)-PLGA-C(O)CH(R)OAc}, 3.87 
[br t, J = 5 Hz, 2H (ca. 20% conversion), mannose-CH2-triazole-CH2CH2O-PEG-
PLGA-OAc], 3.65 [s, 115 H, mannose-CH2-triazole-(CH2CH2O)m-OC(O)CH(R)-
PLGA-C(O)CH(R)OAc, H1, H2, H3, H4, H5, H6a, and H6b], 2.17 {overlapping 
s’s,  1.2 H, mannose-CH2-triazole-PEG-PLGA-OC(O)CH3}, 2.16 (s, 3H, 
OC(O)CH3], and 2.13 [s,  1.8 H, mannose-CH2-triazole-PEG-PLGA-OC(O)CH3]. 
 
 
1(2-(2-methoxyethoxy)ethyl)-1H-pyrrolye-2,5-dione (6.60). 
Triphenylphosphine (0.167 g, 0.637 mmol, 1.05 equiv) was added to an oven-
???????????????????????????????????????? ????????????????????
316 The aromatic traizole resonance could not be observed, likely due to the minimal amount of 
material, low signal-to-noise ratio, and/or previously observed broadness of this resonance in 
CDCl3. 
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dried round bottom flask with stir bar and the vessel was evacuated and filled 
with nitrogen (3x). The triphenylphosphine was dissolved by the addition of 5.0 
mL of dry THF. DIAD (0.12 mL, 0. 609, 1 equiv) was added via a plastic syringe. 
The reaction was cooled to -78 °C and stirred for five minutes. Diethylene glycol 
monomethyl ether 6.64 (0.112 g, 0.932 mmol, 1.5 equiv) was added, and the 
homogeneous mixture was stirred for an additional 20 mins at -78 °C. In a 
separate vial, maleimide (0.0625 g, 0.644 mmol, 1.06 equiv) was dissolved in 3.0 
mL of dry THF, and this solution was added to the bulk reaction via a plastic 
syringe. The solution was allowed to stir at -78 °C for 10 mins after which the 
solution was warmed to rt and stirred for an additional 16 h. After stirring 
overnight, the reaction was noted to be a light yellow color. The reaction was 
then concentrated under reduced pressure, the residue dissolved in 
hexanes:EtOAc (1:1), and purified via MPLC, yielding 6.65 (44.4 mg, 0.223 
mmol, 36.6% based on limiting reagent) as a colorless, viscous oil. 
1H NMR (500 MHz, CDCl3): δ 6.71 [s, 2H, NC(O)CHCHC(O)], 3.74 (t, J = 6.1 Hz, 
2H, NCH2CH2O), 3.66 (t, J = 5.7 Hz, 2H, NCH2CH2O), 3.61 (m, 2H, and 
CH3OCH2CH2O), 3.50 (m, 2H, and CH3OCH2CH2O),  and 3.35 (s, 3H, 
CH3OCH2CH2O). 
GC/MS (Method: 50 °C, hold for two min; ramp at 20 °C/min for 10 min, hold at 
250 °C for three min) tR = 6.79 min; m/z 199 (10, M+), 154 (20, M+-MeOCH2), 124 
(100, M+-MeOCH2CH2O), 110 (20, M+-MeOCH2CH2OCH2), and 59 (30). 
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Mono methyl ether Poly(ethylene glycol) maleimide (6.62). 
Triphenylphosphine (0.167 g, 0.637 mmol, 1.05 equiv) was added to an oven-
dried round bottom flask with stir bar and the vessel was purged with nitrogen. 
The triphenylphosphine was dissolved by the addition of 5.0 mL of dry THF. 
DIAD (0.12 mL, 0. 609, 1 equiv) was added via a plastic syringe. The reaction 
was cooled to -78 °C and stirred for 15 mins. A 4 mL solution of mPEG-OH 4.03 
(1.56 g, 0.312 mmol, 0.5 equiv) was added, and the mixture was stirred for an 
additional 15 mins at -78 °C. A white precipitate was noted, and the reaction was 
allowed to warm to -40 °C. After stirring at -40 °C, the reaction was again 
homogeneous. In a separate vial, maleimide (0.0625 g, 0.644 mmol, 1.06 equiv) 
was dissolved in 2.0 mL of dry THF, and this solution was added to the bulk 
reaction via a plastic syringe. The solution was allowed to stir at -40 °C for 1 h, 
after which the solution was warmed to rt and stirred for an additional 1 h. After 1 
h, a 5 mL aliquot was removed from the reaction flask, concentrated under 
reduced pressure, dissolved in EtOAc, precipitated into an equal volume of 
hexanes cooled to 0 °C, filtered, the solid redissolved in CH2Cl2, and precipitated 
into isopropanol at 0 °C. The solid was collected by filtration, dried under high 
vacuum, and analyzed by 1H NMR, suggesting a 60% conversion. The remainder 
of the reaction was stirred overnight, and purified as described. No significant 
further conversion was noted. 
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1H NMR (500 MHz, CDCl3): δ 6.71 [s, 2H, NC(O)CHCHC(O)], 3.65 (s, 455H, 
MeO-(CH2CH2O)n-CH2CH2maleimide), and 3.38 (s, 3H, CH3O-(CH2CH2O)n-
CH2CH2maleimide). 
 
 
Mono methyl ether Poly(ethylene glycol) maleimide cysteine ethyl ester 
(6.65). Model 6.67 (93 mg, 0.019 mmol, 1 equiv) was co-dissolved with cysteine 
ethyl ester hydrochloride salt 6.68 (40.9 mg, 0.22 mmol, 12 equiv) in 0.8 mL of a 
buffered D2O solution (pD = 7.4) in an oven-dried culture tube with stir bar. The 
vessel was capped with a Teflon-lined cap and allowed to stir for overnight at rt. 
The solution was then precipitated directly into isopropanol at 0 °C. Attempts to 
filter the fine precipitate failed, and so the heterogeneous suspension was 
concentrated to dryness under reduced pressure, redissolved, and precipitated 
into isopropanol at 0 °C. The suspension was centrifuged for two hours, the 
solvent decanted, and the solid dried under high vacuum at 50 °C. The solid 
white precipitate was identified as 6.70. 
1H NMR (500 MHz, D2O):317 δ 4.27 [q, J = 7.2 Hz, 2H, C(O)CCH2CH3], 3.65 (s, 
455 H, MeO-(CH2CH2O)n), 3.38 (s, 3H, CH3O-(CH2CH2O)n), 3.01 (dd, J = 13.6, 
8.6 Hz, 1H, SCHaHbCH), 2.91 (dd, J = 13.5, 7.8 Hz, 1H, SCHaHbCH), and 1.31 [t, 
overlapping with impurities, 3H, C(O)CCH2CH3]. 
???????????????????????????????????????? ????????????????????
317 Relavent 1H NMR data are reported from an impure sample. Impurities are omitted.?
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Chapter 7  
Overall Conclusions and Future Outlook  
 
Through the experiments described in this thesis, there have been a number 
of discoveries that are of interest from both a fundamental as well as practical 
viewpoint. The general strategic concept of silicate esters as promoieties has 
been validated, a novel synthesis for the production of “random” PLGA block 
copolymers has been established, and the utility of these materials in biological 
studies has been confirmed. These studies provide optimism for the outlook of 
these silicate-loaded, FNP-produced nanoparticles. 
 
1. The Silicate Ester Prodrug Strategy. 
 The synthesis, purification, and characterization of a wide variety of 
tetraalkoxysilanes and acyloxytrialkoxysilanes are detailed, and the relative 
hydrolysis rates of these compounds have been benchmarked. The structural 
diversity within this family of compounds was designed to allow for the control of 
two primary physicochemical properties: hydrophobic character and rate of 
hydrolysis of the silicate esters. Based on the study of these models, multiple, 
important trends were established. First, increasing the length of aliphatic, linear 
alkoxy substituents has the power to dramatically alter the solubility of a silicate 
while the rate of hydrolysis differs minimally. The hydrolysis rate, on the other 
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hand, can be slowed by inclusion of sterically bulky substituents or quickened by 
the inclusion of a labile acetoxy group. 
 In order to obtain data relevant to future silicate ester prodrugs, the 
necessity of a well-chosen model study was apparent in these studies. Even in 
the tetraalkoxysilane model system, subtle variations in one of the four sacrificial 
alkoxy groups elicited measurable changes in the observed hydrolysis rate. The 
trends developed from the tetraalkoxysilane models were effectively translated to 
the design of PTX silicate ester prodrugs. Efforts from these studies resulted in a 
class of novel silicate ester prodrugs that varied in their hydrophobicity, 
hydrolysis rate, and site of silylation. An interesting study of a hindered, acetoxy-
containing silicate ester of PTX uniquely allowed for the isolation of a PTX silanol 
intermediate. This study further established the SN2 nature of the hydrolysis 
mechanism. Collaborative efforts measured the IC50 values of a subset of these 
PTX silicate esters, and, encouragingly, found all but two of the most slowly 
hydrolyzing species to be equally as cytotoxic as PTX itself. 
 
2. Block Copolymer Synthesis Methodology and End-Functionalization. 
The biocompatible copolymer PLGA has been widely used in biomedical 
applications. However, the traditional synthetic route to PLGAs has typically 
utilized tin catalysis to access random copolymers via a polymerization that 
incurs significant transesterification, resulting in products that are polydisperse. 
The methodology described in this thesis has demonstrated that the synthesis of 
essentially random, narrowly dispersed PLGA copolymer blocks is achievable. 
This task was accomplished through the use of the organocatalyst DBU and the 
controlled infusion of the glycolide monomer to match the consumption of the 
lactide monomer. Using a monomethoxy PEG as a macroinitiator, PEG-b-PLGA 
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BCPs of varying MWs, and correspondingly different physical properties, were 
synthesized.   
Expanding the utility of this methodology, use of a monobenzyl ether PEG 
(rather than a monomethyl ether PEG) as a macroinitiator allowed access to a 
family of BnO-PEG-b-PLGA BCPs whose termini were end-differentiated and 
amenable to a variety of chemical transformations. Following acetlylation of the 
polyester block, the polyether could be efficiently debenzylated to yield a polymer 
(HO-PEG-b-PLGA-OAc) that could be further functionalized selectively at the 
polyether terminus. Studies reported here focus on efforts to render these 
polymers amenable to various “click” chemistries such as [3 + 2] cycloadditions 
and thiol-maleimide conjugations.  
 
3. PTX Silicate-Loaded Nanoparticles. 
 The bis-triethoxy PTX silicate prodrug was co-formulated via FNP with a 
5K-10K PEG-b-PLGA BCP into highly prodrug-loaded, stable nanoparticles. In 
collaboration with a number of colleagues of varying expertise, the morphology 
and behavior of these nanoparticles was examined by a variety of spectroscopy, 
calorimetry, and microscopy techniques. While it is difficult to definitively 
characterize these inherently broadly dispersed, kinetically trapped 
nanoparticles, the preponderance of the evidence suggests that the 
nanoparticles are composed of a solid core that consists of the crystalline PTX 
silicate and amorphous PLGA polymer block. The nanoparticles are effectively 
dispersed in water by a PEG corona that crystallizes upon freeze drying, leading 
to difficulties during redispersion at high concentration in aqueous buffers.  
 PTX silicate loaded nanoparticles were extensively tested in collaborative 
biological studies. These prodrug loaded formulations were dosed to cancer 
tumor-bearing mice to test for in vivo efficacy. In a highly encouraging result, 
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groups of mice receiving equimolar doses of the PTX silicate nanoparticles, 
Taxol®, and Abraxane® all demonstrated statistically equivalent levels of tumor 
growth suppression. Due to the high loading levels in the PTX silicate 
nanoparticles, notably less excipient was dosed to this group. In addition, the 
PTX silicate may have hydrolyzed and released over a more prolonged period, 
thereby allowing a more sustained drug delivery. These two traits are consistent 
with the critical observation that mice receiving these PTX silicate nanoparticles 
exhibited minimal side effects such as liver and blood toxicity vis-à-vis the clinical 
treatment groups. 
 
4. Future Outlook. 
 Several aspects of this thesis deserve yet greater study. The silicate ester 
prodrug strategy has been well established in the case of tetraalkoxysilanes and 
PTX silicate ester prodrugs, but application of the silicate ester prodrug strategy 
to other hydrophobic, hydroxyl-containing drugs could lead to additional new drug 
formulations. Additionally, silicate esters consisting of other functional groups 
could also prove to be productive. For example, further development of 
aminosilanes and phosphonic acid silicates could expand the utility of this 
concept. In the case of the end-functionalized BCPs, a reliable route to a readily 
derivatized polymeric intermediate (HO-PEG-b-PLGA-OAc) has been 
established. While initial studies have demonstrated that end-functionalization of 
these PEG-b-PLGAs is achievable, optimization of reaction conditions and 
incorporation of high-value imaging, targeting, and cytotoxic agents could 
advance this strategy. Eventually, with the appropriate materials in hand, loading 
these customized BCPs with silicate prodrugs could yield selective and highly 
efficacious therapeutic agents.    
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 The efficacy and minimal toxicity of PTX silicates in PEG-b-PLGA 
nanoparticles is an outcome that inspires future study. However, a number of 
opportunities still exist to further understand the fundamental science as well as 
improve the end application. For instance, specific to these PTX silicate-loaded 
nanoparticles, carefully matching the precipitation rate of the silicate and 
polyester block during the FNP formulation may result in alterations of the 
morphology of the nanoparticle, thereby potentially affecting the 
hydrolysis/release rate. Alternatively, optimization of the loading level of the PTX 
silicate (via either inclusion of higher wt% in the FNP experiment or increasing 
the hydrophobic character of the silicate prodrug) may further minimize any 
undesirable toxicity. Upon conclusion of these optimization studies, determination 
of the maximum tolerated dose is essential. Any one of these studies could 
individually or collectively improve the overall efficacy of this PTX silicate 
nanoparticle formulation.
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